,id,ticker,title,category,content,date,provider,url,article_id
146108,367623,ALXN,Apellis  Lead Drug Tops Alexion s Blockbuster Soliris in a Pivotal Late Stage Study,news,"Apellis Pharmaceuticals  NASDAQ APLS  announced results on Tuesday from its Pegasus late stage clinical study evaluating experimental drug pegcetacoplan  APL 2  in treating adults with paroxysmal nocturnal hemoglobinuria  PNH   a rare blood disorder  The biotech company stated that pegcetacoplan achieved the primary efficacy endpoint of the study by producing greater improvement in patients  hemoglobin levels than Alexion Pharmaceuticals  NASDAQ ALXN  Soliris 
This news caused Apellis stock to soar more than 20  Tuesday morning  Alexion s share price opened down more than 3  but later rebounded 

Digging into the results
The Pegasus study included 41 patients receiving pegcetacoplan and 39 patients receiving Soliris  Apellis reported that pegcetacoplan achieved an improvement in the adjusted means of 3 8 grams per deciliter of hemoglobin at week 16 of the study compared to Soliris with a high level of statistical significance  The company also said that its drug  showed promising results  on key secondary endpoints including avoiding transfusions and reducing fatigue  Pegcetacoplan s safety profile was similar to that of Soliris  
Those results were better than Apellis anticipated  CEO Cedric Francois stated   Going into the study  our most optimistic expectation was to see a 2 g dL or more change in hemoglobin and a trend on the key secondary endpoints  Needless to say  we are thrilled with these results  
Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in patients with PNH  The Pegasus results point to the possibility that Apellis  drug could become the new standard of care in treating the rare blood disorder 
Next steps for Apellis
Apellis plans to present detailed results from the Pegasus study at a future scientific meeting  The company also hopes to meet with regulators in the first half of 2020 to discuss the pathway to approval for pegcetacoplan ",2020-01-07,The Motley Fool,https://invst.ly/pez5u,2054209
146112,367627,ALXN,Alexion Pharmaceuticals Q4 2019 Earnings Preview,news,"Alexion Pharmaceuticals  NASDAQ ALXN  is scheduled to announce Q4 earnings results on Thursday  January 30th  before market open 
The consensus EPS Estimate is  2 61   22 0  Y Y  and the consensus Revenue Estimate is  1 32B   16 8  Y Y  
Over the last 2 years  ALXN has beaten EPS estimates 100  of the time and has beaten revenue estimates 100  of the time 
Over the last 3 months  EPS estimates have seen 8 upward revisions and 1 downward  Revenue estimates have seen 7 upward revisions  and 1 downward ",2020-01-29,Seeking Alpha,https://invst.ly/polx3,2071126
146113,367628,ALXN,Alexion Pharmaceuticals EPS beats by  0 10  beats on revenue,news,"Alexion Pharmaceuticals  NASDAQ ALXN   Q4 Non GAAP EPS of  2 71 beats by  0 10  GAAP EPS of  4 00 beats by  1 91 
Revenue of  1 38B   22 1  Y Y  beats by  60M 
Press Release",2020-01-30,Seeking Alpha,https://invst.ly/povik,2071529
146117,367632,ALXN,Alexion Pharma slips 3  premarket on soft guidance,news,"Alexion Pharmaceuticals  ALXN  Q4 results  Revenues   1 384 3M   22 6    Soliris   1 013 1M   3 7    Ultomiris   170 2M  Strensiq   166 8M   32 3    Kanuma   34 1M   32 7   
Net Income   889M  EPS   4 00  non GAAP Net Income   611M   25 6    non GAAP EPS   2 71   26 6   
2020 Guidance  Revenues   5 500M   5 560M vs  Yahoo Finance consensus of  5 6B  Soliris Ultomiris revenues   4 755M   4 800M  EPS   7 91   8 71  non GAAP EPS   10 65   10 85 vs  Yahoo finance consensus of  11 37 
The Company received Japanese approval for Soliris for neuromyelitis optica spectrum disorder and established Ultomiris as market leader for PNH in U S   Germany and Japan 
ALXN expanded pipeline with 19 clinical stage development programs planned for 2020  following completion of Achillion acquisition 
Shares are down 3  premarket 
Previously  Alexion Pharmaceuticals EPS beats by  0 10  beats on revenue  Jan  30 ",2020-01-30,Seeking Alpha,https://invst.ly/poy51,2071699
146120,367635,ALXN,Acceleron  XLRN  Up On Success Of PAH Drug In Phase II Study,opinion,"Shares of Acceleron Pharma Inc    NASDAQ XLRN   soared more than 66  in after market trading after it announced that the mid stage study on pipeline candidate  sotatercept  in patients with pulmonary arterial hypertension  PAH  was successful 
The phase II study  PULSAR  is a randomized  double blind  placebo controlled trial designed to evaluate the efficacy and safety of sotatercept in PAH patients  The primary endpoint of the trial is the change from baseline in pulmonary vascular resistance  PVR  over a 24 week treatment period 
In the study  106 patients were randomized to receive placebo  0 3 mg kg of sotatercept  or 0 7 mg kg of sotatercept subcutaneously  every 21 days  in combination with stable background PAH specific therapies over a 24 week treatment period 
The study results showed that the candidate demonstrated a statistically significant reduction in PVR  the trial s primary endpoint  at week 24 versus placebo  PVR  as measured by right heart catheterization  is the resistance that the heart must overcome to pump blood through the pulmonary circulatory system 
The study also achieved statistically significant improvements in the key secondary endpoint of six minute walk distance  6MWD  and other secondary endpoints  including amino terminal brain natriuretic propeptide  NT proBNP  and World Health Organization  WHO  functional class 
The candidate was generally well tolerated 
Moreover  97 out of the 106 patients are currently participating in the 18 month extension period of the study 
Additional results will be presented later in the year  
Meanwhile  sotatercept is also being evaluated in another phase II study  SPECTRA  in patients with PAH 
Acceleron s stock has rallied 33 6  in the past year against the  s decline of 5 6  

The company received a major boost with the FDA approval of Reblozyl  luspatercept aamt  for the treatment of anemia in adult patients with beta thalassemia  who require regular red blood cell  RBC  transfusions  in 2019  The drug is being developed in collaboration with pharma major Bristol Myers Squibb   NYSE BMY   
Both companies are also developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis  Acceleron is also advancing its neuromuscular program with ACE 083  a locally acting Myostatin  agent in phase II development in Charcot Marie Tooth disease 
Zacks Rank   Stocks to Consider
Acceleron currently carries a Zacks Rank  4  Sell   A couple of better ranked biotech stocks include Alexion Pharmaceuticals   NASDAQ ALXN   and Clovis Oncology   NASDAQ CLVS    Both stocks carry a Zacks Rank  2  Buy   You can see  
Alexion s earnings per share estimates have increased from  10 35 to  10 43 for 2019 and from  11 10 to  11 36 for 2020 in the past 90 days 
Clovis  loss per share estimates have narrowed to  4 82 from  6 for 2020 in the past 90 days 
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/acceleron-xlrn-up-on-success-of-pah-drug-in-phase-ii-study-200502371,200502371
146121,367636,ALXN,Alexion Pharmaceuticals Inc  ALXN  Q4 2019 Earnings Call Transcript,news,"Alexion Pharmaceuticals Inc  NASDAQ ALXN Q4 2019 Earnings CallJan 30  2020  7 30 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by and welcome to the Alexion Pharmaceuticals Fourth Quarter and Full Year 2019 Results Conference Call  At this time all participant lines are in listen only mode  After the speakers  presentation  there will be a question and answer session  Please be advised  that today s conference may be recorded I would now like to hand the conference over to Morgan Sanford  Director  Investor Relations  Please go ahead ma am Morgan Sanford    Director of Investor RelationsThank you  operator  Good morning  Thank you for joining us on today s call to discuss Alexion s performance for the fourth quarter and full year 2019  Today s call will be led by Ludwig Hantson  our CEO  Ludwig will be joined by Aradhana Sarin  our Chief Financial Officer  John Orloff  our Global Head of R D and Brian Goff  our Chief Commercial and Global Operations Officer  You can access the webcast slides that will be presented on this call  by going to the Events section of our Investor Relations page on our website Before we begin  I would like to point out that we will be making forward looking statements  and these statements involve certain risks and uncertainties that could cause our actual results to differ materially  Please take a look at the risk factors discussed in our SEC filings for additional detail  These forward looking statements apply only as of today  and we undertake no duty to update any of the statements after the call  except as required by law  I d also like to remind you  that we will be using non GAAP financial measures  which we believe provide useful information for the understanding of our ongoing business performance  Reconciliations of our financial results and financial guidance are included in our press release  These non GAAP financial measures should be considered in addition to  but not as a substitute for  our GAAP results  Thank you Ludwig Ludwig Hantson    Chief Executive OfficerThank you  Morgan  and good morning everyone  Before we review our fourth quarter and 2019 full year performance  I would like to take a brief moment to announce that we have successfully closed on our acquisition of Achillion Pharmaceuticals  which represents an important step in diversifying our business  Through this acquisition  we had two clinical stage assets to our portfolio  with danicopan and 5228  We are thrilled to welcome our Achillion colleagues to Alexion and excited about the opportunity to collaborate on the development of these Factor D assets for a broad range of rare diseases Turning now to our 2019 performance  we delivered on all of our key objectives  and in many cases have surpassed our goals  ULTOMIRIS is now the market leader in PNH  in our three largest markets  the U S   Germany and Japan  The ULTOMIRIS HUS conversion is progressing well in the U S   and we anticipate launching in the EU and Japan this year We are also very pleased with the uptake of our neurology franchise  with continued growth of SOLIRIS in gMG and the launch in NMOSD  In just over two years  neurology has become our largest franchise in the U S  by patient volumes  Our ambition is to quadruple the number of MG and NMOSD patients treated by SOLIRIS  and eventually ULTOMIRIS in the U S  by 2025  Our metabolics portfolio continues to deliver strong growth  as we work to expand access for HPP and LAL D patients Importantly  we have made great progress on our pipeline and have an ambition for 10 launches from now until the end of 2023  through a combination of new assets  new formulations and new indications  And once again have delivered on our financials  with 21  revenue growth and 33  non GAAP earnings growth in 2019 Turning to slide 6  we have a clear strategy for long term value creation  First  we will move past SOLIRIS and establish ULTOMIRIS as market leader in PNH and HUS  in our three key geographies  Secondly  we will expand our C5 franchise beyond PNH and HUS into larger rare diseases  We have ULTOMIRIS programs planned in six new indications  including four neurology  and two nephrology indications  In parallel  we will continue to innovate for patients with new formulations and subcu treatment options Finally  we will diversify our portfolio beyond C5  Achillion is the most recent example of this effort  With Factor D  we have the opportunity to pursue development in a broad range of indications  Outside of this transaction  we have built a robust rare disease pipeline over the past few years  and have clear line of sight to multiple potential blockbuster launches  including treatments for Wilson Disease and AL amyloidosis  We have significant financial capacity to continue to diversify our pipeline in the future In addition to bringing in external assets to diversify our business  we are evolving our leadership in complement to expand our addressable patient population  On slide 7  you can see our business is rapidly moving beyond SOLIRIS  ULTOMIRIS is approved for two indications OperatorLadies and gentlemen  please standby  Please continue to standby  While we are experiencing technical difficulties  Ladies and gentlemen  please continue to standby  Ladies and gentlemen  thank you for your patience and please continue to standby  You may resume Ludwig Hantson    Chief Executive OfficerYes hi  this is Ludwig Hantson  We had a technical issue  I hope that you guys can hear us OK  So what I will do is  instead of restarting  we re going to start on slide 6 and then we will take it from there So turning to slide 6  we have a clear strategy for long term value creation  First  we will move past SOLIRIS and establish ULTOMIRIS as market leader in PNH and HUS in our three key geographies  Secondly  we will expand our C5 franchise beyond PNH and HUS into larger rare diseases  We have ULTOMIRIS programs planned and six new indications  including four neurology and two nephrology indications  In parallel  we will continue to innovate for patients with new formulations and subcu treatment options Finally we will diversify our portfolio beyond C5  Achillion is the most recent example of this effort  With Factor D  we have the opportunity to pursue development in a broad range of indications  Outside of this transaction  we have built a robust rare disease pipeline over the past few years and have clear line of sight to multiple potential blockbuster launches  including treatments for Wilson Disease and AL amyloidosis We have significant financial capacity to continue to diversify our pipeline in the future  In addition to bringing in external assets to diversify our business  we are evolving our leadership and complement to expand our addressable patient population  On slide 7  you can see our business is rapidly moving beyond SOLIRIS  ULTOMIRIS is approved for two indications and in development for six additional indications  across neurology and nephrology  This year  we will transition to a high concentration formulation  which will shorten infusions to only 45 minutes  Next year  we plan to launch our once weekly  on body subcu ULTOMIRIS formulation  offering patients a home based self administration option  Our next generation subcu assets  1810 and 1720 offer improved patient dosing regimens  and we have significant optionality for indication selection with each of these assets  From there  we will expand with Achillion s Factor D platform  We see immense opportunity for oral proximal complement treatments  to transform standard of care in many complement mediated diseases On slide 8  you see that once again  we have delivered strong top and bottom line growth for the fourth quarter and the full year  which provides a solid foundation to continue to deliver on our value creation strategy  Again  I m very pleased with our strong execution against our 2019 priorities and excited for 2020  as we build on our successes With that I will now turn the call over to Aradhana Aradhana Sarin    Executive Vice President and Chief Financial OfficerThank you  Ludwig  Starting with slide 10  we reported fourth quarter total revenues of approximately  1 4 billion  an increase of 23  year over year  This was driven by strength in our neurology franchise  continued growth in the core businesses and ULTOMIRIS launch Our non GAAP operating margin was 51   a reduction of 155 basis points versus prior year  driven by increased R D spend  as we advanced and further build our development portfolio  Non GAAP EPS was  2 71  representing 27  growth year over year  driven primarily by strong top line growth and lower effective tax rate Moving to slide 11  fourth quarter total net product sales were primarily driven by patient volume growth in our key markets  Turning to slide 12  SOLIRIS revenues in the fourth quarter were approximately  1 billion  with year over year growth of 4   SOLIRIS revenue growth was driven primarily by gMG revenues  partially offset by ULTOMIRIS conversion dynamics  ULTOMIRIS revenues in the fourth quarter were  170 million  which now includes contributions from atypical HUS in the United States  Metabolics revenues in the fourth quarter were  201 million  representing 32  year over year growth Turning to the P L on slide 13  during the quarter  non GAAP R D expense was  227 million or 16  of revenues  Non GAAP SG A expense was  340 million or 25  of revenues  The non GAAP effective tax rate in the quarter was approximately 12   and continued to benefit from certain one time events  including the release of state income tax reserves related to the conclusion of an audit We reported fourth quarter non GAAP EPS of  2 71  growing 27  year over year  GAAP earnings per share were  4  We ended the fourth quarter with approximately  2 7 billion in cash and marketable securities  This is not adjusted for the Achillion transaction I ll now turn to slide 14 for our 2020 financial guidance  We are guiding to total revenues between  5 5 billion and  5 56 billion  this represents 11  growth year over year at the midpoint of the range  For SOLIRIS and ULTOMIRIS  our revenue guidance is  4 755 billion to  4 800 billion  This assumes continued momentum for SOLIRIS in gMG  our ongoing launch of SOLIRIS in NMOSD  and the launches of ULTOMIRIS for PNH and atypical HUS Turning to metabolics  our revenue guidance is  745 million to  760 million for both STRENSIQ and KANUMA  This includes the impact of the strategic pricing decision for STRENSIQ in the U S  to support sustainability and access  given weight based dosing  In 2020 and beyond  it is important to consider the dynamics associated with conversion from SOLIRIS to ULTOMIRIS  as it relates to the annual cost per patient There is a revenue benefit when each patient starts ULTOMIRIS PNH treatment due to the increased number of vials consumed during the loading dose  We benefited from this loading dose dynamic  having converted 60  plus of patients in PNH to ULTOMIRIS over the course of 2019  We now expect to be impacted by lower annual treatment cost per patient  as the majority of patients move to maintenance dosing In atypical HUS and other indications and development  we will see a lower annual cost per patient compared to SOLIRIS for both loading dose and maintenance dosing  It is also important to consider quarter over quarter variability due to every eight week dosing for ULTOMIRIS  However  this quarterly fluctuation will even out on an annual basis We have included a slide in the appendix of this presentation  to provide a summary of this dynamic  and to serve as a reference  going forward  Non GAAP operating margin is expected to be between 53 5  and 54 5  of revenues  Non GAAP R D expense is expected to be between 17 5  and 18 5  of revenues  and represents a step up of approximately  270 million versus prior year  consistent with our intention to further build out and progress the pipeline Clinical program spend  particularly for late stage development  is planned to increase in 2020  R D expense also includes program costs and potential milestones for previously announced BD transactions and collaborations  Non GAAP SG A spend is expected to be between 19 5  and 20 5  of revenues for the full year 2020  and reflect increased leverage from topline growth We expect the non GAAP effective tax rate to be between 16  and 17   In 2019  the non GAAP effective tax rate benefited from certain one time items  Absent these one time benefits  our 2019 non GAAP tax rate would have been approximately 15   We expect our non GAAP effective tax rate to increase in the future  as a result of tax regulation changes outside the U S GAAP EPS is expected to be between  7 91 and  8 71  Non GAAP EPS is expected to be between  10 65 and  10 85  The midpoint of the non GAAP EPS is approximately 2  growth year over year  as a result of increased R D spend  and an increased tax rate  compared to prior year  This guidance reflects the financial impact of our recently closed Achillion acquisition  but does not reflect any future M A that we may pursue As you can see on slide 15  we have established a track record of strong financial execution  Since 2017  we have delivered double digit total revenue and non GAAP EPS growth  while maintaining a competitive  non GAAP operating margin  We continue to invest in our R D programs and have increased our non GAAP R D spend as a percentage of revenues  to within 16  to 19   in line with our biotech peers With the current momentum of the business  we are well positioned to deliver on our 2020 financial goals I ll now turn the call over to John  to provide an update on R D John Orloff    Executive Vice President and Head of Research   DevelopmentThank you  Aradhana  On slide 17  you can see our current development portfolio  We now have 19 planned clinical stage development programs for 2020  In the coming weeks and months  we expect to report interim data from our Phase III once weekly on body subcutaneous ULTOMIRIS program  an update on our anti FcRn studies  and interim data from the Phase II study of danicopan in C3G We re excited about the acquisition of Achillion and look forward to providing additional detail in the coming months  as we embark on the integration  Just a few weeks ago  we reiterated our ambition to execute 10 launches by 2023 from our current portfolio  On slide 18  you can see our R D highlights  which summarize these programs  including stage and clinical development  and the estimated addressable population We are expanding our C5 presence well beyond the PNH and atypical HUS business  and are advancing ULTOMIRIS into five additional indications across neurology and nephrology  Together  the ULTOMIRIS programs present an opportunity to expand our treated patient population by tens of thousands of patients  We believe in the compelling value proposition of ULTOMIRIS  which has been received well by patients  physicians and other key stakeholders  and are continuing to innovate with a high those concentration  reducing infusion time to 45 minutes and a once weekly on body ULTOMIRIS subcutaneous formulation In addition to ULTOMIRIS indication expansion programs  we see opportunity to diversify our business beyond C5 with four additional late stage novel assets  Our Phase III superiority trial for ALXN1840 and Wilson s Disease remains ongoing  1840 is an oral once daily therapy  with 10 000 fold higher affinity for copper than current standard of care chelators  which have poor compliance rates  due to burdensome dosing regimens  We are on the verge of completing enrollment and expect the top line readout in the first half of next year We plan to initiate a Phase II III program for CAEL 101 in AL amyloidosis in the coming months  We see potential for this late stage asset to transform the treatment of AL amyloidosis  a disease characterized by misfolded kappa and lambda light change  resulting an abnormal deposits of amyloid  which can lead to organ failure  Patients are currently treated with a chemotherapeutic agents  not approved for amyloidosis  and median survival rates are only 18 months post diagnosis  Clinical data supporting our rationale for the collaboration  showed a 63  overall organ response rate  in addition to efficacy on cardiac and renal endpoints  Our Phase II III program will look at an overall survival primary endpoint  with patient function  quality of life cardiac imaging  serving secondary endpoints Last year  we announced a license agreement with Eidos  to develop and commercialize AG10 for ATTR cardiomyopathy in Japan  AG10 is a small molecule  designed to address destabilized and misfolded transthyretin protein  which is the root cause of ATTR  We believe AG10 has potential to stabilize TTR  and halt disease progression  Pending regulatory discussions  we plan to extend the AG10 development program into Japan later this year Finally  we are excited about our acquisition of Achillion  and in its Factor D platform  Achillion reported positive Phase II data for danicopan in PNH patients with extravascular hemolysis at a medical conference last year  We see opportunity for danicopan in the small subset of PNH patients with extravascular hemolysis  We see additional opportunity for danicopan in C3G  and expect interim Phase II data in the coming weeks  and we see great potential for ACH 5228  as twice daily best in class Factor D oral treatment in PNH  and a broad range of rare diseases We are excited about the opportunity for these 10 potential launches to significantly expand the number of treated patients  and look forward to providing you with updates  as we progress through the year Moving to slide 19  we have plans to further expand and diversify our C5 leadership  with our next generation assets  Starting on the left  our weekly subcutaneous formulation of ULTOMIRIS for use in PNH in atypical HUS is in an ongoing Phase III PK based trial  Leveraging the WestGen  Phonetic  on body device  we believe this will provide patients with the flexibility to choose how they wish to manage their disease within their lifestyle  We are expecting interim PK data in the second quarter of this year with a potential launch in 2021 Next  we have the opportunity to evolve our terminal complement subcutaneous treatment options with ALXN1720 and ALXN1810  ALXN1720 is our internally designed bi specific C5 inhibitor  At only 25 kilodaltons  ALXN1720 is a unique mini body tailor made for convenience subcutaneous administration  We see opportunity for this asset in a number of larger rare disease indications and we look to initiate a proof of concept study in the first half of next year Finally  ALXN1810 is our co formulation of ULTOMIRIS and Halozyme s PH20 hyaluronidase  which allows for bi weekly subcutaneous dosing  We recently disclosed our plans to start a Phase II renal basket trial with ALXN1810 and look forward to providing additional updates  as this program progresses  Together  these three assets represent an opportunity for Alexion to expand our offerings for patients living with complement mediated rare disease  Our development portfolio has grown significantly in the last two and a half years  and I m incredibly proud of all the hard work undertaken by the entire R D organization With that  I ll turn the call over to Brian to provide commercial highlights for the quarter  Brian Brian Goff    Executive Vice President  Chief Commercial and Global Operations OfficerThank you  John  Turning first to slide 22  we ve seen unprecedented progress    in establishing ULTOMIRIS as the market leader in PNH  This is due in large part to the compelling value proposition  which include strong data from the largest and most inclusive PNH clinical program ever conducted  The broad inclusion criteria in the two Phase III trials in shorter  Phonetic  study patient population  would be representative of the real world PNH population Specifically  we enrolled transfusion independent and transfusion dependent patients  with no baseline hemoglobin or absolute reticulocyte count requirements  We also included patients with prior history of bone marrow failure  which is critical  because roughly 40  to 50  PNH patients have a history of bone marrow failure or aplastic anemia As of Monday of this week  we ve converted 60  of PNH patients to ULTOMIRIS in the U S   62  in Germany and 53  in Japan  making ULTOMIRIS the PNH market leader in our three largest volume countries  Our latest launch of ULTOMIRIS in atypical HUS in the U S  is also off to a strong start  While it s still early days  conversion is tracking in line  with the PNH conversion curve at the same time point  since launch Our neurology business is now our largest franchise by patient volume  and this was achieved in just two years since launch  On slide 23  you can see we exited the fourth quarter with 1 885 patients on treatment with SOLIRIS for gMG and NMOSD in the U S  We ve made significant progress advancing our presence in gMG and with our NMOSD launch  gMG patients continue to have broad access to SOLIRIS  Our strong NMOSD launch is underpinned by a remarkable Phase III data  showing 98  of patients relapse free at 48 weeks  with sustained efficacy out to three years We re making progress educating payers on the severity of NMOSD attacks  the objective of preventing all relapses  and the difference between NMOSD and MS  As a result of these efforts  payer adoption of coverage policies for NMOSD has been rapid  and we re seeing strong adherence to SOLIRIS therapy in both gMG and NMOSD Looking ahead  we re well positioned to deliver on our ambition of quadrupling our U S  GMG and NMOSD treated patient population within the next five years  With potential for ULTOMIRIS to launch in late 2022 or early 2023  as an every eight week infusion Our once weekly  on body subcutaneous formulation planned to launch simultaneously with the IV formulation  will provide another important treatment option for patients  who prefer self or home based administration  Our target gMG population represents more severe uncontrolled patients  and we believe this is a unique space  where SOLIRIS and then ULTOMIRIS can serve as a highly effective treatment option  In NMOSD  our target patient population mirrors inclusion criteria in our Phase 3 SOLIRIS PREVENT trial  With our dedicated neurology team  we believe our commercial organization is well positioned to deliver on our 2025 ambitions  I d like to take a brief moment to thank both our global commercial and global operations organizations  for their hard work and dedication  which has enabled us to excel with multiple launches  and continue to bring hope to the rare disease patients we serve I ll now turn the call back to Ludwig for closing comments  Ludwig Ludwig Hantson    Chief Executive OfficerThank you  Brian  Once again  I m very proud of what the team delivered in 2019  We re well positioned to further build on our momentum in 2020  and there is much to look forward to this year  We have laid out a clear strategy  to deliver long term shareholder value  by establishing ULTOMIRIS as market leader in PNH and HUS  expanding our presence in C5  including planned programs in neurology and nephrology  and continue to look for opportunities to diversify our business beyond C5 Importantly  we maintain our unwavering focus on patients and our commitment to advance our mission to deliver life changing therapies to people living with rare diseases With that  we will now open the call to questions  Operator Questions and Answers Operator Operator Instructions   Our first question comes from Cory Kasimov of JP Morgan  Your line is open Cory Kasimov    JP Morgan    AnalystGreat  Good morning  guys  Thank you for taking the question  I guess I just want to get a better sense of the drivers behind your guidance for 2020  particularly on the top line  On the surface it looks pretty conservative  is this primarily just a function of the pricing dynamic of assuming more ULTOMIRIS patients on maintenance dosing this year  Or are there other factors that are also important behind the scenes that I m missing Ludwig Hantson    Chief Executive OfficerYeah Aradhana  The answer is  yes  you re right  But go ahead Aradhana Sarin    Executive Vice President and Chief Financial OfficerSo first of all  we had an amazing year in 2019  21  top line growth  33  EPS growth  exceeded all our conversion targets  six BD deals  so 2019 was an amazing year  On 2020  we have guided to 11  top line growth  So there are few dynamics that are going on here  First of all  we had    because we had great conversion from SOLIRIS to ULTOMIRIS in 2019  as we go into 2020  there will be an impact to revenues  due to the lower annual cost of treatment per patient  as majority of patients have now already converted  and will now go into maintenance dosing  that s on the PNH side On the atypical HUS side  we re just starting to launch ULTOMIRIS  There  we do not have the loading dose benefit  There in fact  on the first year  there is a 22  lower price per patient annual treatment cost  and in year two  there is a 33  lower treatment cost annually for the patient  As a result  that dynamic also is sort of a headwind from a revenue standpoint  This is to some extent mitigated by our neurology growth  As you know  we put out our ambition for neurology  having four times the number of patients by 2025  So we re still seeing strong neurology growth on the patient volume side  In addition  we re also seeing high single digit growth for PNH and atypical HUS patients  and our metabolics business continues to grow as well  So it s a mix of all these different factors that impact the top line On the bottom line  there are several other factors that impact the EPS guidance  As you can see  our R D spend is going up substantially  It s about a  270 million increase on a dollar basis  and it s 19 clinical programs that you ve heard about  many of which we did not have in 2018 or 2019  In addition  the R D spend also includes the spend that we will have  as a result of the close of the Achillion transaction  In addition  the R D spend includes the BD transactions that we ve already announced  and the milestones that we expect to pay for those transactions  as those programs move forward In addition  you see that the tax rate  which was on a non GAAP basis  13  in 2019 is on the midpoint  expected to be between 16  and 17  or 16 5   So that s about 350 basis points change from 2019  So those are some of the factors that impact the bottom line Cory Kasimov    JP Morgan    AnalystOkay Ludwig Hantson    Chief Executive OfficerDoes that answer your question Cory Kasimov    JP Morgan    AnalystYes it does  The color is very helpful  Thank you very much Ludwig Hantson    Chief Executive OfficerOkay  We ll take the next question  operator OperatorOur next question comes from Geoff Meacham of Bank of America  Your line is open Geoff Meacham    Bank of America    AnalystGood morning  guys  thanks for the question  I just have a couple of quick ones  For Brian   Ludwig Hantson    Chief Executive OfficerGeoff  do you just mind speaking up a little bit  its very difficult to hear you  Yeah  Is that better  Okay  let s try Geoff Meacham    Bank of America    AnalystOkay  So for Brian on ULTOMIRIS conversion  are there differences between PNH and aHUS  and down the road NMO and MG  with respect to conversion from SOLIRIS  I wasn t sure if there are nuances between the indications  or if the 70  target was broadly applicable  And then  Ludwig  just curious if there have been further dialog with    between you and Elliott  since the announcement and maybe just highlight where you see the biggest differences between    and opinion between the strategies going forward  Thank you Brian Goff    Executive Vice President  Chief Commercial and Global Operations OfficerHey Geoff  it s Brian  I ll start  On the on the conversion  first of all  your comment on  is the 70  broadly applicable to our base business of PNH and atypical HUS  the answer is yes  We have the same ambition  Of course  we ve made excellent progress on PNH and as we ve reported now in our three largest markets  with PNH  we are over the 50  mark  So ULTOMIRIS is definitively the market leader  Atypical HUS is a different dynamic in terms of conversion  because it s a more acute condition  So you have many of the patients  who will start in the inpatient setting  and they may actually start on SOLIRIS  But then  as soon as they are discharged  there is an opportunity for facilitated patient conversion to ULTOMIRIS  and part of that is  hospital formulary dynamics and part is just awareness of ULTOMIRIS availability  But again  same ambition And the other half of your question was around neurology  and I guess here you re asking about with SOLIRIS  because it s too premature to talk about ULTOMIRIS in neurology  And there are very different dynamics between gMG and NMOSD  Though we re really pleased with the progress we re making with both launches  gMG as you know is two years and counting  and in the U S   we continue to make progress in both breadth of prescribing as well as depth of prescribing In NMOSD  we began that journey in the middle part of last year  The launch is very much on track  and we gave the combined numbers of    as of the end of last year  1 885 patients  So that starting point of two years with gMG and six months plus with NMOSD  and the progress we ve made  has really fed our ambition to be at four times  within five years from now Ludwig Hantson    Chief Executive OfficerWith respect to your second question  Geoff  so we continue to have a constructive dialog with Elliott  as we have with all of our shareholders  As you know  our dialog with Elliott started in 2017 and we listened very carefully to all of you  We also believe that  we have a stock that is undervalued  especially given our strong execution in    so the management team  including the Board  believes that we have a strong strategy and that we need to continue to focus on executing that strategy  and that will create long term shareholder value  There is not much more that I can add to that  Operator  can we take the next question OperatorOur next question comes from Geoffrey Porges of SVB Leerink  Your line is open Geoffrey Porges    SVB Leerink    AnalystOkay  thanks  Couple of questions  First Aradhana  just on the guidance  so it sounds to me as though you re saying that ULTOMIRIS is going to be sort of flattish to down  because there is obviously a strong underlying trend in SOLIRIS  So if I just take the Q4 revenue run rate and carry it forward  then I get to your guidance for 2020  So it sounds as though you re telling us  that ULTOMIRIS is actually going to go down compared to the Q4 run rate  because of the dose shift  and I just want to make sure that s clear  And then another communication clarification question  your 10 launches by 2023  is that what you see being possible  or is that your strategic commitment  Meaning if some of those  which are clearly high risk such as ALS or even the Caelum program  if they fall by the wayside and the trials aren t successful  will you add other programs to ensure that you deliver 10 by 2023  I just want to understand how to think about that  Thanks Aradhana Sarin    Executive Vice President and Chief Financial OfficerSure  So I ll address the first question and then John can address the second question  So I don t think it s accurate to assume that ULTOMIRIS revenues are actually going down  We expect ULTOMIRIS revenues to still go up for a number of reasons  First of all  we ve only converted say around 60  of the market in our three major geographies  and there is still a long way to go  on the PNH side  Secondly  we just started launching ULTOMIRIS and atypical HUS  and that s a conversion dynamic that we will see Now  there is a mix of both volume as well as price  and you ve been    you can see in the appendix  the pricing dynamic  So we still expect the conversion to drive the volume and there will obviously be some price headwind  as a result of the lower annual cost per patient  That will be balanced by    on the SOLIRIS side  strong growth on the neurology franchise  as well as on the metabolic side  both of those businesses still continue to grow very well Ludwig Hantson    Chief Executive OfficerYeah  We have     170 million for the quarter  So we have a run rate of  680 million  We plan to do much better than that  Geoff  It s almost no HUS sales in 2019 and U S  is picking up and Brian was talking about the fact that the HUS conversion to ULTOMIRIS is similar to what we ve seen with PNH  which is best in class  Plus  we think that we re on a good track to get European HUS approval before mid of this year  So that will come in as Plus every month  we have another country globally that s launching ULTOMIRIS  So ULTOMIRIS is going to grow substantially And then  with respect to your question on your 10 launches John Orloff    Executive Vice President and Head of Research   DevelopmentYeah  So Geoff  Hi  Its John  I think the 10 launches is clearly our ambition  We believe it s an achievable ambition  Five of those launches are related to ULTOMIRIS  which we think is de risked  based on the data we have so far  Many of those are in disease areas where we ve already established proof of concept and mechanism  The other five relates to new assets  two of those are danicopan and Factor D  where we think we have a strong supporting data  And as you indicate  we continue to press the envelope  if you will  with regard to business development  and bringing in new assets that we think we will be able to kind of plug and play  And so we think that s    it s highly achievable  and if one or more of those fall off  then we have other opportunities as well  that we haven t really talked about  both internally  as well as potentially  through external innovation Ludwig Hantson    Chief Executive OfficerDoes that answer your questions  Geoff  Next question OperatorOur next question comes from Chris Raymond of Piper Sandler  Your line is open Christopher Raymond    Piper Sandler    AnalystThanks for taking the question  Just noticing in your slides  I guess it s slide 12 specifically  it looks like there s a lot more growth in Q4 for ULTOMIRIS in APAC or the rest of the world versus EU  Maybe just if you could talk about the assumptions you made in 2020 for Europe versus the rest of world or APAC on ULTOMIRIS  And also maybe  can you quantify any Russian biosimilar impact for ULTOMIRIS or SOLIRIS  And then maybe just a guidance question around you    just on the R D  can you maybe put some brackets around what those milestones are and maybe quantify some of that impact  Thank you Ludwig Hantson    Chief Executive OfficerYeah  maybe I start with Russia  As a matter of fact  you might know how the Russian market works  but    out of the C5 business in Russia  should you expect any ULTOMIRIS business in Russia moving forward  the answer is not really Then on your second question on APAC fourth quarter  loading Aradhana Sarin    Executive Vice President and Chief Financial OfficerYeah  So the APAC fourth quarter that you see  it s really driven by Japan  and as we launched PNH ULTOMIRIS in Japan  there was very strong uptake  We have shared numbers with you in the past  and that was the loading dose benefit that I talked about for the PNH patients given the pricing and the volume difference  So that explains the APAC numbers Ludwig Hantson    Chief Executive OfficerAnd then we have a question on the milestones Aradhana Sarin    Executive Vice President and Chief Financial OfficerYeah  we ve made public our various partnerships  both on Caelum and Affibody and Dicerna and so forth  and as those programs progress  there ll be milestones owed  I don t think we re breaking down how much is milestones versus not  And then also that  270 million increase  includes the impact of the Achillion transaction and you can estimate sort of how much that spend would be  given  we plan to progress both danicopan and 5228 forward this year Ludwig Hantson    Chief Executive OfficerOkay  we will take the next question OperatorOur next question comes from Josh Schimmer of Evercore ISI  Your line is open Josh Schimmer    Evercore    AnalystThanks for taking the question  I might have missed it  but was there any other contributing factors for the strong performance of SOLIRIS in the U S   given some of the growth drivers  but still a little bit above where I might have expected  And then for SOLIRIS in Japan  with new repricing rule  this label expansion  does the NMO indication addition    is that going to change the price point for SOLIRIS  And if so  how  Thank you Brian Goff    Executive Vice President  Chief Commercial and Global Operations OfficerHi Josh  it s Brian  With SOLIRIS in the U S   I think what you have are mostly a story around neurology  and we re really pleased with the growth that we ve had with gMG  as well as the launch of NMOSD  which again began in July  and that has progressed very nicely  We also    and this is more for SOLIRIS and ULTOMIRIS  which goes back to your earlier questions as well  In addition to all the conversion dynamics that we talk about  we continue to identify new naive patients with PNH as well as atypical HUS as well  And as we ve indicated  we see that continuing in high single digits and low double digit growth pattern  So that s feeding it additionally Ludwig Hantson    Chief Executive OfficerOkay  We ll take the next question OperatorOur next question comes from Matthew Harrison of Morgan Stanley  Your line is open Kostas Biliouris    Morgan Stanley    AnalystHi  this is Kostas on for Matthew  I have a question based on your FcRn gMG study  which is now a Phase II in second half 2020  I m wondering whether there has been any delay to the initiation of this study versus prior expectations  And a follow up question  what do you need to advance this study to the Phase III  Thank you John Orloff    Executive Vice President and Head of Research   DevelopmentYes  thank you  So we have two anti FcRn programs  One is    we have this Syntimmune acquisition  which is 1830  that s back in the clinic now  You may recall that last year  we had a CMC issue that we ve addressed  We have now have new drug product that s been delivered  We initiated with a higher concentration formulation subcutaneously to healthy volunteers that began in December  and we are reinitiating the Phase II program with the IV formulation in hemolytic anemia this quarter  which was also paused for the same reason  So we will complete those dose ranging trials and then be in a position to launch pivotal programs later this year  And with regard to myasthenia gravis  we may need to do some additional dose ranging upfront there  that would be a seamless Phase II III type of trial  And then of course progressing further with hemolytic anemia So no additional delays in the program  We re pressing ahead Ludwig Hantson    Chief Executive OfficerNext question OperatorOur next question comes from Robyn Karnauskas of SunTrust Robinson  Your line is open Robyn Karnauskas    SunTrust Robinson    AnalystHi  thanks for taking my question  Ludwig  just quickly  on the 20 000 eligible target population for MG that you ve noted  How are you thinking about that in terms of that impact to price and the ability to capture that  given the competitive landscape  And then along with that  you ve talked about  you have a way to go still with converging already at 60   with the 70  you had set out originally as a goal  How do we think about bottlenecks for conversion going forward  How quickly could that slow or just any color you could provide  so we could figure out how to model that correctly  Thank you John Orloff    Executive Vice President and Head of Research   DevelopmentHi Robyn  Let me start with the first one on the the approximately 20 000 patient addressable opportunity for ULTOMIRIS in gMG  So the way that we see the gMG market evolving is  first of all as we ve talked about many times  SOLIRIS continues to occupy a relatively  let s call it narrow segment of the larger gMG population  It s about 8 0000 patients  which are uncontrolled  more severe patients  And that really aligns with the regain pivotal Phase III study  We are not by the way  limited from a label perspective to stay in that 8 000 patients  but that has in the last two years  that has really been the sweet spot for SOLIRIS As we move into the opportunity with launch of ULTOMIRIS  based on the trial design that John and the team have put forward  we see that that space expanding such that the burden of previous IST cycles of therapy is not as high as it was for regain  and we see that opening up a larger segment for ULTOMIRIS Now  to your point about price  I mean  neurology is one aspect of price that we will continue to assess  But as we ve said  we have eight indications that we ve announced  that we re pursuing for ULTOMIRIS  And as those unfold  we have consistently said we maintain price flexibility to align the volume opportunity  with the value that ULTOMIRIS offers  and so we ll  we ll stay on that path Your second question was around the continued conversion dynamics  We still maintain the same ambition of 70  within two years of our launch markets  We are well on track with that  We ve talked with a lot of pride about the three largest markets  we have worldwide  U S   Germany  Japan  The only real bottlenecks that we see  and I wouldn t even call them bottlenecks  it s largely a function of time  is moving from so called centers of excellence of treatment with PNH  higher volume centers  as well as with the atypical HUS  to a broader customer segment  and that just takes time for us to continue to penetrate Ludwig Hantson    Chief Executive OfficerCan we take the next question  operator OperatorOur next question comes from Mohit Bansal of Citi  Your line is open Mohit Bansal    Citigroup    AnalystGreat  thanks for taking my question  So just switching toward danicopan as well as 5528 strategy  the doctors seem to like the alternative pathway a lot  and 4471 is clearly not  Indecipherable  monotherapy  But could you please help us understand  what would you want to see with 5528  in terms of profile of the drug  which could potentially make it a viable monotherapy or potentially a frontline agent  ahead of C5  Thank you John Orloff    Executive Vice President and Head of Research   DevelopmentSure  So first of all  we are committed to progressing the clinical development plans that Achillion has already communicated publicly in PNH with 4471  that s completed the Phase II data that we shared at ASH in December  and now planning to move forward with a Phase III study in PNH patients with extravascular hemolysis  At the same time  there is an ongoing Phase II study with 5228 which has better PK characteristics  It has got a longer half life  the half life being about 12 hours  and also has better activity against the alternative pathway  with more than 90  inhibition of that pathway  So we re really excited about that compound  in order to give it less frequently  and it s greater potency that allows us to expand potentially into new opportunities beyond those with the EVA  So there is a Phase II program going on now  that is looking at it  not only on top of C5 inhibition  but also as monotherapy And then I would say  lastly that we re very excited about the opportunities beyond PNH in additional disease areas  that we haven t operated in  where the alternative pathway has been implicated  and where there are exciting opportunities to treat more patients with rare disease Mohit Bansal    Citigroup    AnalystGot it  Helpful Ludwig Hantson    Chief Executive OfficerWe will take the last question OperatorAnd our last question comes from Kennen MacKay of RBC Capital Markets  Your line is open Kennen MacKay    RBC Capital Markets    AnalystHi  thanks for squeezing me in and congrats on the progress throughout 2019 and into the New Year  Maybe a question for Brian  the PNH switch execution has been beyond phenomenal in in the U S   can you maybe help us understand how we should be thinking about the pace of switching in AHUS versus PNH  given differences in presentation and disease morbidity Brian Goff    Executive Vice President  Chief Commercial and Global Operations OfficerYeah  Hey Kennen  Beyond phenomenal  I wrote that one down  so thanks a lot Kennen MacKay    RBC Capital Markets    AnalystPut that in your review Brian Goff    Executive Vice President  Chief Commercial and Global Operations OfficerThe dynamics  as I noted earlier  the dynamics between atypical HUS in PNH are different  But of course  the profile of ULTOMIRIS is the same  and we get the same compelling feedback from patients  from physicians  and certainly from payers  And in fact as Aradhana had noted  the economics on an annual cost of therapy play out even more favorably for atypical HUS with ULTOMIRIS versus SOLIRIS  So I think what we re going to see are different dynamics in terms of inpatient  outpatient starts  But the same 70  ambition and just a couple of months in the launch  we are pleased with how we re tracking  So thanks for the question Ludwig Hantson    Chief Executive OfficerOkay  perfect  Operator  I ll take it from here  I have two topics that I want to close the the meeting with  The first topic is the state of our business  The second one is an update on IP With respect to our business  I believe we have a very healthy business  We talked about the fact that we have a healthy top line growth moving forward  In    driven by volume growth  this is not about price increases  We drive our business through to volume and innovation  We believe we have a healthy R D pipeline and that s why we say we    our ambition is to launch 10 products  new indications  new formulations by 2023  and that s the way it should be for a biotech organization  Then we have an operating margin that is very attractive within our industry  We are now around the mid 50s  We come from the lower 40s  and we believe that s a very healthy operating margin space to play in  so we really feel good about all of this  and this is reflected in our guidance The second topic  as I said is IP  So I have an update  And some of you might have seen that  the U S  Patent Office has allowed a new patent for SOLIRIS  providing additional patent protection in the U S  through 2027  And the new patent covers the methods of treating PNH with SOLIRIS  which is a method of used patents  Just to remind you  we also have an existing patent covering a method of use for HUS with SOLIRIS  which expires in 2032  and none of those two patents have been challenged  Its important that you guys know all the details of what s going on in the U S  Patent Office With that  we ll close the call  Thank you for dialing in  I am really excited about the progress that we re making and hope you will enjoy the rest of your day  Thank you Operator Operator Closing Remarks  Duration  60 minutesCall participants Morgan Sanford    Director of Investor RelationsLudwig Hantson    Chief Executive OfficerAradhana Sarin    Executive Vice President and Chief Financial OfficerJohn Orloff    Executive Vice President and Head of Research   DevelopmentBrian Goff    Executive Vice President  Chief Commercial and Global Operations OfficerCory Kasimov    JP Morgan    AnalystGeoff Meacham    Bank of America    AnalystGeoffrey Porges    SVB Leerink    AnalystChristopher Raymond    Piper Sandler    AnalystJosh Schimmer    Evercore    AnalystKostas Biliouris    Morgan Stanley    AnalystRobyn Karnauskas    SunTrust Robinson    AnalystMohit Bansal    Citigroup    AnalystKennen MacKay    RBC Capital Markets    Analyst
More ALXN analysis
All earnings call transcripts",2020-01-30,The Motley Fool,https://invst.ly/pp0qt,2071982
146126,367641,ALXN,Why Earnings Season Could Be Great For Alexion  ALXN ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Alexion Pharmaceuticals  Inc    NASDAQ ALXN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Alexion is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for ALXN in this report In fact  the Most Accurate Estimate for the current quarter is currently at  2 74 per share for ALXN  compared to a broader Zacks Consensus Estimate of  2 58 per share  This suggests that analysts have very recently bumped up their estimates for ALXN  giving the stock a Zacks Earnings ESP of  5 97  heading into earnings season Alexion Pharmaceuticals  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ALXN has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Alexion  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-alexion-alxn-200502678,200502678
146127,367642,ALXN,Alexion  ALXN  Q4 Earnings Beat Estimates  Revenues Up Y Y,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   posted fourth quarter 2019 adjusted earnings of  2 71 per share  which improved 26 6  from the year ago quarter s  2 14  Earnings also beat the Zacks Consensus Estimate of  2 37 Moreover  revenues rose 22 6  year over year to  1 38 billion in the reported quarter and surpassed the Zacks Consensus Estimate of  1 32 billion  Revenues were driven by higher sales of Soliris  Strensiq  Kanuma and Ultomiris Shares of Alexion have lost 11 8  in the past year compared with the  s decline of 4 1  Revenues in DetailSoliris  for the treatment of paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   sales were up 4  year over year to  1013 1 million in the reported quarter  driven by strong volume growth Strensiq revenues were  166 8 million  up 32  year over year   Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  34 1 million  up 33  year over year  to quarterly revenues Ultomiris   ravulizumab cwvz  net product sales were  170 2 million in the reported quarter  reflecting a sequential increase of 89 3  Cost SummaryAdjusted research and development  R D  expenses were  226 7 million  up 38 2  year over year Adjusted selling  general and administrative  SG A  expenses were  340 million  up 22 3  year over year 2019 ResultsAlexion posted 2019 adjusted earnings of  10 53 per share  up 33  from the last year s figure of  7 92 The company reported sales of  4 99 billion  up 20 8  year over year 2020 GuidanceAlexion expects adjusted earnings per share of  10 65  10 85  The company projects revenues of  5 50  5 56 billion  The Zacks Consensus Estimate for earnings is pegged at  11 36 per share and for sales at  5 62 billion  Both the earnings and sales guidance fall below the estimates Combined revenues from Soliris and Ultomiris are expected to be  4 76  4 80 billion Pipeline UpdateIn November 2019  Soliris was approved for adults with anti aquaporin 4  AQP4  auto antibody positive neuromyelitis optica spectrum disorder  NMOSD  in Japan  Alexion plans to initiate a phase II III study in children and adolescents with NMOSD in the first quarter of 2020  Another phase III study on Soliris is underway for addressing children and adolescents with Generalized Myasthenia Gravis  gMG  Meanwhile  applications for the approval of Ultomiris in aHUS are under review in the EU and Japan Another phase III study of Ultomiris in children and adolescents with aHUSis underway  Also  a phase III study on Ultomiris in children and adolescents with PNH is underway Enrollment is complete  in a  single  PK based phase III study of Ultomiris  delivered subcutaneously once per week  to support registration in PNH and aHUS  Data are expected in the first half of 2020  Another phase III study of the drug for the treatment of gMG is ongoing  In December 2019  Alexion initiated a phase III study of Ultomirisin NMOSD In November and December 2019  applications for the approval of the Ultomiris100mg mL formulation were submitted in the EU and the United States  respectively  This high concentration formulation is designed to reduce infusion time by more than 50  to approximately 45 minutes  Alexion plans to file for regulatory approval of this formulation in Japan in mid 2020 In December 2019  Alexion submitted an investigational new drug application  IND  for Ultomiris in Amyotrophic Lateral Sclerosis  ALS  to the FDA  In January 2020  the company announced the planned initiation of a pivotal phase III study in the first quarter of 2020 Recent DevelopmentsEarlier this month  Alexion acquired clinical stage biopharmaceutical company Achillion Pharmaceuticals  Inc  for  930 million The acquisition adds Achillion s lead candidate danicopan  ACH 4471   currently in phase II development for C3 glomerulopathy  C3G   and ACH 5228  which is in phase II development for PNH to Alexion s pipeline    Alexion is looking to strengthen its PNH franchise with this buyout as a potential approval of danicopan will make the company a market leader in the PNH space Our TakeAlexion s earnings and sales topped estimates in the fourth quarter of 2019  With the recent label expansion of Soliris  we expect the drug to continue driving growth  Ultomiris has also gained traction   The company is also looking to expand the label of Ultomiris which should further boost sales for the company    Alexion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise    Zacks Rank   Other Key PicksAlexion currently carries a Zacks Rank  2  Buy  A few top ranked stocks in the biotech sector are BioDelivery Sciences International Inc    NASDAQ BDSI    Guardant Health Inc    NASDAQ GH   and Denali Therapeutics Inc    NASDAQ DNLI    all sporting a Zacks Rank  1  Strong Buy   You can see  BioDelivery s loss per share estimates have narrowed from 22 cents to 16 cents for 2019 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 159 38   on average Guardant s loss per share estimates have narrowed from  1 27 to 88 cents for 2019 and from  1 29 to  1 13 for 2020 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 39 21   on average Denali s loss per share estimates have narrowed from  2 04 to  2 02 for 2019 and from  2 40 to  2 39 for 2020 in the past 90 days Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-q4-earnings-beat-estimates-revenues-up-yy-200503176,200503176
146128,367643,ALXN,Alexion Pharmaceuticals  ALXN  Q4 Earnings And Revenues Top Estimates,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  came out with quarterly earnings of  2 71 per share  beating the Zacks Consensus Estimate of  2 62 per share  This compares to earnings of  2 14 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 44   A quarter ago  it was expected that this drugmaker would post earnings of  2 49 per share when it actually produced earnings of  2 79  delivering a surprise of 12 05  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Alexion  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  1 38 billion for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 1 72   This compares to year ago revenues of  1 13 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Alexion shares have lost about 1 1  since the beginning of the year versus the S P 500 s gain of 1 3  
What s Next for Alexion 
While Alexion has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Alexion was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 75 on  1 35 billion in revenues for the coming quarter and  11 36 on  5 62 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 29  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-q4-earnings-and-revenues-top-estimates-200503076,200503076
146156,367671,ALXN,ALXN Vs  QGEN  Which Stock Should Value Investors Buy Now ,opinion,"Investors interested in stocks from the Medical   Biomedical and Genetics sector have probably already heard of Alexion Pharmaceuticals  NASDAQ ALXN  and Qiagen  QGEN   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Alexion Pharmaceuticals has a Zacks Rank of  2  Buy   while Qiagen has a Zacks Rank of  4  Sell  right now  Investors should feel comfortable knowing that ALXN likely has seen a stronger improvement to its earnings outlook than QGEN has recently  But this is only part of the picture for value investors 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
ALXN currently has a forward P E ratio of 10  while QGEN has a forward P E of 24 12  We also note that ALXN has a PEG ratio of 0 72  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  QGEN currently has a PEG ratio of 2 64 
Another notable valuation metric for ALXN is its P B ratio of 2 41  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  QGEN has a P B of 3 26 
These metrics  and several others  help ALXN earn a Value grade of B  while QGEN has been given a Value grade of C 
ALXN has seen stronger estimate revision activity and sports more attractive valuation metrics than QGEN  so it seems like value investors will conclude that ALXN is the superior option right now ",2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/alxn-vs-qgen-which-stock-should-value-investors-buy-now-200500644,200500644
146157,367672,ALXN,What s In Store For IDEXX Laboratories   IDXX  Q4 Earnings ,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   is slated to report fourth quarter 2019 results on Jan 31  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 9 7   The company has trailing four quarter earnings beat of 8 9   on average Let s take a look at how things are shaping up prior to this announcement Key CatalystsIDEXX s strong earnings trajectory is expected to have sustained through the fourth quarter  courtesy of a global surge in Companion Animal Group  CAG  Diagnostic revenues Of late  the company has been generating solid organic revenues in this segment on strong contributions from consumable and reference lab as well as the growing adoption of rapid assays  and Veterinary Software  Services and Diagnostic Imaging Systems In the United States  IDEXX has been generating strong CAG Diagnostic recurring revenues  led by steady growth in reference lab  consumables and rapid assay sales  Growth in the Veterinary Software portfolio can be attributed to strength in the global catalyst install base of Cornerstone  Neo  Animana and Smart Flow systems IDEXX Laboratories  Inc  Price and EPS Surprise 
   International reference laboratory services are likely to have seen a robust fourth quarter  courtesy of the company s measures for commercial expansion  like the IDEXX 360 programs  while maintaining momentum in international markets  catalyst install bases  Through the fourth quarter  the rapid assay business is expected to have grown on the continued expansion of global SNAP Pro installed base and robust performance of its 4Dx plus franchise  Global consumable revenues are also expected to reflect strong growth for the to be reported quarter  led by increases in diagnostic test utilization and expansion of the company s installed instrument base The company earlier expected organic growth of 11 5 12  for 2019 CAG Diagnostic recurring revenues  We assume that this segment has started contributing to the company s top line from the fourth quarter The Zacks Consensus Estimate of  525 million for CAG Diagnostics fourth quarter revenues suggests a 9 6  improvement from the year ago quarter s reported figure Other FactorsThe Water Business  of late  is gaining traction from encouraging test results in the United States and the global go direct initiatives  The business witnessed 7  organic growth in the last reported quarter  driven by impressive growth in the United States  and overseas markets  This trend most likely continued in the fourth quarter The consensus mark for Water business revenues stands at  33 3 million for the to be reported quarter  implying a 9 9  increase from the year earlier quarter s reported number Strong organic revenue growth in the Livestock  Poultry and Dairy  LPD  segment  driven by solid demand for new diagnostic testing programs and increase in diagnostic testing for alternative poultry food sources  is likely to show on the company s fourth quarter results However  increased pressure on China LPD revenues in the last reported quarter is likely to have adversely impacted the company s top line during the fourth quarter                                                                                                                                                                                                       Trend in Estimate RevisionsThe Zacks Consensus Estimate for fourth quarter 2019 revenues is pegged at  599 9 million  indicating a 9 2  rise from the prior year quarter s reported figure  The same for earnings is pegged at 91 cents  suggesting a 7 1  decline from the figure reported in the year ago quarter Earnings WhispersPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  But this is not the case here as you will see below Earnings ESP  IDEXX has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP Filter Zacks Rank  It carries a Zacks Rank  3 Stocks Worth a LookHere are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season Alexion Pharmaceuticals   NASDAQ ALXN   has an Earnings ESP of  5 54  and a Zacks Rank  1  You can see  Exact Sciences Corporation   NASDAQ EXAS   has an Earnings ESP of  12 08  and a Zacks Rank of 3 NuVasive   NASDAQ NUVA   has an Earnings ESP of  0 88  and a Zacks Rank of 3 Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-idexx-laboratories-idxx-q4-earnings-200501460,200501460
146158,367673,ALXN,Epizyme Gets FDA Nod For Lead Drug In Epithelioid Sarcoma,opinion,Epizyme  Inc    NASDAQ EPZM   announced that the FDA has granted accelerated approval to lead drug Tazverik  tazemetostat  for the treatment of adults and pediatric patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma  ES  not eligible for complete resection Tazverik is a methyltransferase inhibitor  The approval was based on the overall response rate and the duration of response in a phase II study Per the company  Tazverik is now the first and only FDA approved EZH2 inhibitor as well as a treatment specifically indicated for ES patients An approval was in the cards as the Oncologic Drugs Advisory Committee  ODAC  of the FDA had voted  11 0  in favor of the benefit risk profile of the drug for the above mentioned indication in December The continued approval of Tazverik for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial  Epziyme s ongoing  global  randomized  controlled confirmatory trial assessing the combination of Tazverik and doxorubicin compared with doxorubicin plus placebo as a front line treatment for ES is underway Moreover  Epizyme will conduct certain post marketing activities which include clinical pharmacology evaluations to evaluate the effect of Tazverik on liver function and the effect of CYP3A inhibitors and inducers on the drug to inform aspects of the prescribing information  It will also expand enrollment in cohort 6 of the phase II study to at least 60 ES patients  This expansion is intended to provide more patient experience for potential future inclusion in the label The approval will significantly boost Epizyme s portfolio  which did not have any approved drug in its kitty till now Epizyme s stock has soared 176 6  in the past year against the  s decline of 3 1   Meanwhile  the company is also exploring tazemetostat in investigational clinical studies in other solid tumors and hematological malignancies  as monotherapy and combination therapy in both relapsed and front line disease settings The company also submitted a New Drug Application  NDA  to the FDA for accelerated approval of tazemetostat for the treatment of patients with relapsed or refractory follicular lymphoma  FL   both with or without EZH2 activating mutations  who have received at least two prior lines of systemic therapy Further  the company is exploring additional molecules in its novel G9a inhibitor program  Since Epizyme has limited sources for drug development  it inked collaborations with bigwigs like GlaxoSmithKline   NYSE GSK   and Roche   OTC RHHBY    among others Zacks Rank   Another Stock to ConsiderEpizyme currently carries a Zacks Rank  1  Strong Buy   Another similar ranked stock in the sector is Alexion   NASDAQ ALXN    You can see  Alexion s earnings per share estimates have increased from  10 36 to  10 42 for 2019 and from  11 10 to  11 32 for 2020 in the past 90 days Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/epizyme-gets-fda-nod-for-lead-drug-in-epithelioid-sarcoma-200501457,200501457
146159,367674,ALXN,Will Soliris  Ultomiris Drive Alexion s  ALXN  Q4 Earnings ,opinion,We expect Alexion Pharmaceuticals  Inc    NASDAQ ALXN   to surpass estimates when it reports fourth quarter 2019 results on Jan 30  before market open The company s surprise history has been impressive so far  having delivered an earnings beat in the trailing four quarters by 12 50   on average  In the last reported quarter  Alexion came up with a positive earnings surprise of 12 05  Shares of Alexion have lost 11 7  in the past year compared with the  s decline of 4 7  Let s see how things are shaping up for the quarter to be reported Factors at PlayAlexion s complement franchise consists of key growth driver Soliris  which is approved for the treatment of paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   resulting from chronic uncontrolled activation of the complement component of the immune system In August 2019  the European Commission  EC  approved Soliris for the treatment of neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive with a relapsing course of the disease  The company plans to initiate a phase III study in children and adolescents with NMOSD  Label expansion into additional indications gave Soliris easy access to a higher patient population  which in turn increased its commercial potential significantly  The drug is likely to have performed well and contributed significant revenues in fourth quarter 2019 Investors will be keen to know the sales figures of Alexion s long acting C5 complement inhibitor  Ultomiris  Notably  the drug generated sales of  89 9 million in the third quarter  leading to sequential growth  We expect sales to have further increased in the fourth quarter  In October 2019  the FDA approved the label expansion of the drug  The drug was approved for the treatment of atypical aHUS to inhibit complement mediated thrombotic microangiopathy  TMA  in adult and pediatric  aged one month or older  patients Under its metabolic franchise  Alexion markets Strensiq for the treatment of patients with pediatric onset hypophosphatasia  HPP  and Kanuma for addressing lysosomal acid lipase deficiency  LAL D   These drugs are likely to have performed well in the fourth quarter Key Developments in Q4In October 2019  Alexion announced that it reached a definitive agreement to acquire the clinical stage biopharmaceutical company  Achillion Pharmaceuticals  Inc    NASDAQ ACHN    for  930 million  The transaction is expected to close in the first half of 2020 In October 2019  Alexion announced a collaboration agreement with Stealth BioTherapeutics Corp  for a late stage therapy for mitochondrial diseases  Both companies agreed to co develop and commercialize elamipretide  which is a novel  potential first in class therapy that targets mitochondrial dysfunction  The candidate is currently being evaluated in a phase III study in patients with primary mitochondrial myopathy  PMM    We expect management to provide an update on the deal during the upcoming earnings call as investors will be keen to know the strategic benefits of the acquisition Why a Likely Earnings Beat Our proven model predicts an earnings beat for Alexion this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Alexion has an Earnings ESP of  5 97  as the Zacks Consensus Estimate is pegged at  2 58 and the Most Accurate Estimate stands at  2 74  Alexion Pharmaceuticals  Inc  Price and EPS Surprise   Zacks Rank  It currently has a Zacks Rank  1  You can see   Other Stocks That Warrant a LookHere are a few other healthcare stocks worth considering  as our model shows that these too have the right mix of elements to beat estimates this time around Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  4 45  and a Zacks Rank  3  The company is scheduled to release results on Feb 4 BioDelivery Sciences International  Inc    NASDAQ BDSI   has an Earnings ESP of  50 00  and a Zacks Rank of 1  The company is scheduled to release results on Mar 12 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained an impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7   This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/will-soliris-ultomiris-drive-alexions-alxn-q4-earnings-200501793,200501793
146186,367701,ALXN,Top Ranked Growth Stocks To Buy For January 13th,opinion,"Here are four stocks with buy ranks and strong growth characteristics for investors to consider today  January 13th Legg Mason  Inc   LM   This asset management holding company  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 1  over the last 60 days Legg Mason  Inc  Price and Consensus   Legg Mason has a PEG ratio of 0 77  compared with 1 28 for the industry  The company possesses a  of B 
Legg Mason  Inc  PEG Ratio  TTM    Alexion Pharmaceuticals  NASDAQ ALXN   Inc   ALXN   This company that develops and commercializes various therapeutic products  carries a Zacks Rank  1  Strong Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3 8  over the last 60 days 
Alexion Pharmaceuticals  Inc  Price and Consensus   Alexion has a PEG ratio of 0 70  compared with 0 84 for the industry  The company possesses a Growth Score of B 
Alexion Pharmaceuticals  Inc  PEG Ratio  TTM    Office Depot  Inc   ODP   This provider of business services and supplies  products and technology solutions to small  medium and enterprise businesses  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5 4  over the last 60 days 
Office Depot  Inc  Price and Consensus   Office Depot has a PEG ratio of 0 49  compared with 0 86 for the industry  The company possesses a Growth Score of A 
Office Depot  Inc  PEG Ratio  TTM    TopBuild Corp   BLD   This installer and distributor of insulation and building material products  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 7  over the last 60 days 
TopBuild Corp  Price and Consensus   TopBuild has a PEG ratio of 0 60  compared with 1 40 for the industry  The company possesses a Growth Score of A 
TopBuild Corp  PEG Ratio  TTM    See the 
Learn more about the      Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-growth-stocks-to-buy-for-january-13th-200498387,200498387
146187,367702,ALXN,Ultragenyx s Gene Therapy Positive In Genetic Disorder Study,opinion,Shares of Ultragenyx Pharmaceutical Inc    NASDAQ RARE   rallied 23 4  after it announced positive top line safety and efficacy data from the ongoing phase I II study of an investigational adeno associated virus  AAV  gene therapy   DTX301  DTX301 is being evaluated for the treatment of ornithine transcarbamylase  OTC  deficiency  OTC deficiency leads to the build up of excessive levels of ammonia in the blood  resulting in acute and chronic neurological deficits and other toxicities However  shares of the company have gained 10 7  in the past year against the  s decline of 1 2  The company announced positive safety and efficacy data from Cohort 3 and longer term data from Cohort 2  In Cohort 3  there were two confirmed female responders as well as a third potential male responder who required longer term follow up to confirm response status    In Cohort 2  one female patient newly demonstrated a response starting Week 52  which was confirmed at Week 78  There were nine patients dosed in the study  of which six have demonstrated a response The company expects to start the fourth cohort to evaluate prophylactic steroid administration of DTX301 in the first half of 2020  The data from the fourth cohort are expected in the second half of the year  The company expects the data from the fourth cohort to be consistent with the other cohorts The company is also in discussions with the FDA regarding a potential phase III study design for the same Other than DTX301  the gene therapy pipeline includes DTX401  for the treatment of patients with glycogen storage disease type Ia  in clinical development Moreover  the company has an agreement with Bayer   OTC BAYRY   to research  develop and commercialize AAV gene therapy DTX 201 for the treatment of hemophilia A Ultragenyx Pharmaceutical Inc  Price    Zacks Rank   Stocks to ConsiderUltragenyx is currently a Zacks Rank  3  Hold  stock A couple of better ranked stocks in the biotech sector are Alexion Pharmaceuticals Inc    NASDAQ ALXN   and Cue Biopharma Inc    NASDAQ CUE    both sporting a Zacks Rank  1  Strong Buy   You can see  Alexion s  earnings per share estimates have increased from  9 97 to  10 35 for 2019 and from  10 87 to  11 16 for 2020 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 50   on average Cue s loss per share estimates have narrowed from  1 96 to  1 72 for 2019 and from  1 35 to  1 25 for 2020 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 23 71   on average Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/ultragenyxs-gene-therapy-positive-in-genetic-disorder-study-200498351,200498351
146188,367703,ALXN,Ultragenyx Provides Preliminary Crysvita 2019 Revenues ,opinion,Ultragenyx Pharmaceutical Inc    NASDAQ RARE   reported preliminary 2019 revenues and provided 2020 revenue guidance for one of its lead drugs  Crysvita  Crysvita is an antibody targeting fibroblast growth factor 23  FGF23   approved in the United States for the treatment of X linked hypophosphatemia  XLH  in adult and pediatric patients  It is approved in the EU for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older  and adolescents with growing skeletons Shares of the company went up 6 6  following the announcement of the preliminary results  However  shares have gained 18  in the past year against the  s decline of 2 4  For 2019  Ultragenyx s preliminary total revenues were  102  104 million  The Zacks Consensus Estimate for 2019 revenues is  101 37 million  Preliminary Crysvita revenues were  86  88 million in 2019  This includes collaboration revenues in the North American profit share territory  royalty revenues in the European territory from partner Kyowa Kirin Co  Ltd  and product revenues from Crysvita in other regions For 2020  the company expects Crysvita revenues of  125  140 million  This  however  excludes the European territory royalty revenues  as Ultragenyx sold its royalty interest in Crysvita in the region to Royalty Pharma on Jan 1  2020  for  320 million The company has been in the news  lately  for several reasons The company submitted a supplemental biologics license application  sBLA  to the FDA on Dec 18  2019  for the label expansion of Crysvita  The sBLA is seeking approval for the drug for the treatment of Tumor Induced Osteomalacia  TIO   The company expects to hear back from the FDA on submission acceptance and review designation in February 2020 Meanwhile  the FDA accepted for review Ultragenyx s new drug application  NDA  for UX007 for the treatment of Long Chain Fatty Acid Oxidation Disorders  LC FAOD   The FDA set an action date of Jul 31  2020  The agency indicated that it is currently not planning to hold an advisory committee meeting to discuss the application Earlier this week  Ultragenyx announced positive top line safety and efficacy data from the ongoing phase I II study of an investigational adeno associated virus  AAV  gene therapy   DTX301  DTX301 is being evaluated for the treatment of ornithine transcarbamylase  OTC  deficiency  The company announced positive safety and efficacy data from Cohort 3 and longer term data from Cohort 2  It expects to start the fourth cohort to evaluate prophylactic steroid administration of DTX301 in the first half of 2020  The data from the fourth cohort are expected in the second half of the year The company expects to file an investigational new drug  IND  application for GTX 102 in Angelman Syndromein the first half of 2020  The company also expects to file an IND for new gene therapy  UX701  for the treatment of Wilson disease  a larger  rare  metabolic disease in the first half of 2020   Ultragenyx Pharmaceutical Inc  Price     Zacks Rank   Stocks to ConsiderUltragenyx is currently a Zacks Rank  3  Hold  stock A few better ranked stocks in the medical drugs sector are Alexion Pharmaceuticals Inc    NASDAQ ALXN    ASLAN Pharmaceuticals Ltd    NASDAQ ASLN   and Celsion Corporation   NASDAQ CLSN   all sporting a Zacks Rank  1  Strong Buy   You can see  Alexion s  earnings per share estimates have increased from  9 97 to  10 35 for 2019 and from  10 85 to  11 16 for 2020 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 50   on average ASLAN s loss per share estimates have narrowed from 69 cents to 67 cents for 2019 and from 62 cents to 61 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 24 65   on average Celsion s loss per share estimates have narrowed from  1 00 to 94 cents for 2019 and from 77 cents to 66 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 51 11   on average Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/ultragenyx-provides-preliminary-crysvita-2019-revenues-200498617,200498617
146189,367704,ALXN,Alexion Pharmaceuticals  ALXN  Dips More Than Broader Markets  What You Should Know,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  closed at  112 79 in the latest trading session  marking a  0 99  move from the prior day  This change lagged the S P 500 s daily loss of 0 15   Elsewhere  the Dow gained 0 11   while the tech heavy Nasdaq lost 0 24  
Coming into today  shares of the drugmaker had gained 2 29  in the past month  In that same time  the Medical sector gained 1 01   while the S P 500 gained 3 88  
Wall Street will be looking for positivity from ALXN as it approaches its next earnings report date  In that report  analysts expect ALXN to post earnings of  2 53 per share  This would mark year over year growth of 18 22   Meanwhile  our latest consensus estimate is calling for revenue of  1 30 billion  up 15 03  from the prior year quarter 
It is also important to note the recent changes to analyst estimates for ALXN  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  ALXN is holding a Zacks Rank of  1  Strong Buy  right now 
Digging into valuation  ALXN currently has a Forward P E ratio of 10 21  This valuation marks a discount compared to its industry s average Forward P E of 25 17 
It is also worth noting that ALXN currently has a PEG ratio of 0 73  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  ALXN s industry had an average PEG ratio of 1 61 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 80  putting it in the top 32  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-dips-more-than-broader-markets-what-you-should-know-200498796,200498796
146190,367705,ALXN,Momenta  MNTA  Provides Pipeline Updates  Stock Rallies,opinion,Shares of Momenta Pharmaceuticals Inc    NASDAQ MNTA   rallied 23 7  after it announced positive initial data from a study on M254 in immune thrombocytopenia  ITP  The multi part study has completed Part A  which evaluated the candidate in a single ascending dose  SAD  cohort of healthy volunteers and has advanced into Part B  which will evaluate the same in a SAD cohort of ITP patients Interim data from the study showed that five of six patients treated with M254 responded to the treatment and exhibited platelet counts  Based on the positive early data  Momentaexpects to increase the number of patients in Part B and plans to include a lower dose cohort  The company expects to report additional data from Part B of the study  for which the enrollment is ongoing  in the second quarter of 2020 The company also plans to commence a study of M254 in chronic inflammatory demyelinating polyneuropathy  CIDP  later in 2020 Shares of the company have skyrocketed 129 1  in the past year against the  s decline of 1 8  The company also announced that the phase II study on nipocalimab in myasthenia gravis  gMG  is now 80  enrolled  Momenta expects to report top line data from this study in the third quarter of 2020 Another phase II study  Unity  on nipocalimab in hemolytic disease of the fetus and the newborn  HDFN  is actively enrolling patients  The company expects to report top line data from this study in 2021 Another phase II III study of nipocalimab in warm autoimmune hemolytic anemia  wAIHA  is ongoing  Nipocalimab has been granted Fast Track and Orphan Drug designations by the FDA for this indication  The company expects to report top line data from this study around the end of 2021 The company also stated that it expects to initiate IND enabling studies on CD38 SIFbody candidate in 2020 The company had  545 1 million of cash  cash equivalents and marketable securities  as of Dec 31  2019 2020 GuidanceMomenta expects operating expenses for 2020 to be in the range of  220 240 million  Momenta Pharmaceuticals  Inc  Price    Zacks Rank   Stocks to ConsiderMomenta is currently a Zacks Rank  3  Hold  stock A few better ranked stocks in the biotech sector are Alexion Pharmaceuticals Inc    NASDAQ ALXN    ASLAN Pharmaceuticals Ltd    NASDAQ ASLN   and Celsion Corporation   NASDAQ CLSN    all sporting a Zacks Rank  1  Strong Buy   You can see  Alexion s earnings per share estimates have increased from  9 97 to  10 35 for 2019 and from  10 85 to  11 16 for 2020 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 50   on average ASLAN s loss per share estimates have narrowed from 69 cents to 67 cents for 2019 and from 62 cents to 61 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 24 65   on average Celsion s loss per share estimates have narrowed from  1 00 to 94 cents for 2019 and from 77 cents to 66 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 51 11   on average Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9   This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-provides-pipeline-updates-stock-rallies-200498940,200498940
146195,367710,ALXN,Amgen on hunt for acquisitions to drive growth,news,During its Q4 earnings call  Amgen  AMGN  5 2   chief Bob Bradway said his company is maintaining its attention on potential acquisitions  large and small  that represent reasonable valuations for expected growth  adding that the organization has the resources to make things happen The company is facing biosimilar encroachment on Neulasta and generic in roads on Sensipar  Both accounted for 26  of Amgen s Q4 revenues Bernstein s Ronny Gal says Alexion Pharmaceuticals  ALXN  0 2   is worth a look considering its relatively reasonable valuation and good product line fit led by Soliris  eculizumab  Now read ,2019-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-on-hunt-for-acquisitions-to-drive-growth-1763847,1763847
146213,367728,ALXN,Alexion Pharmaceuticals  ALXN  Gains But Lags Market  What You Should Know,opinion,"In the latest trading session  Alexion Pharmaceuticals  NASDAQ ALXN  closed at  106 58  marking a  0 16  move from the previous day  This change lagged the S P 500 s 0 35  gain on the day  Elsewhere  the Dow gained 0 24   while the tech heavy Nasdaq added 0 56  
Prior to today s trading  shares of the drugmaker had lost 0 94  over the past month  This has lagged the Medical sector s gain of 3 32  and the S P 500 s gain of 4 69  in that time 
Investors will be hoping for strength from ALXN as it approaches its next earnings release  The company is expected to report EPS of  2 53  up 18 22  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  1 29 billion  up 14 69  from the prior year quarter 
Investors should also note any recent changes to analyst estimates for ALXN  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 05  higher  ALXN is currently a Zacks Rank  2  Buy  
In terms of valuation  ALXN is currently trading at a Forward P E ratio of 9 4  This valuation marks a discount compared to its industry s average Forward P E of 25 18 
Investors should also note that ALXN has a PEG ratio of 0 67 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Medical   Biomedical and Genetics industry currently had an average PEG ratio of 1 66 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 57  which puts it in the top 23  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2020-01-06,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-gains-but-lags-market-what-you-should-know-200496749,200496749
146214,367729,ALXN,Incyte s Application For Pemigatinib Gets EMA s Validation,opinion,Incyte Corporation   NASDAQ INCY   announced that the European Medicines Agency  EMA  has validated its Marketing Authorization Application  MAA  for its investigational FGFR inhibitor pemigatinib to treat adult patients with locally advanced metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy  Cholangiocarcinoma is also known as bile duct cancer The marketing application in Europe was based on data from the phase II FIGHT 202 study  which evaluated the safety and efficacy of pemigatinib in the given patient population We remind investors that in November 2019  the FDA accepted and granted a priority review to the new drug application  NDA  for pemigatinib as a second line treatment of locally advanced or metastatic cholangiocarcinoma  A decision from the regulatory body is expected on May 30  2020 The NDA too was based on data from the phase II FIGHT 202 study  Results from the same showed that treatment with pemigatinib monotherapy led to an overall response rate  ORR  of 36   primary endpoint  and a median duration of response  DOR  of 7 5 months  secondary endpoint  with a median follow up of 15 months  No serious side effects were reported Shares of Incyte have increased 4 7  in the past year against its  decrease of 2 4  Cholangiocarcinoma is often diagnosed at an advanced stage when the prognosis is poor  Hence a potential approval of pemigatinib both in the United States and Europe will provide a new treatment option for patients suffering this dreadful disease and drive growth for Incyte in the future Notably  in June 2019  Incyte initiated a phase III study on pemigatinib for the first line treatment of patients with cholangiocarcinoma and FGFR2 fusions or rearrangements  The candidate is also being evaluated in a phase II study for bladder cancer We would like to remind investors that Agios Pharmaceuticals   NASDAQ AGIO   is also evaluating its leukemia drug Tibsovo in the phase III ClarIDHy study for addressing previously treated patients with IDH1 mutant cholangiocarcinoma  The company plans to file a supplemental new drug application  sNDA  to the FDA for Tibsovo to treat cholangiocarcinoma  Currently  there are no treatment options available to treat this cancer Zacks Rank   Stocks to ConsiderIncyte currently carries a Zacks Rank  4  Sell   Better ranked stocks in the biotech sector include Emergent Biosolutions Inc    NYSE EBS   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    both sporting a Zacks Rank  1  Strong Buy   You can see  Emergent s earnings estimates have moved 5 6  north for 2020 over the past 60 days Alexion s earnings estimates have been revised 0 4  upward for 2020 over the past 60 days The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/incytes-application-for-pemigatinib-gets-emas-validation-200497276,200497276
146216,367731,ALXN,Apellis   APLS  PNH Drug Betters Alexion s Soliris In Study,opinion,Apellis Pharmaceuticals  Inc  s   NASDAQ APLS   investigational therapy pegcetacoplan met the primary efficacy endpoint in a phase III head to head study  comparing it to Alexion s   NASDAQ ALXN   Soliris  eculizumab  in patients with paroxysmal nocturnal hemoglobinuria  PNH  A rare blood disorder  PNH is associated with abnormally low hemoglobin levels as the disease destroys red blood cells  Top line data from the PEGASUS study showed that patients treated with pegcetacoplan experienced a bigger increase in hemoglobin levels than those taking Soliris  Pegcetacoplan demonstrated an improvement in adjusted means of 3 8 g dL of hemoglobin at week 16  versus a 1 5 g dL decrease in the Soliris arm  thereby meeting the study s primary endpoint  The change observed in hemoglobin levels on treatment with pegcetacoplan bettered Apellis  most optimistic expectation to see 2 g dL or more change in hemoglobin  Meanwhile  the study also showed promising results in key secondary endpoints  Pegcetacoplan was non inferior to Soliris on transfusion avoidance and absolute reticulocyte count  The safety profile of pegcetacoplan was comparable to eculizumab in the study  Apellis plans to meet regulators in the first half of the year to discuss the next steps Apellis  stock shot up 28 3  on Tuesday in response to the news  The company s shares have risen 178  in the past year against 2 4  decrease registered by the  during this period Soliris  which is used to treat PNH as well as two other ultra rare disorders  made almost  3 0 billion for Alexion in the first nine months of 2020  If approved by the FDA  pegcetacoplan would be Apellis  first commercial product and should bring in significant revenues for the company  However  Alexion also markets long acting C5 complement inhibitor  Ultomiris  a follow up version of Soliris for PNH  The initial uptake of Ultomiris has been strong Alexion is also due to buy clinical stage biopharmaceutical company  Achillion Pharmaceuticals  Inc    NASDAQ ACHN   for  930 million to strengthen its PNH franchise  Achillion s danicopan is being developed in a phase II study in combination with Soliris  to treat patients with PNH  who are suboptimal responders to only Soliris  A potential approval of danicopan will make Alexion a market leader in the PNH space  Notably Amgen   NASDAQ AMGN   is developing a biosimilar of Soliris  All these drugs could pose strong competition to pegcetacoplan on approval Apellis currently carries a Zacks Rank  4  Sell  You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/apellis-apls-pnh-drug-betters-alexions-soliris-in-study-200497207,200497207
146217,367732,ALXN,Gilead  GILD  Inks License Deal With Xencor For HIV Candidate ,opinion,"Gilead Sciences  Inc    NASDAQ GILD   entered into a license agreement with clinical stage biopharmaceutical company  Xencor  Inc    NASDAQ XNCR   
Per the technology license agreement  Gilead will access Xencor s Xtend and Cytotoxic XmAb Fc technologies for developing and commercializing its candidate  GS 9722 
GS 9722 is a first in class  effector enhanced  broadly neutralizing  anti HIV antibody  which is currently in phase I 
Xencor s Xtend XmAb Fc domains enhance circulating half life by increasing binding affinity to the receptor  FcRn  Xencor s Cytotoxic XmAb Fc domain is designed to improve the immune system s elimination of tumor and other pathologic cells by antibody dependent cellular cytotoxicity  ADCC  
Per the agreement  Xencor has granted Gilead an exclusive license for GS 9722 and up to three additional anti HIV antibodies  Xencor retains the right to grant licenses for other antibodies directed to the target  Gilead will be solely responsible for the activities and costs related to research  development  regulatory and commercial activities  Xencor will receive an upfront payment and is eligible to receive milestones and royalties for the successful development and commercialization of these products 
Xencor s plug and play antibody engineering platform enables selective licensing of its Fc domain technologies to partners to improve drug candidate properties in their antibody development programs 
Gilead s stock has gained 4 3  in the past three months compared with the  s growth of 21 6  

 
The company s efforts to develop its HIV portfolio is impressive   The massive decline in sales of the HCV franchise has propelled Gilead to focus on its HIV franchise  Yescarta and other newer avenues  The rapid adoption of Biktarvy continues in the HIV space amid stiff competition from the likes of GlaxoSmithKline   NYSE GSK    Gilead s intention to foray into the inflammation market to diversify the revenue base is encouraging as well Zacks Rank   Another Stock to Consider
Gilead currently carries a Zacks Rank  2  Buy   Another similar ranked stock in the biotech space is Alexion Pharmaceuticals   NASDAQ ALXN    You can see  Earnings estimates for 2019 have increased 30 cents for Alexion in the past 90 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0  and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2020-01-09,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-inks-license-deal-with-xencor-for-hiv-candidate-200497776,200497776
146218,367733,ALXN,New Strong Buy Stocks For January 13th,opinion,"Here are 5 stocks added to the Zacks Rank  1  Strong Buy  List for today 
Arcosa  Inc   ACA   This company that manufactures and sells infrastructure related products and services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 9  over the last 60 days Arcosa  Inc  Price and Consensus
    The Meet Group  Inc   MEET   This company that operates a portfolio of mobile social entertainment applications to meet the need for human connection has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2  over the last 90 days Meet Group  Inc  The  Price and Consensus
    SYNNEX Corporation  SNX   This company that provides business process services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3 6  over the last 60 days SYNNEX Corporation Price and Consensus
    Tronox Holdings plc  TROX   This company that engages in the mining  production  and marketing of inorganic minerals and chemicals has witnessed the Zacks Consensus Estimate for its current year earnings increasing 9 8  over the last 90 days Tronox Limited Price and Consensus
    Alexion Pharmaceuticals  NASDAQ ALXN   Inc   ALXN   This company that develops and commercializes various therapeutic products has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3 8  over the last 60 days Alexion Pharmaceuticals  Inc  Price and Consensus
    You can see 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-january-13th-200498335,200498335
146232,367747,ALXN,Akari announces new Coversin data  key readouts expected next quarter,news,"Thinly traded nano cap Akari Therapeutics  NASDAQ AKTX  announces new data on lead candidate Coversin that it says underscores its differentiation 
A new highly concentrated formulation with small volume  0 3 mL  with the viscosity of water enabling more patient friendly administration 
New pharmacokinetic data supporting once weekly dosing 
A second PNH patient resistant to Alexion Pharmaceuticals   NASDAQ ALXN  Soliris  eculizumab  because of a certain genetic mutation who has been receiving Coversin for over six months has been transfusion independent for five months 
Preliminary data are expected next quarter from a Phase 2 study in bullous pemphigoid and a Phase 1 2 trial in atopic keratoconjunctivitis 
Coversin is a second generation complement inhibitor 
Previously  Akari completes mid stage study of Coversin in PNH  shares up 13  premarket  Feb  6 
Now read ",2018-11-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/akari-announces-new-coversin-data-key-readouts-expected-next-quarter-1707477,1707477
146233,367748,ALXN,DBV Technologies expands leadership team  shares up 14  premarket,news,DBV Technologies   NASDAQ DBVT  announces the following changes to its leadership team  DBV s Chief Scientific Officer  Dr  Hugh Sampson  will assume the role of interim Chief Medical Officer effective today  Dr  Sampson succeeds Dr  Lucia Septien Velez  who has decided to leave to pursue other opportunities  Dr  Sampson will lead both the scientific and medical teams and will report to Daniel Tass   CEO Julie O Neill  has been engaged effective immediately to direct all product development and process optimization at the Company  She will continue serving as a director  while overseeing the anticipated resubmission of the Viaskin Peanut BLA in children four to 11 years of age Most recently  Julie was Executive VP  Global Operations for Alexion Pharmaceuticals  NASDAQ ALXN  Alan Kerr  Senior VP  Head of Global Regulatory Affairs of DBV Technologies  will now report to the Company s CEO  Daniel Tass   effective immediately Shares are up 14  premarket  Now read ,2019-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/dbv-technologies-expands-leadership-team-shares-up-14-premarket-1736098,1736098
146246,367761,ALXN,3 Biotech Stocks Likely To Maintain Solid Momentum In 2020,opinion,It has been a roller coaster ride for the volatile biotech sector in 2019 after a disappointing run in 2018  The year started with a bang for this sector  with the announcement of the mega merger of bigwigs Bristol Myers   NYSE BMY   and Celgene  NASDAQ CELG   This significantly perked up the prices of quite a few stocks  However  these were partially offset by the overall weakness in the global market  Nevertheless  the sector has again picked up in the past couple of months  primarily owing to the recent spree of mergers and acquisitions  and positive pipeline readouts Overall  the Nasdaq Biotechnology Index has seen 23 2  growth in the past year Relatively  the biotech sector continued being riskier than the more stable  industry or the overall medical sector  as investors are mostly banking on companies with very few approved drugs in the portfolios A slowdown in mature products due to increasing competition and the rise of biosimilars forced most pharma biotech behemoths to target lucrative buyouts in the biotech space to bolster their portfolios   In particular  biotechs  both small and big   which have a dominant position in the lesser competitive arena of rare diseases  gene therapy and NASH  and are well equipped with path breaking technologies  are significant acquisition targets A slew of licensing and buyout deals was struck by most companies eyeing smaller entities with impressive pipelines  Novartis   NYSE NVS   recently announced that it will acquire The Medicines Company   NASDAQ MDCO   and add a potentially transformational investigational cholesterol lowering therapy to its portfolio Roche is finally set to acquire Spark Therapeutics after a prolonged delay  while Japanese company Astellas Pharma is taking over gene therapy company Audentes Therapeutics  Inc and has already acquired privately held  development stage biotechnology company Xyphos Biosciences  Inc to boost its immuno oncology pipeline Meanwhile  new drug approvals and label expansions of blockbuster drugs boosted investor sentiment  Key approvals include Vyondys 53  Oxbryta  Givlaari  Reblozyl  Trikafta  Inrebic  Vyleesi and Evenity  among others Choosing a biotech stock for investment can be tricky as smaller biotechs carry a risk with their product pipelines being several years away from commercialization  Nevertheless  here we zero in a few biotech companies  which have a market capitalization of more than  500 million  With a favorable Zacks Rank  2  Buy   these companies are likely to perform well in 2020   You can see  Moreover  the  industry is placed within the top 22  of the 252 Zacks ranked industries Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is a biopharmaceutical company  focused on developing and commercializing life transforming drugs for the treatment of patients with ultra rare disorders  Its blockbuster drug Soliris   approved for paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    continues to perform well  The drug s label expansion for the generalized myasthenia gravis indication has boosted sales further  The company received a significant boost with the FDA approval of its long acting C5 complement inhibitor Ultomiris for the treatment of adult patients with PNH  The approval has strengthened Alexion s PNH franchise and reduced its dependence on Soliris for growth  The company is working on the label expansion of Ultomiris and taking steps to further diversify its pipeline  which should reap returns in the long run Shares of Alexion have gained 10 2  in the past year Amarin Corporation plc    NASDAQ AMRN   focuses on developing and commercializing therapeutics to cost effectively improve cardiovascular health  The company recently obtained FDA approval for the label expansion of its key drug Vascepa  The drug is now approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction  stroke  coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride  TG  levels   150 mg dL  and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease  The label expansion should significantly boost Vascepa sales as  per estimates  millions of high risk patients in the United States could benefit from this one of a kind prescription therapy  We expect the initial uptake of the drug to be strong and boost the top line  given the market potential Amarin s shares have surged 54 5  in the past year  Cellectis   NASDAQ CLLS   is a clinical stage biopharmaceutical company  focused on developing immunotherapies based on gene edited allogeneic CAR T cells  UCART   The company is developing life changing product candidates utilizing TALEN  its proprietary gene editing technology  and PulseAgile  its pioneering electroporation system  to harness the power of the immune system to target and eradicate cancer cells  The company is striving hard to develop life saving UCART product candidates to address unmet needs for multiple cancers  including acute myeloid leukemia  AML   B cell acute lymphoblastic leukemia  B ALL   multiple myeloma  MM   Hodgkin lymphoma  HL  and non Hodgkin lymphoma  NHL  Gene therapy is set to become one of the most vital spaces with high prospects within the volatile biotech sector Cellectis  shares have gained 3 7  in a year  Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 top tickers for the entirety of 2020 These 10 are painstakingly hand picked from over 4 000 companies covered by the Zacks Rank  They are our primary picks to buy and hold ,2019-12-30,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-stocks-likely-to-maintain-solid-momentum-in-2020-200495669,200495669
146247,367762,ALXN,All You Need To Know About Alexion  ALXN  Rating Upgrade To Strong Buy,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  could be a solid choice for investors given its recent upgrade to a Zacks Rank  1  Strong Buy   This rating change essentially reflects an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
Since a changing earnings picture is a powerful factor influencing near term stock price movements  the Zacks rating system is very useful for individual investors  They may find it difficult to make decisions based on rating upgrades by Wall Street analysts  as these are mostly driven by subjective factors that are hard to see and measure in real time 
Therefore  the Zacks rating upgrade for Alexion basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
For Alexion  rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company s underlying business  And investors  appreciation of this improving business trend should push the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Alexion
For the fiscal year ending December  2019  this drugmaker is expected to earn  10 35 per share  which is a change of 30 7  from the year ago reported number 
Analysts have been steadily raising their estimates for Alexion  Over the past three months  the Zacks Consensus Estimate for the company has increased 4 2  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Alexion to a Zacks Rank  1 positions it in the top 5  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2020-01-01,Zacks Investment Research,https://www.investing.com/analysis/all-you-need-to-know-about-alexion-alxn-rating-upgrade-to-strong-buy-200495801,200495801
146248,367763,ALXN,New Strong Buy Stocks For January 2nd,opinion,"Here are 5 stocks added to the Zacks Rank  1  Strong Buy  List for today 
Builders FirstSource  Inc   BLDR   This company that manufactures and supplies building materials has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7 9  over the last 60 days Builders FirstSource  Inc  Price and Consensus
    HomeStreet  Inc   HMST   This company that provides commercial and consumer banking services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 7  over the last 60 days HomeStreet  Inc  Price and Consensus
    Alexion Pharmaceuticals  NASDAQ ALXN   Inc   ALXN   This company that develops and commercializes various therapeutic products has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4  over the last 90 days Alexion Pharmaceuticals  Inc  Price and Consensus
    ManTech International Corporation  MANT   This company that provides technology solutions and services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 3  over the last 60 days ManTech International Corporation Price and Consensus
    PCTEL  Inc   PCTI   This company that delivers performance critical telecom solutions has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7 3  over the last 60 days PCTEL  Inc  Price and Consensus
    You can see 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-01,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-january-2nd-200496010,200496010
146249,367764,ALXN,4 Reasons Why Investors Should Buy Alexion  ALXN  In 2020,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is a biopharmaceutical company  focused on developing and commercializing life transforming drugs for the treatment of patients with ultra rare disorders Here are four reasons to invest in the stock Favorable Rank   Rising Share Price  Alexion s shares have gained 7 9  in the past year compared with the  s growth of 8 7   The company sports a Zacks Rank  1  Strong Buy   You can see Blockbuster Drug Soliris Maintains Momentum  Alexion s blockbuster drug  Soliris  for the treatment of paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    maintains momentum on the back of strong volume growth  The drug is also approved for the treatment of refractory gMG in patients  who are anti acetylcholine receptor antibody positive in the United States and Europe  The growth of the drug for this indication has been strong in the United States  driven by strong patient demand  Moreover  the FDA approved the drug to treat neuromyelitis optica spectrum disorder  NMOSD   To further increase the commercial potential of the drug  Alexion is working on expanding its label into additional indications Ultomiris  Uptake Has Been Strong  To combat generic competition for Soliris  once it loses patent protection  Alexion developed a long acting C5 complement inhibitor  Ultomiris  for the treatment of adults with PNH  which consolidated its PNH franchise  The initial uptake of the drug has been strong  Meanwhile  Alexion is also working to expand Ultomiris  label  The drug was recently approved in the United States for the treatment of aHUS in adults and children one month and older Pipeline Development Efforts Encouraging  Alexion is looking to strengthen its pipeline through acquisitions and collaborations  It inked a definitive agreement to acquire a clinical stage biopharmaceutical company  Achillion Pharmaceuticals  Inc     NASDAQ ACHN   for  930 million to strengthen its PNH franchise  Achillion primarily focuses on the development of oral small molecule Factor D inhibitors to treat people with complement alternative pathway mediated rare diseases  such as PNH and C3 glomerulopathy  C3G   The acquisition will add two clinical stage candidates to Alexion s pipeline   lead candidate danicopan  ACH 4471  in phase II and ACH 5228 in phase I  A potential approval of danicopan will make the company a market leader in the PNH space The company also announced a collaboration agreement with Stealth BioTherapeutics Corp   NASDAQ MITO   for a late stage therapy for mitochondrial diseases  Both companies announced an agreement to co develop and commercialize elamipretide  a novel  potential first in class therapy that targets mitochondrial dysfunction  The candidate is currently being evaluated in a phase III study in patients with primary mitochondrial myopathy  PMM  Conclusion  With a strong portfolio of rare disease drugs and a solid pipeline  we expect the company to continue on its growth trajectory  The development of other drugs will also reduce the company s dependence on Soliris  Notably  Amgen   NASDAQ AMGN   is developing a biosimilar of Soliris 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2020-01-01,Zacks Investment Research,https://www.investing.com/analysis/4-reasons-why-investors-should-buy-alexion-alxn-in-2020-200495966,200495966
146250,367765,ALXN,Global Blood  GBT  Shares Double In A Year  Focus On Oxbryta,opinion,"Shares of Global Blood Therapeutics   NASDAQ GBT   have surged 98 7  in the past year compared with the  s growth of 8 7  

 
In November 2019  the FDA approved its lead candidate voxelotor as an oral  once daily treatment for SCD in patients aged 12 years or above  The drug will be marketed by the trade name Oxbryta  The approval comes almost three months ahead of the scheduled action date of Feb 26  2020  SCD is a chronic  inherited blood disorder that affects hemoglobin levels Following this  Oxbryta became the first approved therapy that directly inhibits sickle hemoglobin polymerization  a major cause for SCD 
The company has another pipeline candidate  inclacumab  a novel fully human monoclonal antibody against P selectin  in its portfolio  The drug is being developed as a treatment for vaso occlusive crises   VOC   in patients with SCD  The company is developing inclacumab with drug giant Roche Holding  SIX ROG  AG   OTC RHHBY   
However  Global Blood has only one approved product in its portfolio  If voxelotor does not do well  the business will be significantly affected  as inclacumab is in the early stages of development 
The company is also battling stiff competition  Novartis    NYSE NVS   drug Adakveo  crizanlizumab  was also approved by the FDA in November 2019 to reduce the frequency of VOCs  or pain crises  in adult and pediatric patients aged 16 years or above with SCD 
Zacks Rank and a Stock to Consider
Global Blood currently has a Zacks Rank  3  Hold  
Another better ranked stock in the biotech sector is Alexion Pharmaceuticals Inc    NASDAQ ALXN   sporting a Zacks Rank  1  Strong Buy   You can see  
Alexion s earnings per share estimates have increased from  1 59 to  2 03 for 2019 and from  1 22 to  1 34 for 2020 in the past 90 days 
 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-02,Zacks Investment Research,https://www.investing.com/analysis/global-blood-gbt-shares-double-in-a-year-focus-on-oxbryta-200496041,200496041
146260,367775,ALXN,Alexion s long acting PNH candidate ALXN1210 on par with Soliris in late stage study  shares up 11  premarket,news,Alexion Pharmaceuticals  NASDAQ ALXN  is up 11  premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria  PNH  The data showed ALXN1210 to be non inferior to Soliris  eculizumab  by virtue of achieving the co primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase  LDH  levels  a direct marker of complement mediated hemolysis in PNH ALXN1210 also demonstrated non inferiority to Soliris on all four key secondary endpoints Detailed results will be submitted for presentation at a future medical conference ALXN1210 is a long acting C5 inhibitor that is administered six times per year compared to 26 times per year for Soliris The company plans to file marketing applications in the U S   EU and Japan in H2 Management will host a conference call this morning at 8 30 am ET to discuss the results PNH related tickers   NASDAQ APLS  NASDAQ RARX  NASDAQ AKTX  NASDAQ ACHN  NASDAQ FBIO Now read ,2018-03-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexions-longacting-pnh-candidate-alxn1210-on-par-with-soliris-in-latestage-study-shares-up-11-premarket-1343193,1343193
146261,367776,ALXN,Alexion Pharma Q1 revenues up 7   non GAAP EPS up 22   raises revenue guidance,news,Alexion Pharmaceuticals  ALXN  Q1 results  Revenues   930 9M   7 0    Operating Income   267 4M   26 1    Net Income   249 1M   46 4    Non GAAP Net Income   380 6M   20 5    EPS   1 11   48 0    Non GAAP EPS   1 68   21 7   2018 Guidance  Revenues   3 925M   3 985M from  3 850   3 950M  Soliris revenues  3 380M   3 420M from  3 325 to 3 400M  Metabolic revenues   545M   565M from  525 to 550M  EPS   1 35   1 75 from  4 35 to 4 75  Non GAAP EPS   6 75   6 90 from  6 60 to 6 80 Shares are up 7  premarket Now read ,2018-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion-pharma-q1-revenues-up-7-nongaap-eps-up-22-raises-revenue-guidance-1416152,1416152
146271,367786,ALXN,Alexion Pharmaceuticals  ALXN  Stock Sinks As Market Gains  What You Should Know,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  closed at  109 82 in the latest trading session  marking a  1 39  move from the prior day  This move lagged the S P 500 s daily gain of 0 03   Elsewhere  the Dow gained 0 11   while the tech heavy Nasdaq added 0 1  
Coming into today  shares of the drugmaker had gained 3 15  in the past month  In that same time  the Medical sector gained 5 4   while the S P 500 gained 1 82  
Wall Street will be looking for positivity from ALXN as it approaches its next earnings report date  The company is expected to report EPS of  2 53  up 18 22  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  1 29 billion  up 14 69  from the year ago period 
ALXN s full year Zacks Consensus Estimates are calling for earnings of  10 35 per share and revenue of  4 91 billion  These results would represent year over year changes of  30 68  and  18 76   respectively 
Investors might also notice recent changes to analyst estimates for ALXN  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 07  higher within the past month  ALXN currently has a Zacks Rank of  2  Buy  
In terms of valuation  ALXN is currently trading at a Forward P E ratio of 10 76  This valuation marks a discount compared to its industry s average Forward P E of 24 59 
We can also see that ALXN currently has a PEG ratio of 0 77  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  ALXN s industry had an average PEG ratio of 1 76 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 56  putting it in the top 22  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-stock-sinks-as-market-gains-what-you-should-know-200493270,200493270
146272,367787,ALXN,Dicerna s  DRNA  A1AT Candidate Gets Orphan Drug Tag In EU,opinion,Dicerna Pharmaceuticals  Inc    NASDAQ DRNA   announced that the European Commission  EC  has granted orphan drug designation to its RNAi therapeutic DCR A1AT  currently being developed for treating congenital alpha 1 antitrypsin  A1AT  deficiency  a protein primarily produced in and released from the liver The prestigious tag for DCR A1AT was based on a positive opinion from the European Medicines Agency s  EMA  Committee for Orphan Medicinal Products  COMP   Currently  there are no approved therapies to treat A1AT deficiency associated liver disease The EMA usually grants orphan medicinal product status to drugs that target serious or life threatening conditions  which are being developed to treat  prevent or diagnose diseases or conditions affecting not more than five in 10 000 people in the region  In addition to providing Dicerna with certain benefits and incentives  this status will allow DCR A1AT to enjoy a period of market exclusivity in the EU  if approved  for the treatment of A1AT deficiency Dicerna submitted a clinical trial application to the Swedish Medical Products Agency for DCR A1AT to treat patients with A1AT deficiency associated liver disease in June 2019  The company began enrolling healthy volunteers during the fourth quarter in the phase I II study on DCR A1AT Notably  DCR A1AT is being evaluated in a phase I II study for the treatment of liver disease in patients with alpha 1 antitrypsin  A1AT  deficiency Shares of Dicerna have skyrocketed 146 5  so far this year  significantly outperforming the  increase of 8 6  Apart from DCR A1AT  Dicerna s other priority programs are DCR PHXC  which is being developed for the treatment of primary hyperoxaluria  and DCR HBVS  presently being evaluated to address chronic hepatitis B virus  HBV  infection We remind investors that Dicerna has strategic alliances with several pharma and biotech companies  such as Roche   OTC RHHBY    Eli Lilly   NYSE LLY    Alexion Pharmaceuticals   NASDAQ ALXN   and Boehringer Ingelheim International GmbH Earlier this week  Alexion exercised its option for gaining exclusive rights to two additional GalXC RNAi targets within the complement pathway  taking the number of targets to four in the existing collaboration agreement  Per the deal  Dicerna is eligible to receive a total of  20 million from Alexion Zacks RankDicerna currently carries a Zacks Rank  3  Hold   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/dicernas-drna-a1at-candidate-gets-orphan-drug-tag-in-eu-200493550,200493550
146273,367788,ALXN,ALXN Vs  HZNP  Which Stock Should Value Investors Buy Now ,opinion,"Investors interested in Medical   Biomedical and Genetics stocks are likely familiar with Alexion Pharmaceuticals  NASDAQ ALXN  and Horizon Therapeutics  HZNP   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
Alexion Pharmaceuticals has a Zacks Rank of  2  Buy   while Horizon Therapeutics has a Zacks Rank of  3  Hold  right now  The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that ALXN has an improving earnings outlook  But this is only part of the picture for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
ALXN currently has a forward P E ratio of 10 74  while HZNP has a forward P E of 19  We also note that ALXN has a PEG ratio of 0 77  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  HZNP currently has a PEG ratio of 1 78 
Another notable valuation metric for ALXN is its P B ratio of 2 37  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  HZNP has a P B of 4 27 
Based on these metrics and many more  ALXN holds a Value grade of B  while HZNP has a Value grade of C 
ALXN sticks out from HZNP in both our Zacks Rank and Style Scores models  so value investors will likely feel that ALXN is the better option right now ",2019-12-19,Zacks Investment Research,https://www.investing.com/analysis/alxn-vs-hznp-which-stock-should-value-investors-buy-now-200494131,200494131
146274,367789,ALXN,Alexion Pharmaceuticals  ALXN  Outpaces Stock Market Gains  What You Should Know,opinion,"In the latest trading session  Alexion Pharmaceuticals  NASDAQ ALXN  closed at  110 46  marking a  0 65  move from the previous day  The stock outpaced the S P 500 s daily gain of 0 09   Meanwhile  the Dow gained 0 34   and the Nasdaq  a tech heavy index  added 0 23  
Coming into today  shares of the drugmaker had gained 0 2  in the past month  In that same time  the Medical sector gained 6 06   while the S P 500 gained 3 81  
ALXN will be looking to display strength as it nears its next earnings release  On that day  ALXN is projected to report earnings of  2 53 per share  which would represent year over year growth of 18 22   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  1 29 billion  up 14 69  from the year ago period 
ALXN s full year Zacks Consensus Estimates are calling for earnings of  10 35 per share and revenue of  4 91 billion  These results would represent year over year changes of  30 68  and  18 76   respectively 
Investors should also note any recent changes to analyst estimates for ALXN  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 07  higher  ALXN is holding a Zacks Rank of  2  Buy  right now 
Digging into valuation  ALXN currently has a Forward P E ratio of 10 6  For comparison  its industry has an average Forward P E of 25 9  which means ALXN is trading at a discount to the group 
Investors should also note that ALXN has a PEG ratio of 0 76 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  ALXN s industry had an average PEG ratio of 1 78 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 62  putting it in the top 25  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-12-23,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-outpaces-stock-market-gains-what-you-should-know-200494532,200494532
146275,367790,ALXN,Incyte  INCY  Surges 44  YTD On Jakafi s Strong Performance ,opinion,Shares of biopharmaceutical company Incyte Corporation   NASDAQ INCY   have surged 43 8  in the year so far  outperforming 10 3  growth recorded by the   Incyte s lead drug Jakafi  ruxolitinib  is a first in class JAK1 JAK2 inhibitor  approved in the United States for the treatment of patients with polycythemia vera  PV   who have had an inadequate response to or are intolerant to hydroxyurea  It is also approved for treating patients with intermediate or high risk myelofibrosis  MF  including primary MF  post PV MF  and post essential thrombocythemia MF  The FDA recently approved Jakafi for the treatment of steroid refractory acute GVHD in adult and pediatric patients aged 12 years or above  This is the third indication for which the drug has been approved in the United States  The drug s performance has been stellar in the year so far  Based on the strong performance of Jakafi in the first nine months of 2019  the company upped its revenue guidance for the same Incyte is working to expand the drug s label into additional indications  which should further boost sales Incyte s efforts to develop its pipeline are highly encouraging  The company has elected to not participate in the development of baricitinib with Eli Lilly   NYSE LLY   in order to reallocate capital over time to other promising internal projects  The company has some very encouraging candidates  including pemigatinib  itacitinib and capmatinib in its pipeline Incyte submitted an NDA to the FDA for pemigatinib seeking approval as a second line treatment for patients with FGFR2 translocated cholangiocarcinoma under Breakthrough Therapy designation  The FDA has accepted the same  With the FDA granting priority review to the NDA  a decision from the regulatory body is expected on May 30  2020  Incyte is evaluating itacitinib in patients with treatment na ve GVHD in the GRAVITAS program Top line results from GRAVITAS 301  the phase III study of itacitinib as a treatment for patients with newly diagnosed acute GVHD  are expected shortly Capmatinib is being developed in collaboration with Novartis   NYSE NVS   for non small cell lung cancer  NSCLC  with MET exon 14 skipping mutations  In June 2019  the FDA granted Breakthrough Therapy designation to capmatinib as a treatment for patients with metastatic NSCLC harboring MET exon 14 skipping mutation with disease progression on or after platinum based chemotherapy Hence  we expect the company to maintain momentum in 2020 backed by solid growth in Jakafi and encouraging pipeline progress  Zacks Rank   Another Stock to ConsiderIncyte currently carries a Zacks Rank  2  Buy   Another top ranked stock in the biotech sector is Alexion Pharmaceuticals   NASDAQ ALXN    which carries a Zacks Rank  2  You can see  Earnings estimates for 2019 have increased by 40 cents for Alexion in the past 90 days 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-25,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-surges-44-ytd-on-jakafis-strong-performance-200494932,200494932
146276,367791,ALXN,Gilead  GILD  Partners With Eisai For RA Candidate In Japan,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced that it has entered into an agreement with Eisai Co   Ltd for the distribution and co promotion of its investigational  oral  selective JAK1 inhibitor  filgotinib  in Japan  The deal is pending approval The candidate is being evaluated for the treatment of rheumatoid arthritis  RA  Per the terms of the deal  Gilead Japan will retain the responsibility of manufacturing and marketing approval of filgotinib  while Eisai will be in charge of product distribution in Japan in RA and other potential future indications  Both the companies will jointly commercialize the drug  if approved We note that filgotinib demonstrated durable efficacy and safety results across multiple RA patient populations  This includes patients with prior inadequate response to methotrexate treatment  MTX   those who were intolerant to one or more biologic treatments and those who were MTX treatment na ve in phase III FINCH studies Per estimates  approximately 600 000 to 1 million patients are living with RA across Japan Earlier in the month  Gilead submitted a New Drug Application  NDA  for filgotinib to the FDA  A priority review voucher was submitted with the NDA  which will shorten the anticipated time for review Gilead and partner Galapagos NV   NASDAQ GLPG   already have a global collaboration for the development and commercialization of filgotinib in inflammatory indications Global studies investigating filgotinib in additional indications are also underway  including the phase III SELECTION study in ulcerative colitis  the DIVERSITY phase III study in Crohn s disease  the phase III PENGUIN studies in psoriatic arthritis and phase II studies in uveitis and in small bowel and fistulizing Crohn s disease The European Medicines Agency has also accepted the marketing authorization application for filgotinib as a treatment for RA Gilead s stock has gained 6 6  in the year so far compared with the  s growth of 10 3  The massive decline in sales of the HCV franchise has propelled the company to focus on its HIV franchise  Yescarta  and in other newer avenues  The rapid adoption of Biktarvy continues in the HIV space amid stiff competition from the likes of GlaxoSmithKline   NYSE GSK    Gilead s intent to foray into the inflammation market to diversify the revenue base is encouraging as well Zacks Rank   A Stock to ConsiderGilead currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech space is Alexion Pharmaceuticals   NASDAQ ALXN    which has a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Earnings estimates for 2019 have increased by 40 cents for Alexion in the past 90 days 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-25,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-partners-with-eisai-for-ra-candidate-in-japan-200494955,200494955
146278,367793,ALXN,Foundation Medicine reports preliminary 2017 results,news,Foundation        Medicine  NASDAQ FMI  announces preliminary total       revenue of   48 9M for Q4 2017 and   152 9M for FY2017  representing a 70  and 31  increase from Q4 2016 and FY2016  respectively  Revenue from biopharmaceutical companies is expected to be   33 4M in Q4 and   99 7M for FY2017  Clinical testing revenues of   15 5M and   53 1M in Q4 and FY2017  respectively  Molecular Information Services revenue of   37 4M and   117 1M in Q4 and FY2017  respectively Pharma R D Services revenue of   11 5M and   35 8M in Q4 and FY2017  respectively The company reported 6 206 tests to biopharmaceutical customers and 20 044 clinical tests to ordering physicians in Q4  A total of 67 375 clinical tests were reported for FY2017  an increase of 54  over FY2016  The Company will also present at the 36th Annual J P        Morgan Healthcare Conference on Monday  January 8 at 3 30 p m        PST  in San Francisco  Now read ,2018-01-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/foundation-medicine-reports-preliminary-2017-results-1074848,1074848
146279,367794,ALXN,Oramed to launch study of ORMD 0801 in NASH this year,news,In a letter to shareholders  Oramed Pharmaceuticals  NASDAQ ORMP  CEO Nadav Kidron says the company has   40M in quick assets to start the year  Key expected milestones ORMD 0801  oral insulin   Initiate studies in HbA1c and NASH ORMD 0901  oral GLP 1 analog   File IND followed by Phase 1 pharmacokinetic study and initiation of Phase 2 Initiate Leptin study and continue to work with Chinese partner HTIT as it prepares to market ORMD 0801 in China Continue Big Pharma collaboration Now read ,2018-01-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/oramed-to-launch-study-of-ormd0801-in-nash-this-year-1125300,1125300
146280,367795,ALXN,UroGen prices stock offering at  41  shares off 1  premarket,news,UroGen Pharma  NASDAQ URGN  prices its public offering of 1 463 414 shares of common stock at  41 per share yielding gross proceeds of   60M  Underwriters over allotment is an additional 219 512 shares  Closing date is January 23 Yesterday s close was  42 46  Shares are down 1  premarket on light volume Now read ,2018-01-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/urogen-prices-stock-offering-at-41-shares-off-1-premarket-1125297,1125297
146281,367796,ALXN,Dar  Bioscience up 37  premarket on license deal for FSAD candidate,news,Thinly traded nano cap Dar  Bioscience  NASDAQ DARE  is up 37  premarket on increased volume in apparent response to its announcement that it has licensed a topical cream  SST 6007  from Strategic Science   Technologies for the potential treatment of women with female sexual arousal disorder  FSAD  The active ingredient in SST 6007 is sildenafil  the active ingredient in  Pfizer   NYSE PFE  s Viagra SST 6607 demonstrated an increase in blood flow to vaginal tissue in a Phase 2 study in women with FSAD  The company plans to pursue U S  approval via the abbreviated 505 b  2  pathway which allows the inclusion of data generated by others Now read ,2018-02-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/dare-bioscience-up-37-premarket-on-license-deal-for-fsad-candidate-1231778,1231778
146300,367815,ALXN,Adopt Rising P E Technique With These 5 Top Ranked Stocks,opinion,"With key U S  equity indexes hovering around all time highs  investors  search for stocks with a low price to earnings  P E  ratio is understandable 
The idea is that the lower the P E  the higher will be the value of the stock  The simple logic that a stock s current market price does not justify  is not equivalent to  its higher earnings and therefore has room to run explains investors  inclination toward low P E stocks 
But stocks with a rising P E can be equally worth buying  We ll tell you why 
Why Rising P E a Valuable Tool 
Investors should note that stock price moves in tandem with earnings performance  If earnings come in stronger  the price of a stock shoots up  Solid quarterly earnings and the forward guidance boost earnings forecasts  leading to stronger demand for the stock and an uptrend in its price  So  if the price is rising steadily  it means that investors are assured of the stock s fundamental strength and expect some strong positives out of it 
Also  studies have revealed that stocks have seen their P E ratios jump over 100  from their breakout point in the cycle  So  if you can pick stocks early in their breakout cycle  you can end up seeing considerable gains 
The Winning Strategy
In order to shortlist stocks that are exhibiting an increasing P E  we chose the following as our primary screening parameters 
EPS growth estimate for the current year is greater than or equal to last year s actual growth
Percentage change in last year EPS should be greater than or equal to zero
 These two criteria point to flat earnings or a growth trend over the years  
Percentage change in price over four weeks greater than the percentage change in price over 12 weeks
Percentage change in price over 12 weeks greater than percentage change in price over 24 weeks
 These two criteria show that price of the stock is increasing consistently over the said time frames  
Percentage price change for four weeks relative to the S P 500 greater than the percentage price change for 12 weeks relative to the S P 500
Percentage price change for 12 weeks relative to the S P 500 greater than the percentage price change for 24 weeks relative to the S P 500
 Here  the case for consistent price gains gets even stronger as it displays percentage price changes relative to the S P 500  
Percentage price change for 12 weeks is 20  higher than or equal to the percentage price change for 24 weeks  but it should not exceed 100 
 A 20  increase in the price of a stock from the breakout point gives cues of an impending uptrend  But a jump of over 100  indicates that there is limited scope for further upside and that the stock might be due for a reversal  
In addition  we place a few other criteria that lead us to some likely outperformers 
Zacks Rank less than or equal to 2  Only companies with a Zacks Rank  1  Strong Buy  or 2  Buy  can get through 
Average 20 day Volume greater than or equal to 50 000  High trading volume implies that the stocks have adequate liquidity 
Just these few factors narrowed down the universe from over 7 700 stocks to 54 
Here are five of 54 stocks that passed the screen 
Alexion Pharmaceuticals Inc    NASDAQ ALXN    Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life transforming drugs  for the treatment of patients with ultra rare disorders  It belongs to a favorable Zacks industry  placed at the top 23  of 250  industries  and carries a Zacks Rank  2  You can see  
OpGen Inc    NASDAQ OPGN    This Zacks  2 Ranked company is a microbial genetics analysis company  It offers optical mapping services for analysis of microbial  yeast and fungal genomic architecture  It comes from a favorable Zacks industry  top 39   
Integer Holdings Corporation   NYSE ITGR    The company manufactures and develops medical devices and components primarily for original equipment manufacturers  OEMs   which depend on it to design  develop and produce intellectual property protected medical device technologies  The company belongs to a favorable Zacks industry  top 36   and carries a Zacks Rank  2 
ReWalk Robotics Ltd   NASDAQ RWLK    This is a developer  manufacturer and marketer of wearable robotic exoskeletons for individuals with spinal cord injury  It comes from a favorable Zacks industry  top 36   and carries a Zacks Rank  2 
Civeo Corporation   NYSE CVEO    The company is a provider of long term and temporary remote site accommodations  logistics and facility management services 
You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge 
The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 
Disclosure  Performance information for Zacks  portfolios and strategies are available at   ",2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/adopt-rising-pe-technique-with-these-5-topranked-stocks-200490216,200490216
146301,367816,ALXN,Zacks com Featured Highlights Include  Alexion Pharmaceuticals  OpGen  Integer  ReWalk Robotics And Civeo,opinion,For Immediate ReleaseChicago  IL   December 6  2019   Stocks in this week s article are Alexion Pharmaceuticals Inc    NASDAQ ALXN    OpGen Inc    NASDAQ OPGN    Integer Holdings Corp    NYSE ITGR    ReWalk Robotics Ltd    NASDAQ RWLK   and Civeo Corp    NYSE CVEO   Adopt Rising P E Technique with These 5 Top Ranked StocksWith key U S  equity indexes hovering around all time highs  investors  search for stocks with a low price to earnings  P E  ratio is understandable The idea is that the lower the P E  the higher will be the value of the stock  The simple logic that a stock s current market price does not justify  is not equivalent to  its higher earnings and therefore has room to run explains investors  inclination toward low P E stocks But stocks with a rising P E can be equally worth buying  We ll tell you why Why Rising P E a Valuable Tool Investors should note that stock price moves in tandem with earnings performance  If earnings come in stronger  the price of a stock shoots up  Solid quarterly earnings and the forward guidance boost earnings forecasts  leading to stronger demand for the stock and an uptrend in its price  So  if the price is rising steadily  it means that investors are assured of the stock s fundamental strength and expect some strong positives out of it Also  studies have revealed that stocks have seen their P E ratios jump over 100  from their breakout point in the cycle  So  if you can pick stocks early in their breakout cycle  you can end up seeing considerable gains For the rest of this Screen of the Week article please visit Zacks com at  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-alexion-pharmaceuticals-opgen-integer-rewalk-robotics-and-civeo-200490697,200490697
146302,367817,ALXN,Top Ranked Growth Stocks To Buy For December 16th,opinion,Here are four stocks with buy ranks and strong growth characteristics for investors to consider today  December 16th D R  Horton  Inc   DHI   This homebuilding company  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6 5  over the last 60 days D R  Horton  Inc  Price and Consensus   D R  Horton has a PEG ratio of 0 95 compared with 1 49 for the industry  The company possesses a  of A D R  Horton  Inc  PEG Ratio  TTM    Callaway Golf Company  ELY   This company that designs  manufactures  and sells golf clubs  golf balls  golf bags  and other golf related accessories  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4 7  over the last 60 days Callaway Golf Company Price and Consensus   Callaway Golf has a PEG ratio of 0 75  compared with 1 22 for the industry  The company possesses a Growth Score of A Callaway Golf Company PEG Ratio  TTM    Legg Mason  Inc   LM   This asset management holding company company  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7 1  over the last 60 days Legg Mason  Inc  Price and Consensus   Legg Mason has a PEG ratio of 0 86  compared with 1 53 for the industry  The company possesses a Growth Score of B Legg Mason  Inc  PEG Ratio  TTM    Alexion Pharmaceuticals  NASDAQ ALXN   Inc   ALXN   This company that develops and commercializes various therapeutic products  carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3 8  over the last 60 days Alexion Pharmaceuticals  Inc  Price and Consensus   Alexion Pharmaceuticals has a PEG ratio of 0 76  compared with 0 77 for the industry  The company possesses a Growth Score of B Alexion Pharmaceuticals  Inc  PEG Ratio  TTM    See the Learn more about the Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-15,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-growth-stocks-to-buy-for-december-16th-200492914,200492914
146303,367818,ALXN,3 Reasons Why Alexion  ALXN  Is A Great Growth Stock,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a growth stock that can live up to its true potential can be a tough task 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Alexion Pharmaceuticals  NASDAQ ALXN  is one such stock that our proprietary system currently recommends  The company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
While there are numerous reasons why the stock of this drugmaker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 17 7   investors should actually focus on the projected growth  The company s EPS is expected to grow 30 7  this year  crushing the industry average  which calls for EPS growth of 12 8  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Alexion is 20 3   which is higher than many of its peers  In fact  the rate compares to the industry average of 19 7  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 26 9  over the past 3 5 years versus the industry average of 8 5  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Alexion have been revising upward  The Zacks Consensus Estimate for the current year has surged 0 1  over the past month 
Bottom Line
Alexion has not only earned a Growth Score of B based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination positions Alexion well for outperformance  so growth investors may want to bet on it ",2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-alexion-alxn-is-a-great-growth-stock-200493202,200493202
146304,367819,ALXN,Premarket analyst action   healthcare,news,Ligand Pharmaceuticals   NASDAQ LGND  initiated with Buy rating and  150 price target  Shares up 1  premarket Zealand Pharma  Pending ZEAL  initiated with Overweight rating and  28 price target by  Morgan Stanley   NYSE MS   Initiated with Buy rating and  28 price target by Guggenheim  Initiated with Buy rating and  26 price target by Needham  Shares up 2  premarket Alexion Pharmaceuticals  NASDAQ ALXN  upgraded to Overweight with a  175 price target by JPMorgan  NYSE JPM   Shares up 1  premarket Sabra Health  NASDAQ SBRA  upgraded to Market Perform with a  23 price target by JMP Securities XOMA  NASDAQ XOMA  upgraded to Outperform with a  19 price target by Wedbush  Shares up 9  premarket Now read ,2017-09-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-525560,525560
146305,367820,ALXN,Alexion confirms move to Boston  20  cut in workforce  shares up 2  premarket,news,"Alexion Pharmaceuticals  NASDAQ ALXN  plans to realign and refocus its organization aimed at lowering operating costs and boosting productivity  The company says the initiative  which includes a 20  downsizing in headcount  should save  270M in annual operating expenses by 2019 
It intends to reinvest   100M per year in R D 
Corporate headquarters will be moved to Boston by mid 2018 while its 450 employee Research Center of Excellence will be based in New Haven  CT 
Management expects to record pretax charges of  340M   440M related to the plan  half of which will be cash outlays 
2017 revenue and non GAAP EPS guidance remain as is  GAAP EPS guidance will be negatively impacted 
Shares are up 2  premarket on light volume 
Now read ",2017-09-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion-confirms-move-to-boston-20-cut-in-workforce-shares-up-2-premarket-527854,527854
146306,367821,ALXN,Premarket Gainers as of 9 05 am,news,"RCON  44  on providing chemical compound agents and microbiological treatment agents and relevant services for oily sewage treatments to Qinghai Oilfield Company 
HMNY  20  on growth of MoviePass 
PTIE  14  on the completion of a Phase I clinical study for PTI 125 
CRIS  8  on positive analyst action 
GPK  8  on transformational deal with International Paper  NYSE IP  
PII  6  on Q3 result 
ZYNE  6  
CAT  6  on Q3 result 
DRYS  5  
ALXN  5  as FDA approved expanded use of Alexion s Soliris 
VKTX  5  as VK2809 shows positive effect in NASH model 
Now read ",2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-gainers-as-of-905-am-546587,546587
146307,367822,ALXN,Alexion Pharma Q3 revenues up 8   non GAAP EPS up 17   updates guidance,news,Alexion Pharmaceuticals  ALXN  Q3 results  Revenues   859M   7 5    Operating Income   80M   55 3    Net Income   78M   17 0    EPS   0 35   16 7    Non GAAP EPS   1 44   17 1    Quick Assets   1 529M   18 3   2017 Guidance  Revenues   3 475   3 525M from  3 450B   3 525B  Soliris sales   3 090 to 3 125M from  3 075B   3 125B  EPS   2 00 to 2 35 from  2 82   3 12  Non GAAP EPS   5 50 to  5 65 from  5 40   5 55 Shares are down a fraction premarket on light volume ,2017-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion-pharma-q3-revenues-up-8-nongaap-eps-up-17-updates-guidance-548433,548433
146308,367823,ALXN,Premarket analyst action   healthcare,news,Spectrum Pharmaceuticals   NASDAQ SPPI  initiated with Buy rating and  26  37  upside  price target by B  Riley FBR citing expected revenue of  125M   130M through 2019 from oncology products and upside from Rolontis and poziotinib starting in 2020  Shares are up 3  premarket on light volume Fate Therapeutics  NASDAQ FATE  initiated with Overweight rating and  10  138  upside  price target by Piper Jaffray  Pacira Pharmaceuticals   NASDAQ PCRX  initiated with Neutral rating and  47  7  upside  price target by JPMorgan  NYSE JPM  Alexion Pharmaceuticals  NASDAQ ALXN  upgraded to Outperform with a  150  30  upside  price target by Robert Baird citing strong Siliris demand and label expansion  Shares are up 3  premarket on light volume Teva Pharmaceutical Industries  NYSE TEVA  upgraded to Outperform with a  21  13  upside  price target by I B I Now read ,2017-12-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1003497,1003497
146320,367835,ALXN,Alexion  ALXN  Up 10   YTD On Soliris   Ultomiris Strength,opinion,Shares of Alexion Pharmaceuticals  Inc    NASDAQ ALXN   have gained 10  in the year so far compared with the  s growth of 1 4   The going has been good for this biotech  which primarily focuses on developing and commercializing drugs for the treatment of patients with ultra rare disorders Alexion recently came out with strong results for the third quarter of 2019  wherein it beat earnings and sales estimates  and raised its annual guidance Lead drug Soliris  for the treatment of paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   maintains momentum on the back of strong volume growth  The drug is also approved for the treatment of refractory gMG in patients  Additionally  the FDA approved the drug to treat neuromyelitis optica spectrum disorder  NMOSD  Moreover  to combat generic competition for Soliris  once it loses patent protection  Alexion developed a long acting C5 complement inhibitor  Ultomiris  for the treatment of adults with PNH  which consolidated its PNH franchise  The initial uptake of the drug has been strong and it recorded sales of  168 7 million in the first nine months of 2019  Meanwhile  Alexion is also working to expand Ultomiris  label  The drug was recently approved in the United States for the treatment of aHUS in adults and children one month and older  The label expansion of the drug into additional indications will boost sales further Concurrently  Alexion is looking to strengthen its pipeline with acquisitions and collaborations  Last month  it entered a definitive agreement to acquire a clinical stage biopharmaceutical company  Achillion Pharmaceuticals  Inc    NASDAQ ACHN    for  930 million to strengthen its PNH franchise  Achillion primarily focuses on the development of oral small molecule Factor D inhibitors to treat people with complement alternative pathway mediated rare diseases  such as PNH and C3 glomerulopathy  C3G   The acquisition will add two clinical stage candidates to Alexion s pipeline   lead candidate  danicopan  ACH 4471   in phase II and ACH 5228 in phase I  A potential approval of danicopan will make the company a market leader in the PNH space  The company also announced a collaboration agreement with Stealth BioTherapeutics Corp   NASDAQ MITO   for a late stage therapy for mitochondrial diseases  Both companies announced an agreement to co develop and commercialize elamipretide  a novel  potential first in class therapy that targets mitochondrial dysfunction  The candidate is currently being evaluated in a phase III study in patients with primary mitochondrial myopathy  PMM  The development of other drugs will also reduce the company s dependence on Soliris  Notably  Amgen   NASDAQ AMGN   is developing a biosimilar of Soliris Nevertheless  with a strong portfolio of rare disease drugs and a solid pipeline  we expect the company to continue on its growth trajectory Alexion currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-13,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-up-10--ytd-on-soliris--ultomiris-strength-200485287,200485287
146322,367837,ALXN,Zacks com Featured Highlights Include  Avinger  Alexion Pharmaceuticals  CyberArk Software  Organovo And Qualys,opinion,"For Immediate Release
Chicago  IL   November 18  2019   Stocks in this week s article are Avinger Inc    NASDAQ AVGR    Alexion Pharmaceuticals Inc    NASDAQ ALXN    CyberArk Software Ltd    NASDAQ CYBR    Organovo Holdings Inc    NASDAQ ONVO   and Qualys Inc    NASDAQ QLYS   
What Bargain Hunting  Tap These 5 Stocks with Rising P Es
Bargain hunting or looking for stocks with a low price to earnings  P E  ratio is among the widely used investing strategies  Investors believe that the lower the P E  the higher will be the value of the stock  The logic is simple   a stock s current market price does not justify its higher earnings and therefore leaves room for upside 
But there is more to this whole P E story as not only low P E  stocks with a rising P E can also fetch solid returns 
Rising P E  An Useful Tool
Generally  the price of a stock rallies on a rise in earnings  As forecasts for expected earnings move higher  demand for the stock should drive its price  After all  astock s P E gives an indication of how much investors are ready to shell out for every dollar of earnings  Thus  if the P E of a stock is rising steadily  it means that investors are pinning their hopes on the company s inherent strength 
Also  studies have revealed that stocks have seen their P E ratios jump over 100  from their breakout point in the cycle  So  if you can pick stocks early in their breakout cycle  you can end up seeing considerable gains 
For the rest of this Screen of the Week article please visit Zacks com at 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 
About Screen of the Week
Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use 
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  
Follow us on Twitter   
Join us on Facebook  NASDAQ FB    
Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 
Contact  Jim Giaquinto
Company  Zacks com
Phone  312 265 9268
Email  
Visit  
Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-11-17,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-avinger-alexion-pharmaceuticals-cyberark-software-organovo-and-qualys-200486094,200486094
146323,367838,ALXN,Alexion  ALXN  Up 3 3  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Alexion Pharmaceuticals  NASDAQ ALXN   Shares have added about 3 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Alexion due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Alexion Beats on Q3 Earnings  Raises ViewAlexion posted third quarter 2019 adjusted earnings of  2 79 per share  which surged 38  from the year ago quarter s  2 02  Earnings also beat the Zacks Consensus Estimate of  2 49 Moreover  revenues rose 23  year over year to  1 26 billion in the reported quarter and also surpassed the Zacks Consensus Estimate of  1 24 billion  Revenues were driven by increased sales of Soliris  Strensiq  Kanuma and the uptake of Ultomiris Revenues in DetailSoliris  for the treatment of paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   sales were up 12  year over year to  990 5 million in the reported quarter  driven by strong volume growth Strensiq revenues were  154 3 million  up 36  year over year   driven by strong volume growth  Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  28 4 million  up 12  year over year  to quarterly revenues Ultomiris   ravulizumab cwvz  net product sales were  89 9 million in the reported quarter  reflecting a sequential increase of 65 9  Cost SummaryAdjusted research and development  R D  expenses were  186 1 million  up 14 6  year over year Adjusted selling  general and administrative  SG A  expenses were  260 4 million  up 16  year over year 2019 GuidanceAlexion raised its revenue and earnings view for 2019  The company expects adjusted earnings per share to be  10 25  10 40  up from the previous guidance of  9 65  9 85  Alexion projects revenues of  4 86  4 89 billion  up from the prior outlook of  4 75  4 80 billion  The Zacks Consensus Estimate for earnings is pegged at  9 97 and for sales at  4 85 billion Combined revenues from Soliris and Ultomiris are expected to be  4 18  4 20 billion  up from  4 10  4 13 billion guided previously Pipeline UpdateIn August 2019  the European Commission  EC  approved Soliris for the treatment of neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive with a relapsing course of the disease Alexion plans to initiate a phase III study in children and adolescents with NMOSD by the end of 2019  Another phase III study on Soliris is also underway for addressing children and adolescents with Generalized Myasthenia Gravis  gMG  Earlier this month  the FDA approved a label expansion of Alexion s long acting C5 complement inhibitor Ultomiris  ravulizumab cwvz   The drug has been approved for the treatment of aHUS to inhibit complement mediated thrombotic microangiopathy  TMA  for adult and pediatric  aged one month or older  patients Meanwhile  aphase III study of Ultomiris in children and adolescents with aHUS is ongoing  Another late stage study of Ultomiris in children and adolescents with PNH is also underway A single  PK based phase III study of Ultomiris delivered subcutaneously once per week is currently underway to support registration in PNH and aHUS  Data are expected in the first half of 2020  Another phase III study of the drug for the treatment of generalized myasthenia gravis  gMG  is also currently ongoing  
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended upward during the past month 
VGM Scores
At this time  Alexion has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with a D  However  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision has been net zero  It comes with little surprise Alexion has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-up-33-since-last-earnings-report-can-it-continue-200487782,200487782
146325,367840,ALXN,Alexion probed by HHS inspector general  shares slide 5 ,news,At the moment  it s just a headline  More details as they come in    ALXN  4 9 Update at 3 35 ET  There is an  open and ongoing investigation  into Alexion  says the HHS s Office of Inspector General  responding to a records request  reports Bloomberg Alexion previously disclosed an SEC DOJ investigation over possible violation of the Foreign Corrupt Practices Act Shares are down 3 6  at the moment Now read ,2017-07-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion-probed-by-hhs-inspector-general;-shares-slide-5-502927,502927
146326,367841,ALXN,Alexion exits FOP discovery program with Blueprint,news,Blueprint Medicines  NASDAQ BPMC  announces that it has received written notification from Alexion Pharmaceuticals  NASDAQ ALXN  that it will terminate their collaboration  inked in March 2015  aimed at advancing therapeutic candidates in fibrodysplasia ossificans progressiva  FOP   an ultra rare connective tissue disorder  Alexion decided to exit the partnership after it completed a strategic review of its business and R D portfolio Blueprint says it has sufficient resources to fund operations into H2 2019 Now read ,2017-07-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion-exits-fop-discovery-program-with-blueprint-510993,510993
146327,367842,ALXN,Titan Pharma secures  10M debt facility from Horizon Tech,news,Titan Pharmaceuticals  NASDAQ TTNP  inks a venture loan and security agreement with Horizon Technology Finance Corp  that provides it with up the  10M in borrowing capacity  A first tranche of  7M was funded when the agreement was signed and the remaining  3M will be available through March 31  2018  at Titan s option In connection with the transaction  Horizon received warrants to purchase up to 280 612 shares of Titan common stock at  1 96 or the price per share of any securities Titan may issue via an equity financing during the next 18 months Now read ,2017-07-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/titan-pharma-secures-$10m-debt-facility-from-horizon-tech-511657,511657
146329,367844,ALXN,Alexion lands three U S  patents covering Soliris,news,The USPTO issues three patents  No  9 732 149  No  9 718 880 and No  9 725 504  to Alexion Pharmaceuticals  NASDAQ ALXN  covering composition of matter of eculizumab  Soliris   pharmaceutical formulations of eculizumab and methods of treating paroxysmal nocturnal hemoglobinuria  PNH  with eculizumab  respectively  All will be effective until 2027 Now read ,2017-08-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion-lands-three-us-patents-covering-soliris-518961,518961
146343,367858,ALXN,Here Is Why Growth Investors Should Buy Alexion  ALXN  Now,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  However  it isn t easy to find a great growth stock 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  the task of finding cutting edge growth stocks is made easy with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Alexion Pharmaceuticals  NASDAQ ALXN  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
While there are numerous reasons why the stock of this drugmaker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 17 7   investors should actually focus on the projected growth  The company s EPS is expected to grow 30 5  this year  crushing the industry average  which calls for EPS growth of 9 6  
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio  also known as sales to total assets  S TA  ratio  but it is an important feature of a real growth stock  This metric shows how efficiently a firm is utilizing its assets to generate sales 
Right now  Alexion has an S TA ratio of 0 33  which means that the company gets  0 33 in sales for each dollar in assets  Comparing this to the industry average of 0 21  it can be said that the company is more efficient 
While the level of efficiency in generating sales matters a lot  so does the sales growth of a company  And Alexion looks attractive from a sales growth perspective as well  The company s sales are expected to grow 18 7  this year versus the industry average of 5 1  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Alexion  The Zacks Consensus Estimate for the current year has surged 3 9  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Alexion a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Alexion is a potential outperformer and a solid choice for growth investors ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/here-is-why-growth-investors-should-buy-alexion-alxn-now-200479413,200479413
146344,367859,ALXN,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  ETRM  14   PBYI  9   TGTX  7   NK  6   RGLS  5  Losers  CERS  19   CCM  18   EKSO  9   ALXN  9   AKTX  7  Now read ,2017-05-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare---top-5-gainers---losers-as-of-11:00-am-487602,487602
146345,367860,ALXN,Midday Gainers   Losers,news,Gainers  HMNY  65   GSOL  49   IHC  16   AMTX  15   BEBE  15   SMRT  14   WTT  12   DEST  11   SGLB  10   SHSP  10  Losers  CERS  25   CCM  18   IDXG  14   APDN  12   KIRK  10   SGOC  10   AMCN  10   REFR  9   FFHL  9   ALXN  9   Now read ,2017-05-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/midday-gainers---losers-487652,487652
146346,367861,ALXN,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  EKSO  22   NDRM  13   AEMD  9   ALXN  8   CRVS  7  Losers  ATNM  17   VKTX  11   APTO  10   ALDX  10   RGLS  9  Now read ,2017-06-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare---top-5-gainers---losers-as-of-11:00-am-495393,495393
146347,367862,ALXN,Technology   Top Gainers   Losers as of 3 00 pm,news,Gainers  APDN  26   SPA  24   ABIL  11   PTI  12   QTM  11  Losers  HSTM  16   SSYS  12   MJCO  8   RNWK  6   GRUB  6   Now read ,2017-06-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/technology---top-gainers---losers-as-of-3:00-pm-499386,499386
146358,367873,ALXN,Alexion  ALXN  Beats On Q3 Earnings  Lifts 2019 Guidance,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   posted third quarter 2019 adjusted earnings of  2 79 per share  which surged 38  from the year ago quarter s  2 02  Earnings also beat the Zacks Consensus Estimate of  2 49 Moreover  revenues rose 23  year over year to  1 26 billion in the reported quarter and also surpassed the Zacks Consensus Estimate of  1 24 billion  Revenues were driven by increased sales of Soliris  Strensiq  Kanuma and the uptake of Ultomiris Shares of Alexion have inched up 2  so far this year versus the  decline of 2 8  Revenues in DetailSoliris  for the treatment of paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   sales were up 12  year over year to  990 5 million in the reported quarter  driven by strong volume growth Strensiq revenues were  154 3 million  up 36  year over year   driven by strong volume growth  Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  28 4 million  up 12  year over year  to quarterly revenues Ultomiris   ravulizumab cwvz  net product sales were  89 9 million in the reported quarter  reflecting a sequential increase of 65 9  Cost SummaryAdjusted research and development  R D  expenses were  186 1 million  up 14 6  year over year Adjusted selling  general and administrative  SG A  expenses were  260 4 million  up 16  year over year 2019 GuidanceAlexion raised its revenue and earnings view for 2019  The company expects adjusted earnings per share to be  10 25  10 40  up from the previous guidance of  9 65  9 85  Alexion projects revenues of  4 86  4 89 billion  up from the prior outlook of  4 75  4 80 billion  The Zacks Consensus Estimate for earnings is pegged at  9 97 and for sales at  4 85 billion Combined revenues from Soliris and Ultomiris are expected to be  4 18  4 20 billion  up from  4 10  4 13 billion guided previously Pipeline UpdateIn August 2019  the European Commission  EC  approved Soliris for the treatment of neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive with a relapsing course of the disease Alexion plans to initiate a phase III study in children and adolescents with NMOSD by the end of 2019  Another phase III study on Soliris is also underway for addressing children and adolescents with Generalized Myasthenia Gravis  gMG  Earlier this month  the FDA approved a label expansion of Alexion s long acting C5 complement inhibitor Ultomiris  ravulizumab cwvz   The drug has been approved for the treatment of aHUS to inhibit complement mediated thrombotic microangiopathy  TMA  for adult and pediatric  aged one month or older  patients Meanwhile  aphase III study of Ultomiris in children and adolescents with aHUS is ongoing  Another late stage study of Ultomiris in children and adolescents with PNH is also underway A single  PK based phase III study of Ultomiris delivered subcutaneously once per week is currently underway to support registration in PNH and aHUS  Data are expected in the first half of 2020  Another phase III study of the drug for the treatment of generalized myasthenia gravis  gMG  is also currently ongoing Recent DevelopmentsIn October 2019  Alexion announced that it reached a definitive agreement to acquire the clinical stage biopharmaceutical company Achillion Pharmaceuticals  Inc    NASDAQ ACHN   for  930 million  The transaction is expected to close in the first half of 2020 The acquisition will add Achillion s lead candidate danicopan  ACH 4471   currently in phase II development  and ACH 5228  which is in phase I  Alexion is looking to strengthen its PNH franchise with this buyout as a potential approval of danicopan will make the company a market leader in the PNH space Also  earlier this month  Alexion announced a collaboration agreement with Stealth BioTherapeutics Corp   NASDAQ MITO   for a late stage therapy of mitochondrial diseases Our TakeAlexion s earnings and sales topped estimates in the third quarter of 2019  With the recent label expansion of Soliris  we expect the medicine to continue driving growth in the future  The company got approval for Ultomiris in the United States to treat PNH and aHUS  The drug s label expansion will further boost sales for the company Diversification with strong acquisition and positive collaborations also looks promising for Alexion Alexion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Zacks RankAlexion currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Incyte Corporation   NASDAQ INCY    which sports a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates have been revised 6 6  upward for 2019 and 9  for 2020 over the past 60 days  The stock has rallied 23 5  year to date Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-10-22,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-beats-on-q3-earnings-lifts-2019-guidance-200476824,200476824
146361,367876,ALXN,Alexion Pharmaceuticals  ALXN  Q3 Earnings And Revenues Top Estimates,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  came out with quarterly earnings of  2 79 per share  beating the Zacks Consensus Estimate of  2 49 per share  This compares to earnings of  2 02 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 12 05   A quarter ago  it was expected that this drugmaker would post earnings of  2 36 per share when it actually produced earnings of  2 64  delivering a surprise of 11 86  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Alexion  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  1 26 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 1 87   This compares to year ago revenues of  1 03 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Alexion shares have added about 2  since the beginning of the year versus the S P 500 s gain of 19 5  
What s Next for Alexion 
While Alexion has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Alexion was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 42 on  1 27 billion in revenues for the coming quarter and  9 97 on  4 85 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 30  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-q3-earnings-and-revenues-top-estimates-200476548,200476548
146364,367879,ALXN,US stocks closer  Dow sheds more than 100 points,news,"Investing com   U S  stocks closed lower on Thursday  as risk off sentiment continued for a third straight day  despite bullish earnings from banks and upbeat U S  economic data 
The three main U S  indexes ended the week in negative  as investors fled risk assets amid a rise in geopolitical tensions  after news that the U S  military dropped its largest non nuclear bomb on an ISIS tunnel 
The U S  deployed the GBU 43B  a 21 000 pound bomb on an ISIS tunnel complex in eastern Afghanistan on Thursday 
President Trump said that  this was another successful mission  and later added that the North Korean problem will be  taken care of  
Meanwhile  upbeat consumer sentiment and initial jobless claims data failed to lift sentiment while US producer prices dropped for the first time in seven months 
The Labor Department said on Thursday  initial jobless claims fell by 1 000 to a 234 000 for the week ended April 8 while the producer price index for final demand slipped 0 1  last month 
The University of Michigan said its consumer sentiment index climbed to 98 0 in April  well above expectations of a fall to 96 5 
In corporate earnings news  Citigroup Inc  Wells Fargo and JPMorgan reported first quarter results on Thursday  with the latter   JPMorgan   the best of the bunch  after the investment bank revealed an impressive first quarter performance 
The Dow Jones Industrial Average closed 0 67  lower at 20 453  The S P 500 lost 0 68  and the Nasdaq Composite closed 0 53  higher at 5805 15 
S P 500  movers and shakers 
The top S P 500 gainers included  Alexion Pharmaceuticals Inc  NASDAQ ALXN  up 3 3   and Incyte Corporation  NASDAQ INCY  1 9   while  Coty Inc   NYSE COTY  added 1 6  
Chesapeake Energy Corporation  NYSE CHK  down 4 2   Advanced Micro Devices Inc  NASDAQ AMD  down 3 5  and  Wells Fargo    Company  NYSE WFC  down 3 3   were among the worst S P 500 performers of the session ",2017-04-13,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-closer:-dow-sheds-more-than-100-points-474335,474335
146365,367880,ALXN,Titan Pharma down 10  after earnings,news,Thanks to sales of Probuphine by Braeburn  Titan  TTNP  9 6   earned  40K in license revenue in Q1 vs  nothing a year ago Total operating expenses of  3 5M nearly double that of last year  with R D moving to  2 1M from  700K due mostly to the Probuphine and ProNeura product development programs Net loss of  3M or  0 14 per share vs   1 8M and  0 09 a year ago At quarter s end cash and equivalents of  10 9M  which is believed to be enough to fund operations through Q2 of 2018 The conference call is set for 4 15 ET Previously  Titan Pharmaceuticals misses by  0 01  misses on revenue  May 10 Now read ,2017-05-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/titan-pharma-down-10-after-earnings-482631,482631
146378,367893,ALXN,Alexion  ALXN  Moves To Buy  Rationale Behind The Upgrade,opinion,"Investors might want to bet on Alexion Pharmaceuticals  NASDAQ ALXN   as it has been recently upgraded to a Zacks Rank  2  Buy   This rating change essentially reflects an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
A company s changing earnings picture is at the core of the Zacks rating  The system tracks the Zacks Consensus Estimate    the consensus measure of EPS estimates from the sell side analysts covering the stock    for the current and following years 
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts  since these are mostly driven by subjective factors that are hard to see and measure in real time  In these situations  the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near term stock price movements 
Therefore  the Zacks rating upgrade for Alexion basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
For Alexion  rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company s underlying business  And investors  appreciation of this improving business trend should push the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Alexion
This drugmaker is expected to earn  9 95 per share for the fiscal year ending December  2019  which represents a year over year change of 25 6  
Analysts have been steadily raising their estimates for Alexion  Over the past three months  the Zacks Consensus Estimate for the company has increased 5 1  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Alexion to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-moves-to-buy-rationale-behind-the-upgrade-200472198,200472198
146379,367894,ALXN,3 Big Drug Biotech Stocks Set To Beat Q3 Earnings Estimates,opinion,The third quarter earnings season for the pharma sector begins next week with J J  NYSE JNJ  set to report earnings on Oct 15 The first half of the year was a mixed bag for big drug and biotech companies as far as earnings performance is concerned  While big names like Pfizer  NYSE PFE   Bristol Myers and Lilly performed relatively poorly  Amgen  AstraZeneca  AbbVie  NYSE ABBV   Sanofi  PA SASY  and Merck delivered decent earnings and sales growth  The focus now shifts to the second half of the year  It is to be seen if the ones who did not do well in the first half recover in the second half and the ones that did well continue to deliver solid earnings and sales performance Overall  relatively newer drugs have been driving the top line of most of the big shots backed by higher demand   a trend we expect to have benefited third quarter sales  However  mature products of some of these companies face an array of generic biosimilar as well as branded competition  which might have put pressure on sales and margins in the to be reported quarter  Meanwhile  greater pricing pressure in the United States and negative currency impacts are some other top line headwinds that the companies might have faced Here we have highlighted three bigshot drug biotech companies  which are expected to deliver positive earnings surprise in the upcoming quarterly earnings By means of the   we have zeroed in on three drug biotech stocks with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive   These are valuable tools for investors looking for stocks with high potential to outpace estimates in the upcoming announcements  Moreover  stocks with a favorable Zacks Rank and a positive ESP have 70  chance to deliver a positive surprise  You can uncover the best stocks to buy or sell before they re reported with our  Our PicksAmgen   NASDAQ AMGN  Amgen has an Earnings ESP of  2 31  and a Zacks Rank of 2  The Zacks Consensus Estimate for third quarter earnings is pegged at  3 47 per share  The company is scheduled to release results on Oct 29 Amgen s performance has been impressive  with the company delivering a positive earnings surprise in each of the trailing four quarters with the average being 6 72  Higher sales of products like Prolia  Xgeva  Kyprolis and Blincyto should make up for lower sales of Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen  Neulasta and Sensipar  which are facing an array of branded and generic competitors  Though Repatha sales are gaining due to higher unit demand  it is being partially offset by lower prices Sales of Prolia  Xgeva  Blincyto  Parsabiv  Kyprolis and Nplate should continue to be driven by higher demand  Biosimilars could once again be an important contributor to top line growth Amgen s new migraine drug  Aimovig recorded sequentially improved sales in the second quarter driven by an increase in the percentage of paid volume with improvement in conversion of free to paid patients  We expect the positive trend to be reflected in third quarter results Alexion Pharmaceuticals   NASDAQ ALXN  Alexion has an Earnings ESP of  8 14  and a Zacks Rank  2  The company is scheduled to release results on Oct 23  The Zacks Consensus Estimate for third quarter earnings is pegged at  2 49 per share  You can see  Alexion s earnings performance has been impressive  with the company delivering a positive surprise in each of the trailing four quarters with the average being 13 34  Alexion s sales should continue to be driven by its blockbuster rare disease drug Soliris whose underlying growth has been robust for both approved indications    paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    The label expansion of the drug for the treatment of refractory generalized myasthenia gravis  gMG  also boosted sales  We expect the positive trend to have contributed to its third quarter performance Alexion s other medicines like Strensiq and Kanuma should also contribute to the top line  Its new medicine  Ultomiris  was approved to treat PNH in the United States in December last year and is off to a strong start  recording sales of  78 8 million in the first half  Ultomiris should bring in higher sales in the third quarter as it was approved in Japan in June and in Europe in July Lilly   NYSE LLY  Lilly has an Earnings ESP of  1 22  and a Zacks Rank  2  The company is scheduled to release results on Oct 23  The Zacks Consensus Estimate for third quarter earnings is pegged at  1 43 per share Lilly s earnings performance has been mixed  Its earnings beat expectations in three of the last four quarters  with the average positive surprise being 0 69  The impact of pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets and currency headwinds are expected to be reflected in third quarter 2019 results However  Like the previous few quarters  strong demand trends of new products namely Trulicity  Taltz  Jardiance  Basaglar  Olumiant and Verzenio as well as new migraine drug  Emgality should make up for the decline in sales of established products like Cialis due to loss of exclusivity and the impact of Lartruvo s impending product withdrawal  Lilly has suspended promotion of its advanced soft tissue sarcoma drug Lartruvo due to the failure of the ANNOUNCE confirmatory study Among the new drugs  in August  Taltz gained FDA approval for its third indication   active ankylosing spondylitis  which expanded the drug s eligible patient population and might have driven sales in the third quarter 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/3-big-drugbiotech-stocks-set-to-beat-q3-earnings-estimates-200472258,200472258
146380,367895,ALXN,Alexion  ALXN  Collaborates With Stealth BioTherapeutics ,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced a collaboration agreement with Stealth BioTherapeutics Corp   NASDAQ MITO   for a late stage therapy for mitochondrial diseases Both companies announced an agreement to co develop and commercialize elamipretide  a novel  potential first in class therapy that targets mitochondrial dysfunction The candidate is currently being evaluated in a phase III study in patients with primary mitochondrial myopathy  PMM  Per the agreement  Alexion will receive an exclusive option to partner with Stealth in the development of subcutaneous elamipretide based on the final results from the ongoing phase III study  If the company decides to exercise this option  both companies will co develop subcutaneous elamipretide in the United States for PMM and other indications like Barth syndrome and Leber s hereditary optic neuropathy  LHON  currently in early stage clinical development   Per the agreement  the companies will co promote the candidate in the United States  Besides  Alexion would receive exclusive rights to develop and commercialize subcutaneous elamipretide outside the United States There are currently no therapies approved to treat PMM  which is marked by debilitating skeletal muscle weakness  chronic fatigue and exercise intolerance Alexion will make initial payments of  30 million to Stealth  including an option fee  an equity investment and development funding  The agreement includes additional payments if the option is exercised  These payments include an option exercise fee  an additional equity investment  development funding and potential milestone payments  However  Stealth s other pipeline assets  including SBT 272  are not included in the option We note that Alexion primarily focuses on developing and commercializing drugs for the treatment of patients with ultra rare disorders  The market potential of these drugs is significant  with less competitive pressure  Alexion is looking to diversify its portfolio and reduce dependence on its blockbuster drug  Soliris  In line with this  the company acquired a clinical stage biotechnology company  Syntimmune  in the fourth quarter of 2018  In January 2019  Alexion entered a collaboration agreement with Caelum Biosciences to develop CAEL 101 for AL amyloidosis  Also  the company recently announced a license agreement with BridgeBio Pharma  Inc  s subsidiary  Eidos Therapeutics  Inc    NASDAQ EIDX   Shares of this biotech bigwig have inched up 1  in the year so far against the  s decline of 8 9   Meanwhile  Alexion s strong rare disease portfolio has made it a hot target for a takeover  Notably  the company was recently in news on the speculations of a potential buyout by biotech bigwig Amgen   NASDAQ AMGN    However  Amgen recently announced an agreement to purchase Celgene  NASDAQ CELG  Corporation s plaque psoriasis and psoriatic arthritis drug Otezla  thereby quashing the rumors of acquiring Alexion Alexion currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-collaborates-with-stealth-biotherapeutics-200472708,200472708
146382,367897,ALXN,Alexion Pharmaceuticals  ALXN  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on October 23  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  2 50 per share in its upcoming report  which represents a year over year change of  23 8  
Revenues are expected to be  1 24 billion  up 20 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 45  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Alexion 
For Alexion  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 80  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Alexion will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Alexion would post earnings of  2 36 per share when it actually produced earnings of  2 64  delivering a surprise of  11 86  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Alexion appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200474046,200474046
146383,367898,ALXN,Alexion  1 3  as it delays 10 Q on internal sales probe,news,Alexion Pharmaceuticals  ALXN  6 5   has resumed trading after a halt  down 1 3   as the company says it s delayed its 10 Q while it pursues an internal probe  The company filed a notification of late filing with the SEC as it undergoes an investigation into sales practices around its product Soliris  eculizumab   The Audit and Finance Committee has hired outside counsel and is probing the practices due to allegations from a former employee  The company says it hasn t identified instances where orders weren t placed by customers for patients  but it s uncertain when the investigation will be complete ,2016-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/alexion--1.3-as-it-delays-10-q-on-internal-sales-probe-439338,439338
146396,367911,ALXN,Will  Virtual Biotechs  Make Drugs Cheaper ,news,"By   

SEATTLE    Ingrid Swanson Pultz s biotech company lacks most of the standard accoutrements  It doesn t have a lab or an office    or any employees  Pultz launched PVP Biologics while still working as a microbiologist at the University of Washington in Seattle  With half a million dollars in grants and donations  she hires the people she needs on a contractual basis or asks them to join one of the company s advisory boards 
Pultz s company is investigating a potential treatment for celiac disease  and while her approach may seem unconventional  a growing number of founders are embracing the  virtual startup  model as a way to save on the onerous upfront costs of creating a business from scratch 
This break from the standard industry playbook is particularly attractive to entreprenuers and investors at a time when the biotech industry faces greater public scrutiny  and presidential candidates threaten to reel in drug prices  While companies are under no obligation to pass on savings  and drug prices do not necessarily reflect the cost of drug development  virtual biotechs are better positioned to introduce their medicines at lower launch prices if they re so inclined 
 I think anything that can take a chunk of the cost out of the system is a step toward making drugs more affordable  and that s one of the main benefits of this model   says Bernard Munos  a biotech analyst and consultant at the InnoThink Center for Research in Biomedical Innovation 
It works like this  Most virtual biotechs own the rights to a potential treatment purchased from another company or developed at a university  Once the company has a drug candidate  one or two people can lead a virtual team of consultants and outsource the research to a company that conducts initial tests and develops the medicine to the point where it is ready to enter clinical trials 
Dr  Richard Stead has helped launch between 40 and 50 virtual biotechs over the past 13 years through his company  BioPharma Consulting Services  near Seattle  Despite his long professional history with brick and mortar operations    he was the first physician employed by Amgen  O AMGN  in 1988 and later worked for Immunex    he now professes a particular fondness for virtual companies 
 I don t think the virtual team is for every company or for every function within a company  but I think it can be more capital efficient and I think you can get  on average  a higher quality of person and experience in that way   he says   I think there s a real place for it  
Stead is currently advising Pultz on PVP Biologics  So far  she has hired a toxicologist to help plan animal studies  a consultant who specializes in manufacturing and Stead  who designs clinical trials  She calls them from her home office each week  When they do meet in person  it s in a nondescript conference room in the Life Sciences Building 

In the early days of biotech  companies spent millions to build elaborate headquarters with labs and office suites long before any of their products were ever approved by the U S  Food and Drug Administration  Biotech leaders thought companies needed to be fully integrated and able to handle all aspects of researching  developing  commercializing and marketing a potential drug from Day One 
But many of these companies failed to ever produce an FDA approved treatment  Those that did were often bought by pharmaceutical companies  which unceremoniously disposed of their headquarters anyway  It wasn t long before this model began to seem inefficient 
 That s not how companies are started these days   Chris Rivera  president of the Washington Biotechnology and Biomedical Association  says    I think going from ground zero to building infrastructure from Day One is probably kind of a bygone era that we probably won t see going forward  

Over the past decade  more biotechs have forgone the luxuries of lab space and full time employees to operate virtually during the early stages of research  Now many investors even prefer it  Patrick Heron  who oversees life sciences for Seattle based investment group Frazier Healthcare Partners  says between 30 and 50 percent of the companies that he funds begin as virtual companies  He estimates that 15 years ago  only 10 percent of companies were virtual 
In September  biotech stocks temporarily dropped following widespread public criticism of Turing Pharmaceutical s sudden price hike on a prescription medicine and vows by several Democratic presidential candidates to fight skyrocketing drug costs  If that pressure continues  Heron says the industry can expect to see more virtual companies launched on lean budgets 
 If the market continues on its current trend  I think you re going to see more virtual companies and more use of outside resources   he says 
Munos tends to agree   If there is a backlash and the prices are ratcheted down  companies that operate on a virtual model will be able to withstand the shock much better than others   he says 
Already  there are plenty of success stories about companies that went the virtual route  Take  for example  Zafgen  Its founders used a virtual model to take a drug to treat obesity all the way through midstage clinical trials for about  68 million  a sum that Munos says is about one fifth of what a major pharmaceutical company might spend  In June of 2014  it earned  96 million in an initial public offering  This year  Alexion Pharmaceuticals  O ALXN  acquired a virtual company called Synageva BioPharma  which makes rare disease treatments  for  8 4 billion 

Seattle is well positioned for this model to take hold  The state is a hive of activity    120 new life sciences companies have been launched in Washington this year  bringing the total number of new ventures to over 400 since 2009   It s been a frenzy  maybe is the right word   Rivera says 
But at the same time  the city suffers from a lack of available lab space and a dearth of talent  Together  these factors convince many founders and CEOs that a virtual model is the right fit 
 More and more companies are becoming virtual   Rivera says   I think most of the startups are starting in that form and fashion now just because it s so darn expensive to put a brick and mortar together or find lab space  

Pultz says her model is a great fit for investors who are more skittish about making a substantial contribution for a large infrastructure project before a drug is even proved   It s a way to compensate for the fact that a lot of groups in biotech are more risk averse than they used to be   she says 
In the crowded university office and lab space she shares with other early career researchers and graduate students  Pultz is putting the finishing touches on an enzyme called KumaMax that breaks down fragments of gluten that naturally pass through healthy individuals but are known to cause inflammation in the intestines of those with celiac disease 
She says KumaMax breaks down gluten fragments  orders of magnitude better  than enzymes already in clinical trials  Her company  called PVP Biologics  a sly reference to  player versus player   a phase popular with gamers  has no venture capital    yet  But when she spins out PVP Biologics from the university in the coming year  KumaMax will be nearly ready to enter trials 
Traditional companies might have had to raise millions in venture capital to engineer an enzyme to such an advanced stage  So far  Pultz has paid for consultants through a  250 000 grant from Washington state s Life Sciences Discovery Fund  which was matched by  250 000 in contributions from private donors  Her salary is paid by the Institute for Protein Design at the university  Heron estimates companies can save between 20 and 30 percent of their costs by starting out virtually as compared with launching as a traditional company 
Pultz hopes to have KumaMax in clinical trials by 2017  She estimates that the company will need between  20 million to  30 million in venture capital to complete the remaining preclinical work and usher the enzyme through the first two phases of testing  Consultants tell her the cost may balloon to as much as  225 million for the third and final stage 
That sounds like a lot of money  But as she watches other companies raise millions of dollars on the promise of a molecule that has yet to be built in a lab   it gives me hope that we ll be able to raise our funding   she says 
Heron says investing in a virtual company requires something of a paradigm shift for investors  who can be easily dazzled by a company s corporate headquarters filled with legions of staff scientists 
 Your initial concern is  you re going to lose the chatter and all of the hallway talk that really drives an organization   he says   But as you see the productivity of these teams that operate in a virtual fashion  you sort of get religion that this is a good way to go  ",2015-11-10,International Business Times,https://www.investing.com/news/stock-market-news/will-'virtual-biotechs'-make-drugs-cheaper -370652,370652
146403,367918,ALXN,Akari s Nomacopan Gets Orphan Drug Tag For Rare Skin Disease,opinion,"Akari Therapeutics  Plc   NASDAQ AKTX   announced that the FDA has granted an orphan drug designation to its lead pipeline candidate nomacopan for the treatment of bullous pemphigoid   BP  LON BP     Currently  there is no approved therapy for this rare disease  which causes severe blistering of the skin  The status makes nomacopan eligible for seven years of marketing exclusivity in the United States Notably  the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200 000 people in the United States  This designation also makes the company entitled to certain other benefits including tax credits related to clinical study expenses and an exemption from certain administrative fees The company is currently evaluating the candidate in a phase II study for treating patients with BP  In April  it had reported positive initial data from this study Please note that nomacopan was granted orphan drug designation for the treatment of hematopoietic stem cell transplantation associated thrombotic microangiopathy  HSCT TMA  by the FDA last month Shares of Akari have increased 21 6  so far this year against the  s decline of 1 7    Nomacopan is a C5 complement inhibitor that specifically inhibits leukotriene B4  LTB4  activity  Complement component C5  the target of nomacopan  is mostly found in the blood  Pre clinical studies on nomacopan demonstrated that it is significantly more effective than LTB4 or C5 alone  Currently marketed LTB4 and C5 drugs include Zileuton and Alexion Pharmaceuticals    NASDAQ ALXN   Soliris  respectively Apart from BP  the company is developing the candidate in three other rare diseases   HSCT TMA  atopic keratoconjunctivitis   AKC   and paroxysmal nocturnal hemoglobinuria   PNH   Nomacopan is in most advanced stage of development as a treatment for HSCT TMA in pediatric patients  The company is planning to initiate a pivotal phase III study for this indication in the fourth quarter of 2019  Meanwhile  the company has successfully completed a phase II study  evaluating the candidate in PNH patients With no approved products  the company is dependent on successful development of nomacopan Akari Therapeutics PLC Price
    Zacks Rank   Stocks to ConsiderAkari currently carries a Zacks Rank  5  Strong Sell  A couple of better ranked stocks in the healthcare sector include Emmaus Life Sciences   OTC EMMA   and Acorda Therapeutics   NASDAQ ACOR    both sporting a Zacks Rank  1  Strong Buy   You can see  Emmaus Life s loss per share estimates have narrowed 17 8  for 2019 and 26 4  for 2020 over the past 60 days Acorda s loss per share estimates have narrowed 27 7  for 2019 and 4 6  for 2020 over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/akaris-nomacopan-gets-orphan-drug-tag-for-rare-skin-disease-200464984,200464984
146404,367919,ALXN,Will Alexion  ALXN  Beat Estimates Again In Its Next Earnings Report ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Alexion Pharmaceuticals  NASDAQ ALXN   which belongs to the Zacks Medical   Biomedical and Genetics industry 
This drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 10 50  
For the most recent quarter  Alexion was expected to post earnings of  2 36 per share  but it reported  2 64 per share instead  representing a surprise of 11 86   For the previous quarter  the consensus estimate was  2 19 per share  while it actually produced  2 39 per share  a surprise of 9 13  
Price and EPS Surprise

For Alexion  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Alexion has an Earnings ESP of  8 14  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/will-alexion-alxn-beat-estimates-again-in-its-next-earnings-report-200469971,200469971
146407,367922,ALXN,Why Alexion Is A Hot Takeover Target In The Biotech Sector,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   has been in the spotlight as a potential takeover target from the onset of 2019  after the mega merger announcement of Bristol Myers   NYSE BMY   and Celgene   NASDAQ CELG   Notably  a slowdown in mature products due to the increasing competition and rise of biosimilars have forced most pharma biotech behemoths to target lucrative buyouts in this space to bolster their pipelines   Evidently  the focus is back on mergers and acquisitions  The recent spree of consolidations is expected to continue with both big and small biotech stocks  which have a dominant position in the lesser competitive arena of rare diseases and NASH and are well equipped with path breaking technology  respectively Here we look at the factors  which make Alexion a hot target for a takeover Alexion primarily focuses on developing and commercializing drugs for the treatment of patients with ultra rare disorders  The market potential of these drugs is significant  with less competitive pressure  The company s blockbuster drug  Soliris  approved for the treatment of two severe and ultra rare disorders   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    continues to perform well  The FDA approval of the generalized myasthenia gravis  gMG  indication has boosted the drug s prospects further Additionally  to combat generic competition for Soliris  once it loses patent protection  Alexion developed a long acting C5 complement inhibitor  Ultomiris  for the treatment of adults with PNH  which consolidated its PNH franchise  The initial uptake of the drug has been strong  The company is working to expand the drug s label into various other indications Concurrently  Alexion is looking to strengthen its pipeline with acquisitions and collaborations  It acquired Sweden based Wilson Therapeutics and added a late stage candidate  ALXN1840  to its pipeline  It also acquired a clinical stage biotechnology company  Syntimmune  The company has also collaborated with Dicerna Pharmaceuticals to jointly discover and develop up to four subcutaneously delivered GalXC RNA interference  RNAi  candidates  Additionally  it entered a partnership with Complement Pharma to co develop the preclinical C6 complement inhibitor  CP010  for neurodegenerative disorders Notably  the company was recently in news on the speculations of a potential buyout by biotech bigwig Amgen   NASDAQ AMGN    However  Amgen decided to purchase Celgene s plaque psoriasis and psoriatic arthritis drug Otezla  thereby quashing the rumors of acquiring Alexion  Consequently  Alexion s stock declined The company recently announced the departure of its current chief financial officer  Paul Clancy  later this year  Clancy will be succeeded by Aradhana Sarin  M D   who is currently the chief strategy and business officer of the company  The stock most likely declined due to uncertainties regarding this transition Nevertheless  with a strong portfolio of rare diseases drugs and a solid pipeline  Alexion is a potential target for big pharma companies looking to foray into the rare diseases market Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/why-alexion-is-a-hot-takeover-target-in-the-biotech-sector-200471481,200471481
146418,367933,ALXN,U S  equities rally amid gains in tech stocks  ahead of key Jobs report,news,"Investing com    Bolstered by substantial gains among tech stocks on Thursday  U S  equities markets moved broadly higher reversing losses from Wednesday after Federal Reserve chair Janet Yellen sounded alarm bells on the potential dangers from high stock valuations 
The Dow Jones Industrial Average  the NASDAQ Composite index and S P Composite all gained more than 0 35  to pare losses from the previous two sessions  The Dow gained 82 08 or 0 46  to 17 924 06  moving back into positive territory for the year  Powered by a surge in semiconductor stocks  the NASDAQ rose 25 91 or 0 53  to 4 945 55  while the S P 500 gained 7 85 or 0 38  to 2 088 00 
Stocks in the Financials  Technology and Consumer Services sectors led on the S P 500  as nine of 10 industries moved higher for the session  Stocks in the Energy sector lagged  closing down by 1 16  amid a sharp decline in crude futures 
Investors also await a critical U S  jobs report on Friday  where analysts expect an uptick of 224 000 in nonfarm payroll jobs for the month of April  On Thursday  initial jobless claims rose modestly last week by 3 000 to 265 000 
Shares in Yahoo  Inc  NASDAQ YHOO  skyrocketed on Thursday after Chinese e commerce giant  Alibaba  Group Holdings Ltd  NYSE BABA  posted stronger than expected earnings for the first quarter  In overnight trading  Alibaba shares surged more than  8 or 10  to reach its highest level since going public in the fall  The move resulted in roughly a  3 1 windfall for Yahoo  which owns a 15 4  stake in the company  Yahoo  which finished the session as the top performer on the NASDAQ and the S P 500  gained 2 21 or 5 30  to 43 87 
Yahoo was also rumored on Thursday to become a potential buyer of  Yelp  Inc  NYSE YELP   after reports surfaced from Dow Jones that the San Francisco based online business review company could be up for sale  Shares in Yelp soared nearly 25  upon the news  gaining 8 79 points to 47 01  Previously  Yelp shares had plunged more than 20  on the year amid worse than expected quarterly earnings 
The top performer on the Dow was  Home Depot  Inc  NYSE HD   which gained 1 73 or 1 60  to 110 04  The worst performer on the Dow was  Exxon Mobil  Corporation  NYSE XOM   which fell 0 59 or 0 67  to close at 87 60   Caterpillar  Inc  NYSE CAT  also dropped 0 56 or 0 64  to 86 43  On Wednesday  a longtime family dealership in Saskatchewan announced plans to sell its Caterpillar franchise for  230 million 
On the NASDAQ  Activision Blizzard Inc  NASDAQ ATVI  gained 1 21 or 5 22  to 24 41  finishing just behind Yahoo as the session s top performer  Whole Foods Market Inc  NASDAQ WFM  and Keurig Green Mountain Inc  NASDAQ GMCR   finished as the session s worst performers after posting weaker than expected earnings a day earlier  Keurig  a Vermont based coffee company  reported profits of  155 5 million or 97 cents for the quarter that ended on March 28  versus profits of  162 1 million or 1 03 per share for the same period in 2014  Shares in both companies fell by more than 9  on Thursday  
On the S P 500  Alexion Pharmaceuticals Inc  NASDAQ ALXN  rose 7 95 or 5 13  to 162 96  finishing just behind Yahoo as the session s biggest gainer  It came one day after Alexion agreed to acquire Synageva BioPharma Corp  NASDAQ GEVA  for  8 4 billion or  230 a share  Whole Foods and Keurig were also the worst performers on the S P 500 ",2015-05-07,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-equities-rally-amid-gains-in-tech-stocks,-ahead-of-key-jobs-report-340820",340820
146422,367937,ALXN,Alexion Wins EC Nod For Soliris In Nervous System Disorder,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the European Commission  EC  has approved the label expansion of lead drug  Soliris The drug is now approved for the treatment of neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive with a relapsing course of the disease The EC approval was based on comprehensive results from the phase III randomized  double blind  placebo controlled PREVENT study and a long term extension study  ECU NMO 302   which is still underway  The study met its primary endpoint of prolonging the time to first adjudicated relapse and reducing the risk of relapse  Per the data  98  of adult AQP4 antibody positive patients treated with Soliris were relapse free compared to 63  receiving placebo at 48 weeks  The encouraging results demonstrated the potential of Soliris to change the treatment paradigm for this rare  devastating  complement mediated disorder of the central nervous system We remind investors that the FDA has already approved the drug for the treatment of NMOSD in adult patients  who are AQP4 antibody positive  in June 2019  A supplemental New Drug Application is currently under review by regulatory authorities in Japan  The drug enjoys an Orphan Drug designation  ODD  for the treatment of NMOSD in the United States  the EU and Japan Soliris  a first in class complement inhibitor that inhibits the C5 protein  is already approved for the treatment of two severe and ultra rare disorders  paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome   in the United States and Europe  The FDA has also approved the drug for the indication of the generalized myasthenia gravis The label expansion of the drug should further boost sales  The FDA recently approved Alexion s long acting C5 complement inhibitor  Ultomiris  for the treatment of adults with PNH  This consolidated the company s PNH franchise  It plans to evaluate the drug for the NMOSD indication as well Shares of the company have gained 13 2  in the year so far against the  s decline of 2 3    We note that Alexion was recently in the news on speculations of a potential buyout by biotech bigwig Amgen   NASDAQ AMGN    However  Amgen recently announced an agreement to acquire Celgene Corporation s   NASDAQ CELG   plaque psoriasis and psoriatic arthritis drug  Otezla  for more than  13 4 billion  thereby squashing the speculations of buying out Alexion  Alexion s stock declined on the news  Nevertheless  the company has been one of the prime candidates for acquisition from the onset of 2019 after the mega merger announcement of Bristol Myers   NYSE BMY   and Celgene Alexion currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/alexion-wins-ec-nod-for-soliris-in-nervous-system-disorder-200459264,200459264
146423,367938,ALXN,Regeneron Sanofi Get Favorable Ruling Against Amgen In Court ,opinion,Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi   NASDAQ SNY   announced that the U S  District Court for the District of Delaware ruled in their favor in the ongoing litigation for PCSK9 inhibitor Praluent s  alirocumab  patent against rival Amgen  Inc    NASDAQ AMGN    which sells its own PCSK9 inhibitor  Repatha The court determined that Amgen s asserted patent claims for antibodies targeting PCSK9  proprotein convertase subtilisin kexin type 9  are invalid based on lack of enablement The latest ruling overturned portions of an earlier jury verdict upholding the validity of three claims  In February 2019  a jury determined that two other asserted Amgen patent claims are invalid  As a result  Regeneron and Sanofi have successfully invalidated all five asserted Amgen patent claims  Both companies have been involved in a longstanding duel regarding Praluent and Repatha  whereby Amgen is trying to prevent the manufacture  use and sale of Praluent claiming infringement of patents Nevertheless  the latest ruling bodes well for Regeneron and Sanofi  Regeneron s shares have lost 23  in the year so far compared with the  s  decline of 2 4   We note that both Praluent and Repatha inhibit the protein known as PCSK9  which lowers the liver s ability to remove  bad  cholesterol  LDL C  from the blood  Praluent was developed by Regeneron and Sanofi under a global collaboration agreement and invented by the former using its proprietary VelocImmune technology  Though both drugs were approved in 2015  the uptake has been disappointing as these are expensive  The companies have been striving hard to capture market share and secure deals with health insurers and pharmacy benefit managers Amgen s Repatha has captured a significant market share in certain jurisdictions  Repatha also received regulatory approval for cardiovascular risk reduction before Praluent in certain jurisdictions  including the United States  In a bid to improve access  Sanofi and Regeneron announced a 60  cut in the U S  list price of Praluent earlier this year  Last year  Amgen too had taken similar action Zacks Rank   A Stock to ConsiderRegeneron currently carries a Zacks Rank  3  Hold  A better ranked stock in the biotech space is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which carries a Zacks Rank  2  Buy   You can see  Alexion s earnings estimates have been revised 4 2  upward for 2019 and 2 1  for 2020 over the past 60 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/regeneronsanofi-get-favorable-ruling-against-amgen-in-court-200459947,200459947
146424,367939,ALXN,Biotech Stock Roundup  AMGN s Lung Cancer Candidate  ALXN s Deal With Eidos In Focus,opinion,It was a pretty ho hum week for the biotech sector  with updates from only a few players  While Amgen   NASDAQ AMGN   reported positive data on its lung cancer candidate  Alexion   NASDAQ ALXN   signed a licensing deal with Eidos for amyloidosis drug  Meanwhile  there were a few updates from certain smaller biotechs as well Recap of the Week s Most Important Stories Amgen Announces Promising Data on Lung Cancer Drug   Amgen  new data from a phase I study evaluating its novel investigational KRAS inhibitor  AMG 510  in patients with previously treated KRAS G12C mutated solid tumors at IASLC 2019 World Conference on Lung Cancer  WCLC  Data showed anti tumor activity  with no dose limiting toxicities in a large group of lung cancer patients  Per the data  54  of the evaluable NSCLC patients  n 13   who were given a high dose of 960 mg once daily  showed a partial response at one or more timepoints  Additionally  46  of these patients experienced stability in disease  Amgen earlier said that AMG 510 showed responses in patients with colorectal and appendiceal cancer  It is also enrolling patients in an NSCLC cohort to evaluate the combination of AMG 510 and a PD 1 inhibitor  It plans to initiate a registration enabling phase II study soon Alexion In licenses Amyloidosis Candidate in Japan  Alexion Pharmaceuticals  Inc   a license agreement with BridgeBio Pharma  Inc  s subsidiary  Eidos Therapeutics  Inc  Per the deal  Alexion will obtain an exclusive license from Eidos to develop and commercialize an investigational  orally administered small molecule AG10 in Japan  In exchange  the latter will receive an upfront payment of  25 million and an equity investment of  25 million at a premium to the market price from the former upon the deal execution  Also  Eidos is eligible to receive additional milestones and royalty dependent fees   AG10 has been designed to treat the root cause of transthyretin amyloidosis  ATTR    destabilized and misfolded transthyretin  TTR  protein   by binding and stabilizing TTR in the blood   The deal expands Alexion s amyloidosis portfolio Alexion currently carries a Zacks Rank  2  Buy   You can see  Horizon s Ophthalmology Drug Gets FDA s Priority Review  Horizon Therapeutics plc   NASDAQ HZNP    that the FDA has accepted the Biologics License Application  BLA  for its investigational medicine  teprotumumab  for the treatment of active thyroid eye disease  TED   and granted it Priority Review designation  If approved  teprotumumab would be the first FDA approved medicine for the treatment of active TED  The candidate was added to the company s portfolio after the acquisition of River Vision in 2017  The FDA completed its filing review and determined that the application is sufficiently complete to permit a substantive review  The FDA set an action date of Mar 8  2020   The agency notified that it is currently planning to hold an advisory committee meeting to discuss the application per guidelines  Acceleron s PAH Drug Gets Orphan Drug Status  Acceleron Pharma Inc    NASDAQ XLRN    that the FDA has granted the Orphan Drug designation to its investigational candidate  sotatercept  for the treatment of patients with pulmonary arterial hypertension  PAH    Sotatercept is currently being evaluated in two phase II studies in PAH  In June  Acceleron completed enrolling patients in the PULSAR study and plans to report top line data from the same during the first quarter of 2020  Also  the company is currently recruiting subjects in the SPECTRA exploratory study to have a better understanding of sotatercept s potential impact on PAH patients  Preliminary results from this study are expected in 2020 AVEO Announces Positive Data on Kidney Cancer Drug   AVEO Oncology   NASDAQ AVEO   announced results from the second prespecified analysis of overall survival  OS  in the phase III multi center  open label study  TIVO 3  The study is evaluating Fotivda compared to Nexavar in 350 subjects with highly refractory metastatic renal cell carcinoma  RCC   These results showed an OS hazard ratio  HR  below 1 00  which was in favor of Fotivda as it indicates that treatment with the drug led to a lower risk of death  Per the company  this is the first phase III study in RCC to investigate a predefined subpopulation of patients  who received prior immunotherapy  an emerging standard of care for earlier lines of therapy PerformanceMedical   Biomedical and Genetics Industry 5YR   Return The Nasdaq Biotechnology index gained 1 98  in the last five trading sessions  Among the biotech giants  Alexion gained 15 15  in the period  Over the past six months  shares of Celgene  NASDAQ CELG  have gained 14 53   whereas the Regeneron stock has slumped 31 14    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for more pipeline updates Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-amgns-lung-cancer-candidate-alxns-deal-with-eidos-in-focus-200463771,200463771
146425,367940,ALXN,ALXN Or CBM  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in stocks from the Medical   Biomedical and Genetics sector have probably already heard of Alexion Pharmaceuticals  NASDAQ ALXN  and Cambrex  CBM   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Alexion Pharmaceuticals has a Zacks Rank of  2  Buy   while Cambrex has a Zacks Rank of  3  Hold  right now  The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that ALXN has an improving earnings outlook  But this is only part of the picture for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
ALXN currently has a forward P E ratio of 10 91  while CBM has a forward P E of 29 13  We also note that ALXN has a PEG ratio of 0 93  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  CBM currently has a PEG ratio of 2 91 
Another notable valuation metric for ALXN is its P B ratio of 2 39  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  CBM has a P B of 2 97 
Based on these metrics and many more  ALXN holds a Value grade of B  while CBM has a Value grade of C 
ALXN sticks out from CBM in both our Zacks Rank and Style Scores models  so value investors will likely feel that ALXN is the better option right now ",2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/alxn-or-cbm-which-is-the-better-value-stock-right-now-200464495,200464495
146445,367960,ALXN,Alexion  ALXN  Is An Incredible Growth Stock  3 Reasons Why,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a great growth stock is not easy at all 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  the task of finding cutting edge growth stocks is made easy with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Alexion Pharmaceuticals  NASDAQ ALXN  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this drugmaker a great growth pick right now 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 14 5   investors should actually focus on the projected growth  The company s EPS is expected to grow 25  this year  crushing the industry average  which calls for EPS growth of 10 8  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Alexion is 20 3   which is higher than many of its peers  In fact  the rate compares to the industry average of 18 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 26 9  over the past 3 5 years versus the industry average of 9  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Alexion have been revising upward  The Zacks Consensus Estimate for the current year has surged 4 4  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Alexion a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination positions Alexion well for outperformance  so growth investors may want to bet on it ",2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-is-an-incredible-growth-stock-3-reasons-why-200457222,200457222
146446,367961,ALXN,Alexion Pharmaceuticals  ALXN  Jumps  Stock Rises 7 5 ,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   was a big mover last session  as the company saw its shares rise more than 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  107 65 to  122 42 in the past one month time frame The company has seen three positive estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks  suggesting that more solid trading could be ahead for Alexion Pharmaceuticals  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road Alexion Pharmaceuticals currently has a Zacks Rank  2  Buy  while its  is 0 00  Alexion Pharmaceuticals  Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider Acorda Therapeutics  Inc    NASDAQ ACOR    which has a Zacks Rank  1  Strong Buy   You can seeIs ALXN going up  Or down  Predict to see what others think Up or DownWall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-jumps-stock-rises-75-200458044,200458044
146448,367963,ALXN,Why Is Alexion  ALXN  Up 4 6  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Alexion Pharmaceuticals  NASDAQ ALXN   Shares have added about 4 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Alexion due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Alexion Earnings Beat Estimates  Guidance RaisedAlexion posted second quarter 2019 adjusted earnings of  2 64 per share  which increased 27 5  from the year ago quarter s  2 07  Earnings also beat the Zacks Consensus Estimate of  2 36  Strong product revenues drove the bottom line in the quarter Revenues rose 15 2  year over year to  1 203 billion and exceeded the Zacks Consensus Estimate of  1 174 billion  Revenues were driven by increased sales of Soliris  Strensiq and Kanuma  However  foreign currency negatively impacted revenues by 1  Revenues in DetailSoliris  paroxysmal nocturnal hemoglobinuria   PNH   and atypical hemolytic uremic syndrome  aHUS   sales were up 9 2  to  980 8 million in the reported quarter  driven by strong volume growth  Soliris net product sales for the second quarter declined  31 6 million due to a recent judicial order on the drug s pricing in Canada While Strensiq  hypophosphatasia   HPP    revenues were  141 3 million  up 13  year over year   Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  26 2 million  up 22   to quarterly revenues Ultomiris  ravulizumab cwvz  net product sales were  54 2 million in the reported quarter Cost SummaryAdjusted research and development  R D  expenses were  148 7 million  down 6 1  year over year Adjusted selling  general and administrative  SG A  expenses were  255 8 million  up 11  year over year 2019 GuidanceAlexion raised its revenue and earnings guidance for 2019  The company expects earnings per share to be  9 65  9 85  up from the previous guidance of  9 25  9 45  Alexion projects revenues of  4 75  4 80 billion  up from the prior outlook of  4 68  4 75 billion  The Zacks Consensus Estimate for earnings is pegged at  9 51 and for sales at  4 78 billion Combined revenues for Soliris and Ultomiris are expected to be  4 10  4 13 billion up from  4 02  4 07 billion guided previously Pipeline UpdateIn June 2019  the FDA approved Soliris for adults with anti aquaporin 4  AQP4  auto antibody positive NMOSD  Applications for approval in the European Union  EU  and Japan are under review  Alexion plans to initiate a phase III study in children and adolescents with NMOSD by the end of 2019 Ultomiris was approved for adults with PNH in Japan in June 2019 and in the EU in July 2019  A phase III study of Ultomiris in children and adolescents with PNH is underway The FDA granted Priority Review to the drug for the treatment of atypical hemolytic uremic syndrome  aHUS  and set an action date of Oct 19  2019  Alexion plans to file for regulatory approvals in the EU and Japan in the second half of the year  A phase III study of Ultomiris in children and adolescents with aHUS is underway Dosing is underway in a single  PK based phase III study of Ultomirisdelivered subcutaneously once per week to support registration in PNH and aHUS  Data are expected by early 2020  Dosing is also underway in a phase III study of the drugin generalized myasthenia gravis  gMG  Alexion plans to initiate a phase III study of Ultomirisin NMOSD by the end of the year Dosing is ongoing in a phase III study of ALXN1840  WTX101  in Wilson disease  a rare genetic disorder with devastating hepatic and neurological consequences   Enrollment is expected to complete in early 2020 Alexion plans to initiate a phase II III study of ALXN1830  SYNT001  in warm autoimmune hemolytic anemia  WAIHA  in early 2020  
How Have Estimates Been Moving Since Then 
It turns out  estimates review have trended upward during the past month  The consensus estimate has shifted 5 29  due to these changes 
VGM Scores
Currently  Alexion has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise Alexion has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/why-is-alexion-alxn-up-46-since-last-earnings-report-200457976,200457976
146449,367964,ALXN,ALXN Vs  CBM  Which Stock Is The Better Value Option ,opinion,"Investors with an interest in Medical   Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals  NASDAQ ALXN  and Cambrex  CBM   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Alexion Pharmaceuticals and Cambrex are sporting Zacks Ranks of  2  Buy  and  3  Hold   respectively  right now  Investors should feel comfortable knowing that ALXN likely has seen a stronger improvement to its earnings outlook than CBM has recently  But this is just one piece of the puzzle for value investors 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
ALXN currently has a forward P E ratio of 11 65  while CBM has a forward P E of 29  We also note that ALXN has a PEG ratio of 1  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  CBM currently has a PEG ratio of 2 90 
Another notable valuation metric for ALXN is its P B ratio of 2 54  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  CBM has a P B of 2 95 
Based on these metrics and many more  ALXN holds a Value grade of B  while CBM has a Value grade of C 
ALXN has seen stronger estimate revision activity and sports more attractive valuation metrics than CBM  so it seems like value investors will conclude that ALXN is the superior option right now ",2019-08-25,Zacks Investment Research,https://www.investing.com/analysis/alxn-vs-cbm-which-stock-is-the-better-value-option-200458553,200458553
146450,367965,ALXN,Gilead   Galapagos Close Research   Development Agreement,opinion,Gilead Sciences  Inc    NASDAQ GILD   closed global research and development collaboration agreement with Galapagos NV   NASDAQ GLPG   The agreement  which was signed on Jul 14  2019  received clearance from the U S  Federal Trade Commission under the Hart Scott Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority Both the companies entered a 10 year global research and development collaboration  whereby Gilead will gain access to an innovative portfolio of compounds  including six molecules currently in clinical trials  more than 20 preclinical programs and a proven drug discovery platform  The company will receive an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe Both companies have agreed to amend certain terms of the agreement  involving filgotinib  the candidate being advanced for rheumatoid arthritis and other inflammatory diseases  to create a broader commercialization role for Galapagos in Europe Per the agreement  the closure leads to an upfront license fee payment of  3 95 billion by Gilead to Galapagos  Additionally  Gilead has made an equity investment of  1 1 billion in Galapagos by subscribing for new shares  Consequently  the company now owns 13 589 686 ordinary shares of Galapagos  representing approximately 22  of the currently outstanding share capital of Galapagos Earlier in the month  the European Medicines Agency   EMA   accepted the marketing authorization application   MAA   for filgotinib  The MAA is seeking approval of the drug as a treatment for rheumatoid arthritis in Europe  The MAA includes data from the phase III clinical program  FINCH  which comprises three studies Gilead s stock has dipped 0 1  in the year so far compared with the  decline of 3 4   Gilead has shifted focus to the HIV franchise  and newer avenues like CAR T therapy and inflammation  due to a decline in sales of the HCV franchise  The company is signing deals with other companies to strengthen its pipeline for the inflammation market  Gilead has also collaborated with Novo Nordisk   NYSE NVO   for NASH treatments Zacks Rank   A Stock to ConsiderGilead currently carries a Zacks Rank  3  Hold    A better ranked biotech is Alexion Pharmaceuticals    NASDAQ ALXN   which carries a Zacks Rank  2  Buy   You can see  Alexion s earnings estimates have been revised 4 2  upward for 2019 and 2 1  for 2020 over the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/gilead--galapagos-close-research--development-agreement-200458516,200458516
146455,367970,ALXN,Biotech Stock Roundup  AMGN To Buy CELG s Otezla  ALXN s Soliris Gets EC Nod   More,opinion,"It was a busy week for the biotech sector with updates from quite a few players  While pharma bigwig Amgen   NASDAQ AMGN   agreed to buy Celgene s   NASDAQ CELG   Otezla  Alexion   NASDAQ ALXN   won European Commission s  EC  approval for the label expansion of Soliris  Meanwhile  Gilead   NASDAQ GILD   closed its deal with Galapagos Recap of the Week s Most Important Stories Amgen to Acquire Celgene s Otezla  Amgen  that it will acquire global commercial rights to Celgene s blockbuster psoriasis drug  Otezla  which the latter had to divest to conclude its impending merger with Bristol Myers  Amgen has agreed to pay Celgene  13 4 billion in cash or approximately  11 2 billion net of anticipated future cash tax benefits for the drug  Since Enbrel is reeling under pressure  Otzela will strengthen Amgen s portfolio of inflammatory drugs  Otezla  approved to treat psoriasis  psoriatic arthritis and oral ulcers associated with Beh et s disease  has been one of the key growth drivers for Celgene  The closing of this deal  however  is contingent on the U S  Federal Trade Commission s  FTC  approval and meeting of other closing conditions of the merger Earlier  Amgen and partner Allergan s comparative clinical JASMINE study evaluating ABP 798  their biosimilar candidate to Roche s Rituxan  showed clinical equivalence of the candidate to the branded drug  The study evaluated the efficacy and safety of ABP 798 compared to Rituxan in patients with non Hodgkin s lymphoma  NHL   Top line data from the study showed that the primary endpoint  an assessment of overall response rate  ORR  by week 28  was within the prespecified margin for ABP 798 compared to Rituxan  This is the second study on ABP 798 that has shown positive top line results Alexion Gets EC Approval for Label Expansion of Soliris  Alexion announced that the EC has approved the label expansion of lead drug  Soliris   The drug is now approved for the treatment of neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive with a relapsing course of the disease  The approval was based on comprehensive results from the phase III randomized  double blind  placebo controlled PREVENT study and a long term extension study  ECU NMO 302   which is still underway  The drug is already approved in the United States for this indication  Soliris is already approved for the treatment of two severe and ultra rare disorders  paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome   in the United States and Europe  The FDA has also approved the drug for the treatment of generalized myasthenia gravis Alexion currently carries a Zacks Rank  2  Buy   You can see  Gilead Closes Research Deal With Galapagos  Gilead  global research and development collaboration agreement with Galapagos NV   NASDAQ GLPG    The agreement  which was signed on Jul 14  received clearance from the FTC under the Hart Scott Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority  Both companies entered a 10 year global research and development collaboration  whereby Gilead will gain access to an innovative portfolio of compounds  including six molecules currently in clinical trials  more than 20 preclinical programs and a proven drug discovery platform  Per the agreement  the closure leads to an upfront license fee payment of  3 95 billion by Gilead to Galapagos  Additionally  Gilead has made an equity investment of  1 1 billion in Galapagos by subscribing for new shares  Consequently  the company now owns 13 589 686 ordinary shares of Galapagos  representing approximately 22  of the currently outstanding share capital of Galapagos Retrophin Down on Study Failure  Shares of Retrophin  Inc    NASDAQ RTRX    after it announced the failure of its late stage study evaluating fosmetpantotenate in patients with pantothenate kinase associated neurodegeneration  PKAN   a rare genetic neurological disorder  The phase III study  FORT  was evaluating the safety and efficacy of fosmetpantotenate compared to placebo in 84 PKAN patients  Patients received either three times daily dosing of fosmetpantotenate or placebo using a 1 1 randomization over 24 weeks  The primary endpoint of the study was the change from baseline in the PKAN ADL scale through 24 weeks of treatment  After completing the 24 week treatment period  all patients were eligible to receive fosmetpantotenate as part of an open label extension study However  neither did the study meet its primary endpoint nor did it demonstrate a difference between treatment groups  The study also did not meet its secondary endpoint  Fosmetpantotenate was a late stage candidate and a potential approval would have boosted the company s top line significantly  Moreover  the failure of the study will most likely lead to the termination of the entire clinical program on this candidate Clearside Biomedical Plunges on Setback  Shares of Clearside Biomedical  Inc    NASDAQ CLSD   plummeted after the company provided an update on its New Drug Application  NDA  for Xipere  triamcinolone acetonide suprachoroidal injectable suspension  to the FDA  The FDA s Office of Pharmaceutical Quality  OPQ  requested Clearside to provide stability data for the triamcinolone acetonide  TA  suspension produced utilizing an enhanced manufacturing process implemented by the company  Though the formulation of the TA suspension has not changed  the data was requested to verify the comparability of the stability profiles of the batches made using an enhanced manufacturing process with that of the batches originally submitted as part of the NDA Consequently  Clearside expects to receive a CRL from the FDA on or before its PDUFA  Prescription Drug User Fee Act  date of Oct 19  2019  The company plans to re submit the NDA in the first quarter of 2020 with the requested stability data PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index lost 2 64  in the last five trading sessions  Among the biotech giants  Amgen gained 1 63  in the period  Over the past six months  shares of Amgen have gained 9 57   whereas Regeneron stock has declined 35 06    See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more pipeline updates Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-amgn-to-buy-celgs-otezla-alxns-soliris-gets-ec-nod--more-200459434,200459434
146470,367985,ALXN,ALXN Vs  CBM  Which Stock Should Value Investors Buy Now ,opinion,"Investors with an interest in Medical   Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals  NASDAQ ALXN  and Cambrex  CBM   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Currently  Alexion Pharmaceuticals has a Zacks Rank of  2  Buy   while Cambrex has a Zacks Rank of  3  Hold   Investors should feel comfortable knowing that ALXN likely has seen a stronger improvement to its earnings outlook than CBM has recently  But this is just one piece of the puzzle for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
ALXN currently has a forward P E ratio of 11 32  while CBM has a forward P E of 29 44  We also note that ALXN has a PEG ratio of 0 97  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  CBM currently has a PEG ratio of 2 94 
Another notable valuation metric for ALXN is its P B ratio of 2 47  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  CBM has a P B of 2 99 
These are just a few of the metrics contributing to ALXN s Value grade of B and CBM s Value grade of C 
ALXN sticks out from CBM in both our Zacks Rank and Style Scores models  so value investors will likely feel that ALXN is the better option right now ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/alxn-vs-cbm-which-stock-should-value-investors-buy-now-200453608,200453608
146471,367986,ALXN,Achillion  ACHN  Reports Wider Y Y Loss In Q2  Revenues Nil,opinion,"Achillion Pharmaceuticals  Inc    NASDAQ ACHN   incurred a loss of 14 cents per share in the second quarter of 2019  in line with the Zacks Consensus Estimate  However  it was wider than the year ago loss of 12 cents The company did not generate any revenues in the reported quarter due to the absence of an approved product in its portfolio The company s shares were up 8 6  on Aug 8  following the earnings release  Shares of Achillion have soared 203 2  so far this year against the  s decrease of 2 5   Shares displayed a significant uptrend following the announcement of regulatory submission for initiation of phase II study on ACH 5228 in July  Quarter in DetailResearch and development  R D  expenses increased nearly 44 5  from the year ago period to  15 9 million  primarily due to increased research costs related to pipeline candidates   danicopan  previously ACH 4471  and ACH 5228  Moreover  higher manufacturing and formulation costs for ACH 5228 and ACH 5548 also increased R D expenses General and administrative expenses declined 31 5  year over year to  5 1 million due to lower personnel fees and stock based compensation Pipeline UpdateAchillion anticipates completing the phase II study evaluating danicopan in patients with paroxysmal nocturnal hemoglobinuria   PNH   in the third quarter  In May  the company presented interim data from the study  which showed that the addition of danicopan to Alexion s   NASDAQ ALXN   Soliris  eculizumab  nearly eliminated patients  needs for blood transfusions  Top line data is expected in the fourth quarter of 2019  The company has initiated an extension of the study to evaluate Alexion s latest PNH drug  Ultomiris  in combination with danicopan Meanwhile  the company has completed enrollment in two phase II studies evaluating danicopan in C3 glomerulopathy  rare kidney disorder  However  the company postponed the end of phase II meeting with the FDA from the fourth quarter of 2019 to 2020 Achillion is also developing its next generation oral factor D inhibitors  ACH 5228 and ACH 5548  in two separate phase I studies targeting alternative pathway diseases  Data from the phase I study on ACH 5228 showed that the candidate achieved near complete and sustained alternative pathway inhibition for the dose of 120 mg twice daily  The company expects to submit an investigational new drug application to the FDA to support phase II development of ACH 5228 in the fourth quarter of 2019 Achillion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderAchillion currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the biotech drugs sector are Theravance Biopharma   NASDAQ TBPH   and Neurocrine Biosciences   NASDAQ NBIX    both carrying a Zacks Rank  2  Buy   You can see  Theravance s loss estimates narrowed from  4 74 to  4 28 for 2019 and from  4 27 to  4 01 for 2020 over the past 60 days Estimates for Neurocrine have improved from a loss of 35 cents to earnings of 80 cents for 2019 and increased from  3 01 to  3 36 for 2020 over the past 60 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-09,Zacks Investment Research,https://www.investing.com/analysis/achillion-achn-reports-wider-yy-loss-in-q2-revenues-nil-200453567,200453567
146472,367987,ALXN,Has Alexion Pharmaceuticals  ALXN  Outpaced Other Medical Stocks This Year ,opinion,"Investors focused on the Medical space have likely heard of Alexion Pharmaceuticals  NASDAQ ALXN   but is the stock performing well in comparison to the rest of its sector peers  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Alexion Pharmaceuticals is a member of the Medical sector  This group includes 866 individual stocks and currently holds a Zacks Sector Rank of  3  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  ALXN is currently sporting a Zacks Rank of  2  Buy  
Within the past quarter  the Zacks Consensus Estimate for ALXN s full year earnings has moved 4 72  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that ALXN has returned about 10 57  since the start of the calendar year  In comparison  Medical companies have returned an average of 1 06   This shows that Alexion Pharmaceuticals is outperforming its peers so far this year 
Looking more specifically  ALXN belongs to the Medical   Biomedical and Genetics industry  a group that includes 367 individual stocks and currently sits at  98 in the Zacks Industry Rank  On average  stocks in this group have lost 2 78  this year  meaning that ALXN is performing better in terms of year to date returns 
Going forward  investors interested in Medical stocks should continue to pay close attention to ALXN as it looks to continue its solid performance ",2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/has-alexion-pharmaceuticals-alxn-outpaced-other-medical-stocks-this-year-200455469,200455469
146474,367989,ALXN,Nabriva  NBRV  Gains FDA Approval For Pneumonia Drug Xenleta,opinion,"Nabriva Therapeutics plc   NASDAQ NBRV   announced that the FDA has approved its new drug application  NDA  for both intravenous  IV  and oral formulations of Xenleta  lefamulin  to treat adult patients with community acquired bacterial pneumonia  CABP  
Notably  last December  Nabvira submitted two NDAs to the FDA for both IV and oral formulations of lefamulin to treat CABP in the United States 
The approval was based on data from two pivotal phase III studies  known as LEAP 1 and LEAP 2   which evaluated the safety and efficacy of Xenleta compared to moxifloxacin for treating the given patient population  The drug was generally well tolerated in both studies 
Following the nod  Xenleta became the first IV and oral antibiotic monotherapy treatment option for adults with CABP to be approved by the FDA in nearly two decades  The drug is available for oral  600 mg  as well as IV  150 mg  formulations  both to be administered every 12 hours in patients with CABP for a period of five to seven days 
Nabriva plans to make Xenleta available mid next month through specialty distributors in the United States  The wholesale acquisition cost  WAC  of the drug would be  205 day for treating patients with IV formulation and  275 day for oral treatment 
Meanwhile  in June this year  the European Medicines Agency  EMA  accepted the Marketing Authorization Application  MAA   seeking approval for both IV and oral formulations of lefamulin to treat community acquired pneumonia  CAP  in adult patients 
If approved  lefamulin will be available across all the 28 member states of the EU along with Norway  Liechtenstein and Iceland 
Shares of Nabriva have soared 51 4  so far this year against the  decline of 2  

 
We would like to remind investors that Nabvira has another candidate in its portfolio called Contepo  fosfomycin   which is a potentially first in class epoxide intravenous antibiotic developed for treating adult patients with complicated urinary tract infection  cUTI  
Yesterday  the company announced that it plans to resubmit an NDA for Contepo injection to the FDA early in the fourth quarter of 2019 for treating patients with cUTI including acute pyelonephritis 
The decision was made following the receipt of the final Type A Meeting minutes from the regulatory body 
Zacks Rank   Other Stocks to Consider
Nabvira currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the healthcare sector include FibroGen  Inc   NASDAQ FGEN    Eagle Pharmaceuticals  Inc    NASDAQ EGRX   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    while FibroGen and Eagle Pharmaceuticals sport a Zacks Rank  1  Strong Buy   Alexion has a Zacks Rank  2  Buy   You can see  
FibroGen s loss per share estimates have been narrowed 57 5  for 2019 and 64 2  for 2020 over the past 60 days 
Eagle Pharmaceuticals  earnings estimates have been revised 5 2  upward for 2019 and 1 2  for 2020 over the past 60 days  The stock has surged 46 3  year to date 
Alexion s earnings estimates have been revised 4 2  upward for 2019 and 2 1  for 2020 over the past 60 days  The stock has rallied 15 8  year to date 
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ",2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/nabriva-nbrv-gains-fda-approval-for-pneumonia-drug-xenleta-200456925,200456925
146478,367993,ALXN,Inovio Ends Enrollment In Anal Dysplasia Study On VGX 3100,opinion,"Inovio Pharmaceuticals  Inc    NASDAQ INO   announced that it has completed enrollment in a phase II study evaluating its lead HPV immunotherapy   VGX 3100   for the treatment of anal dysplasia caused by human papillomavirus  HPV   The study will assess the efficacy and safety of VGX 3100 in 24 adult men and women with anal high grade squamous intraepithelial lesions  anal HSIL   Preliminary efficacy data from the study is expected to be announced later this year 
Anal HSIL can often lead to HPV associated squamous cell carcinoma of the anus  SCCA  
Notably  surgical excision  electro cautery or laser therapy are the only forms of treatment available for patients with HPV related anal dysplasia  However  half of these patients experience recurrence of the disease within one year of treatment and approximately 70  within three years of treatment  thereby requiring multiple treatment and repeated surgeries 
If approved  Inovio will be able to address this unmet medical need  which could effectively eliminate or delay surgery for the given patient population 
Shares of Inovio were up 2 5  following this news on Monday  However  the stock has plunged 39 3  so far this year wider than the  decline of 2 1  

 
VGX 3100  an HPV immunotherapy  is the most advanced candidate in Inovio s pipeline 
Last month  the company concluded enrollment in another phase II study on VGX 3100 for the treatment of vulvar dysplasia caused by HPV  Interim data from this study is also expected before the end of 2019 
Moreover  in June  Inovio completed enrolling patients in the pivotal phase III study REVEAL 1  which is currently evaluating VGX 3100 for the treatment of cervical dysplasia caused by HPV  In March this year  Inovio had started recruiting patients in the confirmatory REVEAL 2 study  Based on the outcomes from this REVEAL 2 analysis  Inovio plans to submit a regulatory filing  seeking approval for VGX 3100 in 2021 
We would like to remind investors that in July  Inovio announced a strategic restructuring to prioritize the development of its late stage HPV assets and reallocate capital to develop the fast to market product candidates  Following this  the company reduced its annual burn rate by 25  and cut workforce by 28   Inovio also decided to trim some early stage R D programs while terminating the phase I II study evaluating INO 5401 for the treatment of advanced bladder cancer 
Notably  in April this year  Inovio closed patient enrollment in the phase I II study on its immuno oncology combo of INO 5401 plus INO 9012 in combination with Regeneron   NASDAQ REGN     Sanofi s   NASDAQ SNY   PD 1 inhibitor Libtayo  cemiplimab  for treating the newly diagnosed patients with glioblastoma  GBM  
The company expects to provide the interim progression free survival and safety data on the above study by this year end and the overall survival data in 2020 
Zacks Rank   Key Pick
Inovio currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which has a Zacks Rank  2  Buy   You can see  
Alexion s earnings estimates have been revised 4 2  upward for 2019 and 2 1  for 2020 over the past 60 days  The stock has rallied 15 8  year to date 
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ",2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/inovio-ends-enrollment-in-anal-dysplasia-study-on-vgx3100-200456923,200456923
146495,368010,ALXN,Is A Beat In Store For Repligen  RGEN  This Earnings Season ,opinion,We expect Repligen Corporation   NASDAQ RGEN   to beat on earnings when it reports second quarter 2019 results Shares of Repligen have soared 67 4  so far this year against the  decrease of 0 2  The company s track record has been mixed so far  having delivered a positive earnings surprise in three of the last four quarters  missing expectations once  The average four quarter beat is 1 92   In the last reported quarter  Repligen came up with a positive surprise of 7 69  Let s see  how things are shaping up for this quarter to be reported Factors to ConsiderRepligen is a leading provider of advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs  The company earns revenues from the sale of several products  which can be categorized mainly under three segments  namely Filtration  Chromatography and Protein products The company s filtration products include KrosFlo hollow fiber  HF  TFF membranes and modules  ProConnex single use flow path connectors  flat sheet TFF cassettes and hardware  and XCell alternating tangential flow  ATF  devices and related consumables  The franchise has been performing well  led by the acceleration in ATF sales The chromatography franchise comprises products used in the downstream purification and quality control of biological drugs  led by the OPUS packed chromatography column line The protein product line generates revenues through the sale of Protein A ligands and growth factors  This too performed well in the first quarter with strength in growth factors and a solid uptick in ligand All the aforementioned three franchises grew both sequentially and on a year over year basis  We expect this positive trend to continue in the upcoming quarterly results The company did not give a quarterly guidance but raised its annual projection for revenues to  235  241 million for 2019 In April this year  Repligen entered into an agreement to acquire the privately held C Technologies  Inc  to add a franchise to process analytics with market leading technology and protein concentration measurement using VPE  ph  platforms  We expect management to provide an update on the same during second quarter investors  call Why a Likely Positive Surprise Our proven model indicates that Repligen is likely to beat on earnings this to be reported quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Repligen has an Earnings ESP of  29 31   representing the percentage difference between the Most Accurate Estimate  30 cents  and the Zacks Consensus Estimate  23 cents   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Repligen sports a Zacks Rank of 1  which increases the predictive power of ESP  Thus  the combination of a positive ESP and a favorable Zacks Rank makes us reasonably confident about a likely positive earnings surprise Conversely  the Sell rated stocks   4 or 5  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions Repligen Corporation Price and EPS Surprise   Other Stocks That Warrant a LookHere are some other biotech stocks worth considering as our model shows that these too have the right combination of elements to beat on earnings this reporting cycle Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is a Zacks  1 Ranked player and has an Earnings ESP of  3 10   The company is scheduled to release second quarter results on Jul 24  before the market opens  You can see  Gilead Sciences  Inc    NASDAQ GILD   is scheduled to release second quarter results on Jul 30  after the market closes  The company has an Earnings ESP of  3 69  and a Zacks Rank  2 Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has a Zacks Rank  3 and an Earnings ESP of  5 76   The company is scheduled to release second quarter results on Aug 6  before the market opens Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-repligen-rgen-this-earnings-season-200443242,200443242
146496,368011,ALXN,Is A Beat In The Cards For Celgene s  CELG  Q2 Earnings ,opinion,"Celgene Corporation   NASDAQ CELG   is expected to have significantly benefited from key drug Revlimid s performance  which is expected to reflect in the upcoming quarterly results 
The company surpassed earnings estimates in the trailing four quarters  In the last reported quarter  it delivered a positive earnings surprise of 2 41  Celgene Corporation Price  Consensus and EPS Surprise

    
Let s see how things are shaping up ahead of this announcement 
Earnings Whispers
Our proven model indicates that Celgene is likely to beat earnings estimates this quarter  This is because it has the right combination of two key ingredients   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  
Earnings ESP  The company s Earnings ESP is  6 28   You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Celgene has a Zacks Rank  3  Hold   which when combined with a positive ESP makes us confident of an earnings beat  
Note that we caution against the stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Factors at Play
For 2019  Celgene expects revenues to be  17 0  17 2 billion  Revlimid sales are projected to be  10 8 billion and Abraxane sales  1 1 billion  Pomalyst s revenues are expected to be  2 4 billion  whereas Otezla sales are projected to be  1 9 billion 
Celgene s key product  Revlimid  is likely to be the main growth driver in the second quarter  Revlimid  an oral  immunomodulatory drug  is currently approved for several indications  including the newly diagnosed multiple myeloma   MM    myelodysplastic syndromes   MDS   and mantle cell lymphoma   MCL   
Share gains in key markets and longer treatment duration are contributing to the drug s growth  Continued uptake in front line  non stem  cell eligible and post stem cell transplant maintenance segments should further propel sales of the drug in the second quarter 
Meanwhile  in May 2019  the European Commission  EC  approved Revlimid in combination with Velcade and dexamethasone  RVd  for the treatment of adult patients with previously untreated multiple myeloma  who are not eligible for transplant  Also  the FDA approved the drug  lenalidomide  in combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma  FL  or marginal zone lymphoma  MZL   The label expansion of the drug will further boost sales in the second quarter 
Apart from Revlimid  Pomalyst  Otezla and Abraxane are expected to contribute to the top line  Psoriasis drug  Otezla  missed the consensus mark in the first quarter but we expect it to perform impressively in the second quarter 
Apart from the regular top and bottom line numbers  investors will also focus on pipeline updates from the company  The FDA has accepted for review the new drug application  NDA  for ozanimod to treat patients with relapsing forms of multiple sclerosis  RMS  in the United States  The European Medicines Agency  EMA  also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing remitting multiple sclerosis in the European Union 
The FDA also accepted its Biologics License Application  BLA  for investigational erythroid maturation agent  luspatercept  The candidate is being developed in collaboration with Acceleron Pharma Inc  Luspatercept is being developed for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes  MDS  associated anemia  who have ring sideroblasts and require red blood cell  RBC  transfusions  and those with beta thalassemia associated anemia  who require RBC transfusions  The FDA has granted Priority Review to the BLA for the treatment of beta thalassemia 
Key Anticipated Updates
Celgene has been in news since the beginning of 2019  owing to the announcement of a merger agreement with large cap pharma company  Bristol Myers Squibb Company   NYSE BMY    The transaction was earlier anticipated to close in the third quarter of 2019 but might be delayed now  given certain regulatory conditions  We expect an update on the same during the earnings call 
Share Price Performance
Celgene s stock has gained 39 5  in the year so far   while the performance of the  remained flat 

 
Other Stocks to Consider
Here are some other stocks you may want to consider  as our model shows that these too have the right combination of elements to post an earnings beat this quarter 
Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to report results on Jul 24  The company has an Earnings ESP of  3 10  and a Zacks Rank  1  You can see  
Amgen  Inc    NASDAQ AMGN   is scheduled to release results on Jul 30  The company has an Earnings ESP of  1 05  and a Zacks Rank  3 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-celgenes-celg-q2-earnings-200443623,200443623
146497,368012,ALXN,Alexion Pharmaceuticals  ALXN  Surpasses Q2 Earnings And Revenue Estimates,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  came out with quarterly earnings of  2 64 per share  beating the Zacks Consensus Estimate of  2 36 per share  This compares to earnings of  2 07 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 11 86   A quarter ago  it was expected that this drugmaker would post earnings of  2 19 per share when it actually produced earnings of  2 39  delivering a surprise of 9 13  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Alexion  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  1 20 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 2 49   This compares to year ago revenues of  1 04 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Alexion shares have added about 25 7  since the beginning of the year versus the S P 500 s gain of 19 9  
What s Next for Alexion 
While Alexion has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Alexion was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  1  Strong Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 36 on  1 21 billion in revenues for the coming quarter and  9 51 on  4 78 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 20  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-surpasses-q2-earnings-and-revenue-estimates-200443790,200443790
146498,368013,ALXN,Incyte  INCY  Q2 Earnings Beat Estimates  Revenues Up Y Y,opinion,Incyte Corporation   NASDAQ INCY   reported strong results for the second quarter of 2019  wherein both earnings and sales comprehensively beat expectations  Shares are up in pre market trading Shares of the company have gained 26 2  in the year so far against the  s 0 3  decline  The company reported earnings of 75 cents per share  which easily surpassed the Zacks Consensus Estimate of 49 cents and 63 cents in the year ago quarter Including milestones and contracts  revenues came in at  529 9 million  which increased 2  year over year and beat the Zacks Consensus Estimate of  501 million Quarter in DetailTotal product related revenues came in at  433 9 million  up 18 7  from the year ago quarter  Jakafi revenues came in at  409 5 million  increasing 18  from the year ago quarter and beating the Zacks Consensus Estimate of  397 million  Net product revenues of Iclusig amounted to  24 4 million  up from  19 9 million in the year ago quarter   Product royalty revenues from Novartis AG   NYSE NVS   for the commercialization of Jakafi in ex U S  markets grew 21  to  56 9 million  Olumiant s product royalty revenues came in at  19 1 million R D expenses were  262 million  down from  273 million in the year ago quarter  SG A expenses amounted to  93 million  down from  96 million in the prior year quarter 2019 Outlook UpdatedThe company expects Jakafi revenues of  1 610  1 650 million in 2019  previous guidance   1 580  1 650 million   Iclusig revenues are still expected to be  90  100 million  R D expenses are expected to be  1 020  1 070 million  SG A expenses are anticipated to be  420  470 million Pipeline UpdatePipeline progress in the second quarter was impressive  In May 2019  the FDA approved a label expansion of Jakafi for the treatment of steroid refractory acute graft versus host disease  GVHD  in adult and pediatric patients aged 12 years or older  This is the third indication  for which the drug has been approved in the United States The REACH2 and REACH3 trials  evaluating steroid refractory acute and steroid refractory chronic GVHD  respectively  are ongoing in collaboration with Novartis  Results are expected before the end of this year Results from the global phase III GRAVITAS 301 trial on itacitinib for the treatment of patients with newly diagnosed acute GVHD are expected before the end of 2019 as well Incyte expects to submit the NDA for pemigatinib as a second line treatment for patients with FGFR2 translocated cholangiocarcinoma in the second half of 2019  The company initiated a phase III trial for the first line treatment of patients with cholangiocarcinoma in June Enrollment in the continuous dosing cohort of the phase II trial of pemigatinib in patients with bladder cancer is expected to complete by the end of 2019  A phase II study of pemigatinib in patients with driver activations of FGFR is expected to open in the coming months The primary endpoint was met in the phase II trial of ruxolitinib cream in patients with vitiligo  The phase III development of ruxolitinib cream in patients with vitiligo is expected to begin by the end of the year Incyte has elected to no longer co fund the development of baricitinib and in order to reallocate the capital to develop its pipeline  However  the company will continue to receive royalties on global net sales of Olumiant  baricitinib   per the terms of its agreement with partner Eli Lilly   NYSE LLY   Our TakeIncyte s performance in the second quarter was encouraging  The label expansion of Jakafi in acute GVHD should further boost sales   The company s efforts to diversify its revenue base are impressive  but pipeline setbacks are a concern Zacks Rank   Stock to ConsiderIncyte currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which carries a Zacks Rank  2  Buy   You can see  Earnings estimates for Alexion have increased 35 cents for 2019 in the past seven days following strong second quarter results Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-q2-earnings-beat-estimates-revenues-up-yy-200447347,200447347
146501,368016,ALXN,Alexion Pharmaceuticals Sees Hammer Chart Pattern  Time To Buy ,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   has been struggling lately  but the selling pressure may be coming to an end soon  That is because ALXN recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern  A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 5 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if ALXN stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-sees-hammer-chart-pattern-time-to-buy-200446860,200446860
146503,368018,ALXN,IVERIC Bio s  ISEE  Q2 Loss Narrows  Gene Therapy In Focus,opinion,"IVERIC bio   NASDAQ ISEE   reported loss of 35 cents per share for second quarter 2019  narrower than the year ago loss of 37 cents With no approved products in its portfolio  IVERIC bio derives revenues from milestone and other payments under collaborations  However  there were no such revenues in the quarter On Apr 16  the company announced that it has changed its name from Ophthotech Corporation to IVERIC bio  The company s ticker was also changed from OPHT to ISEE Shares of IVERIC bio have decreased 2 5  so far this year compared with the  s decline of 0 4  Quarter in DetailResearch and development expenses in the second quarter were up 17 5  year over year to  10 million  The increase in expenses related to development of gene therapy and HtrA1 inhibitor programs was offset by lower costs associated with the Zimura programs General and administrative expenses decreased 17 9  from the year ago period to  5 2 million due to lower infrastructure and operational costs Cash BalanceIVERIC bio s cash balance was  106 9 million as of Jun 30  2019 compared with  116 6 million as on Mar 31  2019 The company reiterated its expectation for 2019 cash and cash equivalents in the range of  80  85 million  The estimate takes into account the impact of preclinical development  collaborative research programs for gene therapies and continuation of Zimura development Gene Therapy UpdatesFollowing the change of the company s name to IVERIC bio  it is now primarily focused on developing gene therapy programs for treating orphan inherited retinal diseases  IRDs   The company has several gene therapy candidates in pre clinical stage The company expects to initiate phase I II studies on its gene therapy candidates   IC 100 and IC 200   in 2020 and 2021  respectively  The company will develop IC 100 for treating rhodopsin mediated autosomal dominant retinitis pigmentosa  RHO adRP   a retinal disease impacting peripheral and night vision  and IC 200 as a treatment for BEST1 related retinal diseases In July  the company exercised its option under the research agreement with University of Massachusetts to gain rights to develop and commercialize novel adeno associated virus   AAV   minigene therapy product candidates under the miniCEP290 program  which are being developed for treating Leber congenital amaurosis type 10  LCA10  In July  the company expanded its gene therapy portfolio by entering into a research agreement with the University of Massachusetts to develop novel AAV gene therapy product candidates under miniUSH2A program as a treatment for USH2A related IRDs including Usher Syndrome type 2A and USH2A associated nonsyndromatic adRP  The agreement includes an exclusive option for IVERIC bio to gain rights to develop and commercialize the candidate Zimura ProgressThe company s C5 complement inhibitor candidate  Zimura  is being evaluated in several mid stage clinical studies for the treatment of dry and wet AMD  Stargardt disease and geographic atrophy  The company remains on track to announce top line data from the phase IIb studies on the candidate in geographic atrophy and Stargardt disease patients in the fourth quarter of 2019 and second half of 2020  respectively IVERIC bio Inc Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderIVERIC bio currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharmaceutical sector include Axovant Sciences   NASDAQ AXGT    Alexion Pharmaceuticals   NASDAQ ALXN   and Acorda Therapeutics   NASDAQ ACOR    While Axovantand Acorda sport a Zacks Rank  1  Strong Buy   Alexion carries a Zacks Rank  2  Buy   You can see  Axovant s loss estimates have narrowed from  7 00 to  5 34 for 2019 and from  6 48 to  3 59 for 2020 over the past 60 days Alexion s earnings estimates increased from  9 50 to  9 90 for 2019 and from  10 50 to  10 74 for 2020 over the past 60 days Acorda s loss estimates narrowed from  3 59 to  3 51 for 2019 and from  3 09 to  3 05 for 2020 over the past 60 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/iveric-bios-isee-q2-loss-narrows-gene-therapy-in-focus-200450147,200450147
146506,368021,ALXN,Looking For A Growth Stock  3 Reasons Why Alexion  ALXN  Is A Solid Choice,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a growth stock that can live up to its true potential can be a tough task 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  the task of finding cutting edge growth stocks is made easy with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Our proprietary system currently recommends Alexion Pharmaceuticals  NASDAQ ALXN  as one such stock  This company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this drugmaker a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 14 5   investors should actually focus on the projected growth  The company s EPS is expected to grow 25  this year  crushing the industry average  which calls for EPS growth of 9 8  
Cash Flow Growth
While cash is the lifeblood of any business  higher than average cash flow growth is more important and beneficial for growth oriented companies than for mature companies  That s because  growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds 
Right now  year over year cash flow growth for Alexion is 20 3   which is higher than many of its peers  In fact  the rate compares to the industry average of 18 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 26 9  over the past 3 5 years versus the industry average of 9  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Alexion  The Zacks Consensus Estimate for the current year has surged 4 5  over the past month 
Bottom Line
Alexion has not only earned a Growth Score of B based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Alexion is a potential outperformer and a solid choice for growth investors ",2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-3-reasons-why-alexion-alxn-is-a-solid-choice-200450783,200450783
146521,368036,ALXN,Alexion Receives FDA Approval For Label Expansion Of Soliris,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the FDA has approved a label expansion of lead drug  Soliris  eculizumab  The drug is now approved for the treatment of neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive  The FDA approved Soliris following an expedited six month priority review The approval was based on comprehensive results from the phase III randomized  double blind  placebo controlled PREVENT study  Patients suffering from NMOSD  who were anti AQP4 antibody positive  were treated with Soliris or placebo  At 48 weeks  98  of patients treated with the drug were relapse free compared with 63  with placebo The drug is under review for the same in Europe and Japan  Soliris has received Orphan Drug designation  ODD  for the treatment of patients with NMOSD in the United States  the EU and Japan We remind investors that the drug is already approved in the United States  the EU  Japan and other countries as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria  PNH   and for adults and children with atypical hemolytic uremic syndrome  aHUS   Soliris is also approved for the treatment of adult patients with generalized MG  gMG  in the United States  the EU and Japan  The underlying growth of the drug has been robust  Label expansion of the drug into additional indications should further boost sales Alexion s share price has rallied 29 5  year to date compared with the  s growth of 2 7  The approval of long acting C5 complement inhibitor  Ultomiris  has boosted growth prospects significantly for the company  The drug is approved for PNH in the United States  Moreover  the company is working to expand the drug s label  The FDA recently accepted Alexion s supplemental biologics license application  sBLA  for Ultomiris under a priority review for the treatment of patients with aHUS to inhibit complement mediated thrombotic microangiopathy  TMA   The regulatory body has set an action date of Oct 19  2019 Meanwhile  companies like Achillion Pharmaceuticals Inc    NASDAQ ACHN   and Akari Therapeutics  Plc   NASDAQ AKTX   are also developing drugs to address PNH Zacks Rank   Key PickAlexion currently carries a Zacks Rank  3  Hold  A better ranked stock in the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries a Zacks Rank  2  Buy   You can see  Gilead s earnings estimates have moved up by 24 cents to  6 89 for 2019 over the past 90 days Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-28,Zacks Investment Research,https://www.investing.com/analysis/alexion-receives-fda-approval-for-label-expansion-of-soliris-200435599,200435599
146522,368037,ALXN,Alexion s Ultomiris Receives EU Approval For PNH In Adults,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the European Commission has approved its long acting C5 complement inhibitor  Ultomiris The drug has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  PNH  with hemolysis  with clinical symptoms indicative of high disease activity  The drug is also approved for adult patients who are clinically stable after treatment with Alexion s lead drug  Soliris  for at least the past six months The approval in the European Union was based on comprehensive results from two phase III studies  which included more than 440 patients who had either never been treated with a complement inhibitor or had been stable on Soliris Data from the studies show that the efficacy of Ultomiris administered every eight weeks was non inferior to the efficacy of Soliris administered every two weeks at all 11 primary and secondary endpoints Additional data showed that Ultomiris provided immediate and complete C5 inhibition that was sustained for eight weeks between doses  The drug eliminated breakthrough hemolysis associated with incomplete C5 inhibition Moreover  patients could easily transition to Ultomiris from Soliris The approval will strengthen Alexion s PNH franchise  as Soliris is already approved for the same  The drug is already approved in the United States for this indication  Initial conversion rates of Soliris patients have been encouraging  Most recently  the drug has been also approved in Japan Alexion s share price has rallied 36 9  year to date compared with the  s growth of 7 1   The approval of long acting C5 complement inhibitor  Ultomiris  has boosted growth prospects significantly for the company  Moreover  the company is working to expand the drug s label  The FDA recently accepted Alexion s supplemental biologics license application  sBLA  for Ultomiris under priority review for the treatment of patients with typical hemolytic uremic syndrome  aHUS  to inhibit complement mediated thrombotic microangiopathy  TMA   The regulatory body has set an action date of Oct 19  2019 Meanwhile  companies like Achillion Pharmaceuticals Inc   NASDAQ ACHN   and Akari Therapeutics  Plc   NASDAQ AKTX   are also developing drugs to address PNH Zacks Rank   Key PickAlexion currently carries a Zacks Rank  3  Hold  A better ranked stock in the same space is AMAG Pharmaceuticals  Inc    NASDAQ AMAG    which carries a Zacks Rank  2  Buy   You can see  AMAG s loss estimates have narrowed to  2 15 from  2 27 for 2019 over the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-04,Zacks Investment Research,https://www.investing.com/analysis/alexions-ultomiris-receives-eu-approval-for-pnh-in-adults-200437113,200437113
146525,368040,ALXN,Alexion  ALXN  Moves To Strong Buy  Rationale Behind The Upgrade,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  could be a solid choice for investors given its recent upgrade to a Zacks Rank  1  Strong Buy   This upgrade primarily reflects an upward trend in earnings estimates  which is one of the most powerful forces impacting stock prices 
The sole determinant of the Zacks rating is a company s changing earnings picture  The Zacks Consensus Estimate    the consensus of EPS estimates from the sell side analysts covering the stock    for the current and following years is tracked by the system 
The power of a changing earnings picture in determining near term stock price movements makes the Zacks rating system highly useful for individual investors  since it can be difficult to make decisions based on rating upgrades by Wall Street analysts  These are mostly driven by subjective factors that are hard to see and measure in real time 
As such  the Zacks rating upgrade for Alexion is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Alexion imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Alexion
For the fiscal year ending December  2019  this drugmaker is expected to earn  9 50 per share  which is a change of 20  from the year ago reported number 
Analysts have been steadily raising their estimates for Alexion  Over the past three months  the Zacks Consensus Estimate for the company has increased 1 1  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Alexion to a Zacks Rank  1 positions it in the top 5  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-moves-to-strong-buy-rationale-behind-the-upgrade-200440918,200440918
146526,368041,ALXN,New Strong Buy Stocks For July 17th,opinion,"Here are 5 stocks added to the Zacks Rank  1  Strong Buy  List today 
Delta Air Lines  NYSE DAL   Inc   DAL   This company that provides scheduled air transportation for passengers and cargo has seen the Zacks Consensus Estimate for its current year earnings increasing 6 3  over the last 60 days Delta Air Lines  Inc  Price and Consensus
    Sunoco LP  SUN   This company that engages in the distribution and retailing of motor fuels has seen the Zacks Consensus Estimate for its current year earnings increasing 16 7  over the last 60 days Sunoco LP Price and Consensus
    Alexion Pharmaceuticals  NASDAQ ALXN   Inc   ALXN   This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 0 1  over the last 60 days Alexion Pharmaceuticals  Inc  Price and Consensus
    Exelixis  Inc   EXEL   This oncology focused biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 1 1  over the last 60 days Exelixis  Inc  Price and Consensus
    Hologic  Inc   HOLX   This medical technology company has seen the Zacks Consensus Estimate for its current year earnings increasing 0 4  over the last 90 days Hologic  Inc  Price and Consensus
    You can see 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-july-17th-200440898,200440898
146529,368044,ALXN,Why Alexion  ALXN  Is Poised To Beat Earnings Estimates Again,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Alexion Pharmaceuticals  NASDAQ ALXN   which belongs to the Zacks Medical   Biomedical and Genetics industry  could be a great candidate to consider 
When looking at the last two reports  this drugmaker has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 13 04   on average  in the last two quarters 
For the last reported quarter  Alexion came out with earnings of  2 39 per share versus the Zacks Consensus Estimate of  2 19 per share  representing a surprise of 9 13   For the previous quarter  the company was expected to post earnings of  1 83 per share and it actually produced earnings of  2 14 per share  delivering a surprise of 16 94  
Price and EPS Surprise

For Alexion  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Alexion currently has an Earnings ESP of  3 10   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  1  Strong Buy  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on July 24  2019 
With the Earnings ESP metric  it s important to note that a negative value reduces its predictive power  however  a negative Earnings ESP does not indicate an earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/why-alexion-alxn-is-poised-to-beat-earnings-estimates-again-200441581,200441581
146531,368046,ALXN,Alexion  ALXN  To Report Q2 Earnings  What s In The Cards ,opinion,Alexion Pharmaceuticals Ltd    NASDAQ ALXN   is scheduled to report second quarter 2019 results  before the market opens  on Jul 24 In the last reported quarter  the company s earnings beat the Zacks Consensus Estimate by 9 13   Moreover  Alexion s earnings beat the Zacks Consensus Estimate in the trailing four quarters  the average positive surprise being 16  The company s shares have rallied 24  year to date compared with the  s growth of 0 2  What Our Model IndicatesOur proven model shows that Alexion is likely to beat earnings estimates in the to be reported quarter  This is because a stock needs to have   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to be able to beat estimates Earnings ESP  Alexion has an Earnings ESP of  3 10  as the Zacks Consensus Estimate is pegged at  2 36 and the Most Accurate Estimate is pegged at  2 44  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  The company carries a Zacks Rank  1  which increases the predictive power of ESP Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided Let s see how things are shaping up for this announcement Factors at PlayAlexion s complement franchise consists of key growth driver  Soliris  which is approved for the treatment of two severe and ultra rare disorders   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    resulting from chronic uncontrolled activation of the complement component of the immune system The company continues to identify and treat a consistently high number of new patients suffering from PNH and aHUS with Soliris across its 50 country operating platform  The underlying growth of the drug has been robust  We expect the drug to continue driving sales in the second quarter Alexion is looking to expand Soliris  label  The FDA  in June  approved Soliris to treat neuromyelitis optica spectrum disorder  NMOSD   based on positive data from the phase III study  PREVENT  The drug is under review for the same in Europe and Japan  Label expansion into additional indications would give Soliris access to a higher patient population and increase the commercial potential of the drug significantly In December 2018  The FDA approved Alexion s long acting C5 complement inhibitor  Ultomiris  for the treatment of adult patients with PNH  to be administered every eight weeks  The company launched the drug in the United States  ahead of schedule  At the first quarter earnings call  management had said that the launch of Ultomiris has been strong  The drug recorded revenues of  24 6 million in the first quarter   Sales are expected to be higher in the second quarter  Meanwhile  Ultomiris was approved in Japan in June and in the EU earlier this month  However  these will not contribute to sales in the second quarter Under its metabolic franchise  the company markets Strensiq for the treatment of patients with pediatric onset hypophosphatasia  HPP  and Kanuma for the treatment of patients with lysosomal acid lipase deficiency  LAL D   These drugs are expected to drive revenues in the second quarter Alexion also has an impressive pipeline  It has completed dosing in a phase I study of subcutaneous ALXN1210 co administered with Halozyme s   NASDAQ HALO   ENHANZE drug delivery technology  PH20  Pending co formulation data  this next generation subcutaneous formulation will be called ALXN1810  Alexion plans to initiate a first in human study of ALXN1720  a novel anti C5 albumin binding bi specific mini body that binds and prevents activation of human C5  later this year  We expect the company to provide updates on the pipeline when it reports second quarter 2019 results Alexion Pharmaceuticals  Inc  Price and Consensus   Stocks That Warrant a LookHere are some large cap pharma stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Gilead Sceinces Inc    NASDAQ GILD   has an Earnings ESP of  3 69  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Jul 30  You can see  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  5 76  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Aug 6 Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-to-report-q2-earnings-whats-in-the-cards-200442648,200442648
146536,368051,ALXN,AMAG  AMAG  To Report Q2 Earnings  What s In The Cards ,opinion,"Investors will primarily focus on the performance of marketed drugs Feraheme and Makena during AMAG Pharmaceuticals Inc  s   NASDAQ AMAG   second quarter 2019 earnings call In the last reported quarter  the company s earnings missed the Zacks Consensus Estimate by 503 64   Moreover  AMAG s earnings beat the Zacks Consensus Estimate in one of the trailing four quarters  the average negative surprise being 180 50  The company s shares have declined 42  year to date against  the  s growth of 0 5  What Our Model IndicatesOur proven model shows that AMAG is likely to beat earnings estimates in the to be reported quarter  This is because a stock needs to have   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to be able to beat estimates Earnings ESP  AMAG has an Earnings ESP of  16 67  as the Zacks Consensus Estimate is pegged at a loss of 48 cents and the Most Accurate Estimate at a loss of 40 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  The company carries a Zacks Rank  3  which increases the predictive power of ESP Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided Let s see how things are shaping up for this announcement Factors at PlayAMAG has three marketed products in its portfolio  One of these is Feraheme  ferumoxytol   which is approved as an intravenous  IV  iron replacement therapy for the treatment iron deficiency anemia  IDA  in adults with chronic kidney disease  CKD   Makena  hydroxyprogesterone caproate injection   a progestin  is approved to reduce the risk of preterm birth in women pregnant with a single baby  who have a history of singleton spontaneous preterm birth  The third product is MuGard  approved for the management of oral mucositis and stomatitis Makena and Ferahame are the primary sources of revenues for AMAG and the drugs are expected to perform well in the second quarter  Though Makena sellers are affected by entry of generic competition to the Makena IM product and IM supply constraints  the company is encouraged by strong underlying demand for the expanded label of the drug as a subcutaneous auto injector    and the progress made to replace its previous primary supplier of Makena IM with new inventory from two suppliers in the second quarter of 2019 The company has also expanded the label of Feraheme  The FDA approved a label expansion of the drug beyond the current CKD indication  The new approval includes all eligible adult Iron Deficiency Anemia   IDA   patients  who have intolerance to or have had unsatisfactory response to oral iron  The drug is already capturing additional market share and expected to continue the trend in the second quarter of 2019 In June 2019  AMAG announced that the FDA approved Vyleesi  bremelanotide injection  to treat acquired  generalized hypoactive sexual desire disorder  HSDD  in premenopausal women  The drug is an injection to be taken before sex and the first treatment for this patient population  Vyleesi will be commercially available this September  We expect management to discuss launch plans during the earnings call AMAG s Intrarosa  prasterone   approved by the FDA to treat women experiencing moderate to severe pain during sexual intercourse  dyspareunia   a symptom of vulvar and vaginal atrophy  VVA   is the first and only non estrogen product to treat dyspareunia in the United States  The company is optimistic about the drug  AMAG Pharmaceuticals  Inc  Price and Consensus
    Other Stocks That Warrant a LookHere are some other large cap pharma stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Gilead Sceinces Inc    NASDAQ GILD   has an Earnings ESP of  3 69  and a Zacks Rank  2  The company is scheduled to release second quarter 2019 results on Jul 30  You can see  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  6 25  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Aug 6 Alexion Pharmaceuticals Inc    NASDAQ ALXN   has an Earnings ESP of  3 10  and a Zacks Rank  1  The company is scheduled to release second quarter 2019 results on Jul 24 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/amag-amag-to-report-q2-earnings-whats-in-the-cards-200443060,200443060
146561,368076,ALXN,3 Reasons Growth Investors Will Love Alexion  ALXN ,opinion,"Investors seek growth stocks to capitalize on above average growth in financials that help these securities grab the market s attention and produce exceptional returns  But finding a growth stock that can live up to its true potential can be a tough task 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
Alexion Pharmaceuticals  NASDAQ ALXN  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this drugmaker a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 12 1   investors should actually focus on the projected growth  The company s EPS is expected to grow 19 8  this year  crushing the industry average  which calls for EPS growth of 7 6  
Cash Flow Growth
While cash is the lifeblood of any business  higher than average cash flow growth is more important and beneficial for growth oriented companies than for mature companies  That s because  growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds 
Right now  year over year cash flow growth for Alexion is 20 3   which is higher than many of its peers  In fact  the rate compares to the industry average of 17 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 26 9  over the past 3 5 years versus the industry average of 8 9  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Alexion have been revising upward  The Zacks Consensus Estimate for the current year has surged 0 9  over the past month 
Bottom Line
Alexion has not only earned a Growth Score of B based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination positions Alexion well for outperformance  so growth investors may want to bet on it ",2019-05-20,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-growth-investors-will-love-alexion-alxn-200423066,200423066
146563,368078,ALXN,Alexion s SBLA For Ultomiris Gets Priority Review From FDA,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the FDA has accepted its supplemental biologics license application  sBLA  for its long acting C5 complement inhibitor  Ultomiris  ravulizumab cwvz   under a priority review for the treatment of patients with atypical hemolytic uremic syndrome  aHUS  to inhibit complement mediated thrombotic microangiopathy  TMA   The regulatory body has set an action date of Oct 19  2019 Shares of Alexion were up almost 4 1  following this news on Thursday  In fact  so far this year  the stock has surged 32 3   outperforming the  rise of 5 8  This sBLA was based on data from the phase III study on Ultomiris  conducted in complement inhibitor naive patients with aHUS  which met its primary objective of complete TMA response  The results were announced this January  The primary endpoint of a complete TMA response was defined by hematologic normalization and improved kidney function  Further  a phase III program of Ultomiris on adolescents and children with aHUS is underway Notably  aHUS is a chronic  ultra rare disease that affects both children and adults  inducing a potentially irreversible damage to kidneys and other vital organs  sudden or progressive kidney failure  requiring dialysis or transplant  and premature death Last December  Ultomiris received the FDA approval for treating adult patients with paroxysmal nocturnal hemoglobinuria  PNH   to be administered every eight weeks  This nod came well ahead of its action date set for Feb 18  2019  Following the same  Ultomiris became the first and the only long acting C5 complement inhibitor to get an approval for PNH  A phase III study on Ultomiris evaluating children and adolescents with PNH is currently underway Alexion has launched Ultomiris in the United States  ahead of schedule  Initial conversion rates of Soliris   Alexion s key PNH drug   patients have been encouraging  Applications for approval in the EU are currently under review  Earlier this week  Japan s Ministry of Health  Labour and Welfare  MHLW  approved Ultomiris for the treatment of adult patients with PNH  The approval will strengthen Alexion s PNH franchise Notably  companies like Achillion Pharmaceuticals Inc    NASDAQ ACHN   and Akari Therapeutics  Plc   NASDAQ AKTX   are also developing drugs for addressing PNH Meanwhile  Alexion is working to expand Ultomiris  label  It has initiated a single  PK based phase III probe on Ultomiris  administered subcutaneously once a week to support registration in PNH and aHUS The company also initiated a phase III investigation on the drug for generalized myasthenia gravis  gMG  in the first quarter of 2019 and plans to initiate another phase III study on the same for the neuromyelitis optica spectrum disorder  NMOSD  indication by the end of 2019  Additionally  the company plans to conduct a proof of concept analysis on Ultomiris for amyotrophic lateral sclerosis  ALS  and an exploratory clinical study for primary progressive multiple sclerosis  PPMS  Zacks Rank   Key PickAlexion currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Acorda Therapeutics  Inc    NASDAQ ACOR    which sports a Zacks Rank  1  Strong Buy   You can see  Acorda s loss per share estimates have been narrowed 6 5  for 2019 and 6 9  for 2020 over the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/alexions-sbla-for-ultomiris-gets-priority-review-from-fda-200433671,200433671
146587,368102,ALXN,Is Alexion  ALXN  A Solid Growth Stock  3 Reasons To Think   Yes  ,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a great growth stock is not easy at all 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
Alexion Pharmaceuticals  NASDAQ ALXN  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
While there are numerous reasons why the stock of this drugmaker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 12 1   investors should actually focus on the projected growth  The company s EPS is expected to grow 19 8  this year  crushing the industry average  which calls for EPS growth of 8 7  
Cash Flow Growth
While cash is the lifeblood of any business  higher than average cash flow growth is more important and beneficial for growth oriented companies than for mature companies  That s because  growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds 
Right now  year over year cash flow growth for Alexion is 20 3   which is higher than many of its peers  In fact  the rate compares to the industry average of 17 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 26 9  over the past 3 5 years versus the industry average of 8 9  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Alexion  The Zacks Consensus Estimate for the current year has surged 1  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Alexion a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Alexion is a potential outperformer and a solid choice for growth investors ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/is-alexion-alxn-a-solid-growth-stock-3-reasons-to-think--yes--200413645,200413645
146590,368105,ALXN,Is Alexion  ALXN  A Solid Growth Stock  3 Reasons To Think   Yes  ,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a great growth stock is not easy at all 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
Alexion Pharmaceuticals  NASDAQ ALXN  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
While there are numerous reasons why the stock of this drugmaker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Alexion is 12 1   investors should actually focus on the projected growth  The company s EPS is expected to grow 19 8  this year  crushing the industry average  which calls for EPS growth of 8 7  
Cash Flow Growth
While cash is the lifeblood of any business  higher than average cash flow growth is more important and beneficial for growth oriented companies than for mature companies  That s because  growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds 
Right now  year over year cash flow growth for Alexion is 20 3   which is higher than many of its peers  In fact  the rate compares to the industry average of 17 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 26 9  over the past 3 5 years versus the industry average of 8 9  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Alexion  The Zacks Consensus Estimate for the current year has surged 1  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Alexion a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Alexion is a potential outperformer and a solid choice for growth investors ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/is-alexion-alxn-a-solid-growth-stock-3-reasons-to-think--yes--200413774,200413774
146591,368106,ALXN,Bluebird s  BLUE  Loss Wider Than Expected  Revenues Down Y Y,opinion,Shares of bluebird bio  Inc    NASDAQ BLUE   inched up 0 94  after the company reported mixed results for the first quarter The company reported a loss of  2 99 per share in the first quarter of 2019  wider than the Zacks Consensus Estimate of a loss of  2 80 and the year ago quarter s loss of  2 31  The wider than expected year over year loss was due to higher research   development  R D   and general   administrative  G A  expenses on lower revenues Revenues of  12 5 million beat the Zacks Consensus Estimate by 2 58   Revenues were down from  16 million in the year ago quarter bluebird s stock has soared 42 1  in the year so far compared with 5 2  growth registered by the   Quarter in DetailR D expenses escalated to  122 6 million in the first quarter of 2019 from  97 1 million a year ago  driven by costs incurred by the company to advance and expand the pipeline  resulting in increased clinical trial related costs and manufacturing costs for development programs  higher laboratory expenses  elevated employee related costs due to headcount growth  and escalated facility related costs G A expenses of  60 3 million were up 72 5  from the year ago quarter  owing to overall growth of pipeline and commercial readiness activities Pipeline Developmentbluebird s pipeline progress has been impressive in the first quarter  The pipeline includes candidates for severe genetic diseases  The company s portfolio consists of candidates like LentiGlobin for the treatment of transfusion dependent   thalassemia  TDT  and severe sickle cell disease  SCD   and Lenti D for the treatment of cerebral adrenoleukodystrophy  CALD  In March 2019  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  adopted a positive opinion recommending conditional marketing authorization for Zynteglo  autologous CD34  cells encoding   A T87Q globin gene   a gene therapy for patients aged 12 years or older with TDT  The CHMP s positive opinion will now be reviewed by the European Commission  EC  In April 2019  bluebird bio treated the first patient in ALD 104  the company s international  non randomized  open label  multi site phase III study of Lenti D product after myeloablative conditioning  using busulfan and fludarabine  in patients younger than or equal to 17 years of age with CALD The oncology pipeline includes CAR T cell product candidates   idecabtagenevicleucel   formerly known as bb2121  and bb21217   for the treatment of multiple myeloma  The company is co developing and co promoting bb2121 in the United States with Celgene Corp    NASDAQ CELG   Our Takebluebird s progress with its pipeline is encouraging  The company has an impressive pipeline of gene therapies for genetic diseases and cancer  Zynteglo looks promising and a tentative approval in Europe is expected later this year  We are also positive about bluebird s collaboration with Regeneron   NASDAQ REGN    as this provides the former with funds  We expect investors to focus on pipeline updates Zacks Rank   A Stock to Considerbluebird currently carries a Zacks Rank  2  Buy  Another attractive stock in the healthcare sector is Alexion Pharmaceuticals  NASDAQ ALXN   Inc    which currently sports the same rank as bluebird  You can see  Alexion earnings per share estimates are up by 19 cents in the past 30 days Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-05,Zacks Investment Research,https://www.investing.com/analysis/bluebirds-blue-loss-wider-than-expected-revenues-down-yy-200417481,200417481
146592,368107,ALXN,What Makes Alexion  ALXN  A New Buy Stock,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN  appears an attractive pick  as it has been recently upgraded to a Zacks Rank  2  Buy   An upward trend in earnings estimates    one of the most powerful forces impacting stock prices    has triggered this rating change 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts  since these are mostly driven by subjective factors that are hard to see and measure in real time  In these situations  the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near term stock price movements 
As such  the Zacks rating upgrade for Alexion is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  The influence of institutional investors has a partial contribution to this relationship  as these big professionals use earnings and earnings estimates to calculate the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
For Alexion  rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company s underlying business  And investors  appreciation of this improving business trend should push the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Alexion
For the fiscal year ending December  2019  this drugmaker is expected to earn  9 49 per share  which is a change of 19 8  from the year ago reported number 
Analysts have been steadily raising their estimates for Alexion  Over the past three months  the Zacks Consensus Estimate for the company has increased 1  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Alexion to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/what-makes-alexion-alxn-a-new-buy-stock-200419524,200419524
146593,368108,ALXN,ALXN Or ALKS  Which Is The Better Value Stock Right Now ,opinion,"Investors with an interest in Medical   Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals  NASDAQ ALXN  and Alkermes  ALKS   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Currently  Alexion Pharmaceuticals has a Zacks Rank of  2  Buy   while Alkermes has a Zacks Rank of  3  Hold   Investors should feel comfortable knowing that ALXN likely has seen a stronger improvement to its earnings outlook than ALKS has recently  But this is only part of the picture for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
ALXN currently has a forward P E ratio of 13 53  while ALKS has a forward P E of 74 48  We also note that ALXN has a PEG ratio of 0 92  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  ALKS currently has a PEG ratio of 3 22 
Another notable valuation metric for ALXN is its P B ratio of 2 97  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  ALKS has a P B of 3 62 
These are just a few of the metrics contributing to ALXN s Value grade of B and ALKS s Value grade of D 
ALXN stands above ALKS thanks to its solid earnings outlook  and based on these valuation figures  we also feel that ALXN is the superior value option right now ",2019-05-15,Zacks Investment Research,https://www.investing.com/analysis/alxn-or-alks-which-is-the-better-value-stock-right-now-200422160,200422160
146609,368124,ALXN,Ra Pharmaceuticals Closes End of Phase 2 Interaction With FDA,opinion,"Ra Pharmaceuticals  Inc    NASDAQ RARX   announced that it has successfully completed the End of Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis  gMG  
Based on FDA s feedback  Ra Pharma plans to initiate a pivotal  phase III study to evaluate the efficacy of a once daily  subcutaneously  SC  self administered dose of 0 3 mg kg of zilucoplan versus placebo  The study is expected to enroll about 130 patients with gMG  who are acetylcholine receptor  AChR  antibody positive  regardless of their prior therapies  The primary endpoint will be the change in the MG Activities of Daily Living  MG ADL  score from baseline to week 12  
Once the phase III study is complete  patients will have the option to enroll themselves in an open label  long term extension study  Ra Pharma expects to initiate the phase III study in the second half of 2019 
The End of Phase II interactions were conducted after the company completed the phase II study on zilucoplan for the treatment of gMG  Statistically significant improvements in the pre specified primary and key secondary endpoints were observed for both zilucoplan dose groups versus placebo at 12 weeks 
Shares of the company have increased 30 9  in the past year compared with the  s growth of 10  

 
After having reached an alignment with the FDA based on the phase III study  Ra Pharma has decided to prioritize gMG as the lead indication for zilucoplan  with aim to build a complement focused neurology franchise  The company thus plans to initiate a phase II study in an undisclosed neuromuscular indication in the second half of 2019 
As a result  the company has decided to postpone further clinical development of zilucoplan in paroxysmal nocturnal hemoglobinuria  PNH   Dosing will continue in the company s long term extension of the phase II PNH program 
Notably  Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   blockbuster drug  Soliris is also approved for the treatment gMG and PNH 
Zacks Rank   Stocks to Consider
Ra Pharmaceuticals currently carries a Zacks Rank  3  Hold   You can see  
Some better ranked stocks worth considering are Johnson   Johnson   NYSE JNJ   and Bayer  DE BAYGN  AG   OTC BAYRY    each carrying a Zacks Rank  2  Buy  
Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters at an average of 1 61  
Bayer s earnings per share estimates have increased from  1 92 to  1 95 for 2019 over the past 60 days 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/ra-pharmaceuticals-closes-endofphase-2-interaction-with-fda-200405695,200405695
146610,368125,ALXN,Alexion Pharmaceuticals  ALXN  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Alexion Pharmaceuticals  NASDAQ ALXN  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on April 25  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  2 19 per share in its upcoming report  which represents a year over year change of  30 4  
Revenues are expected to be  1 11 billion  up 19  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 24  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Alexion 
For Alexion  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 37  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Alexion will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Alexion would post earnings of  1 83 per share when it actually produced earnings of  2 14  delivering a surprise of  16 94  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Alexion doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-alxn-reports-next-week-wall-street-expects-earnings-growth-200408475,200408475
146611,368126,ALXN,Can Alexion  ALXN  Keep The Earnings Surprise Streak Alive ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Alexion Pharmaceuticals  NASDAQ ALXN   which belongs to the Zacks Medical   Biomedical and Genetics industry 
This drugmaker has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 16 18  
For the last reported quarter  Alexion came out with earnings of  2 14 per share versus the Zacks Consensus Estimate of  1 83 per share  representing a surprise of 16 94   For the previous quarter  the company was expected to post earnings of  1 75 per share and it actually produced earnings of  2 02 per share  delivering a surprise of 15 43  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Alexion  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Alexion currently has an Earnings ESP of  1 17   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on April 25  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/can-alexion-alxn-keep-the-earnings-surprise-streak-alive-200409623,200409623
146614,368129,ALXN,Will Biotech ETFs Continue To Rally In Q1 Earnings ,opinion,"First quarter earnings results have been pretty impressive so far  Notably  79 2  of the that have reported Q1 results till Apr 18 have crushed earnings estimates while 54 5  have surpassed the revenue mark  Fundamentals of the U S  economy are decent as evident from rising wages  increasing consumer spending  solid manufacturing and strengthening labor market  Also  moderately dovish Fed minutes from the latest meeting reflect less chances of a rate hike in 2019  Moreover  the U S  government recently postponed a tariff hike on Chinese imports  suggesting improving trade relations between the nations In such a scenario  investors with money parked in the biotech industry must be excited to gauge the sector s first quarter 2019 performance The industry has kept its promise for solid returns so far  The rally in some major biotechnology indexes reflects the same  In this context  the  has returned 10 4  year to date  Following the trend  has returned around 20 8   Increasing M A deals  growing AI dominance and favorable regulatory tidings continue to boost the biotech market  read    Moreover  broader biotech ETFs such as iShares Nasdaq Biotechnology ETF   VanEck Vectors Biotech ETF   LON BBH    ProShares Ultra Nasdaq Biotechnology ETF  and First Trust Amex Biotechnology Index   LON FBT   have gained 10 75   10 77   19 6  and 12 8   respectively  so far this year  The strength is likely to continue with some big names like Amgen   NASDAQ AMGN    Gilead Sciences   NASDAQ GILD   and Alexion Pharmaceuticals   NASDAQ ALXN   lined up to report this week  These stocks collectively account for 20 2  share in IBB  19 6  in BBH  20 1  in BIB and 9 94  in FBT Let s dig deeper into the earnings picture of these companies  which will drive the performance of the above mentioned funds in the coming days  see    According to our proven Zacks model   a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  when combined with a positive increases chances of an earnings beat  while Zacks Rank  4 or 5  Sell rated  stocks are best avoided  You can uncover the best stocks to buy or sell before they re reported with our   You can see  Is There a Surprise in the Cards Amgen carries a Zacks Rank  3 and has an Earnings ESP of  0 06   The company has a four quarter average positive surprise of 7 26   It has witnessed negative earnings estimate revision of 9 cents over the past 60 days for the quarter to be reported  The stock has a  of C  Amgen will report earnings on Apr 30  after markets close 
Amgen Inc  Price and EPS Surprise    Gilead is expected to release earnings on May 2  after market close  It has a Zacks Rank  2 and an Earnings ESP of  1 37   Gilead has average positive earnings surprise of 1 99  for the last four quarters and has seen negative earnings estimate revision of a penny over the past two months for the to be reported quarter  It has a VGM Score of C 
Gilead Sciences  Inc  Price and EPS Surprise    Alexion Pharmaceuticals has a Zacks Rank  3 and an Earnings ESP of  1 17    The company has a four quarter average earnings beat of 17 1   It has seen negative earnings estimate revision of two cents for the to be reported quarter over the past 60 days  The stock has a VGM Score of C  The company is scheduled to report on Apr 25  before the opening bell 
Alexion Pharmaceuticals  Inc  Price and EPS Surprise   ConclusionWith the criterions for beat holding true for three of the four major companies  investors can expect a strong Q1 earnings season for the biotech sector  In turn  the ETFs with solid exposure to these stocks are expected to maintain momentum  Meanwhile  BBH has a Zacks Rank  1  Strong Buy  while IBB and FBT have a Zacks Rank  2  Buy  Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/will-biotech-etfs-continue-to-rally-in-q1-earnings-200410556,200410556
146631,368146,ALXN,Alexion  ALXN  To Report Q4 Earnings  What s In The Cards ,opinion,"Alexion Pharmaceuticals Ltd    NASDAQ ALXN   is scheduled to report fourth quarter 2018 results  before the market opens  on Feb 4 
Alexion s shares have increased 1 7  in the past year  against the  s decline of 21 3  

 
Let s see how things are shaping up for this announcement 
Factors in Play
Alexion s complement franchise consists of key growth driver  Soliris  approved for the treatment of two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS  
Alexion continues to identify and treat a consistently high number of new patients with PNH and aHUS with Soliris across its 50 country operating platform  The underlying growth of Soliris has been robust  We expect Soliris to drive sales in the fourth quarter 
In order to further increase the commercial potential of the drug  Alexion is working on expanding Soliris  label into additional indications  The FDA had also approved the drug for the treatment of refractory gMG in patients who are anti acetylcholine receptor antibody positive  The drug was approved in Europe as well for this indication  Label expansion should further boost sales for the drug 
Under its metabolic franchise  the company markets Strensiq for the treatment of patients with pediatric onset hypophosphatasia  HPP  and Kanuma for the treatment of patients with lysosomal acid lipase deficiency  LAL D   These drugs are expected to drive revenues in the fourth quarter 
Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug  Soliris  In May 2018  Alexion acquired Sweden based biopharmaceutical company  Wilson Therapeutics AB  The acquisition added a late stage candidate  WTX101 to the company s pipeline  The candidate is currently in phase III for the treatment of Wilson disease  a rare genetic disorder 
Alexion s efforts to develop its pipeline are impressive  Recently  the company announced that the phase III study of its long acting C5 complement inhibitor Ultomiris  ravulizumab cwvz ALXN1210   conducted in complement inhibitor naive patients with atypical hemolytic uremic syndrome  aHUS   met its primary objective of complete thrombotic microangiopathy  TMA  response  The company plans to file regulatory submission in the United States in the first half of 2019  followed by similar applications in the European Union and Japan 
Last month  the FDA approved Ultomiris for the treatment of adult patients with PNH  well ahead of its action date of Feb 18  2019  Ultomiris is the first and the only long acting C5 complement inhibitor to get an approval for this indication 
Alexion is also conducting a phase I study of subcutaneous ALXN1210  co administered with Halozyme Therapeutics  Inc  s   NASDAQ HALO   ENHANZE drug delivery technology  PH20  Pending the co formulation data  this next generation subcutaneous formulation will be called ALXN1810 and has potential to further extend the dosing interval to once every two weeks or once a month 
We expect updates on the candidate in fourth quarter earnings call 
 Alexion Pharmaceuticals  Inc  Price and EPS Surprise

   Stocks That Warrant a Look
Here are some health care stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter  According to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   Zacks Rank  4 or  5  Strong Sell  stocks are best avoided 
Regeneron Pharmaceuticals Inc    NASDAQ REGN   has an Earnings ESP of  6 80  and a Zacks Rank  3  The company is scheduled to release fourth quarter report on Feb 6 
Bausch Health Cos Inc    NYSE BHC   has an Earnings ESP of  6 08  and a Zacks Rank  2  The company is scheduled to release fourth quarter results on Feb 20 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-02-01,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-to-report-q4-earnings-whats-in-the-cards-200382341,200382341
146632,368147,ALXN,Is Alexion  ALXN  A Great Growth Stock  ,opinion,Growth stocks can be some of the most exciting picks in the market  as these high flyers can captivate investors  attention  and produce big gains as well  However  they can also lead on the downside when the growth story is over  so it is important to find companies which are still seeing strong growth prospects in their businesses One such company that might be well positioned for future earnings growth is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    This firm  which is in the Medical   Biomedical and Genetics industry  saw EPS growth of 35 2  last year  and is looking great for this year too In fact  the current growth estimate for this year calls for earnings per share growth of 15 2   Furthermore  the long term growth rate is currently an impressive 15 8   suggesting pretty good prospects for the long haul Alexion Pharmaceuticals  Inc  Price and Consensus   And if this wasn t enough  the stock has actually seen estimates rise over the past month for the current fiscal year by about 4 1   Thanks to this rise in earnings estimates  ALXN has a Zacks Rank  2  Buy  which further underscores the potential for outperformance in this company  You can see  So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon  make sure to consider ALXN  Not only does it have double digit earnings growth prospects  but its impressive Zacks Rank suggests that analysts believe better days are ahead for ALXN as well Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-10,Zacks Investment Research,https://www.investing.com/analysis/is-alexion-alxn-a-great-growth-stock-200386271,200386271
146649,368164,ALXN,Achillion Reports Positive Interim Data On Factor D Inhibitors,opinion,"Achillion Pharmaceuticals  Inc    NASDAQ ACHN   announced positive interim data from clinical studies evaluating its factor D inhibitors   ACH 4471  ACH 5228 and ACH 5548  Two phase II studies are evaluating the first generation oral factor D inhibitor  ACH 4471  in patients with paroxysmal nocturnal hemoglobinuria   PNH   and C3 glomerulopathy  C3G   The company is developing its next generation factor D inhibitors  ACH 5228 and ACH 5548  in two separate phase I studies 
Data from the mid stage studies on ACH 4471 demonstrated proof of concept as monotherapy or in combination with a C5 Inhibitor in PNH patients  Moreover  ACH 4471 achieved proof of mechanism on C3G patients   Achillion is currently enrolling patients in six and 12 month studies to evaluate ACH 4471 in C3G patients  The company is planning an end of phase II meeting in the fourth quarter of 2019 
Data from the early stage studies evaluating ACH 5228 and ACH 5548 showed that these have the potential of higher alternative pathway inhibition along with a reduced dosing frequency  The company is planning to initiate a multiple ascending dose phase I study to evaluate ACH 5228 in January 2019 
Shares of Achillion rose 7 5  in after market trading on Dec 17 following the news  However  the shares of the company have lost 16 7  year to date compared with the  s decline of 20 7  

 
Achillion is focused on its factor D portfolio  The company is working on to develop oral inhibitors of complement Factor D  Targeted therapeutic areas include PNH  C3G  immune complex membranoproliferative glomerulonephritis  atypical hemolytic uremic syndrome and dry age related macular degeneration 
Factor D  an essential protein of the complement pathway is integral to the human innate immune system  Though this area has commercial opportunity  the complement mediated space is extremely crowded with many biotech companies working to introduce these treatments to the market 
We remind investors that another phase II study is evaluating ACH 4471 in combination with Alexion s   NASDAQ ALXN   Soliris  eculizumab  for potentially long term treatment of PNH patients  who are already being treated with Soliris Achillion Pharmaceuticals  Inc  Price
 

   Zacks Rank   Other Key Picks
Achillion currently carries a Zacks Rank  2  Buy   Some other top ranked stocks from the same sector include Genomic Health  Inc    NASDAQ GHDX   and Asterias Biotherapeutics  Inc    NYSE AST    While Genomic Health sports a Zacks Rank  1  Strong Buy   Asterias carries a Zacks Rank  2  You can see  
Genomic Health s earnings estimates have been revised 86  upward for 2018 over the past 60 days  The stock has soared 92 9  so far this year 
Asterias  loss per share estimates have been narrowed by 5 6  for 2018 over the past 60 days 
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline 
So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/achillion-reports-positive-interim-data-on-factor-d-inhibitors-200369310,200369310
146650,368165,ALXN,Alexion Pharmaceuticals Enters Oversold Territory,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   has been on a bit of a cold streak lately  but there might be light at the end of the tunnel for this overlooked stock  And for technical investors there is some hope when looking at ALXN given that  according to its RSI reading of 27 64  it is now in oversold territory What is RSI RSI stands for  Relative Strength Index  and it is a popular indicator used by technically focused investors  It compares the average of gains in days that closed up to the average of losses in days that closed down  readings above 70 suggest an asset is overbought  while an RSI below 30 suggests undervalued conditions are present Other FactorsYet  ALXN s low RSI value isn t the only reason to have some optimism over a coming turnaround  as there has been plenty of positive earnings estimate revision activity as of late  This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Alexion Pharmaceuticals  earnings consensus Over the past two months  investors have seen 10 earnings estimate revision move higher  compared with none lower  at least when looking at the key current year time frame  And the consensus estimate for ALXN has also been on an upward trend over the past 60 days  as estimates have risen by 5 3  over the last two months If this wasn t enoughAlexion Pharmaceuticals also has a Zacks Rank  1  Strong Buy  which puts it into rare company among its peers  So  given all of these factors  investors may want to consider getting in on this stock now  or holding on   as there are some favorable trends that could bubble up for this stock before long  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/alexion-pharmaceuticals-enters-oversold-territory-200369767,200369767
146651,368166,ALXN,Alexion s  ALXN  Soliris Drives Growth Amid Pricing Pressure,opinion,"We issued an updated report on Alexion Pharmaceuticals  Inc    NASDAQ ALXN   on Dec 26  2018 
Alexion is a biopharmaceutical company that focuses on the development and commercialization of life transforming drugs for the treatment of patients with ultra rare disorders 
The company s lead drug Soliris  the key growth driver  is approved for the treatment of two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   Alexion is working on expanding Soliris  label into additional indications 
The FDA had also approved the drug for the treatment of refractory gMG in patients who are anti acetylcholine receptor antibody positive  The drug was approved in Europe as well for this indication  The initial uptake of the drug for this indication has been encouraging as the company continues to add new patients in the United States 
Alexion received a significant boost with the FDA approval of its long acting C5 complement inhibitor  Ultomiris for the treatment of adult patients with PNH  The FDA approval comes well ahead of its action date set for Feb 18  2019  The approval will strengthen Alexion s PNH franchise 
Alexion is also conducting a phase I study of subcutaneous ALXN1210  co administered with Halozyme Therapeutics  Inc  s   NASDAQ HALO   ENHANZE drug delivery technology  PH20  In the meantime  Strensiq and Kanuma are doing well and will boost revenues 
Meanwhile  Alexion is making strategic acquisitions to diversify its portfolio  The company acquired Sweden based Wilson Therapeutics for  855 million  The acquisition added a late stage candidate  WTX101 to Alexion s pipeline  The candidate is currently in phase III for the treatment of Wilson disease  a rare genetic disorder 
Alexion also acquired clinical stage biotechnology company  Syntimmune  for  1 2 billion  Syntimmune develops antibody therapeutics  targeting the neonatal Fc receptor  FcRn   The acquisition will add a mid stage candidate  SYNT001 to Alexion s pipeline  Alexion announced a partnership with Complement Pharma to co develop the preclinical C6 complement inhibitor  CP010  for neurodegenerative disorders 
Share price of Alexion has decreased 21 1  year to date  narrower than the  s decline of 25 6  

 
However  pricing is likely to impact sales  Moreover  the company relies heavily on Soliris for growth 
Zacks Rank   Key Picks
Alexion currently carries a Zacks Rank  3  Hold   A couple of better placed stocks in the healthcare sector include Bristol Myers Squibb Company   NYSE BMY   and Exelixis  Inc   NASDAQ EXEL    Both the stocks carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 84 to  3 87 for 2018 and  4 03 to  4 14 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 11 99  
Exelixis  earnings estimates have moved up from  1 03 to  1 30 for 2018 and from  1 09 to  1 25 for 2019 over the past 60 days  The company delivered positive earnings surprise in all the trailing four quarters with the average beat being 83 43  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-27,Zacks Investment Research,https://www.investing.com/analysis/alexions-alxn-soliris-drives-growth-amid-pricing-pressure-200371412,200371412
146652,368167,ALXN,Alexion s Ultomiris Meets Primary Endpoint In AHUS Study,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the phase III study of its long acting C5 complement inhibitor Ultomiris  conducted in complement inhibitor naive patients with atypical hemolytic uremic syndrome  aHUS   met its primary objective of complete thrombotic microangiopathy  TMA  response  The primary endpoint of complete TMA response was defined by hematologic normalization and improved kidney function Share price of Alexion has decreased 5 9  in the past year  narrower than the  s decline of 24 6    The study evaluated the safety and efficacy of Ultomiris  ravulizumab cwvz ALXN1210  administered by intravenous infusion in 56 adults  greater than or 18 years of age  who hadn t been treated with a complement inhibitor before  In the initial 26 week treatment period  53 6  of patients demonstrated complete TMA response  The study demonstrated 83 9  of patients treated with Ultomiris experience reduced thrombocytopenia as measured by normalization in platelet count  In the Ultomiris arm  76 8  of patients experienced reduced hemolysis or the destruction of red blood cells  and 58 9  reported improved kidney function We note that aHUS is a chronic  ultra rare disease that affects both children and adults  leading to potentially irreversible damage to kidneys and other vital organs  sudden or progressive kidney failure  requiring dialysis or transplant  and premature death  The results from the study prove that Ultomiris has the potential to become the new standard of care for patients with aHUS The company plans to file regulatory submission in the United States in the first half of 2019  followed by similar applications in the European Union and Japan We remind investors that last month the FDA approved Ultomiris for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  PNH   well ahead of its action date of Feb 18  2019  Ultomiris is the first and the only long acting C5 complement inhibitor to get an approval for this indication Alexion is also conducting a phase I study of subcutaneous ALXN1210  co administered with Halozyme Therapeutics  Inc  s   NASDAQ HALO   ENHANZE drug delivery technology  PH20  Pending the co formulation data  this next generation subcutaneous formulation will be called ALXN1810 and has potential to further extend the dosing interval to once every two weeks or once a month Companies like Achillion Pharmaceuticals Inc    NASDAQ ACHN   and Akari Therapeutics  Plc   NASDAQ AKTX   are also developing drugs for the treatment of PNH Alexion Pharmaceuticals  Inc  Price   Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/alexions-ultomiris-meets-primary-endpoint-in-ahus-study-200380697,200380697
146674,368190,ALXN,Amgen s BiTE Immunotherapies Show Promise In Early Studies,opinion,"Amgen Inc    NASDAQ AMGN   announced first clinical data from the early stage studies on its two investigational novel bispecific T cell engager  BiTE  immunotherapies   AMG 420 and AMG 330 
Two separate phase I studies evaluated AMG 420  which targets B cell maturation antigen  BCMA  and AMG 330  which targets CD33 in heavily pre treated patients with multiple myeloma and acute myeloid leukemia  AML  
Data from the studies showed that both AMG 420 and AMG 330 demonstrated anti tumor activity and early evidence of tolerability in patients with relapsed and or refractory multiple myeloma and relapsed or refractory AML  respectively 
The phase I study evaluating AMG 420  showed that seven out of 10 patients who were administered with 400  g d dose of AMG420 experienced complete response  while four patients showed no detectable cancer  Six patients were still responding at 7 5 months of follow up 
The findings were presented at the annual meeting of American Society of Hematology  ASH  
Notably  the FDA granted a fast track designation to AMG 420 based on this positive result from the early stage dose escalation study  The FDA grants a fast track designation to expedite development and the review process of a candidate  which is being developed to treat serious and unmet medical conditions 
Shares of Amgen have rallied 16 7  so far this year versus the  decline of 15 3  

 
The positive data seen in these early stage studies on the investigational BiTE immunotherapies is encouraging  especially when considered in the context of heavily pre treated patients  who have exhausted all available treatment options 
Amgen is developing approximately a dozen novel molecules leveraging its BiTE platform across hematologic and solid tumor targets  Its only marketed BiTE immunotherapy  Blincyto  gained an earlier than expected FDA approval in December 2014 and has now become a key top line driver for Amgen 
The drug recorded worldwide sales of  167 million during the first nine months of 2018 an increase of 29 5  year over year 
Blincyto has the potential to be developed for other hematologic malignancies 
Zacks Rank   Stocks to Consider
Amgen currently carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Vanda Pharmaceuticals Inc    NASDAQ VNDA   and Gilead Sciences  Inc    NASDAQ GILD    all sporting a Zacks Rank  1  Strong Buy   You can see  
Alexion s earnings estimates have been revised 5 3  upward for 2018 and 2 1  for 2019 over the past 60 days  The stock has gained 4 9  year to date 
Vanda Pharmaceuticals  earnings estimates have been raised 112 5  for 2018 and 11 1  for 2019 over the past 60 days  The stock has skyrocketed 107  year to date 
Gilead Sciences  earnings estimates have moved 5  north for 2018 and 4 8  for 2019 over the past 60 days 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/amgens-bite-immunotherapies-show-promise-in-early-studies-200365032,200365032
146675,368191,ALXN,UNITY  UBX  Soars  Stock Adds 5 1  In Session,opinion,UNITY Biotechnology  Inc    NASDAQ UBX   was a big mover last session  as the company saw its shares rise more than 5  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  The stock picked up sharply from the near flat trend of  11 79 to  13 67 in the past one month time frame The company has seen one negative estimate revision in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last UNITY currently has a Zacks Rank  3  Hold  while its  is 0 00    UNITY Biotechnology  Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which has a Zacks Rank  1  Strong Buy   You can see Is UBX going up  Or down  Predict to see what others think Up or DownLooking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/unity-ubx-soars-stock-adds-51-in-session-200365247,200365247
146676,368192,ALXN,Inovio  INO  To Receive Milestone Payment From AstraZeneca,opinion,Inovio Pharmaceuticals  Inc    NASDAQ INO   announced that it will receive an undisclosed amount of milestone payment from AstraZeneca   NYSE AZN   as the latter dosed the first patient in a phase II study on T cell activating immunotherapy  MEDI0457  The study will evaluate MEDI0457 in combination with AstraZeneca s anti PD L1 checkpoint inhibitor  Imfinzi  durvalumab   for treating several human papilloma virus  HPV  related cancers We remind investors that in August 2015  MedImmune in licensed exclusive rights to Inovio s INO 3112  which is now known as MEDI0457  Medimmune is a wholly owned subsidiary of AstraZeneca The open label phase II program will be funded by MedImmune and will be conducted as part of MD Anderson s  Moon Shot  cancer initiative  MD Anderson is a cancer research center in Houston  Dr  Michael Frumovitz  managing director  MD Anderson research center  is a noted cancer researcher  who is sponsoring the above mentioned phase II analysis The program looks to treat patients with HPV related cervical  anal  penile and vulvar cancers  Inovio is entitled to receive an additional milestone and royalty payments with the amplification of HPV cancer targets Shares of Inovio have rallied 26 4  year to date versus the  decline of 14 4  We remind investors that MedImmune is also evaluating MEDI0457  combo of Inovio s VGX 3100 immunotherapy and a DNA based immune activator encoded for IL 12  in combination with Imfinzi  for the treatment of HPV caused cervical plus head and neck cancers VGX 3100 is the most advanced candidate in Inovio s pipeline  developed for treating HPV 16 18 related high grade cervical dysplasia  CIN 2 3   Currently  the candidate is being evaluated in a phase III investigation  REVEAL 1  for addressing cervical dysplasia caused by HPV  The company expects to complete enrollment in REVEAL 1 study by early 2019 and initiate the phase II thereafter  It is also conducting a phase II assessment to examine the efficacy of VGX 3100 in women with HPV related vulvar neoplasia Zacks Rank   Other Stocks to ConsiderInovio currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the healthcare sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Vanda Pharmaceuticals Inc    NASDAQ VNDA    both sporting a Zacks Rank  1  Strong Buy   You can see  Alexion s earnings estimates have been revised 5 3  upward for 2018 and 2 1  for 2019 over the past 60 days  The stock has gained 2 2  year to date Vanda Pharmaceuticals  earnings estimates have been raised 112 5  for 2018 and 11 1  for 2019 over the past 60 days  The stock has soared 90 3  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/inovio-ino-to-receive-milestone-payment-from-astrazeneca-200365272,200365272
146677,368193,ALXN,Clovis Oncology  CLVS  In Focus  Stock Moves 6 9  Higher,opinion,Clovis Oncology  Inc    NASDAQ CLVS   was a big mover last session  as the company saw its shares rise nearly 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company as the stock is now up 46 7  in the past one month time frame The company has seen six negative estimate revisions in the past few months  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Clovis Oncology currently has a Zacks Rank  3  Hold  while its  is negative   Clovis Oncology  Inc  Price   A better ranked stock in the Medical   Biomedical and Genetics industry is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which currently carries a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here Is CLVS going up  Or down  Predict to see what others think  Up or DownLooking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-09,Zacks Investment Research,https://www.investing.com/analysis/clovis-oncology-clvs-in-focus-stock-moves-69-higher-200366626,200366626
146678,368194,ALXN,Abeona Therapeutics  ABEO  In Focus  Stock Moves 5 5  Higher,opinion,Abeona Therapeutics Inc    NASDAQ ABEO   was a big mover last session  as the company saw its shares rise more than 5  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  The stock picked up sharply from the near flat trend of  7 50 to  8 50 in the past one month time frame The company has seen two negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Abeona Therapeutics currently has a Zacks Rank  4  Sell  while its  is negative Abeona Therapeutics Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which has a Zacks Rank  1  Strong Buy   You can see Is ABEO going up  Or down  Predict to see what others think Up or DownWill You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-12-10,Zacks Investment Research,https://www.investing.com/analysis/abeona-therapeutics-abeo-in-focus-stock-moves-55-higher-200366966,200366966
146694,368210,ALXN,Looking For A Growth Stock  Why It Is Time To Focus On Alexion Pharmaceuticals  ALXN ,opinion,Growth stocks can be some of the most exciting picks in the market  as these high flyers can captivate investors  attention  and produce big gains as well  However  they can also lead on the downside when the growth story is over  so it is important to find companies which are still seeing strong growth prospects in their businesses One such company that might be well positioned for future earnings growth is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    This firm  which is in the Medical   Biomedical and Genetics industry  saw EPS growth of 26 8  last year  and is looking great for this year too In fact  the current growth estimate for this year calls for earnings per share growth of 29 1   Furthermore  the long term growth rate is currently an impressive 17   suggesting pretty good prospects for the long haul Alexion Pharmaceuticals  Inc  Price and Consensus   And if this wasn t enough  the stock has actually seen estimates rise over the past month for the current fiscal year by about 4 9   Thanks to this rise in earnings estimates  ALXN has a Zacks Rank  1  Strong Buy  which further underscores the potential for outperformance in this company  You can see  So  if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon  make sure to consider ALXN  Not only does it have double digit earnings growth prospects  but its impressive Zacks Rank suggests that analysts believe better days are ahead for ALXN as well Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-why-it-is-time-to-focus-on-alexion-pharmaceuticals-alxn-200359523,200359523
146695,368211,ALXN,Acorda Down More Than 30  In The Past 3 Months  Here s Why,opinion,Shares of Acorda Therapeutics  Inc    NASDAQ ACOR   have witnessed a decline by a huge margin in the past three months  In fact  the biotech company s stock has plunged 33 2   wider than the  decline of 13 6  The company s lead multiple sclerosis  MS  drug Ampyra is facing generic competition in the United States while the FDA extended its lead Parkinson disease candidate Inbrija s review timeline by three months  The above mentioned reasons induced a sharp decline in the stock over the past three months Ampyra Facing Generic CompetitionThe drug generated sales of  137 8 million in the third quarter of 2018 Sales of Ampyra rose 4  year over year but decreased 8 3  sequentially due to severe competition from Mylan s   NASDAQ MYL   authorized generic version  The latter launched its authorized generic product in September 2018 In March 2017  the U S  District Court for the District of Delaware invalidated four patents pertaining to Ampyra on the basis of obviousness  Originally  these patents were set to expire between 2025 and 2027  In July 2018  the Federal Circuit denied Acorda s plea for a preliminary injunction to avoid at risk launches prior to the Appeals Court decision In September 2018  the U S  Court of Appeals for the Federal Circuit upheld the District Court s previous ruling by a 2 to 1 vote to invalidate four patents of Ampyra  This paved the way for the entry of a generic product Though Ampyra s sales were better than expected in the third quarter due to additional six weeks of exclusivity  which led to an increase in full year guidance  sales are expected to decline in the future quarters          The company remains heavily dependent on Ampyra to draw major part of its revenues and losing out on the same in the upcoming quarters will be a major blow to the company s sales and cash flow Inbrija Approval DelayedAcorda is focused on its late stage Parkinson disease candidate  Inbrija  A regulatory application for Inbrija is under review in the United States as well as in the EU  A response from the regulatory body was expected on Oct 5  2018  However  in September 2018  the FDA extended the review timeline by three months and has now set an action date of Jan 5  2019 The verdict in the EU is awaited before the end of this year The FDA postponed the timeline after Acorda submitted additional information regarding chemistry  manufacturing and controls on the regulatory agency s request  The FDA stated that these submissions deemed a major amendment to the NDA and will require more time to reassess Meanwhile  Inbrija will face competition from a similar product of small pharma company Sunovion  which also has a Prescription Drug User Fee Act  PDUFA  in January 2019  However  Acorda believes that Inbrija will hold the majority market share Acorda Therapeutics  Inc  Price   Zacks Rank   Stocks to ConsiderAcorda currently carries a Zacks Rank  3  Hold   Two better ranked stocks in the healthcare sector are Gilead Sciences  Inc    NASDAQ GILD   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    both sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days Alexion s earnings estimates have moved 4 8  north for 2018 and 1 8  for 2019 over the past 60 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/acorda-down-more-than-30-in-the-past-3-months-heres-why-200359567,200359567
146696,368212,ALXN,Amgen s Blincyto Gets Positive CHMP Opinion For Line Extension,opinion,"Amgen Inc    NASDAQ AMGN   announced that Committee for Medicinal Products for Human Use   CHMP   has given a positive opinion recommending approval for a new indication of Blincyto in Europe  Amgen is looking to get approval to expand the European label of Blincyto to include treatment of patients with minimal residual disease  MRD  positive B cell precursor acute lymphoblastic leukemia   ALL   It is to be noted that the CHMP had provided a negative opinion for this label expansion earlier in July following which Amgen requested a re examination The drug is already approved for the treatment of Philadelphia chromosome negative  Ph   relapsed or refractory B cell precursor ALL in Europe as well as United States Blincyto was approved for the MRD positive B cell precursor ALL indication in the United States in March this year  Blincyto will become the first drug in Europe for the treatment of MRD in ALL patients  upon potential approval Amgen s shares are up 11 6  so far this year compared with the  s decline of 18 6  The approval was based on data from phase II BLAST study  evaluating Blincyto in MRD positive ALL patients who have achieved complete hematologic remission after receiving three or more cycles of intensive chemotherapy  Data showed that the drug achieved complete MRD response  no detectable MRD  in 78  of the patients within one treatment cycle We note that MRD refers to detectable cancer cells in patients who have achieved complete remission by conventional treatment methods  Consequently  the treatment of MRD will enable in achieving better possible clinical outcomes in patients by delaying or stopping relapse of ALL by destroying the remaining detectable traces of leukemia Blincyto has shown an impressive sales growth rate of almost 30  in the first nine months of 2018  with sales reaching  167 million  Sales are expected to improve further in the fourth quarter on the back of continued demand  However  the impact of expansion of label to include treatment of MRD has not been meaningful in the United States so far We remind investors that Blincyto competes with Pfizer Inc  s   NYSE PFE   Besponsa which is approved for the treatment of relapsed or refractory B cell precursor ALL in the United States and Europe Amgen Inc  Price
    Zacks Rank   Stocks to ConsiderAmgen currently has a Zacks Rank  3  Hold  Some better ranked stocks in the health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Gilead Sciences  Inc    NASDAQ GILD    Both the stocks carry a Zacks Rank  2  Buy   You can see  Alexion s earnings estimates increased from  7 23 to  7 61 for 2018 and  8 59 to  8 77 for 2019 over the last 30 days  The company delivered a positive earnings surprise in the four trailing quarters with average beat of 16 77  Gilead s earnings per share estimates increased from  6 63 to  6 87 for 2018 and  6 58 to  6 75 for 2019 over the last 30 days  The company delivered a positive earnings surprise in three of the four trailing quarters with average beat of 6 99  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-18,Zacks Investment Research,https://www.investing.com/analysis/amgens-blincyto-gets-positive-chmp-opinion-for-line-extension-200360626,200360626
146697,368213,ALXN,Fortress Biotech  FBIO  In Focus  Stock Moves 6 5  Higher,opinion,Fortress Biotech  Inc    NASDAQ FBIO   was a big mover last session  as the company saw its shares rise more than 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  0 83 to  1 12 in the past one month time frame The move came after the company announced that it has inked a deal to divest its majority stake in National Holdings Corporation to NHC Holdings  LLC  for roughly  22 9 million  The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Fortress Biotech currently has a Zacks Rank  3  Hold  while its  is 0 00  Fortress Biotech  Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which has a Zacks Rank  1  Strong Buy   You can see Is FBIO going up  Or down  Predict to see what others think Up or DownThe Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/fortress-biotech-fbio-in-focus-stock-moves-65-higher-200361018,200361018
146698,368214,ALXN,Eyenovia Initiates Phase III Study For Mydriasis Candidate,opinion,"Eyenovia  Inc    NASDAQ EYEN   announced that it has initiated enrollment of patients in a phase III study   MIST 1   to evaluate MicroStat as a treatment for pharmacologic mydriasis  dilation of the pupil   The study is part of a program that includes two pivotal phase III studies   MIST 1 and MIST 2   for evaluating MicroStat  a fixed combination phenylephrine  2 5   and tropicamide  1   ophthalmic solution administered as micro dose through Optejet dispenser The company expects to announce top line data from both the studies in the first half of 2019 Eyenovia s stock rallied 30 7  in after market trading on Nov 26 following the news  However  the company s shares have declined 71  so far this year compared with the  s decline of 19 6  The MIST 1 study will administer MicroStat combination solution and each component of the solution in both eyes of patients on separate days while the MIST 2 study will administer MicroStat and a placebo in patients on separate days  The primary endpoint of both the studies is the mean change in pupil diameter at 35 minutes after administration from baseline Per the press release  pharmacologic mydriasis is an important part of office based comprehensive and diabetic eye exams conducted every year in the United States  It is essential for the standard dilated retinal fundoscopic examination  An estimated 80 million such exams are performed every year in the country  This represents significant opportunity for the candidate Eyenovia has another late stage ready candidate  MicroProst  in its pipeline  which is being developed for the treatment of chronic angle closure glaucoma  The company plans to initiate a phase III study to evaluate the candidate in the first half of 2019 The company also has an over the counter product candidate  MicroTears  for treating dry eye  The candidate does not require evaluation in a phase III study and the company will start registration activities soon Eyenovia  Inc  Price
    Zacks Rank   Stock to ConsiderEyenovia carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharma sector include Gilead Sciences  Inc    NASDAQ GILD    Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and NeoGenomics  Inc    NASDAQ NEO    All the three stocks carry a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings estimates have increased from  6 60 to  6 93 for 2018 and from  6 53 to  6 83 for 2019 over the past 60 days  The company delivered positive earnings surprise in three of the four trailing quarters with the average beat being 6 99  Alexion s earnings estimates have moved up from  7 23 to  7 61 for 2018 and from  8 59 to  8 77 for 2019 over the past 60 days  The company came up with a positive earnings surprise in all the four trailing quarters with the average beat being 16 77  NeoGenomics  earnings per share estimates have increased from 15 cents to 18 cents for 2018 and 21 cents to 24 cents for 2019 over the past 60 days  The company delivered a positive surprise in all the four trailing quarters with the average beat being 37 5   The stock is up 85 9  so far this year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-26,Zacks Investment Research,https://www.investing.com/analysis/eyenovia-initiates-phase-iii-study-for-mydriasis-candidate-200362704,200362704
146699,368215,ALXN,Why Immunomedics  IMMU  Could Be Positioned For A Slump,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Immunomedics  Inc    NASDAQ IMMU    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  4  Sell  further confirms weakness in IMMU A key reason for this move has been the negative trend in earnings estimate revisions  For the full year  we have seen three estimates moving down in the past 30 days  compared with no upward revision  This trend has caused the consensus estimate to trend lower  going from a loss of  1 09 a share a month ago to its current level of a loss of  1 20 Also  for the current quarter  Immunomedics has seen three downward estimate revisions versus one revision in the opposite direction  dragging the consensus estimate down to a loss of 32 cents a share from a loss of 28 cents over the past 30 days The stock also has seen some pretty dismal trading lately  as the share price has dropped 17 2  in the past month Immunomedics  Inc  Price and Consensus   So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Medical   Biomedical and Genetics industry  you may instead consider a better ranked stock   Alexion Pharmaceuticals  Inc    NASDAQ ALXN    The stock currently holds a Zacks Rank  1  Strong Buy  and may be a better selection at this time  You can see the complete list of today s Zacks  1 Rank stocks here 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/why-immunomedics-immu-could-be-positioned-for-a-slump-200363949,200363949
146701,368217,ALXN,FDA Committee To Review Amgen s  AMGN  Osteoporosis Candidate,opinion,Amgen Inc    NASDAQ AMGN   along with European partner UCB announced that the FDA s Bone  Reproductive and Urologic Drugs Advisory Committee  BRUDAC  will review its biologics license application  BLA  for Evenity  romosozumab  on Jan 16  2019  Amgen is looking to get Evenity approved for the treatment of osteoporosis in postmenopausal women in the United States  who are at increased risk of fracture Evenity treats osteoporosis by increasing bone mineral density  BMD   Also  it reduces the risk of fracture The Evenity clinical program comprises three pivotal phase III studies  namely FRAME  ARCH and BRIDGE study  The FRAME study evaluated Evenity on postmenopausal women with osteoporosis  The ARCH study assessed the candidate on postmenopausal women suffering osteoporosis and who are at increased risk of fracture while the BRIDGE study evaluated Evenity on men with osteoporosis We remind investors that the first BLA seeking approval for Evenity regarding the same disease in the United States was issued a complete response letter  CRL  from the FDA in July 2017  The CRL was issued due to a cardiovascular side effect observed in the ARCH study  The BLA included data only from the FRAME program and the FDA then requested a resubmission of the application with additional data from the ARCH and the BRIDGE studies  This induced a delay in the drug s approval However  in July 2018  Amgen along with UCB refiled the BLA for Evenity to the FDA The second BLA now includes data from both ARCH and BRIDGE studies The marketing applications for Evenity are currently under review in Europe and Japan Shares of Amgen have rallied 19 8  so far this year versus the  decline of 14 6  Apart from Evenity  Amgen has several interesting candidates with significant commercial potential in its pipeline  namely CNP520  BACE inhibitor for Alzheimer s disease   tezepelumab  uncontrolled asthma  and omecamtiv mecarbil  chronic heart failure   All these candidates are in late stage development and results from these pivotal programs are expected in the near term Zacks Rank   Stocks to ConsiderAmgen currently carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Vanda Pharmaceuticals Inc    NASDAQ VNDA   and Gilead Sciences  Inc    NASDAQ GILD    all sporting a Zacks Rank  1  Strong Buy   You can see  Alexion s earnings estimates have been revised 5 3  upward for 2018 and 2 1  for 2019 over the past 60 days  The stock has gained 3  year to date Vanda Pharmaceuticals  earnings estimates have been raised 112 5  for 2018 and 11 1  for 2019 over the past 60 days  The stock has soared 64 8  year to date Gilead Sciences  earnings estimates have moved 5  north for 2018 and 4 8  for 2019 over the past 60 days  The stock has inched up 0 5  year to date Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-12-02,Zacks Investment Research,https://www.investing.com/analysis/fda-committee-to-review-amgens-amgn-osteoporosis-candidate-200364492,200364492
146705,368221,ALXN,Global Blood Therapeutics  Voxelotor On Faster Approval Path,opinion,"Global Blood Therapeutics  Inc    NASDAQ GBT   announced that the FDA has agreed to its proposal of an accelerated approval pathway for its sickle cell disease   SCD   candidate  voxelotor The company will file a new drug application   NDA   under this pathway  The company anticipates that a rise in hemoglobin levels on treatment with voxelotor is likely to lead to reduction in strokes in SCD patients Per the discussion with the FDA  the company stated that the regulatory body has agreed to a post approval confirmatory study to demonstrate stroke risk reduction with transcranial doppler flow velocity as its primary endpoint Accelerated approval is generally granted to therapies for severe and life threatening conditions that address significant unmet medical needs  It is a conditional approval that will help the company to bring the drug faster in the market The company has made plans to request a pre NDA meeting with the FDA in the first quarter of 2019  The company will announce the timing for submission of the NDA and specifics of the confirmatory study following the meeting Shares of Global Blood Therapeutics rallied 47 8  on Dec 3 following the news  The company s shares have gained 18 5  so far this year against the  s decline of 15 3  The company is developing voxelotor as a once daily  oral therapy for improving anemia in patients with SCD  thereby preserving brain function and reducing strokes A phase III study   HOPE   and a phase IIa study   HOPE KIDS 1   are evaluating voxelotor in SCD patients aged 12 years and older and patients between 4 and 17 years of age  respectively Preliminary data from the late stage study presented at the annual meeting of the American Society of Hematology  ASH  earlier this week demonstrated that the candidate achieved rapid  robust and sustained improvements in hemoglobin levels over 24 weeks of treatment  The increase in hemoglobin levels was clinically meaningful and statistically significant  These data were the key factors that led the FDA to accept the proposal We note that treatment options are limited for SCD  This increases the likelihood of success for voxelotor  upon potential approval  Last year  the FDA approved privately held Emmaus Medical s Endari as a new treatment option for SCD in almost two decades  Meanwhile  Novartis   NYSE NVS   and bluebird bio  Inc    NASDAQ BLUE   are developing crizanlizumab and LentiGlobin  respectively  for treating SCD in early to mid stage clinical studies Global Blood Therapeutics  Inc  Price
    Zacks Rank and Stock to ConsiderGlobal Blood Therapeutics currently carries a Zacks Rank  3  Hold   You can see  A better ranked from the biotech stock is Alexion Pharmaceuticals  Inc    NASDAQ ALXN   with a Zacks Rank  1  The company s earnings estimates have increased from  7 23 to  7 61 for 2018 and from  8 59 to  8 77 for 2019 over the past 60 days  The company delivered positive earnings surprise in all the trailing four quarters with the average beat being 16 77  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/global-blood-therapeutics-voxelotor-on-faster-approval-path-200364832,200364832
146727,368243,ALXN,Puma Biotech  PBYI  Q3 Loss Narrows  Nerlynx Pulls Stock Down,opinion,Shares of Puma Biotechnology  Inc    NASDAQ PBYI   plunged 48  on Friday following the company s third quarter earnings release on Thursday In fact  so far this year  Puma Biotech stock has plummeted 79 7  compared with the  decline of 16 5  Puma Biotech incurred a loss of 37 cents per share for the third quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of  1 07 and the year ago loss of  2 07 Total revenues consist of net product revenues from the sales of Nerlynx as well as the company s license revenues  In the third quarter of 2018  total revenues were  62 6 million  of which   52 6 million were net product revenues and  10 million were license revenues  Moreover  sales beat the Zacks Consensus Estimate of  55 million in the reported quarter and the year ago figure of  6 million Product revenues comprised sales of Puma Biotech s only marketed product Nerlynx  However  Nerlynx sales were up a mere 3 5  on a sequential basis  which hurt investor sentiments and led to the stock price decline  The softer Nerlynx sales were due to increased patient discontinuations in the last reported quarter On third quarter conference call  the company stated that the percentage of patients  who discontinued Nerlynx due to adverse events  has increased since the second quarter and is now approximately 18  since the product s launch Nerlynx was launched in July 2017 in the United States for an extended adjuvant treatment of HER2 positive early stage breast cancer in patients  previously treated with Roche s   OTC RHHBY   Herceptin based adjuvant therapy  In September 2018  the European Commission gave a marketing approval to Nerlynx for the same indication Puma Biotech plans to commercialize Nerlynx in Europe during 2019  starting with a launch in Germany during the first half of 2019 followed by other European countries in the second half of 2019 During the third quarter  the new drug submission for Nerlynx was accepted in Canada for the given indication  Additionally  Puma Biotech s licensing partner CANbridge Pharmaceutical filed a new drug application  NDA  for Nerlynx to the National Medical Products Administration  NMPA  in China  The drug received a confirmation from the regulatory agency in China for the same disease Puma Biotech expects to submit regulatory applications for Nerlynx in additional countries later this year as well as in the first half of 2019 During the reported quarter s conference call  the company mentioned that as of Oct 31  there are 2 139 active patients on Nerlynx  of which  an estimated 87  received the drug through specialty pharmacies  The company expects Nerlynx sales to be in the range of  175  200 million for fiscal year 2018 Total operating costs  including SBC  in the third quarter were  73 9 million  down almost 11 5  year over year Research and development  R D  expenses were  36 4 million  down 26 5  from the year ago period owing to lower clinical study costs and stock based compensation expenses  Puma Biotech expects its R D costs to decrease in subsequent quarters as clinical studies wind down Selling  general and administrative expenses reduced 12 3  year over year to  28 5 million Other UpdatesSeveral additional studies on Nerlynx targeting different types of breast cancer patient populations and in earlier line settings are under way  Also  multiple phase II combination programs evaluating Nerlynx for the treatment of breast cancer are on  Significantly  Puma Biotech hopes to present data from the phase III NALA analysis  assessing Nerlynx for addressing third line HER2 positive metastatic breast cancer patients during the fourth quarter of 2018 or the first half of 2019 In July 2018  Puma Biotech signed a collaborative agreement with privately held Strata Oncology  Inc to drive patient enrollment in the phase II SUMMIT study on Nerlynx  As of October  the study enrolled approximately 250 patients  The company plans to report additional data from the study by this year end or the first half of 2019 Puma Biotech is also conducting another phase II CONTROL study for using antidiarrheal prophylaxis on neratinib associated diarrhea regarding patients with HER2 positive early stage breast cancer  The company plans to report additional data from this study during the fourth quarter of 2018 Apart from the HER2 positive breast cancer indication  the company believes that neratinib holds great potential for treating multiple cancers including NSCLC and other tumor types  which over express or have a mutation in HER2  The label expansion of the drug will allow it to treat and access an expanded patient population Puma Biotechnology  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Other Stocks to ConsiderPuma Biotech currently carries a Zacks Rank  2  Buy   Two other top ranked stocks in the healthcare sector are Gilead Sciences  Inc    NASDAQ GILD   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    both sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days Alexion s earnings estimates have moved 4 3  north for 2018 and 1 5  for 2019 over the past 60 days  The stock has inched up 2 8  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/puma-biotech-pbyi-q3-loss-narrows-nerlynx-pulls-stock-down-200354892,200354892
146728,368244,ALXN,Pacira  PCRX  Q3 Earnings And Revenues Surpass Estimates,opinion,Shares of Pacira Pharmaceuticals  Inc    NASDAQ PCRX   decreased 3 5  on Friday following the company s third quarter earnings release the day before However  so far this year  Pacira stock has gained 10 2  against the  decline of 4 4  The company delivered third quarter 2018 earnings of 31 cents per share  surpassing the Zacks Consensus Estimate of 7 cents and the year ago bottom line of 11 cents Revenues increased 23 9  year over year to  83 4 million  beating the Zacks Consensus Estimate of  79 million and the year ago figure of  67 million  Exparel sales came in at  82 2 million for the third quarter of 2018  rising 23  year over year  On an average  Exparel sales rose 6  sequentially Quarter in DetailPacira s top line comprises product revenues  other product sales plus royalty revenues  Royalty revenues more than doubled to  0 74 million in the reported quarter Research and development  R D  expenses  excluding the impact of stock based compensation  were up 25 8  to  13 7 million  This increase in R D expenses was due to the scale up of the company s manufacturing capacity in Swindon Selling  general and administrative  SG A  expenses increased 11 8  to  38 3 million because of an expanded public affairs campaign focused on improving access to non opioid options and expenses related to the launch of Exparel for brachial plexus nerve block Recent DevelopmentsPacira s collaboration with Aetna  NYSE AET  has been lucrative  The latter provides a separate reimbursement for Exparel as well as its online DocFind directory to help its members identify surgeons  who are committed to offering non opioid options like Exparel for postsurgical pain In October  Aetna announced that it will reimburse select ambulatory surgical centers  ASCs  for the use of Exparel as part of a pilot program in Florida and New Jersey Pacira is also developing Exparel for its use in pain management with respect to various other surgeries and is also expanding its label to address complications in pediatric patient population Notably  Pacira s partnership with Johnson   Johnson   NYSE JNJ   is a positive move as the latter regularly opens doors to new hospital systems for the former where it previously did not have any access OutlookPacira raised its guidance for Exparel sales in 2018 and expects it to be in the range of  325  330 million  The previous view was in the band of  320  325 million The company expects R D expenses  excluding stock based compensation  to be within  50  60 million while SG A expenses  excluding stock based compensation  are anticipated in the  150  160 million range  Also  stock based compensation is projected between  30 million and  35 million  All these remain unchanged from the last reported quarter s forecast Pacira Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderPacira currently carries Zacks Rank  3  Hold   Two better ranked stocks in the healthcare sector are Gilead Sciences  Inc    NASDAQ GILD   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    both sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days Alexion s earnings estimates have moved 4 3  north for 2018 and 1 5  for 2019 over the past 60 days  The stock has inched up 2 8  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/pacira-pcrx-q3-earnings-and-revenues-surpass-estimates-200354861,200354861
146729,368245,ALXN,Is Alexion Pharmaceuticals  ALXN  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors interested in Medical stocks should always be looking to find the best performing companies in the group  Has Alexion Pharmaceuticals  NASDAQ ALXN  been one of those stocks this year  Let s take a closer look at the stock s year to date performance to find out 
Alexion Pharmaceuticals is one of 845 companies in the Medical group  The Medical group currently sits at  3 within the Zacks Sector Rank  The Zacks Sector Rank considers 16 different groups  measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  ALXN is currently sporting a Zacks Rank of  1  Strong Buy  
Over the past 90 days  the Zacks Consensus Estimate for ALXN s full year earnings has moved 5 69  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Based on the most recent data  ALXN has returned 3 03  so far this year  Meanwhile  the Medical sector has returned an average of 2 32  on a year to date basis  As we can see  Alexion Pharmaceuticals is performing better than its sector in the calendar year 
Breaking things down more  ALXN is a member of the Medical   Biomedical and Genetics industry  which includes 341 individual companies and currently sits at  82 in the Zacks Industry Rank  This group has lost an average of 13 49  so far this year  so ALXN is performing better in this area 
ALXN will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/is-alexion-pharmaceuticals-alxn-stock-outpacing-its-medical-peers-this-year-200355399,200355399
146731,368247,ALXN,Amarin s Vascepa Cuts Heart Risk In Outcomes Test  Stock Down,opinion,Shares of Amarin Corporation plc   NASDAQ AMRN   were down almost 6  after it presented detailed data from a late stage cardiovascular outcomes study  REDUCE IT  on its fish oil capsule  Vascepa  at the Scientific Sessions of the American Heart Association  AHA  in Chicago  Illinois However  the stock has skyrocketed 394 3  so far this year versus the  decrease of 16 6  Notably  Vascepa is already approved in the United States as an adjunct to diet in order to reduce triglyceride levels in adult patients with severe   500 mg dL  hypertriglyceridemia  The REDUCE IT study evaluated whether patients with bad cholesterol  controlled by statin therapy  and at cardiovascular risk can achieve a significant cardiovascular risk reduction after being treated with Vascepa In September 2018  the company presented top line data from the study  which demonstrated that Vascepa can significantly lower cardiovascular risk in patients with LDL C  bad cholesterol  controlled by statin therapy  Back then  the REDUCE IT analysis showed that the use of Vascepa 4gms day resulted in 25  relative risk reduction  RRR  as the primary endpoint of a major adverse cardiovascular event  MACE  when compared with placebo MACE is a composite endpoint of CV death  non fatal myocardial infarction  non fatal stroke  coronary revascularization or unstable angina requiring hospitalization  Along with its latest release  the company confirmed the 25  RRR in the five component primary MACE endpoint The company also stated that treatment with Vascepa led to a 26  reduction in key secondary composite endpoint of cardiovascular death  heart attacks and stroke  The study also achieved the additional secondary endpoints including reductions in cardiovascular death  20    fatal or nonfatal heart attacks  31    fatal or nonfatal stroke  28    urgent or emergent coronary revascularization  35   and hospitalization for unstable angina  32    However  the study failed to achieve a statistical significance for the all cause mortality secondary endpoint However  despite the positive data  shares of the company declined on Monday because of investor concerns regarding the use of mineral oil in the placebo arm  which might have caused an unexpected rise in bad cholesterol levels  This in turn  overstated Vascepa s cardiovascular benefits Amarin plans to file a supplemental new drug application  sNDA  to the FDA in early 2019 for expanding the label of Vascepa based on results acquired from the REDUCE IT study  The company anticipates a potential approval in late next year following the regulatory body s review If Amarin gets the nod to include the outcomes data on Vascepa s label  it can cater to a larger patient population and generate higher sales  The company has moderately priced the drug to make it affordable for its patients Zacks Rank   Stocks to ConsiderAmarin currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector are Gilead Sciences  Inc    NASDAQ GILD    Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Genomic Health  Inc    NASDAQ GHDX    all sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days Alexion s earnings estimates have moved 4 8  north for 2018 and 1 8  for 2019 over the past 60 days Genomic Health s earnings estimates have been raised 89 3  for 2018 and 36 7  for 2019 over the past 60 days  The stock has skyrocketed 132 8  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/amarins-vascepa-cuts-heart-risk-in-outcomes-test-stock-down-200358804,200358804
146745,368261,ALXN,5 Best Performing Health Care Mutual Funds Of Q1,opinion,In the first quarter  among the three major U S  indexes  both the Dow and the S P 500 finished in the red  Although  healthcare was one such S P 500 sector that registered declines in the first quarter  it surpassed all the other sectors to witness highest venture capital funding Such a high level of venture capital funding in the healthcare sector indicated that innovation will reach exponential level  This is why investing in mutual funds with significant exposure to the healthcare sector could be one of the most suitable investment options at present Why Invest in Healthcare Mutual Funds After strong growth in the first month of this year  all the three indexes entered correction territory in February and then registered a sharp decline in March following the tech slump and trade war fears Moreover  Wall Street s  fear gauge   the Cboe Volatility Index  surged 81  in the first quarter  marking its biggest quarterly increase since 2011  according to the WSJ Market Data Group Among the key S P 500 sectors  only consumer discretionary and technology managed to end in the green  while the remaining finished in negative territory  Despite closing in the red  the healthcare industry raised venture capital of  6 85 billion in the first quarter of this year  accounting for 26 6  of the total venture capital funds  per a Dow Jones VentureSource report Venture capital funding in the healthcare sector rose 21  from last year s fourth quarter figure and 4  year over year  with Pacific Northwest being the major contributor  Bio pharma companies constituted around 50  of the total venture capital funding  boosted by innovations in gene editing and cell therapies Top 5 Healthcare Mutual Funds to BuyThe aforementioned bullish factors call for investing in healthcare funds  We have  thus  selected five strong performing healthcare mutual funds  These funds have given impressive one year annualized and year to date  YTD  returns  These funds boast a Zacks Mutual Fund Rank  1  Strong Buy  or 2  Buy   offer a minimum initial investment within  5 000 and carry a low expense ratio We expect these funds to outperform their peers in the future  Remember  the goal of the Zacks Mutual Fund Rank is to guide investors to identify potential winners and losers  Unlike most of the fund rating systems  the Zacks Mutual Fund Rank is not just focused on past performance  but also on the likely future success of the fund Fidelity Select Health Care Portfolio  invests a large chunk of its assets in securities of companies involved in design  manufacture and sale of products as well as services related to the healthcare sector  The fund invests in common stocks of both U S  as well as non U S  companies Further  as of the last filing  Unitedhealth Group Inc  Amgen Inc  NASDAQ AMGN  and Becton Dickinson   Co were the top holdings for FSPHX  This Zacks Mutual Fund Rank  1 fund was incepted in 1981  FSPHX carries an expense ratio of 0 73  as compared with the category average of 1 30  Specifically  the fund s one year annualized and YTD returns are 16 2  and 5 2   respectively  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   Hartford Healthcare HLS Fund IA  invests a huge part of its assets in equity securities of companies engaged in the healthcare industry  These companies are located in different nations including the United States  HIAHX may invest in securities issued by companies of any market capitalization Further  as of the last filing  Unitedhealth Group Inc  Medtronic  NYSE MDT  Plc and Bristol Myers Squibb Co were the top holdings for HIAHX  This Zacks Mutual Fund Rank  2 fund was incepted in 2000  HIAHX carries an expense ratio of 0 89  as compared with the category average of 1 30  Specifically  the fund s one year annualized and YTD returns are 10 2  and 1 7   respectively  To see how this fund performed compared in its category  and other  1 and 2 Ranked Mutual Funds   Franklin Biotechnology Discovery A  invests the majority of its assets in securities of companies from the biotechnology domain  The non diversified fund may invest a maximum of one fifth of its assets in equities as well as debt securities of U S  and non U S  biotech companies Further  as of the last filing  Celgene Corp  NASDAQ CELG   Alexion Pharmaceuticals Inc  NASDAQ ALXN  and Incyte Pharmaceuticals Inc were the top holdings for FBDIX  This Zacks Mutual Fund Rank  1 fund was incepted in 1997  FBDIX carries an expense ratio of 1 02  as compared with the category average of 1 30  Specifically  the fund s one year annualized and YTD returns are 5 4  and 0 1   respectively  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   Delaware Healthcare I  seeks growth of capital for the long run mainly through capital appreciation  The fund will normally invest more than 80  of its assets in equity securities of companies based in the healthcare industry  The fund focuses on investing in companies that are involved in developing  producing and distributing products or services for the healthcare and medical industries Further  as of the last filing  Morphosys AG  Sanofi  PA SASY  ADR and Chugai Pharmaceutical Ltd were the top holdings for DLHIX  This Zacks Mutual Fund Rank  2 fund was incepted in 2007  DLHIX carries an expense ratio of 1 13  as compared with the category average of 1 30  Specifically  the fund s one year annualized and YTD returns are 21 9  and 1 2   respectively  To see how this fund performed compared in its category  and other  1 and 2 Ranked Mutual Funds   Fidelity Select Medical Equipment and Systems Portfolio  invests a bulk of its assets in securities of companies that focus on research  development  manufacture  distribution  supply  or sale of medical equipment and devices and related technologies  The fund invests in securities of U S  and non U S  companies  FSMEX seeks long term capital appreciation Further  as of the last filing  Becton Dickinson   Co  Medtronic Plc and Boston Scientific Corp  NYSE BSX  were the top holdings for FSMEX  This Zacks Mutual Fund Rank  2 fund was incepted in 2007  FSMEX carries an expense ratio of 0 76  as compared with the category average of 1 30  Specifically  the fund s one year annualized and YTD returns are 16 3  and 5 4   respectively  To see how this fund performed compared in its category  and other  1 and 2 Ranked Mutual Funds   Want key mutual fund info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/5-bestperforming-health-care-mutual-funds-of-q1-200311771,200311771
146746,368262,ALXN,Achillion  ACHN  Posts Wider Than Expected Q1 Loss  Names CEO,opinion,"Achillion Pharmaceuticals  Inc    NASDAQ ACHN   reported a loss of 15 cents per share for the first quarter of 2018  same as the year ago loss but wider than the Zacks Consensus Estimate of a loss of 14 cents The company generated no revenues in the reported quarter Shares of Achillion were down 2 4  on May 2  However  the company s stock have outperformed the  year to date  The company s shares have gained 28 1  against the industry s decrease of 10 9  Research and development  R D  expenses decreased nearly 4 8  from the year ago period to  14 6 million  The decrease was due to decreased stock based compensation  lower personnel costs as the February restructuring resulted in reduced number of employees and lower manufacturing and formulation expenses for next generation factor D inhibitor candidate  ACH 5228  This was partially offset by increased costs related to clinical studies of ACH 4471 and ACH 5228 and preclinical costs of ACH 5548 General and administrative  G A  expenses decreased 5 9  year over year to  5 3 million due to lower legal and consulting fees Restructuring DetailsIn February 2018  the company announced an operational restructuring plan to focus on its existing factor D inhibitor candidates and reduce expenses  Achillion reduced its workforce by 20  under its restructuring plan  The restructuring is expected to save  10 million in 2018 Pipeline UpdateAchillion is planning to complete a phase II study on its most advanced candidate  ACH 4471  in C3 glomerulopathy  C3G  or immune complex mediated membranoproliferative glomerulonephritis  IC MPGN  in 2018  with interim data planned for the third quarter of 2018  Two more studies are planned for 2018  which will evaluate ACH 4471 in C3G Meanwhile  interim data from the ongoing phase II study evaluating ACH 4471 monotherapy in paroxysmal nocturnal hemoglobinuria   PNH   is planned for the fourth quarter of 2018  An add on study is planned for the evaluation of ACH 4471 in combination with Alexion Pharmaceuticals    NASDAQ ALXN   PNH drug  Soliris  eculizumab   Interim data is expected in the fourth quarter of 2018 The company also targets to complete phase I studies on its two next generation factor D inhibitors   ACH 5228 and ACH 5548   in the fourth quarter of 2018 CEO TransitionConcurrent with the earnings release  Achillion announced that Joseph Truitt  current president and chief operating officer  will take the responsibilities of chief executive officer  Milind Deshpande is stepping down from this role  Joseph will also be appointed to the board of directors Achillion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderAchillion Pharma currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the biotech sector are Ligand Pharmaceuticals   NASDAQ LGND    and Protagonist Therapeutics   NASDAQ PTGX    Both the stocks sport a Zacks Rank  1  Strong Buy  You can see  Ligand s earnings per share estimates moved up from  4 24 to  4 43 for 2018 and remained stable at  5 32 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 14 6  year to date Protagonist Therapeutics  loss estimates narrowed from  1 68 to 66 cents for 2018 and from  2 43 to  1 26 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/achillion-achn-posts-widerthanexpected-q1-loss-names-ceo-200312406,200312406
146747,368263,ALXN,Why Is Alexion  ALXN  Down 3 5  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Shares have lost about 3 5  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is ALXN due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Alexion s Earnings Beat Estimates in Q1  Guidance UpAlexion posted first quarter 2018 adjusted earnings of  1 68 per share which were higher than the year ago earnings of  1 38 by 22   Earnings also beat the Zacks Consensus Estimate of  1 48  Strong product revenues drove the bottom line in the quarter Revenues rose 7  year over year to  930 9 million and exceeded the Zacks Consensus Estimate of  918 million  Revenues were driven by increased sales of Soliris  Strensiq and Kanuma   Revenues in DetailSoliris  paroxysmal nocturnal hemoglobinuria   PNH   and atypical hemolytic uremic syndrome  aHUS   sales were up 2 1  to  800 1 million in the quarter driven by strong volume growth  While Strensiq  hypophosphatasia   HPP    contributed  110 7 million to revenues  up 50 4  year over year  Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  19 6 million  up 63 3   to quarterly revenues Cost SummaryAdjusted research and development  R D  expenses were  161 6 million  down 16 9  year over year Adjusted selling  general and administrative  SG A  expenses were  220 4 million  down 2 5  year over year 2018 GuidanceThe company raised its earnings per share and revenue guidance for 2018  It expects earnings per share to be in the range of  6 75  6 90 up from the previous range of  6 60  6 80  It projects revenues in the range of  3 93  3 99 billion up from its previous expectation of  3 85  3 95 billion  Revenues for Soliris are expected in the range of  3 38  3 42 billion compared with  3 33  3 40 billion expected earlier  The Zacks Consensus Estimate for earnings for 2018 was  6 90 per share while for sales it was  3 99 billion and both of them reflect the higher end of the guidance range The outlook assumes unfavorable Soliris revenue impact of  90 million to  110 million from ALXN1210 and other clinical trial recruitment versus prior year Alexion expects to incur additional restructuring and related expenses of approximately  15 million to  80 million related to the 2017 restructuring activities Pipeline UpdateThe company announced positive top line results from the phase III study of its long acting C5 complement inhibitor   ALXN1210 which showed that patients with PNH can be effectively and safely switched from treatment with Soliris every two weeks to treatment with ALXN1210 every eight weeks  The study showed non inferiority of ALXN1210 to Soliris in patients with PNH who had been stable on Soliris based on the primary endpoint of change in lactate dehydrogenase  LDH  levels  a direct marker of complement mediated hemolysis in PNH  The study also demonstrated non inferiority on all four key secondary endpoints In addition  ALXN1210 achieved non inferiority on the primary and all four key secondary endpoints in the phase III PNH Switch study of ALXN1210 administered intravenously every eight weeks compared to patients currently treated with Soliris Alexion plans to file for regulatory approval for ALXN1210 in patients with PNH in the United States and EU in mid 2018  followed by Japan later in 2018 Enrollment of ALXN1210 in phase III study for aHUS is expected to be completed in the second quarter of 2018 and Alexion expects to report data from this study in the fourth quarter of 2018 AcquisitionIn April 2018  Alexion announced that it will acquire Sweden based Wilson Therapeutics  Alexion has offered SEK 232 in cash for each outstanding share of Wilson Therapeutics which translates into a total transaction value of  855 million  The transaction is expected to close in the second quarter of 2018 The acquisition will add a late stage candidate  WTX101 to Alexion s pipeline  The candidate is currently in phase III for the treatment of Wilson disease  a rare genetic disorder Alexion is looking to diversify its portfolio and reduce its dependence on Soliris  The deal will strengthen Alexion s rare disease pipeline with a late stage candidate 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been six revisions higher for the current quarter compared to three lower Alexion Pharmaceuticals  Inc  Price and Consensus
    VGM Scores
At this time  ALXN has a nice Growth Score of B  however its Momentum is doing a bit better with an A  The stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is primarily suitable for momentum investors while also being suitable for those looking for growth and to a lesser degree value 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions indicates a downward shift  Notably  ALXN has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-28,Zacks Investment Research,https://www.investing.com/analysis/why-is-alexion-alxn-down-35-since-its-last-earnings-report-200319714,200319714
146748,368264,ALXN,5 Trade Ideas For Monday  Alexion Pharma  Green Dot  Generac  Meet Group   Nutrien,opinion,"Alexion Pharmaceuticals  NASDAQ ALXN 

Alexion Pharmaceuticals  ALXN  pulled back from a top in October finding support in November  It bounced from there to just over the 200 day SMA and then retreated again  The range then held with a brief trip over the 200 day SMA in March  In May the consolidation tightened to a symmetrical triangle and it broke that to the upside in June  A retest last week and Friday s reversal make it interesting  The RSI is moving up in the bullish zone with the MACD avoiding a cross down  Look for continuation to participate higher   
Green Dot Corporation  NYSE GDOT  
Green Dot  GDOT  gapped higher in May and then consolidated the move  It then pushed higher again into June but fell back at the end of the month  The drop brought it back to the 50 day SMA and it prior support  Friday it confirmed a reversal off of support  It has a RSI that is also turning back higher after holding in the bullish zone during the pullback but the MACD is still falling  Look for continuation to participate   
Generac Holdlings Inc  NYSE GNRC  
Generac Holdings  GNRC  ran higher fast to a top at the beginning of November  It pulled back in a shallow arc at first and then to the 200 day SMA in March  It consolidated in a range then for 2 months before moving higher  Three weeks ago it retested the January high and pulled back to a higher low  Last week it started higher again  The RSI is rising in the bullish zone and the MACD is turning to cross up and positive  Look for continuation to participate higher   
Meet Group Inc  NASDAQ MEET  
Meet Group  MEET  started moving higher in April  It crossed the 200 day SMA in May and continued to a top in June  This is at the gap down level from August last year  The RSI is holding after pulling back from an overbought condition and the MACD is leveling  Look for a push over resistance to participate   
Nutrien Ltd  NYSE NTR  
Nutrien  NTR  started to pullback from a top in January  finding a bottom in February  It bounced to a lower high and then fell back  It consolidated and confirmed a double bottom on a move over the April high with a gap up in May  It stalled at the March bounce high and retreated to a higher low  Since then it has pushed through resistance and is approaching the January high  The RSI is bullish and rising with the MACD flat and positive  Look for continuation to participate higher   
Up Next  Bonus Idea
The Best
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which as we close the books on the 2nd Quarter and prepare for a holiday shortened 4th of July week  sees that the equity markets look to have run out of gas  Maybe the short week will re energize them  All the indexes had a positive quarter with the IWM just out pacing the QQQ  7 9  to 6 5  and the SPY gaining 3 1   The QQQ won the month up 0 9  to the 0 6  for the IWM and the SPY eked out a 0 1  gain  The monthly candles all look toppy with long upper shadows  while the quarterly candles are all looking strong 
Elsewhere Gold looks as it may pause in its downtrend while Crude Oil continues to race higher  The US Dollar Index is pausing in its uptrend while US Treasuries are on the edge of a break out to the upside  The Shanghai Composite may be ready to pause in its downtrend while Emerging Markets are setting up for a possible reversal higher  Volatility looks to remain low but above recent levels keeping the wind at the backs of the equity markets but the breeze blowing softer 
The equity index ETFs SPY  IWM and QQQ  all had a mixed week with early signs of strength Friday fading into the close  leaving questions about the short term  The longer weekly timeframe was much less troublesome showing consolidation for the SPY continuing and the IWM and QQQ digesting recent moves higher  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original Post",2018-07-02,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-alexion-pharma-green-dot-generac-meet-group--nutrien-200328814,200328814
146765,368281,ALXN,Alexion  ALXN  Gains On Positive Date From Lead Candidate ,opinion,Shares of Alexion Pharmaceuticals  Inc    NASDAQ ALXN   gained 3 38  after the company reported positive data on candidate  ALXN1210 from a pivotal phase III study Alexion s shares have declined 11 7  in the last six months  worse than the loss of 8 8   This phase III randomized  open label  active controlled  multinational  and multicenter study evaluated the efficacy and safety of ALXN1210 compared to Alexion s lead drug Soliris administered by intravenous  IV  infusion to adult patients with paroxysmal nocturnal hemoglobinuria  PNH  who are na ve to complement inhibitor treatment The study was designed to evaluate the non inferiority of ALXN1210 compared to Soliris  ALXN1210 demonstrated non inferiority to Soliris in complement inhibitor treatment na ve patients with PNH based on the co primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase   LDH   levels In addition  the study also demonstrated non inferiority on all four key secondary endpoints   percentage change from baseline in LDH levels  change from baseline in quality of life as assessed by the Functional Assessment of Chronic Illness Therapy   FACIT     Fatigue scale  proportion of patients with breakthrough hemolysis  and proportion of patients with stabilized hemoglobin levels ALXN1210 was well tolerated with a safety profile that is consistent with that seen for Soliris  The candidate was then evaluated for superiority testing as non inferiority was achieved across both co primary and all four key secondary endpoints  While ALXN1210 did not achieve superiority  a numeric trend in favor of ALXN1210 was observed for breakthrough hemolysis for Soliris with a p value of 0 074  The data also showed that ALXN1210 provides immediate and complete inhibition of the complement C5 protein that is sustained over the entire 8 week dosing interval The positive results should support ALXN1210 as the new standard of care for patients with PNH  Alexion plans to submit ALXN1210 in PNH in the United States  EU  and Japan in the second half of 2018 In addition to PNH  ALXN1210 is also being evaluated for atypical hemolytic uremic syndrome  aHUS   and anti acetylcholine receptor  AchR  antibody positive myasthenia gravis  MG    ALXN210 is also being evaluated in a phase III study in complement inhibitor na ve patients with aHUS  administered intravenously every eight weeks The company also plans to initiate a single  pharmacokinetics based phase III study of ALXN1210 delivered subcutaneously once per week as a potential treatment for patients with PNH and aHUS  Alexion also plans to initiate the development of ALXN1210 as a potential treatment for patients with generalized MG  gMG  and patients with immunoglobulin A nephropathy  IgAN  The candidate has also received Orphan Drug Designation  for the treatment of patients with PNH in the United States and EU  and for the subcutaneous treatment of patients with aHUS in the United States Alexion s blockbuster drug  Soliris  continues to perform well and the FDA approval of the drug for generalized myasthenia gravis will further boost sales  However  the company relies heavily on Soliris for growth and sales of Soliris will be impacted by ramp of ALXN1210 trials The successful development and commercialization of ALXN1210 will reduce the company s dependence on Soliris and extend the patent of the PNH franchise as well Zacks Rank   Key picksAlexion currently carries a Zacks Rank  4  Sell  A few better ranked stocks from the same space are Regeneron Pharmaceuticals   NASDAQ REGN   Ligand Pharmaceuticals   NASDAQ LGND   and Enanta Pharma   NASDAQ ENTA    While Regeneron sports a Zacks Rank  1  Strong Buy   Ligand and Enanta Pharma carry a Zacks Rank  2  Buy   each  You can see  Regeneron s earnings per share estimates have moved up from  18 65 to  18 68 for 2018 and 2019 respectively in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  Ligand s earnings per share estimates have moved up  3 78 to  4 20 from  4 75 to  5 32 for 2018 and 2019  respectively over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 24 88  Enanta Pharma delivered a positive earnings surprise in three of the last four quarters  with an average beat of 373 1   The company s shares surged 193 6  over a year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-gains-on-positive-date-from-lead-candidate-200298689,200298689
146766,368282,ALXN,Alexion  ALXN  To Acquire Wilson Therapeutics For  855M,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is the latest company to join the ongoing acquisitions spree in the biotech sector  The company recently announced that it will acquire Sweden based Wilson Therapeutics Details of The TransactionAlexion has offered SEK 232 in cash for each outstanding share of Wilson Therapeutics which translates into a total transaction value of  855 million  Alexion has already obtained shareholder support agreements from the four largest shareholders accounting for 57 4  of Wilson Therapeutics  outstanding shares and two additional shareholders accounting for 8 7  for a total of 66 1  of the company s outstanding shares  The transaction is expected to close in the second quarter Rationale Behind the TransactionThe acquisition will add a late stage candidate  WTX101 to Alexion s pipeline  The candidate is currently in phase III for the treatment of Wilson disease  a rare genetic disorder  The candidate is a first in class oral copper binding agent with a unique mechanism of action and ability to access and bind copper from serum and promote its removal from the liver  The candidate has also obtained Fast Track designation in the United States and enjoys Orphan Drug Designation for the treatment of Wilson disease in the United States and EU    Our Take
Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris  The deal will strengthen Alexion s rare disease pipeline with a late stage candidate However  investors weren t much impressed with the news as the acquisition adds a candidate to the pipeline and not an approved drug  Thus  the stock lost 2 35  following the announcement  Moreover  the market opportunity for such a rare disease will be limited and might not boost the top line as expected   Alexion s shares have lost 21 7  in the last six months  compared with the  decline of 16 2  Of late  quite a few biotech companies have been looking to strengthen their portfolio pipeline  While 2017 was pretty ho hum on this front with just a few key deals  2018 is expected to see a surge in M A primarily due to lower U S  tax rates   Taking a clue from Gilead Sciences   NASDAQ GILD   acquisition of Kite Pharma  Celgene   NASDAQ CELG   recently acquired Juno Therapeutics to gain traction in the promising CAR T space   Sanofi   NYSE SNY   acquired Bioverativ Inc  which focuses on therapies for hemophilia and other rare blood disorders 
Zacks Rank 
Alexion currently carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-11,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-to-acquire-wilson-therapeutics-for-855m-200305171,200305171
146787,368303,ALXN,Will Bristol Myers   BMY  Q4 Earnings Exceed Expectations ,opinion,"We expect Bristol Myers Squibb Company   NYSE BMY   to beat expectations when it reports fourth quarter 2017 results on Feb 5  before the market opens Bristol Myers  shares have increased 30 1  in the past year while the  recorded an increase of 26 6  Bristol Myers  track record has been mixed so far  The company delivered positive earnings surprise in two of the last four quarters and missed expectations twice  The average positive earnings surprise in the last four quarters is 2 72   In the last reported quarter  Bristol Myers delivered a negative surprise of 2 6  Let s see how things are shaping up for this quarter Factors at PlayBristol Myers  blockbuster immuno oncology drug  Opdivo is expected to continue as the primary sales driver in the fourth quarter  The drug is already approved in multiple cancer indications  In the past two quarters  the drug received approval for five line extensions  which is expected to boost sales  Moreover  in December 2017  Opdivo s label was expanded as adjuvant therapy for completely resected melanoma The FDA s approval of Merck s   NYSE MRK   Keytruda in May for the first line treatment of metastatic non squamous NSCLC had a lower than expected impact on third quarter sales  The Zacks Consensus Estimate for fourth quarter Keytruda sales is pegged at  1 3 billion  flat with the year ago actual figure In January 2018  the European Commission approved the label expansion of Yervoy injection in pediatric patients 12 years of age and older with unresectable or metastatic melanoma  The FDA had approved the drug for this indication in July 2017  The Zacks Consensus Estimate for the drug s sales in the fourth quarter is  315 million In November 2017  Bristol Myers announced that the FDA has approved line extension of Orencia in pediatric patients with Ph  chronic myeloid leukemia in chronic phase  The label expansions  including psoriatic arthritis in July 2017  and new administration option approved in June 2017 is expected to fuel growth of the drug  which registered growth of 10  in the previous quarter  The Zacks Consensus Estimate for Orencia sales is  686 million On the other hand  the decline in Hepatitis C franchise is expected to continue due to intense competition from multiple drugs including Epclusa whose label was expanded to include HIV co infection in August  Moreover  the HIV business continues to face competitive pressure  Recent launches by other companies in the same space are expected to further impact the Sustiva franchise  The Zacks Consensus Estimate for Hepatitis C franchise sales is pegged at  55 million this quarter  down 75 7  from year ago quarter actual figure The company is developing its key drug  Opdivo as monotherapy as well as combination therapy for several tumor types in multiple studies  with two label expansion applications under review in the United States  We expect investor focus on updates related to Opdivo on the conference call Why a Likely Positive Surprise Our proven model indicates that Bristol Myers is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  stands at  0 35   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bristol Myers has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bristol Myers Squibb Company Price and Consensus
    Other Stocks to ConsiderHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to release its results on Feb 8  The company has an Earnings ESP of  3 45  and a Zacks Rank  3  You can see  Anthera Pharmaceuticals  Inc    NASDAQ ANTH   is expected to release its results on Feb 26  The company has an Earnings ESP of  20 47  and a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/will-bristolmyers-bmy-q4-earnings-exceed-expectations-200285420,200285420
146790,368306,ALXN,Is A Beat In The Cards For Glaxo  GSK  This Earnings Season ,opinion,We expect GlaxoSmithKline plc   NYSE GSK   to beat expectations when it reports fourth quarter 2017 results on Feb 7  before the market opens  Last quarter  the company delivered a positive surprise of 1 19  Glaxo s shares have underperformed the in a year s time  The stock has lost 4 3  against the industry s rally of 21 1  Glaxo s earnings performance has been pretty good so far  The company s earnings surpassed estimates thrice in the trailing four quarters  meeting estimates in the remaining quarter  Overall  the company came up with an average beat of 6 69  Let s see  how things are shaping up for this quarter Factors to Consider Glaxo should continue to see strong sales of in its Pharmaceuticals and Vaccines business segment Glaxo s Pharmaceuticals segment is expected to be driven by solid sales of new HIV products  Tivicay and Triumeq  Sales of newly launched respiratory drugs  the Ellipta products and Nucala are likely to offset the declines in sales of older respiratory products Seretide  Advair and Avodart   On the third quarter conference call  Glaxo had said that its inhaled respiratory products  particularly the older ones  are facing competitive and continued pricing pressure  which is expected to continue Meanwhile  many of Glaxo s key drugs like Lovaza and Avodart are facing a sales decline due to generic competition    a trend we expect will continue in Q4  Importantly  pricing dynamics and rivalry pressure are hurting sales of the company s top selling drug  Advair in the United States while generic competition is hampering Advair sales in Europe The Vaccines segment will consistently benefit from a sustained uptake of meningitis vaccines like Bexsero and Menveo  acquired from Novartis AG   NYSE NVS    While Shingrix vaccine  prevention of shingles  was approved in the United States in October 2017  Trelegy Ellipta  only once daily single inhaler triple therapy for COPD  was granted an EU approval in November 2017  Trelegy Ellipta is already approved in the United States for COPD  Meanwhile  Juluca  dolutegravir   rilpivirine    the first dual treatment for HIV   received approval in the United States last November  We expect management to comment on the commercialization plans for these newly approved products on the Q4 conference call Importantly  sales growth is on the wane in the Consumer Healthcare segment due to a slowdown in market conditions and the impact of divestitures  The Consumer Healthcare segment is anticipated to remain under stress in the fourth quarter and is not much predicted to push up the sales Meanwhile  cost savings from restructuring and continued efficiencies should boost operating profits Earnings WhispersOur proven model shows that Glaxo is likely to beat estimates because it has the right combination of the two key ingredients  A stock needs to have both a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for an earnings beat and Glaxo precisely has the correct mix Zacks ESP  Glaxo has an Earnings ESP of  10 35   representing the difference between the Most Accurate estimate  72 cents per share  and the Zacks Consensus Estimate  65 cents   A positive ESP indicates a likely positive surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Glaxo has a Zacks Rank  3  The combination of Glaxo s Zacks Rank  3 and a positive ESP makes us confident of an earnings beat in the upcoming release Conversely  the Sell rated stocks   4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions GlaxoSmithKline PLC Price and EPS Surprise   Other Stocks to ConsiderHere are some other health care stocks worth considering with the right combination of elements to beat on earnings this time around Exelixis  Inc    NASDAQ EXEL   is expected to release results on Feb 26  The company has an Earnings ESP of  7 23  and a Zacks Rank  2  You can see  Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to report earnings on Feb 8  The company has an Earnings ESP of  3 45  and a Zacks Rank of 3 Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-glaxo-gsk-this-earnings-season-200286450,200286450
146791,368307,ALXN,What s In The Cards For Teva  TEVA  This Earnings Season ,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   will report fourth quarter and full year 2017 earnings on Feb 8  before the market opens  Last quarter  the company delivered a negative earnings surprise of 4 76  This generic drug maker s shares have lost 40 1  in the past year  while the  witnessed a decrease of 27 7  Teva s earnings have surpassed expectations in only one of the last four quarters  met the same in one and missed expectations in the remaining two  resulting in an average negative surprise of 2 66  Teva Pharmaceutical Industries Limited Price and EPS Surprise    Let s see how things are shaping up for this announcement Factors to ConsiderIncreased pricing erosion and volume declines in Teva s U S  Generics unit  ongoing political turmoil in Venezuela and loss of exclusivity in the Specialty segment are hurting the company s top line  We do not expect any improving trend in the fourth quarter The U S  generics industry is witnessing significant competitive and pricing pressure  thereby affecting the company s top line performance  An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry  Drug price erosion was 10  in the third quarter and management had warned on the call that the erosion will accelerate in the fourth quarter and beyond  Moreover  accelerated FDA approvals of additional generic versions of competing off patent medicines  lower than expected contribution of new generic launches and increased competition for its largest product   Concerta authorized generic   will also continue to hurt sales in the Generics unit Meanwhile  in the Specialty segment  loss of exclusivity of key drugs like Copaxone  Azilect and Nuvigil will hurt sales Sales of Teva s blockbuster multiple sclerosis  MS  treatment Copaxone should continue to erode due to generic competition  Glatopa  a generic version of Copaxone 20 mg  has been on the market since June 2015  In October  in a major blow to Teva  Mylan   NASDAQ MYL   launched  at risk  its generic version of the 40 mg formulation  much earlier than expected  Mylan also launched its version of the 20 mg formulation in October  With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  Copaxone sales are expected to erode rapidly  Teva had previously estimated a negative impact of at least 30 cents per share on fourth quarter earnings Meanwhile  a generic version of Azilect was launched in the United States in January 2017 and sales have started to decline sharply  ProAir also lost exclusivity in the United States in 2017 and its fourth quarter sales are likely to be lower To combat the rapid decline in sales  last month  Teva announced a restructuring plan that will see more than 25  of the company s global workforce being laid off over the next two years with the majority expected in 2018  Though management then provided quite a few details on how the plan will be executed  we expect an update on the upcoming conference call  Also  in November  Teva had announced a new organizational and leadership structure to save costs and increase productivity that included the departure of heads of three divisions  The company had also said then that it will no longer have two separate global groups for its two businesses   generics and specialty medicines  Instead  Teva will now operate through three regions  North America  Europe and Growth Markets   which will include generics  specialty  and over the counter  OTC  medicines  An update on the progress made on the new strategy so far is expected on the call Earnings WhispersOur proven model does not conclusively show that Teva is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  3 10  as the Most Accurate estimate stands at 78 cents per share while the Zacks Consensus Estimate is pegged higher at 81 cents per share  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Teva has a Zacks Rank  4  Sell   We caution against stocks with a Zacks Rank  4 or  5  Strong Sell  going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some other drug biotech stocks that have the right combination of elements to beat on earnings this time around Alexion Pharmaceuticals  Inc    NASDAQ ALXN   with an Earnings ESP of  8 92  and a Zacks Rank  3  The company is scheduled to release results on Feb 8 Puma Biotechnology  Inc    NASDAQ PBYI    with an Earnings ESP of  2 02  and a Zacks Rank  3  The company is expected to release results later this month  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-teva-teva-this-earnings-season-200287004,200287004
146794,368310,ALXN,Alexion  ALXN  Tops Q4 Earnings And Revenues Beat Estimates,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   focuses on the development and commercialization of life transforming drugs for treating patients suffering from ultra rare disorders  Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven  CT based company  In this scenario  investors focus should remain on Soliris performance Under its metabolic franchise  the company markets Strensiq for the treatment of patients with pediatric onset hypophosphatasia  HPP  and Kanuma for the treatment of patients with lysosomal acid lipase deficiency  LAL D  The company s track record has been impressive  Over the last four quarters  the company has beaten estimates on all four occasions  Overall  Alexion has posted an average positive earnings surprise of 11 91  for the trailing four quarters Currently  Alexion has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  Alexion surpassed earnings expectations in the fourth quarter of 2017  Our consensus called for EPS of  1 09  and the company reported EPS of  1 48 Revenue  Revenues  also  beat expectations  Alexion posted revenues of  909 7 million  compared to our consensus estimate of  878 million Key Stats Soliris sales increased 5 8  in the quarter to  791 9 million  During the quarter the company received approval for expanded indication of Soliris in the United States  Europe and Japan for the treatment of refractory generalized myasthenia gravis  gMG  in patients who are anti acetylcholine receptor antibody positive 2018 Guidance  The company provided guidance for 2018  The company expects earnings per share to be in the range of  6 60 to  6 80  It projects revenues to be in the range of  3 85 to  3 95 billion  The Zacks Consensus Estimate for earnings for 2018 was  7 07 per share while for sales it was  4 06 billion Share Price Impact There was no movement in pre market trading  Alexion Pharmaceuticals  Inc  Price and Consensus    Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-tops-q4-earnings-and-revenues-beat-estimates-200288440,200288440
146795,368311,ALXN,Alexion s  ALXN  Earnings And Sales Beat Estimates In Q4,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   posted fourth quarter 2017 adjusted earnings of  1 48 per share which were higher than the year ago earnings of  1 26 by 17 1   Earnings also beat the Zacks Consensus Estimate of  1 28  Strong product revenues drove the bottom line in the quarter Revenues rose 9 5  year over year to  909 7 million and exceeded the Zacks Consensus Estimate of  878 million  Revenues were driven by increased sales of Soliris  Strensiq and Kanuma   Following the earnings release  shares of the company rose 0 7   Over a year  Alexion s share price has declined 7 3   underperforming the gain of 1 4     Revenues in DetailSoliris  paroxysmal nocturnal hemoglobinuria   PNH   and atypical hemolytic uremic syndrome  aHUS   sales were up 6  to  791 9 million during the quarter driven by strong volume growth  While Strensiq  hypophosphatasia   HPP    contributed  95 6 million to revenues  up 36  year over year  Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  21 9 million  up 99   to quarterly revenues Cost SummaryAdjusted research and development  R D  expenses were  188 6 million  up 1 3  year over year Adjusted selling  general and administrative  SG A  expenses were  245 2 million  up 4 8  year over year 2017 ResultsEarnings per share for 2017 were  5 86  up 27  year over year Revenues in 2017 came in at  3 55 billion  up 15  year over year 2018 GuidanceAlexion expects adjusted earnings per share in the range of  6 60  6 80  It projects revenues in the range of  3 85  3 95 billion  Revenue guidance for Soliris is expected to be in the range of  3 33  3 40 billion  The Zacks Consensus Estimate for earnings for 2018 was  7 07 per share which is line with the guidance  while for sales it was  4 06 billion which is higher than the guidance range The outlook assumes unfavorable Soliris revenue impact of  90 million to  110 million from ALXN1210 and other clinical trial recruitment versus prior year Alexion expects to incur additional restructuring and related expenses of approximately  30 million to  70 million related to the 2017 restructuring activities Pipeline UpdateAlexion received FDA approval for label expansion of Soliris to treat patients with refractory generalized myasthenia in adults who are anti acetylcholine receptor  AchR  antibody positive in United States  and Japan during the fourth quarter  Further  the European Commission also approved the drug for the same indication in August 2017  The label expansion should help the company in boosting the revenues Currently  Alexion is evaluating Soliris in a couple of other phase III studies   PREVENT   for the treatment of relapsing neuromyelitis optica spectrum disorder  The company completed enrollment in the trail and expects to report data in mid 2018 The company also advanced the ALXN1210 clinical development program which is being evaluated in phase III studies for the treatment of PNH and aHUS during the quarter  The company completed enrollment in the PNH trial and expects to report data from the study in the second quarter of 2018  Enrollment for aHUS is expected to be complete in the second quarter of 2018 and Alexion expects to report data from this study in the fourth quarter of 2018 Our TakeAlexion exceeded earnings estimates and sales estimates in the fourth quarter  We expect growth at Alexion to continue being driven by Soliris  In the meantime  other new products   Strensiq and Kanuma   are doing well and should boost revenues  Mention a qualitative line on 2018 guidanceWe are also impressed by Alexion s efforts to develop its pipeline  especially the label expansion efforts for Soliris and the recent approval of Soliris to treat patients with refractory generalized myasthenia in the United States  Europe and Japan  Alexion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise     Zacks Rank   Stocks to ConsiderAlexion carries a Zacks Rank  3  Hold  Some better ranked stocks from the health care space are XOMA Corp   NASDAQ XOMA    Exelixis   NASDAQ EXEL   and Sucampo Pharma   NASDAQ SCMP    All of them carry a Zacks Rank  2  Buy   You can see  XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days  The company pulled off a positive earnings surprise in one of the last four quarters  with an average beat of 47 92   Share price of the company skyrocketed 556 9  over a year Exelixis  earnings per share estimates have moved up from 72 cents to 77 cents for 2018 in the last 60 days  The company delivered positive earnings surprise in the last four quarters  with an average beat of 572 92   Share price of the company surged 37 6  over a year Sucampo s delivered a positive earnings surprise in three of the last four quarters  with an average beat of 15 63   Share price of the company surged 55 2  over a year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/alexions-alxn-earnings-and-sales-beat-estimates-in-q4-200288633,200288633
146801,368317,ALXN,Omeros Inks Agreement With FDA For OMS721 Phase III Trial,opinion,Omeros Corporation   NASDAQ OMER   announced that it has entered into an agreement with the FDA on its protocol to start a phase III study to evaluate its lead pipeline candidate  OMS721  for treatment of patients with IgA nephropathy  IgAN   Enrollment of patients for the study is expected to start early next month Notably  OMS721 is Omeros  lead human monoclonal antibody targeting mannan binding lectin associated serine protease 2  MASP 2  Shares of Omeros have outperformed the in a year  The stock has soared 88 2  compared with the industry s rally of 26 7  The single arm phase III study will be conducted on biopsy confirmed IgAN patients aged minimum 18 years  In the trial  patients will be administered with intravenous doses of OMS721 through 12 weeks  The primary endpoint of the study will be reduction of proteinuria after the dosing starts  To further evaluate the safety and efficacy of the candidate  the initial sample size is estimated at 140 patients in either of the treatments including the placebo arm The company said that based on the degree of effect on proteinuria  either full or an accelerated approval for the candidate is possible in the United States We remind investors that in June last year  the FDA had granted a breakthrough therapy designation to OMS721  It is important to note that this designation enables expedited development and review of a drug candidate for the treatment of a serious or life threatening disease  It has also been granted an orphan drug designation by the FDA for the given indication  Additionally  the orphan drug status for the candidate in the EU is pending Meanwhile  OMS721 is also being evaluated in a phase III clinical program for atypical hemolytic uremic syndrome  aHUS  in both the United States and the EU  The candidate has been granted both fast track and orphan drug designations for aHUS by the FDA Meanwhile  the company has recently initiated another phase III study for hematopoietic stem cell transplant associated thrombotic microangiopathy  HCT TMA  Per the company  approximately 120 000 to 180 000 patients in the United States suffer from IgA nephropathy  Absence of an approved treatment for IgA nephropathy reflects a significant unmet need for the same  Approximately 40  of IgA nephropathy patients develop end stage renal disease The successful development and a subsequent approval of the candidate will significantly boost the company s growth prospects We note that Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   Soliris is also approved for aHUS Omeros  portfolio comprises a single approved drug  Omidria  The drug was launched in the United States in the second quarter of 2015 for its use during cataract surgery or intraocular lens or IOL replacement Omeros Corporation Price   Zacks Rank   Key PicksOmeros carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   and AcelRx Pharmaceuticals  Inc    NASDAQ ACRX    both carrying a Zacks Rank  2  Buy   You can see  Sucampo s earnings per share estimates have moved north from  1 15 to  1 19 for the current year in the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 63   Share price of the company has surged 28 6  year to date AcelRx stock has seen the Zacks Consensus Estimate loss per share being narrowed from  1 08 to  1 07 for 2017 and from  1 02 to 99 cents over the last 30 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/omeros-inks-agreement-with-fda-for-oms721-phase-iii-trial-200277573,200277573
146804,368320,ALXN,Can Merck  MRK  Deliver A Positive Surprise In Q4 Earnings ,opinion,"We expect Merck   Co   Inc    NYSE MRK   to beat expectations when it reports fourth quarter and full year 2017 results on Feb 2  before market opens  Last quarter  the company delivered a positive earnings surprise of 7 77  Merck s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 7 76 Merck   Company  Inc  Price and EPS Surprise
     
Merck s shares have declined 0 6  in the past year against a 27 5  increase for the  Factors to ConsiderMerck s new products like Keytruda  cancer  and Bridion  sugammadex  Injection are likely to drive the top line this quarter  However  loss of market exclusivity for several drugs and lower sales of key products like Januvia and Gardasil Gardasil 9 may hurt sales Keytruda sales are being driven by the launch of new indications globally  Keytruda sales are gaining particularly from strong momentum in the first line lung cancer indication as the therapy is the only anti PD 1 approved in first line setting The Keytruda development program also significantly advanced in 2017 with regulatory approvals for six new indications in the United States  four in Europe and three in Japan The approvals expanded the patient population  driving up sales in the third quarter  This momentum is likely to drive fourth quarter as well as 2018 results Strong demand in most markets is driving sales of Bridion  sugammadex  Injection Meanwhile  rising competitive pressure is hurting sales of relatively newer drugs like Zostavax and Zepatier  On the third quarter earnings call  Merck management had warned that Zepatier uptake in the fourth quarter and in 2018 may be impacted by evolving marketplace and competitive landscape While continued pricing pressure is hurting sales of older products like Januvia  lower demand due to competitive pressure is dampening sales of Isentress  Importantly  on the Q3 call  the company had said that though pricing pressure will continue to hurt sales of Januvia Janumet  volumes may improve in the future quarters  especially outside the United States The animal health franchise should also boost sales this quarter  On the Q4 call  investors will be keen to find out if the vaccine segment has recovered from product shutdown issues related to the last year s cyber attack Finally  higher investments for ongoing launches  remediation expenses related to the cyber attack  as well as additional R D costs associated with the new oncology collaboration with AstraZeneca   NYSE AZN   will raise costs and hurt profits Earnings WhispersOur proven model shows that Merck is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  95 cents per share  and the Zacks Consensus Estimate  94 cents per share   is  1 06   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Merck has a Zacks Rank  3  The combination of Merck s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderHere are some other drug biotech stocks that have the right combination of elements to beat on earnings this time around Alexion Pharmaceuticals  Inc    NASDAQ ALXN   with an Earnings ESP of  3 45  and a Zacks Rank  3  The company is scheduled to release results on Feb 8  You can see  Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  2 66  and a Zacks Rank  2  The company is scheduled to release results on Feb 1 Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-01-29,Zacks Investment Research,https://www.investing.com/analysis/can-merck-mrk-deliver-a-positive-surprise-in-q4-earnings-200284975,200284975
146809,368325,ALXN,What s In The Cards For GW Pharma  GWPH  In Q1 Earnings ,opinion,GW Pharmaceuticals plc    NASDAQ GWPH   will report fiscal first quarter 2018 results on Feb 5  before the market opens GW Pharma s share price has increased 20 8  over a year compared with the  s gain of 26 7    Factors at PlayGW Pharma s growth is solely dependent on Sativex  which is marketed outside the United States for the treatment of spasticity due to multiple sclerosis  The company in December 2017  terminated its agreement with Japan based Otsuka Pharmaceutical for Sativex in the United States  As a result  GW Pharma reacquired full ownership of the development and commercialization rights of the product in the United States  The drug s sales is expected to remain on a growth trajectory in fiscal first quarter like the past several quarters  though the impact of the reacquisition will not be felt much this quarter GW Pharma made significant progress with its lead cannabinoid pipeline candidate  Epidiolex for the treatment of Lennox Gastaut syndrome   LGS   and Dravet syndrome in Q4  In October 2017  the company submitted a new drug application for Epidiolex to the FDA seeking approval in both the indications  In December 2017  the FDA accepted the filing with Priority Review and set an action date of Jun 27  2018  In December 2017  the company also submitted its marketing authorisation application   MAA   to the European Medicines Agency   EMA   for Epidiolex   It is also gearing up for the launch of the candidate  which is expected to increase operational expenses in fiscal first quarter The company is also developing GWP42006  CBDV  in a phase II clinical trial for epilepsy  with data expected to be announced soon  The candidate received orphan drug designation from the FDA for treating Rett syndrome Investor focus at the call will be on management s comments commercialization plan for Epidiolex  if approved e  An update on progress of CBDV development is also expected Surprise HistoryGW Pharma s performance over the last four quarters has been rather poor  with the company surpassing the Zacks Consensus Estimate only once and missing the same on three other occasions  The average surprise over the last four quarters is  4 01   The company missed estimates last quarter  resulting in a negative earnings surprise of 26 01  What Our Model IndicatesOur proven model shows does not conclusively show an earnings beat for GW Pharma this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  loss of  2 39  and the Zacks Consensus Estimate  loss of  2 03   is  17 26   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  GW Pharma currently has a Zacks Rank  3  which increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing negative estimate revisions  GW Pharmaceuticals PLC Price and EPS Surprise     Stocks That Warrant a LookHere are some biotech stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to release fourth quarter results on Feb 8  The company has an Earnings ESP of  3 45  and a Zacks Rank  3  You can see  Anthera Pharmaceuticals  Inc    NASDAQ ANTH   is expected to release fourth quarter results on Feb 26  The company has an Earnings ESP of  20 47  and a Zacks Rank  2 Exelixis  Inc    NASDAQ EXEL    which is expected to release fourth quarter results on Feb 26  has an Earnings ESP of  7 23  and a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-gw-pharma-gwph-in-q1-earnings-200285330,200285330
146830,368346,ALXN,3 Biotech And Pharma Stocks With Key FDA Catalysts This October,opinion,"The FDA  which approved 22 novel drugs last year  has given its approval to 34 drugs so far in 2017 including three in September  Key approvals this year include Novartis s Kymriah  the first gene therapy in the United States   Lilly s Verzenio  advanced or metastatic breast cancer   Gilead s Vosevi  hepatitis C virus   Puma s Nerlynx  to reduce the risk of breast cancer returning   J J s Tremfya  moderate to severe plaque psoriasis   Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s multiple sclerosis treatment  Ocrevus  Regeneron and Sanofi s eczema treatment  Dupixent  Tesaro s PARP inhibitor  Zejula  and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Quite a few of these drugs have blockbuster potential With the drug development process being lengthy and time consuming and requiring the utilization of a lot of funds and resources  key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts  Here is a look at a few important regulatory events scheduled for the month of October Will Flexion Gain Approval for its First Drug Specialty pharma company  Flexion Therapeutics   NASDAQ FLXN   is awaiting FDA approval of its first product  Zilretta  The company  which is focused on the development and commercialization of novel  local therapies for the treatment of patients with musculoskeletal conditions  beginning with osteoarthritis   OA    expects a decision from the agency on Oct 6  2017  Flexion is looking to get Zilretta approved for the treatment of OA related knee pain  Zilretta  a non opioid  could provide OA patients with a new and alternative treatment option on approval  Flexion already has a sales leadership team in place and said that the pre approval inspection of the Patheon manufacturing facility was concluded without any observations Flexion stock has gained 27 1  year to date  substantially outperforming the 3 6  rally of the  it belongs to 
Alexion s Soliris Label to be Expanded Again Alexion Pharmaceuticals   NASDAQ ALXN   is working on expanding the label of its flagship product  Soliris  eculizumab   Soliris  currently approved in the United States for serious ultra rare disorders like paroxysmal nocturnal hemoglobinuria   PNH   and atypical hemolytic uremic syndrome  aHUS   brought in sales of  1 6 billion in the first half of the year  Alexion has a key catalyst coming up with a decision from the FDA expected by Oct 23  2017 regarding the approvability of Soliris for refractory generalized myasthenia gravis  gMG   EU approval for this indication came in August making it the first and only complement based therapy approved for an ultra rare subset of gMG  The gMG indication represents incremental growth opportunity for Soliris Alexion s shares are up 14 7  year to date  compared to the  16 2  rally  Alexion is a Zacks Rank  3  Hold  stock   you can see  

CRL Likely for PTC s TranslarnaPTC Therapeutics   NASDAQ PTCT   is expecting a decision from the FDA regarding the approval status of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy  nmDMD   While approved in the EU  Translarna is yet to gain approval in the United States  The company had initially filed a new drug application   NDA   in the United States in December 2015  However  in February 2016  the FDA issued a refusal to file   RTF   letter saying that the NDA was not sufficiently complete to allow a substantive review  The company was told that both the phase IIb and phase III ACT DMD studies were negative and did not provide sufficient evidence of effectiveness and adequate information about the abuse potential of Translarna  PTC filed a NDA in the first quarter of 2017 and was assigned an FDA action date of Oct 24  2017 However  chances of gaining approval seem low considering Translarna failed to gain the support of an FDA advisory panel last week  While the panel found the drug to be effective  they found the submitted data inconclusive and said that more data would be needed to support efficacy  Given this situation  we believe the FDA will issue a complete response letter   CRL   and ask for additional data PTC s shares are up 83 4  year to date  compared to the  s 3 6  rally 
Apart from the above three companies  quite a few other companies are awaiting decisions from the FDA  Industry bellwether  Johnson   Johnson   NYSE JNJ   is seeking FDA approval for a 10mg dose of Xarelto for reducing the risk of recurrent venous thromboembolism  VTE   With the FDA granting priority review  a response should be out on Oct 28  2017 Cancer focused company  TESARO   NASDAQ TSRO   is expecting a decision from the FDA for its intravenous   IV   formulation of rolapitant on Oct 25  2017  The company had received a CRL earlier this year for the IV formulation Specialty pharma company  AcelRx Pharmaceuticals   NASDAQ ACRX   expects a response from the FDA regarding its NDA for Dsuvia  sufentanil sublingual tablet  30 mcg  on Oct 12  2017  Dsuvia is under review for the treatment of moderate to severe acute pain in medically supervised settings Meanwhile  Aerie Pharmaceuticals s   NASDAQ AERI   Rhopressa will be evaluated by an FDA advisory panel for the treatment of patients with open angle glaucoma or ocular hypertension on Oct 13  2017 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-01,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-and-pharma-stocks-with-key-fda-catalysts-this-october-200216500,200216500
146831,368347,ALXN,What s In The Cards For Amgen  AMGN  This Earnings Season ,opinion,"Biotech major Amgen Inc    NASDAQ AMGN   will report third quarter 2017 results on Oct 25 after the market closes  Amgen delivered a positive earnings surprise of 5 83  in the last quarter Amgen shares are up 25 9  so far this year  This compares favorably with the 12 1  increase registered by the  during this period Amgen s performance has been pretty impressive  with the company reporting positive surprises consistently  The average earnings beat over the last four quarters is 5 85  Let s see how things are shaping up for the company this quarter Factors at PlayAmgen s newer products like Prolia  Xgeva  Kyprolis  and Blincyto  should continue to perform well backed by higher demand  thus making up for lower sales of mature brands like Enbrel  Epogen  Neulasta and Neupogen due to competitive pressure Neulasta demand is being hurt due to competition from PD 1s and other new cancer therapiesNeupogen sales are also being hurt by biosimilar competition in the United States mainly from Zarxio  Sandoz s biosimilar version of Neupogen  which was launched in September 2015 Neulasta and Neupogen sales are expected to be hurt by competitive dynamics in the third and fourth quarters  The Zacks Consensus Estimate for Neulasta and Neupogen are  1 10 billion and  133 million  respectively for the third quarter However  management mentioned on the Q2 call that   no new U S  biosimilar competition  is expected this year  This suggests that Neulasta and Epogen may not start facing any biosimilar competition this year  contrary to previous expectations Three companies   Mylan Biocon  Novartis   NYSE NVS    and Coherus   looking to launch generic versions of Neulasta and one company looking to launch generic version of Epogen have received complete response letter from the FDA for their respective applications  which can delay their launch The bottom line will continue to be driven by the company s overall cost cutting efforts and share buyback  The company s restructuring plan will likely make it leaner and more cost efficient Investor focus will remain on the performance of the company s PCSK9 inhibitor  Repatha  Uptake of Repatha  which gained FDA approval in August 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  However  in the second quarter  Repatha revenues improved sequentially driven by higher demand  Management said that the presentation of the outcomes study data  FOURIER  had a positive impact on Repatha share trends  It remains to be seen if the positive trends continue in the third quarter Earnings WhispersOur proven model does not conclusively show that Amgen is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  0 37  as the Most Accurate estimate stands at  3 07 while the Zacks Consensus Estimate is pegged higher at  3 08  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Amgen s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions  Amgen Inc  Price and EPS Surprise   Stocks to Consider
 Some stocks in the Biomed Genetics sector that have both a positive ESP and a favorable Zacks Rank are Celgene Corporation   NASDAQ CELG   with an Earnings ESP of  0 93  and a Zacks Rank  3  The company is scheduled to release results on Oct 26 Also scheduled to release results on Oct 26  Alexion Pharmaceuticals  Inc    NASDAQ ALXN   has an Earnings ESP of  1 26  and a Zacks Rank  3  You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-amgen-amgn-this-earnings-season-200220140,200220140
146832,368348,ALXN,Achillion  ACHN  Q3 Loss Narrows  Pipeline Expansion In Focus,opinion,"Achillion Pharmaceuticals  Inc    NASDAQ ACHN   reported a loss of 14 cents per share in the third quarter of 2017  narrower than the Zacks Consensus Estimate of a loss of 18 cents  In the year ago quarter  the company had reported a loss of 15 cents per share The company generated no revenues in the reported quarter as was the case in the year ago quarter Shares of Achillion have underperformed the  year to date  The company s shares lost 3 2  whereas the industry registered an increase of 2 3  Research and development expenses decreased nearly 6 6  from the year ago period to  15 6 million due to lower costs related to preclinical studies and manufacturing of ACH 4471 and lower legal fees as well  General and administrative expenses remained flat year over year at  4 8 million Pipeline UpdateThe company is developing its most advanced candidate  ACH 4471  in   paroxysmal nocturnal hemoglobinuria  PNH   immune complex mediated membranoproliferative glomerulonephritis  IC MPGN  and C3 glomerulopathy  C3G     in the United States A phase II study on its factor D inhibitor  ACH 4471 for the treatment of patients with PNH is ongoing  An interim analysis has shown clinically meaningful complement inhibition of factor D and a favorable tolerability profile for ACH 4471  The company expects to announce updated interim results by the year end Another phase II study on ACH 4471 is expected to start in the first half of 2018  The study will evaluate the candidate in combination with Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   Soliris for potential long term treatment in PNH patients already being treated with Soliris Moreover  the company initiated a phase II study in September on ACH 4471 in patients with C3G to evaluate the effect of a factor D inhibitor on the complement pathway  The company has plans to start another phase II study in the first half of 2018 to evaluate the candidate in patients with biopsy confirmed C3G or IC MPGN Achillion will evaluate the potential of extended release formulations of ACH 4471 in phase I study  which is expected to start later this year Meanwhile  Achillion is planning to advance a number of next generation factor D inhibitors in preclinical or clinical studies including a phase I study on ACH 5228 expected to start by 2017 end In September  Johnson   Johnson   NYSE JNJ   terminated its worldwide license and collaboration arrangement with the company related to development of its hepatitis C treatment  Achillion lost a strong partner with this termination Achillion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderAchillion Pharma carries a Zacks Rank  3  Hold  A stock in the health care sector worth considering is Exelixis  Inc    NASDAQ EXEL   carrying a Zacks Rank  2  Buy   You can see  Exelixis  earnings per share estimates remained stable at 26 cents for 2017 and increased from 63 cents to 64 cents for 2018 over the last 30 days  The company delivered positive earnings surprise in all the four trailing quarters with an average beat of 572 92   The company s shares are up 71 2  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-03,Zacks Investment Research,https://www.investing.com/analysis/achillion-achn-q3-loss-narrows-pipeline-expansion-in-focus-200258143,200258143
146833,368349,ALXN,Achillion  ACHN  Shares Down As J J Announces Stake Sale,opinion,"Achillion Pharmaceuticals  Inc  s   NASDAQ ACHN   shares fell almost 7 9  in after market trading on Tuesday  following the announcement that Johnson   Johnson s   NYSE JNJ   will sell its stake in the company 
We remind investors that J J had terminated the global license and collaboration agreement with Achillion for developing hepatitis C treatments earlier in September  The decision was taken by J J as part of its strategy to focus on areas of greatest unmet medical need 
The termination of the agreement is a major setback for Achillion  as it has no marketed drug and was dependent on J J for funds  The company has lost out on future revenues in the form of milestone payments 
Achillion s shares are down 10 7  so far this year  underperforming the  which remained flat in that period 

In a separate press release  Achillion also announced promising preliminary data from group 1 of a phase II study on its factor D inhibitor  ACH 4471  in renal diseases  The candidate demonstrated potential in treating C3 glomerulopathy  C3G   a serious renal disease  The study is evaluating the candidate in patients with C3G or immune complex mediated membranoproliferative glomerulonephritis  IC MPGN  
The phase II study is evaluating the candidate in two separate groups in patients with C3G or IC MPGN  Group 1 evaluated a dose of 100 mg of ACH 4471 thrice daily for 14 days in two patients  Along with proteinuria  the study also measured the ratio of C3 fragments to intact C3 in plasma  which also decreased rapidly compared to baseline during the course of the study  Higher C3 fragments are believed to be responsible for kidney damage and loss of function seen in this disease over time 
Presently  no FDA approved therapies are available to treat C3G  However  the promise shown by the candidate is a boost for the company as it indicates a potential treatment under development 
Achillion is currently selecting patients for enrollment in group 2 of the study 
Moreover  the company has plans to initiate two separate phase II studies on ACH 4471 to evaluate it in C3G   IC MPGN patients over six and twelve months during the first half of 2018 
Other than C3G and IC MPGN  Achillion is also developing ACH 4471 in paroxysmal nocturnal hemoglobinuria   PNH    atypical hemolytic uremic syndrome  and dry age related macular degeneration 
In August 2017  the company had announced positive data from a phase II study in PNH patients  Achillion has plans to initiate another phase II study on ACH 4471 to evaluate the candidate in combination with Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   Soliris for potential long term treatment in PNH patients already being treated with Soliris Achillion Pharmaceuticals  Inc  Price
 

   Zacks Rank   Key Pick
Achillion carries a Zacks Rank  2  Buy  
Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   is a better ranked health care stock  sporting a Zacks Rank  1  Strong Buy   You can see  
Sucampo s earnings per share estimates have increased from  1 01 to  1 11 for 2017 and from  1 06 to  1 21 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15 63  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-11-15,Zacks Investment Research,https://www.investing.com/analysis/achillion-achn-shares-down-as-jj-announces-stake-sale-200265537,200265537
146834,368350,ALXN,Alexion  ALXN  In Focus  Stock Moves 7 2  Higher,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   was a big mover last session  as the company saw its shares rise more than 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  106 78 to  111 75 in the past one month time frame  The move came after the company announced its collaboration with Halozyme Therapeutics  which will enable Alexion to use Halozyme s technology for drug delivery The company has seen one negative estimate revisions in the past few months  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Alexion currently has a Zacks Rank  3  Hold  while its  is positive   Alexion Pharmaceuticals  Inc  Price   A better ranked stock in the Medical   Biomedical and Genetics industry is Akari Therapeutics PLC   NASDAQ AKTX    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is ALXN going up  Or down  Predict to see what others think   or Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-12-10,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-in-focus-stock-moves-72-higher-200272168,200272168
146856,368372,ALXN,Akari Therapeutics  AKTX  Stock Is Skyrocketing Over 60  Today  Here s Why,opinion,"On Thursday  shares of biopharmaceutical company Akari Therapeutics   NASDAQ AKTX   are skyrocketing  up over 60  in midday trading the stock was up 90  in premarket trading after it announced it would advance its lead drug candidate 
In a   Akari said that after an End of Phase 2 meeting with the FDA and based on the agency s feedback  the company would be pushing forward Coversin into Phase 3 development for the treatment of Paroxysmal Nocturnal Hemoglobinuria  PNH  in the first quarter of 2018 
In the U S   the PNH indication has  Fast Track  status  PNH is a rare  life threatening disease of the blood  it s characterized by the destruction of red blood cells  blood clots  and impaired bone marrow function  PNH affects about 1 to 1 5 persons per million  and primarily impacts younger adults  according to Johns Hopkins 
 Following our recent FDA meeting  we are working to initiate a Phase III clinical trial of Coversin in PNH in Q1 2018   said Dr  David Horn Solomon  Chief Executive Officer of Akari Therapeutics   We will continue to work closely with the FDA  benefitting from our Fast Track status in the U S   and with the EMA towards submission of a BLA and MAA  respectively  for Coversin in PNH  
Akari said that it plans to perform two Phase 3 clinical studies  CAPSTONE and ASSET  CAPSTONE will carry out on  na ve  PNH patients where Alexion s   NASDAQ ALXN   Soliris  or eculizumab  is not the standard of care  while ASSET is a Phase 3 clinical study that switches PNH patients from eculizumab to treatment with Coversin 
With Coversin delivered subcutaneously  patients may have greater independence due to self administration  Phase II studies are also planned for a number of other indications where Coversin s actions on both the complement and leukotriene  LTB4  pathways play a role  Its two leading targets in this area are atopic keratoconjunctivitis  AKC   a rare eye disorder and severe bullous pemphigoid  BP  LON BP    a rare skin disorder   added Solomon 
Akari focuses on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases  The stock is a  1  Strong Buy  on the Zacks Rank  with a VGM Score of  F  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-09-21,Zacks Investment Research,https://www.investing.com/analysis/akari-therapeutics-aktx-stock-is-skyrocketing-over-60-today-heres-why-200214756,200214756
146857,368373,ALXN,Bayer  BAYRY  Focuses On Pipeline Development   Acquisitions ,opinion,"We issued an updated report on Bayer Aktiengesellschaft   OTC BAYRY   on Sep 21 Notably  Bayer is a life science company with core competencies in the areas of health care and agriculture  The company reports results under five divisions   Pharmaceuticals  Consumer Health  Crop Science  Animal Health and Covestro The company has a robust pipeline ranging from phase I to phase III development  Interesting late stage candidates include BAY 1841788  ODM 201  AR antagonist  non metastatic castration resistant prostate cancer   BAY 1841788  ODM 201  AR antagonist  metastatic hormone sensitive prostate cancer   copanlisib  PI3K inhibitor  various forms of non Hodgkin lymphoma  and finerenone  MR antagonist  diabetic kidney disease  among others Bayer s shares have outperformed the industry year to date  The stock has been up 26 8  compared with the  s gain of 16 6  in the same time frame  In September 2017  the FDA approved copanlisib under the brand name Aliqopa 60 mg vial for injection to treat adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies Meanwhile  Bayer is looking for a label expansion of its oncology drug Stivarga  which is approved for the treatment of metastatic colorectal cancer and metastatic gastrointestinal stromal tumors  The drug was granted marketing authorization by the European Commission  EC  in Aug 2017  for the treatment of adult patients with hepatocellular carcinoma  HCC  who have been previously treated with Nexavar  sorafenib  Also  the company announced the submission of a Biologics License Application  BLA  with FDA for its long acting site specifically PEGylated recombinant human Factor VIII  BAY94 9027  for the treatment of Hemophilia A in August In fact  Bayer has made several acquisitions and entered into a number of deals to boost its portfolio in the past few quarters  It is planning to acquire Monsanto Company   NYSE MON   in an all cash transaction worth approximately  66 billion as well Going forward  the combined business is expected to boost Bayer s Crop Science business and provide accretion to its core earnings from the first full year of the closing of the transaction  slated to close by the end of 2017   followed by double digit percentage growth Furthermore  Bayer expects annual earnings contributions of around  1 5 billion from synergies after three years of closing the transaction as well as additional future benefits from integrated offerings  Markedly  we believe that the proposed Monsanto acquisition is a strategic move which will offer Bayer with a broad set of solutions to meet farmers  current and future needs However  the company is facing generic threats competition for many of its products including the Yaz franchise  oral contraceptives   The genericization of key drugs might negatively impact revenues  Bayer AG  DE BAYGN  Price and Consensus
    Zacks Rank   Other Stocks to ConsiderBayer currently carries a Zacks Rank  2  Buy   Other top ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   sporting a Zacks Rank  1  Strong Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 32 to  5 60 for 2017 and from  6 56 to  7 06 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 16 9  year to date Regeneron s earnings per share estimates have increased from  12 84 to  14 99 for 2017 and from  15 32 to  16 64 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 18 1  year to date 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-21,Zacks Investment Research,https://www.investing.com/analysis/bayer-bayry-focuses-on-pipeline-development--acquisitions-200214966,200214966
146858,368374,ALXN,The Medicines Co  Continues To Focus On Pipeline Development,opinion,"We issued an updated report on The Medicines Company   NASDAQ MDCO   on Sep 21 Notably  the Medicines Co  has undertaken a restructuring program to boost shareholder value  In fact  the company is exploring options for optimizing capital structure and liquidity position by divesting certain non core products and businesses in order to generate non dilutive cash and reduce associated cash burn and capital requirements In February 2016  the Medicines Co  divested its hemostasis portfolio  which included drugs such as Recothrom  PreveLeak and Raplixa to Mallinckrodt plc   NYSE MNK   for up to  409 million However  the Medicines Co  s shares have underperformed the industry year to date  The stock has been up 3  compared with the  s gain of 15 8  in the same time frame With the divestment of non core products  The Medicines Co  is focusing on developing pipeline candidates targeting its key focus areas  Currently company has one candidate representing blockbuster potential  namely Inclisiran  formerly PCSK9si  hypercholesterolemia   currently in phase II ORION studies   In August 2017  the company announced new encouraging one year safety and efficacy data from the ongoing ORION 1 phase II study Also  The Medicines Co declared that the FDA has granted accelerated approval to its experimental antibiotic  Vabomere  a combination of meropenem and vaborbactam  for treating complicated urinary tract infections  cUTI   including the pyelonephritis in August  this year The company expects to make Vabomere available in the market in fourth quarter 2017  Markedly  the FDA s accelerated approval of Vabomere is a huge positive for the company given the lucrative market it targets  The Medicines Co also filed a new drug application  NDA  for the antibiotic in February  which is currently under review in the EU However  with The Medicines Co  s flagship product Angiomax facing generic competition it has entered a challenging period where driving top line growth will become increasingly difficult  Evidently  the company recorded lower sales from Angiomax in the second quarter of 2017  due to the loss of exclusivity  The Medicines Company Price and Consensus
    Zacks Rank   Stocks to ConsiderThe Medicine Co  currently carries a Zacks Rank  3  Hold   Better ranked stocks in the health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    sporting a Zacks Rank  1  Strong Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates moved up from  5 32 to  5 60 for 2017 and from  6 56 to  7 06 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 16 9  year to date Regeneron s earnings per share estimates increased from  12 84 to  14 99 for 2017 and from  15 32 to  16 64 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 18 1  year to date 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-21,Zacks Investment Research,https://www.investing.com/analysis/the-medicines-co-continues-to-focus-on-pipeline-development-200214944,200214944
146859,368375,ALXN,Werner Enterprises  Cott  Akari Therapeutics  And Alexion Highlighted As Zacks Bull And Bear Of The Day,opinion,For Immediate ReleaseChicago  IL   September 22  2017    Werner Enterprises  Nasdaq    NASDAQ WERN      as the Bull of the Day  Cott Corporation  NYSE    NYSE COT      as the Bear of the Day  In addition  Zacks Equity Research provides analysis on Akari Therapeutics  Nasdaq    NASDAQ AKTX      and Alexion Nasdaq    NASDAQ ALXN      Here is a synopsis of all four stocks   Werner Enterprises Nasdaq      is a Zacks Rank  1  Strong Buy  and sports a clean slate of A s for the Zacks Style Scores  With all that going for it  you should not be surprised that I picked it as the Bull of the Day DescriptionWerner Enterprises is a transportation company primarily engaged in hauling truckload shipments of general commodities in both interstate and intrastate commerce  The Company operates throughout the 48 contiguous states pursuant to operating authority  both common and contract  granted by the Department of Transportation and pursuant to intrastate authority granted by various states  They also have authority to operate in the ten provinces of Canada and have through trailer service in and out of Mexico Earnings HistoryWERN has a good earnings history  beating the Zacks Consensus Estimate in three of the last four quarters  Earnings EstimatesThe Zacks Consensus Estimate for WERN has been moving higher over the last three months  The 2017 number has moved from  1 13 to  1 24 over the last 90 days while the 2018 number has increased from  1 40 to  1 50 over the same time period   Cott Corporation NYSE      is the Bear of the Day today because it is a Zacks Rank  5  Strong Sell    It became a Strong Sell because earnings estimates were falling and we will go over that later  but I also want to point out the oppressive tax that residents of Chicago face when they are buying a sweetened beverage Can you believe a city government pretends to care about your health in a way to make you pay for sweetened beverages at a rate of one cent per ounce   That is 12 cents on a regular can of soda or  1 44 in taxes on a twelve pack   Maybe the former  Top Cop  will repeal this tax when he runs for  and becomes  Mayor    GarryForMayor Not all of the problems that COT has seen come from Chicago taxes pushing potential consumers to other beverages to avoid an oppressive tax  Let s take a look at the reason why this stock is a Zacks Rank  5  Strong Sell  DescriptionCott Corporation is one of the world s largest non alcoholic beverage companies and the world s largest retailer brand soft drink provider  The Company commercializes its business in over Sixty countries worldwide  with its principal markets being the United States  Canada  the United Kingdom and Mexico  Cott markets or supplies over two hundred retailer and licensed brands  and Company owned brands including Cott  RC  Vintage  Vess and So Clear  Its products include carbonated soft drinks  sparkling and flavored waters  energy drinks  sports drinks  juices  juice drinks and smoothies  ready to drink teas  and other non carbonated beverages Earnings HistoryThere are two recent misses of the Zacks Consensus Estimate  The most recent miss was a negative 62  earnings surprise   The previous miss was a 42  negative earnings surprise Earnings EstimatesThe reason most stocks fall to a Zacks Rank  5  Strong Sell  is that earnings estimates are falling   This table can be found on the Zacks website under the detailed estimates page Additional content Why Akari Therapeutics  AKTX  Skyrocketed on ThursdayOn Thursday  shares of biopharmaceutical company Akari Therapeutics  Nasdaq      skyrocketed  up over 60  by midday trading the stock was up 90  in premarket trading after it announced it would advance its lead drug candidate In a   Akari said that after an End of Phase 2 meeting with the FDA and based on the agency s feedback  the company would be pushing forward Coversin into Phase 3 development for the treatment of Paroxysmal Nocturnal Hemoglobinuria  PNH  in the first quarter of 2018 In the U S   the PNH indication has  Fast Track  status  PNH is a rare  life threatening disease of the blood  it s characterized by the destruction of red blood cells  blood clots and impaired bone marrow function  PNH affects about 1 to 1 5 persons per million  and primarily impacts younger adults  according to Johns Hopkins  Following our recent FDA meeting  we are working to initiate a Phase III clinical trial of Coversin in PNH in Q1 2018   said Dr  David Horn Solomon  Chief Executive Officer of Akari Therapeutics   We will continue to work closely with the FDA  benefitting from our Fast Track status in the U S   and with the EMA towards submission of a BLA and MAA  respectively  for Coversin in PNH  Akari said that it plans to perform two Phase 3 clinical studies  CAPSTONE and ASSET  CAPSTONE will carry out on  na ve  PNH patients where Alexion s  Nasdaq      Soliris  or eculizumab  is not the standard of care  while ASSET is a Phase 3 clinical study that switches PNH patients from eculizumab to treatment with Coversin With Coversin delivered subcutaneously  patients may have greater independence due to self administration  Phase II studies are also planned for a number of other indications where Coversin s actions on both the complement and leukotriene  LTB4  pathways play a role  Its two leading targets in this area are atopic keratoconjunctivitis  AKC   a rare eye disorder and severe bullous pemphigoid  BP  LON BP    a rare skin disorder   added Solomon Akari focuses on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases  The stock is a  1  Strong Buy  on the Zacks Rank  with a VGM Score of  F  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think  About the Bull and Bear of the DayEvery day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-09-22,Zacks Investment Research,https://www.investing.com/analysis/werner-enterprises-cott-akari-therapeutics-and-alexion-highlighted-as-zacks-bull-and-bear-of-the-day-200214902,200214902
146860,368376,ALXN,Abbvie Bristol Myers Inks Deal To Develop Therapeutic Cancer ,opinion,AbbVie   NYSE ABBV   and Bristol Myers Squibb Company   NYSE BMY   entered into a deal to evaluate the combination of AbbVie s investigational antibody drug conjugate  ABBV 399  and Bristol Myers Squibb s immune oncology drug  Opdivo  nivolumab   in c Met overexpressing non small cell lung cancer  NSCLC  Currently  the combination is in a phase I study that evaluates the patients for second line treatment who have failed one prior line of chemotherapy  But the specific terms of the deal were not disclosed  Notably  AbbVie is the sponsor conducting the trial AbbVie s shares have outperformed the industry year to date  The stock has been up 39 7  compared with the  s gain of 17  in the same time frame We remind investors that Opdivo is approved for varied indications in the EU and the United States  The drug has also received approvals for several indications including melanoma  head and neck  lung  kidney and blood cancer ABBV 399 is an anti c Met antibody drug conjugate that targets both MET amplified and c Met overexpressing tumors  It is currently being developed to treat advanced solid tumors In fact  Opdivo continues to be launched globally on approvals and label expansions  Label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug  significantly   Markedly  Opdivo is being studied in combination with Bristol Myers  other drug Yevroy   In the melanoma indication  the Opdivo Yervoy regimen is contributing to growth in both Opdivo and Yervoy  Also  the drug became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin lymphoma in the United States  May 2016  and the EU  November 2016  In the second quarter of 2017  Opdivo generated revenues of  1 19 billion  up 42  from the year ago period AbbVie Inc  Price   Zacks Rank   Stocks to ConsiderAbbVie currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   sporting a Zacks Rank  1  Strong Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 49 to  5 60 for 2017 and from  6 82 to  7 06 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 16 8  year to date Regeneron s earnings per share estimates have increased from  12 84 to  14 99 for 2017 and from  15 32 to  16 65 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 17 9  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-24,Zacks Investment Research,https://www.investing.com/analysis/abbviebristolmyers-inks-deal-to-develop-therapeutic-cancer-200215234,200215234
146879,368395,ALXN,Glaxo s Triple Therapy COPD Inhaler Gets CHMP Nod In The EU,opinion,GlaxoSmithKline plc   NYSE GSK   and partner Innoviva  Inc    NASDAQ INVA   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has granted a positive opinion recommending approval of its once daily single inhaler triple therapy in the EU So far this year  Glaxo  share price has increased 4 5   comparing unfavorably with a gain of 16 4  recorded by the  it belongs to The once daily single inhaler triple therapy is proposed to be called Trelegy Ellipta  Glaxo is looking to get Trelegy Ellipta approved for the treatment of moderate to severe chronic obstructive pulmonary disease  COPD  in patients who are already being treated with a combination of inhaled corticosteroid  ICS  and a long acting beta2 adrenergic agonist  LABA  but require additional bronchodilation Trelegy Ellipta is a combination of fluticasone furoate   an ICS  umeclidinium     a long acting muscarinic antagonist  LAMA  and vilanterol   a LABA therapy  Trelegy Ellipta will be delivered in Glaxo  Ellipta dry powder inhaler Glaxo s Ellipta products have been quite successful and are a key driver of the company s sales  In the last reported quarter   second quarter of 2017   Ellipta products recorded a 73  surge in sales  driven by market share gains and the ongoing rollout in Europe and other international markets Trelegy Ellipta  if approved  will be the first single inhaler triple therapy to be approved anywhere in the world  We believe the therapy will enjoy strong demand as it can remove the need for multiple inhalers for COPD patients  This can further boost sales of Glaxo s Ellipta products A final decision from the European Commission is expected around the end of the year  The candidate is also under review in many countries including the United States Glaxo carries a Zacks Rank  3  Hold  Stocks to ConsiderBetter ranked biotech stocks include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    each sporting a Zacks Rank  1  Strong Buy   You can see Shares of Alexion have gained 19 9  year to date  The Zacks Consensus Estimate for 2017 and 2018 increased 5 2  and 7 5   respectively  over the past 60 days Regeneron s shares have rallied 18 1  this year so far  Its estimates have moved up 16 7  for 2017 while that for 2018 have climbed 8 9  over the past 60 days New Report  An Investor s Guide to CybersecurityCyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020 The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ,2017-09-17,Zacks Investment Research,https://www.investing.com/analysis/glaxos-triple-therapy-copd-inhaler-gets-chmp-nod-in-the-eu-200213875,200213875
146880,368396,ALXN,Pluristem s Ischemia Candidate Gets Fast Track Designation,opinion,"Pluristem Therapeutics  Inc    NASDAQ PSTI   announced that the FDA has granted Fast Track designation to a phase III study evaluating its critical limb ischemia   CLI   candidate  PLacental eXpanded  PLX  PAD cells  The candidate is being evaluated in patients who are not eligible for revascularization The FDA grants fast track designation to help the development and a faster review of drugs  which treat serious and unmet medical conditions  With this designation  the drug is expected to be granted priority review once it files a New Drug Application  NDA  Pluristem s shares were up almost 8 2  including after market movement on Monday as investors cheered the FDA s decision  However  shares of the company are down 0 7  so far this year  underperforming the  s gain of 15 6  The phase III study is currently enrolling patients in the United States and Europe  The candidate has also been included in Adaptive Pathways program by the European Medicines Agency  Any positive results from interim analysis of the phase III study will help Pluristem to receive an early conditional marketing authorization for the candidate 
Meanwhile  Japan s Pharmaceuticals and Medical Devices Agency has also included PLX PAD cells into its accelerated regulatory pathway for regenerative therapies Critical limb ischemia is a severe form of peripheral arterial disease where blood flow is reduced in the arteries in the legs due to deposition of fatty acids  Revascularization  a method of restoration of perfusion of blood to the blocked parts in ischemia patients  is generally achieved by surgery  Patients with CLI remain at the risk of limb amputation and death  which may be prevented by revascularization Per the press release  the number of CLI patients is expected to be around 5 to 6 million in the United States and Europe  The company estimates that 40  of CLI patients are ineligible for revascularization and the CLI market is estimated to be  25 billion per year The company is evaluating PLX cells in multiple indications  which includes inflammation  ischemia  muscle trauma  hematological disorders  and radiation damage  The candidate has shown promising results in earlier studies Pluristem Therapeutics  Inc  Price and Consensus
    Zacks Rank   Stocks to ConsiderPluristem has a Zacks Rank  3  Hold   Some better ranked stocks in the biotech sector include PDL BioPharma  Inc    NASDAQ PDLI    Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While Alexion and Regeneron carry a Zacks Rank  1  Strong Buy   PDL BioPharma carries a Zacks Rank  2  Buy   You can see  PDL BioPharma s earnings per share estimates increased 263  to 69 cents for 2017 and 174  to 63 cents for 2018 over the last 60 days  The company has topped estimates in two of the trailing four quarters with an average of 33 79   Shares are up 56 6  so far this year Alexion Pharmaceuticals  earnings per share estimates have moved up 5 3  to  5 60 for 2017 and 7 5  to  7 05 for 2018 over the last 60 days  The company delivered positive earnings surprises in the trailing four quarters  with an average beat of 11 12   Share price of the company has increased 17 4  year to date Regeneron s earnings per share estimates have increased 16 7  to  14 99 for 2017 and 8 6  to  16 64 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   Share price of the company has increased 18 4  year to date 4 Promising Stock Picks to Keep an Eye OnWith news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-18,Zacks Investment Research,https://www.investing.com/analysis/pluristems-ischemia-candidate-gets-fast-track-designation-200214118,200214118
146881,368397,ALXN,Clovis Oncology  CLVS  In Focus  Stock Moves 10 5  Higher,opinion,"Clovis Oncology  Inc    NASDAQ CLVS   was a big mover last session  as the company saw its shares rise nearly 11  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  67 17 to  78 26 in the past one month time frame The company has seen two negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last 
Clovis Oncology currently has a Zacks Rank  3  Hold  while its is negative 
Clovis Oncology  Inc  Price   A better ranked stock in the Medical sector is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is CLVS going up  Or down  Predict to see what others think  or 4 Promising Stock Picks to Keep an Eye On With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/clovis-oncology-clvs-in-focus-stock-moves-105-higher-200214183,200214183
146882,368398,ALXN,Karyopharm s Liposarcoma Candidate Superior In Phase II Study,opinion,"Karyopharm Therapeutics Inc    NASDAQ KPTI   announced positive data from a phase II portion of phase II III SEAL study  demonstrating superiority of its liposarcoma candidate  selinexor  in improving progression free survival  PFS  when compared to a placebo  The company s oral Selective Inhibitor of Nuclear Export compound is being evaluated in patients with advanced unresectable dedifferentiated liposarcoma who have received prior treatment Karyopharm s shares were up more than 6  on Wednesday  In fact  shares of the company are  have risen 18 7  year to date  outperforming the  s gain of 1 5  Data from the phase II study demonstrated that selinexor achieved the primary endpoint pf PFS by reducing the risk of progression or death in liposarcoma patients by 40   In a separate assessment by the World Health Organization  WHO   the candidate prolonged the PFS by 16   The detailed analysis of the study will be presented at a future medical meeting The company has already initiated the phase III portion of the SEAL study where 60mg of selinexor administered to patients until disease progression or intolerability will be compared to a placebo  The FDA approved PFS is the primary endpoint of the study  Top line data from this study will be available in 2019 Liposarcoma is a rare form of cancer  which occurs in the soft tissues of the body  especially fatty tissues  The disease is generally treated with surgery in combination with radiation therapy  Hence  an oral dose medicine is a better option for patients However  there are drugs that are administered intravenously for treating advanced liposarcoma patients  These include Johnson   Johnson s   NYSE JNJ   Yondelis and Eisai Co   Ltd  s   OTC ESALY   Halaven Karyopharm is also evaluating selinexor in several mid  and later phase studies in multiple cancer indications  the most advanced being the phase III study of the candidate in combination with J J s Velcade in multiple myeloma patients  Selinexor is also being evaluated in patients with gynecological malignancies Karyopharm Therapeutics Inc  Price and Consensus
    Zacks Rank   Stock to ConsiderKaryopharm has a Zacks Rank  3  Hold   Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is a better ranked stock in the biotech sector  sporting a Zacks Rank  1  Strong Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up 5 3  to  5 60 for 2017 and 7 6  to  7 06 for 2018 over the last 60 days  The company delivered positive earnings surprises in the trailing four quarters  with an average beat of 11 12   Share price of the company has increased 16 8  year to date Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-09-20,Zacks Investment Research,https://www.investing.com/analysis/karyopharms-liposarcoma-candidate-superior-in-phase-ii-study-200214716,200214716
146897,368413,ALXN,Glaxo s Shingles Candidate Gets Positive FDA Committee Vote,opinion,GlaxoSmithKline plc   NYSE GSK   recently announced that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate  Shingrix  in older patients Glaxo said the FDA s Vaccines and Related Biological Products Advisory Committee were impressed by the efficacy safety data from Shingrix studies  which evaluated the candidate for the prevention of herpes zoster  shingles  in adults aged between 50 years and more  In this regard  although the FDA is not bound to follow the Committee s opinion but it usually does So far this year  Glaxo  share price has increased 4 1   comparing unfavorably with a gain of 16  recorded by the  it belongs to Notably  the biologics license application  BLA  for Shingles was filed with the FDA in October  2016  Regulatory applications are currently under review in the EU  Canada and Japan as well The regulatory submission was based on data from a clinical trial program comprising two phase III studies   ZOE 50 and ZOE 70   that evaluated the safety  efficacy and immunogenicity of the candidate in more than 37 000 individuals  The results showed that in addition to reducing the incidence of shingles  the candidate was able to reduce the overall incidence of postherpetic neuralgia  which is a nerve pain due to the damage caused by the varicella zoster virus Glaxo expects approval of Shingrix in the United States and Europe in the fourth quarter of 2017 In fact  Shingles is a common but potentially serious condition in which the patients develop a painful itchy rash  Glaxo estimates that more than one in three people over 50 are likely to have shingles in their lifetime  which shows the disease has significant unmet need Glaxo expects Shingles  if approved  to be a key contributor to its top line from the next year  Additionally  the company anticipates new pharmaceutical and vaccine products including Shingrix to deliver sales of  6 billion per annum by 2018 Glaxo carries a Zacks Rank  3  Hold  Stocks to ConsiderBetter ranked biotech stocks include Alexion Pharmaceuticals  Inc    NASDAQ ALXN     Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    each sporting a Zacks Rank  1  Strong Buy   You can see Shares of Alexion have gained 19 8  year to date  The Zacks Consensus Estimate for 2017 and 2018 have climbed 5 5  and 6   respectively  over the past 60 days Regeneron s shares have rallied 19 2  this year so far  Its estimates have moved up 16 8  for 2017 while that for 2018 have climbed 8 2  over the past 60 days Shares of Ligand have surged 35 8  so far this year 5 Trades Could Profit   Big League   from Trump Policies  If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-09-13,Zacks Investment Research,https://www.investing.com/analysis/glaxos-shingles-candidate-gets-positive-fda-committee-vote-200213314,200213314
146899,368415,ALXN,Pfizer Xtandi Succeeds In Early Stage Prostate Cancer Study,opinion,Pfizer  Inc    NYSE PFE   and its Japanese partner Astellas announced that their prostate cancer drug Xtandi met the primary endpoint in a late stage study  which can expand the label of the drug to include early stage patients Top line data from the phase III PROSPER study showed that treatment with Xtandi plus androgen deprivation therapy  ADT  led to a statistically significant improvement in metastasis free survival  MFS    the primary endpoint   in men with castration resistant non metastatic prostate cancer  CRPC  compared to ADT alone Many prostate cancer patients with non metastatic CRPC   an earlier stage of prostate cancer   can experience disease progression despite ADT  However  presently no FDA approved treatment options are available to cater to this condition until these patients develop metastatic disease Xtandi is presently approved for the treatment of metastatic CRPC in patients who have previously received docetaxel  If approved for the non metastatic patient population  the label of Xtandi can be expanded to cover all patients with CRPC Shares of Pfizer were up almost 2  in response to the positive news  However  Pfizer s shares have underperformed the this year so far  The stock has returned 10  during this period  comparing unfavorably with an increase of 16  for the industry Pfizer plans to discuss the PROSPER study data with the FDA and other regulatory authorities and also present detailed data at a future medical meeting Xtandi was added to Pfizer s portfolio with the acquisition of Medivation in September  While Pfizer sells Xtandi in the United States in partnership with Astellas  the latter owns the marketing right outside U S  markets  Pfizer recorded Xtandi alliance revenues of  141 million in the second quarter and  131 million in the first In December 2016  Pfizer and Astellas had announced that a phase IV study   PLATO   evaluating the efficacy and safety of continued treatment with Xtandi did not meet the primary endpoint  The PLATO study evaluated Xtandi plus Johnson   Johnson s   NYSE JNJ   Zytiga and prednisone compared to Zytiga and prednisone alone Xtandi is a key drug in Prizer s oncology portfolio pipeline  The New York based pharma giant is aggressively working on expanding the labels of its marketed cancer drugs like Xtandi  Ibrance and Xalkori Xtandi is in several studies including late stage studies in hormone sensitive prostate cancer  It is also in mid stage development for the treatment of advanced breast cancer and hepatocellular carcinoma Pfizer carries a Zacks Rank  3  Hold   You can see  Stocks to ConsiderBetter ranked drug biotech stocks include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    both with a Zacks Rank  1 Shares of Alexion are up 18 2  year to date  The Zacks Consensus Estimate for 2017 and 2018 have climbed 5 8  and 6 4   respectively  over the past 60 days Regeneron s shares up 20 2  this year so far  Its estimates have moved up 16 8  for 2017 while that for 2018 have increased 8 2  over the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-14,Zacks Investment Research,https://www.investing.com/analysis/pfizer-xtandi-succeeds-in-early-stage-prostate-cancer-study-200213521,200213521
146901,368417,ALXN,J J s  JNJ  Psoriasis Drug Guselkumab Gets CHMP Nod In EU,opinion,Johnson   Johnson   NYSE JNJ   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has granted a positive opinion recommending approval of its pipeline candidate  guselkumab for the treatment of moderate to severe plaque psoriasis in the EU The drug was approved in the United States in July this year and is marketed by the trade name of Tremfya for the treatment of this immune system related skin disorder  A decision from the European Commission  EC  is expected later this year So far this year  J J s share price has increased 16 7   comparing favorably with a gain of 16 4  recorded by the it belongs to The application in the EU was based on three studies   phase III VOYAGE 1  VOYAGE 2 and NAVIGATE   evaluating the efficacy and safety of guselkumab  an anti IL 23 human monoclonal antibody  administered by subcutaneous injection for the treatment of adults with moderate to severe plaque psoriasis Data from the VOYAGE 2 trial  n 992  showed that significantly higher proportion of patients with moderate to severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo  Around 70  of the patients receiving guselkumab achieved at least 90  clearer skin versus 2 4  on placebo The VOYAGE 2 trial evaluated guselkumab versus AbbVie  Inc  s   NYSE ABBV   blockbuster drug  Humira  The study demonstrated the statistically significant efficacy of guselkumab compared to Humira at week 16  which was maintained through 24 weeks of treatment  Almost 46 8  of the patients treated with Humira achieved at least 90  clearer skin versus 70  for guselkumab The NAVIGATE  n 871  study evaluated the efficacy and safety of switching to guselkumab in moderate to severe plaque psoriasis patients who were not achieving clear or almost clear skin with J J s other plaque psoriasis medicine  Stelara  Data from the study showed that patients who switched to guselkumab showed significantly greater improvements in skin clearance compared with patients who continued to receive Stelara Meanwhile  a phase III head to head study of Tremfya against Novartis AG s   NYSE NVS   Cosentyx for moderate to severe plaque psoriasis is ongoing  Also  a phase III study evaluating guselkumab in moderate to severely active psoriatic arthritis is also ongoing J J had previously mentioned that Tremfya has blockbuster potential and could rake in sales of more than  1 billion J J carries a Zacks Rank  3  Hold  Stocks to ConsiderA better ranked biotech stock is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    sporting a Zacks Rank  1  Strong Buy   You can see  Shares of Alexion have gained 19 9  year to date  The Zacks Consensus Estimate for 2017 and 2018  increased 5 2  and 7 5   respectively  over the past 60 days New Report  An Investor s Guide to CybersecurityCyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020 The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ,2017-09-17,Zacks Investment Research,https://www.investing.com/analysis/jjs-jnj-psoriasis-drug-guselkumab-gets-chmp-nod-in-eu-200213882,200213882
146923,368439,ALXN,Amgen Gets EU Nod To Expand Hyperparathyroidism Drug Label,opinion,Amgen  Inc    NASDAQ AMGN   announced that the European Commission has approved the marketing application for a pediatric formulation  granules in capsule for opening  of Mimpara for the treatment of secondary hyperparathyroidism  sHPT  With this approval  the drug s label has been expanded to include use in children aged three years and above with end stage renal disease  ESRD  on maintenance dialysis therapy where standard of care therapy cannot adequately control secondary HPT We remind investors that in June  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  had rendered a positive opinion  recommending marketing approval of Mimpara for the expanded label Amgen s shares have rallied 17 8  this year so far  better than the  s 12 3  registered increase The approval was based on data from studies assessing the use of Mimpara in pediatric secondary HPT patients  conducted by Amgen since 2007 Mimpara is already approved and marketed in the EU as an oral therapy for treating secondary HPT in adult patients with ESRD on maintenance dialysis therapy and for mitigating hypercalcemia in adult patients with parathyroid carcinoma  In the United States  the drug is marketed by the trade name Sensipar Sensipar Mimpara generated sales of  427 million in the second quarter of 2017  up 10  year over year  The label expansion is expected to boost international sales of the drug We remind investors that Sensipar is set to face generic competition in March next year  Many companies are seeking to market the drug s generic versions regarding formulation patent Secondary hyperparathyroidism is often progressive in patients suffering from chronic kidney disease  CKD   It affects around 88  of CKD patients on hemodialysis  Meanwhile  very few treatment options are available to treat this condition Investors must also note that Amgen markets another sHPT medicine  Parsabiv  approved in the United States earlier in February and in the EU  back in November 2016  Parsabiv is approved to treat sHPT in adult patients with CKD on hemodialysis  the first therapy in 12 years to be approved for this condition  The drug has to be administered intravenously thrice a week at the end of a dialysis session Amgen currently carries a Zacks Rank  3  Hold   You can see  Stocks to ConsiderBetter ranked biotech stocks include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Ligand Pharmaceuticals Incorporated   NASDAQ LGND   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    all with a Zacks Rank  1  Strong Buy  Shares of Alexion have increased 13 1  year to date while estimates for both 2017 and 2018 have risen by almost 6  over the past 60 days Regeneron s shares have surged 30 5  this year so far  Estimates have risen 16  for 2017 while that for 2018  have gone up by 6   over the past 30 days Shares of Ligand have risen 24 9  so far this year while estimates for 2017 and 2018 have risen by 10 4  and 2 2   respectively  over the past 30 days Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2017-08-31,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-eu-nod-to-expand-hyperparathyroidism-drug-label-200211120,200211120
146924,368440,ALXN,4 Biotech Stocks To Improve Your Portfolio s Health,opinion,"The pharmaceuticals and biotech industry has been blessed with good health so far this year  The sector has recovered from the pricing controversy of 2016 and defied uncertainties surrounding President Trump s proposed healthcare policy 
The NYSE ARCA Pharmaceutical Index has risen almost 9 8  year to date after declining almost 11 1  last year  Even the NASDAQ Biotechnology Index is up 26 8   after sliding 22  in 2016 
In fact  the Zacks Drug sector is up 9 5  year to date  Importantly  the  sector ranks amongst the top 35  of the  
The Medical sector  which includes both pharmaceutical biotech and medical device companies  recorded earnings growth of 6 7  on revenue growth of 4 2  in Q2  The beat ratio for earnings and revenues was 83 3  was and 64 8   respectively  in the quarter under review  as of Aug 25  2017  
Within the Medical sector  biotech stocks have performed well in the first half of the year  despite challenges like rising competition  pipeline setbacks  slowdown in growth of mature products and generic competition for certain key drugs  Some of the companies also raised their guidance for 2017  Additionally  sales of newly launched drugs hold potential to mitigate the impact of genericization of key drugs to an extent  Moreover  the companies are also focusing on bringing newer candidates and categories  gene editing  NASH and Parkinson s disease  in the market 
Key Picks
Given this scenario  it might be the perfect time to dip your toe in to this growing market  Here are four big pharmaceutical biotech stocks that carry a favorable rank and can prove lucrative additions to your portfolio  You can see  
Alexion Pharmaceuticals  Inc    NASDAQ ALXN  
The company is witnessing strong sales figure for its blockbuster drug  Soliris and making efforts expand the label  Notably  FDA s decision regarding the approvability of Soliris for refractory generalized myasthenia gravis  gMG  is expected by Oct 23  2017  The potential approval of Soliris for this indication is likely to boost the top line 
Among the company s other new products  the drug Strensiq is doing well while it has redefined strategy for Kanuma which has lagged expectations previously  The company expects Strensiq to be a strong additional catalyst this year and beyond  In order to focus better in core areas  Alexion is de prioritizing a few clinical programs and terminating partnerships with Moderna Therapeutics  Blueprint Medicines and Arbutus Biopharma 
Alexion  a Zacks Rank  1 stock  has seen the Zacks Consensus Estimate for earnings rise 5 5  and 6  for 2017 and 2018  respectively in the last 60 days  The company delivered positive earnings surprises in the trailing four quarters  with an average beat of 11 12  
Per the Zacks Consensus Estimate  sales are expected to grow 14 28  and 15  on year over year basis in 2017 and 2018  respectively  Meanwhile  earnings are expected to grow by 21 50  in 2017 and 23 35  in 2018 
Shares of the company have risen 19 7  year to date  outperforming the gain of 10 8  witnessed by the  

Regeneron Pharmaceuticals  Inc    NASDAQ REGN  
Tarrytown  NY based Regeneron s key growth driver  Eylea  continues to drive revenues  Consequently the company is expanding the drug s label for additional indications which would give Eylea access to higher patient population and increase its commercial potential 
The company has also been working on diversifying its portfolio and gained FDA approval for two drugs this year    Dupixent  atopic dermatitis  and Kevzara  rheumatoid arthritis   Both drugs developed in partnership with Sanofi   NYSE SNY   have blockbuster potential 
Dupixent  which could prove to be an important growth driver for the company and the company is also working to expand the label of Dupixent and anticipates filing for regulatory approval in the United States for the treatment of asthma in adults in fourth quarter 2017 
Regeneron has observed the Zacks Consensus Estimate for current year earnings  advancing 16 7  in the last 30 days  Earnings for 2018 has risen 7 9   The company sports a Zacks Rank  1  and its shares have surged 36 7  year to date  outperforming the  s gain of 10 7   The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11  

Per the Zacks Consensus Estimate  sales are expected to grow 18 67  and 8 6  on year over year basis in 2017 and 2018  respectively  Earnings are anticipated to grow by 32 42  and 9 99  in 2017 and 2018  respectively 
Ligand Pharmaceuticals Inc    NASDAQ LGND  
The company s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen  NASDAQ AMGN   Notably  these tie ups have provided it with funds in the form of milestone and royalty payments  Moreover  Ligand s internal pipeline has several candidates in development that are likely to develop in to future licensing opportunities  Nonetheless  the company s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is also encouraging 
Ligand has seen the Zacks Consensus Estimate for earnings advancing 10 4  in the last 30 days for 2017 and 2 2  for 2018  The company flaunts a Zacks Rank  1  and shares of the company have risen 26 4  so far this year  outperforming the gain of 10 7  of the  it belongs to  The company delivered positive earnings surprises in two of the preceding four quarters  with an average beat of 6 19  

Per the Zacks Consensus Estimate  sales are expected to grow 23 78  and 31 91  on year over year basis in 2017 and 2018  respectively  Earnings are expected to grow by 38 60  in 2017 and 25 17  in 2018 
Gilead Sciences  Inc    NASDAQ GILD  
Gilead is a dominant player in the HIV and hepatitis C virus  HCV  market with an impressive portfolio for the same  The company s HIV franchise maintains momentum driven by the rapid adoption of TAF based regimens in the United States and EU  which now represents 51  of total HIV prescription volume as of June end  Genvoya is now the company s bestselling HIV product with a treatment na ve patient share of 41  
Further  strong uptake for Truvada for use in the pre exposure prophylaxis setting is likely to boost sales  Gilead raised outlook for the year at the second quarter 2017 conference call 
Recently  the company announced that it will buy Kite Pharma  Inc    NASDAQ KITE    The acquisition will diversify Gilead s portfolio and position it as a dominant player in cellular therapy space  The deal is expected to close in the fourth quarter of this year 
The company has seen the Zacks Consensus Estimate for 2017 earnings increasing 7 4  in the last 60 days and 1  for 2018  Gilead carries a Zacks Rank  2  Buy   and shares of the company have gained 16 4  so far this year  outperforming the  advance of 10 7   The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 6 38  

Zacks  10 Minute Stock Picking Secret
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-09-05,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-to-improve-your-portfolios-health-200211566,200211566
146925,368441,ALXN,AstraZeneca s COPD Candidate Duaklir Reports Positive Data ,opinion,AstraZeneca Plc   NYSE AZN   announced positive top line results from the phase III AMPLIFY study for Duaklir  aclidinium bromide formoterol 400 g 12 g twice daily   The candidate is being evaluated for the treatment of chronic obstructive pulmonary disease  COPD  The study met its primary endpoint and showed a statistically significant improvement in lung function in patients with moderate to very severe stable COPD compared to each individual component  either aclidinium bromide or formoterol    AstraZeneca s shares have outperformed the industry year to date  The stock has rallied 11 1  compared with the  gain of 10 2  in the same time frame A full evaluation of the AMPLIFY data is ongoing and further results will be presented at a forthcoming medical meeting  AstraZeneca expects to submit an new drug application  NDA   for Duaklir to the FDA during the first half of 2018 based on the AMPLIFY data In April  the company entered a strategic collaboration with Circassia Pharmaceuticals PLC for the development and commercialization of COPD drugs Tudorza and Duaklir in the United States In a separate release  AstraZeneca along with partner Amgen Inc    NASDAQ AMGN   also announced results from the PATHWAY phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe  uncontrolled asthma  Tezepelumab is a first in class anti TSLP monoclonal antibody being developed by MedImmune  Astrazeneca  LON AZN  PLC Price    Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   both sporting a Zacks Rank  1  Strong Buy    You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 32 to  5 61 for 2017 and from  6 53 to  6 92 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 18 7  year to date Regeneron s earnings per share estimates have increased from  12 86 to  14 99 for 2017 and from  15 52 to  16 49 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 36 2  year to date One Simple Trading Idea Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-09-06,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-copd-candidate-duaklir-reports-positive-data-200211976,200211976
146953,368469,ALXN,Intra Cellular  ITCI  Soars  Stock Adds 27 7  In Session,opinion,"Intra Cellular Therapies  Inc    NASDAQ ITCI   was a big mover last session  as the company saw its shares rise nearly 28  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  10 77 and  12 53 in the past one month time frame The stock gained after the company received a positive regulatory update from U S  FDA concerning its lumateperone treatment for schizophrenia The company has seen three positive estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher  suggesting that more solid trading could be ahead for Intra Cellular  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road   Intra Cellular currently has a Zacks Rank  2  Buy  while its  is 0 00  Intra Cellular Therapies Inc  Price      Another stock worth considering in the Medical   Biomedical and Genetics industry is Alexion Pharmaceuticals  Inc    NASDAQ ALXN   which carries a Zacks Rank  1  Strong Buy  You can see  Is ITCI going up  Or down  Predict to see what others think   or 
One Simple Trading Idea
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars 
This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/intracellular-itci-soars-stock-adds-277-in-session-200209333,200209333
146954,368470,ALXN,Novo Nordisk s Tresiba Gets Canadian Nod ,opinion,"Novo Nordisk  CO NOVOb  A S   NYSE NVO   announced that the Canadian regulatory authority has approved its basal insulin  Tresiba  for the once daily treatment of adults with diabetes mellitus to improve glycemic control  Notably  Tresiba is expected to be launched in the Canadian market in October 
Tresiba is already marketed in many countries including the United States and EU  Sales of Tresiba increased 149  in local currencies in the first half of 2017 
Consequently  Novo Nordisk s shares have outperformed the  year to date  The stock has rallied 29 9  compared with the industry s gain of 11 3  in the same time frame 

 
Earlier this week  Novo Nordisk announced that the FDA has approved the label expansion of Victoza  The diabetes drug is now approved as a treatment to reduce the risk of major adverse cardiovascular  CV  events including heart attack  stroke and CV death  in adults with type II diabetes and established CV disease 
The FDA s approval was based on data from the pivotal LEADER study on CV outcomes  which evaluated the drug in more than 9 300 people with type II diabetes at high risk of major CV events  Markedly  the data from the study demonstrated that Victoza significantly reduced the risk of CV death  The drug lowered the risk of non fatal heart attack or non fatal stroke by 13  compared with placebo and showed an absolute risk reduction of 1 9  
We believe the Canadian approval for Tresiba and the label expansion for Victoza should improve the diabetes revenues of the Danish phama giant going forward Novo Nordisk A S Price

   Zacks Rank   Stocks to Consider
Novo Nordisk currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Aduro BioTech  Inc    NASDAQ ADRO    While Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   Aduro holds a Zacks Rank  2  Buy   You can see  
Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 57 to  5 61 for 2017 and from  6 90 to  6 92 for 2018 over the last 30 days  The company delivered positive earnings surprises in each of the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 13 7  year to date 
Regeneron s earnings per share estimates have increased from  12 84 to  14 78 for 2017 and from  15 32 to  16 21 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 30 5  year to date 
Aduro s loss estimates per share have narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 for 2018 over last 30 days  The company came up with positive earnings surprises in two of the trailing four quarters  with an average beat of 2 53  
Zacks  10 Minute Stock Picking Secret
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-tresiba-gets-canadian-nod-200210273,200210273
146955,368471,ALXN,Advanced Accelerator Gets Action Date For Lutathera From FDA,opinion,"Advanced Accelerator Applications S A    NASDAQ AAAP   announced that the FDA has accepted and considered complete the resubmission of the New Drug Application  NDA  for its investigational drug lutetium Lu 177 dotatate  Lutathera   The FDA has set an action date of Jan 26  2018 
Advanced Accelerator is looking to get Lutathera approved for the treatment of gastroenteropancreatic neuroendocrine tumors  GEP NETs  in adults Advanced Accelerator s shares have outperformed the industry year to date  The stock rallied 82 5  as against the  decline of 1 2   over the same time frame 

We remind investors that Advanced Accelerator received a complete response letter  CRL  from the FDA for the NDA for Lutathera in December last year  The FDA showed concerns about issues related with format  traceability  uniformity  and completeness relating to the NETTER 1  phase III study that compared treatment using lutetium Lu 177 oxodotreotide with a double dose of Octreotide LAR  and Erasmus  Phase I II study conducted in patients with a wide range of NET indications  clinical datasets 
Further  the CRL requested subgroup analyses for gender  age and racial subgroups  as well as other stratification factors and important disease characteristics  The CRL also noted that that any observations made during inspections of manufacturing facilities supporting the NDA need to be resolved prior to approval of the NDA  However  the FDA did not request for additional studies 
The company resubmitted the application in July 2017 after taking into consideration the concerns expressed by the FDA   As part of this process  the company sent a test dataset to the FDA to confirm that the data and format were compatible and able to be analyzed  Further  the company also engaged a team of consultants experienced in FDA reviews to perform a rigorous critique of both the datasets and the major clinical sections of the dossier prior to resubmitting 
Last month  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  issued a positive opinion recommending the marketing authorization of lutetium for the treatment of gastroenteropancreatic neuroendocrine tumors  GEP NETs  in adults Advanced Accelerator Applications S A  Price

   Zacks Rank   Stocks to Consider
Advanced Accelerator currently holds a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Aduro BioTech  Inc    NASDAQ ADRO    While Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   Aduro carries Zacks Rank 2  Buy   You can see  
Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 57 to  5 61 for 2017 and from  6 90 to  6 92 for 2018 over the last 30 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 13 7  year to date 
Regeneron s earnings per share estimates have increased from  12 84 to  14 78 for 2017 and from  15 32 to  16 21 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 30 5  year to date 
Aduro s loss estimates per share have narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 for 2018 over last 30 days  The company came up with positive earnings surprises in two of the trailing four quarters  with an average beat of 2 53  
Zacks  10 Minute Stock Picking Secret 
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars  But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/advanced-accelerator-gets-action-date-for-lutathera-from-fda-200210268,200210268
146956,368472,ALXN,Juno Therapeutics  JUNO  Soars  Stock Adds 20 1  In Session,opinion,Juno Therapeutics  Inc    NASDAQ JUNO   was a big mover last session  as the company saw its shares rise over 20  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company   as the stock is now up 54 1  in the past one month time frame The upmove could have been driven by Gilead Sciences  acquisition of Kite Pharma  which marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T cell therapy  or CAR T  Juno Therapeutics is presently working in CAR T therapy The company has seen three negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Juno Therapeutics currently has a Zacks Rank  4  Sell  while its  is 0 00    Juno Therapeutics  Inc  Price    Investors interested in the Medical   Biomedical and Genetics industry may consider a better ranked stock like Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which carries a Zacks Rank  1  Strong Buy   You can see  Is JUNO going up  Or down  Predict to see what others think   or 4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/juno-therapeutics-juno-soars-stock-adds-201-in-session-200210436,200210436
146957,368473,ALXN,Roche s  RHHBY  Actemra Gets FDA Nod For Label Expansion,opinion,Roche Holding  SIX ROG  AG s   OTC RHHBY    member  Genentech announced that the FDA has approved a label expansion for Actemra  tocilizumab    Actemra is now approved for the treatment of chimeric antigen receptor  CAR  T cell induced severe or life threatening cytokine release syndrome  CRS  in patients aged between two years and older  CRS  which is caused by an overactive immune response  has been identified as a potentially severe and life threatening side effect of CAR T cell therapy for certain cancers  This is the first FDA approved treatment to manage severe cytokine release syndrome associated with CAR T cell therapy Roche s shares have underperformed the industry year to date  The stock has gained 10  compared with the  gain of 11 1  in the same time frame We note that Actemra is already approved for the treatment of adult patients suffering from moderately to severely active rheumatoid arthritis  RA  who have used one or more disease modifying antirheumatic drugs  DMARDs   such as methotrexate  MTX  that did not provide enough relief   Actemra is also approved to be used as an IV formulation for patients with active polyarticular juvenile idiopathic arthritis  PJIA  or systemic juvenile idiopathic arthritis  SJIA  aged between two years and older  Actemra subcutaneous injection is also approved for the treatment of adult patients with giant cell arteritis  GCA  Coming back to the release  the FDA s approval was based on a retrospective analysis of pooled outcome data from studies of CAR T cell therapies for blood cancers  which evaluated the efficacy of Actemra in the treatment of CRS The FDA had granted priority review and orphan drug designation to Actemra for treating CAR T cell induced CRS based on the rare  severe  and life threatening nature of CRS and available data on the safety and efficacy of Actemra A label expansion of the drug will boost Actemra sales On August 30  the CAR T cells space got a significant boost when the FDA approved Novartis    NYSE NVS   Kymriah  tisagenlecleucel  suspension for intravenous infusion  the first chimeric antigen receptor T cell  CAR T  therapy  for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia  ALL  that is refractory or in second or later relapse  Kymriah is the first therapy based on gene transfer approved by the FDA  Roche Holding AG Price    Zacks Rank   Key PicksRoche currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Both Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 32 to  5 61 for 2017 and from  6 53 to  6 92 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 13 2  year to date Regeneron s earnings per share estimates have increased from  12 85 to  14 91 for 2017 and from  15 28 to  16 45 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 32 7  year to date One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-actemra-gets-fda-nod-for-label-expansion-200210823,200210823
146958,368474,ALXN,Teva Austedo Gets FDA Nod For Label Expansion In Dyskinesia,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that the FDA has approved a label expansion for its drug  Austedo  With the latest FDA approval  Austedo s label has been expanded to include treatment of tardive dyskinesia  a debilitating and often irreversible movement disorder We remind investors that Austedo was approved for treating chorea associated with Huntington s disease in April 2017  Both TD and chorea are characterized by involuntary or diminished voluntary movement of muscles Shares of the company are up almost 2 4  in pre market trading  However  shares of Teva have underperformed the  so far this year as it is facing challenges in the U S  generic industry  The company s shares have plunged 57 1  while the industry has lost 20 1  in that period Coming back to the news  the FDA approval for TD was based on data from two pivotal studies   AIM TD and ARM TD   demonstrating statistically significant reduction in severity of abnormal involuntary movements associated with tardive dyskinesia Teva s chief scientific officer said that Austedo has a flexible dosing regimen and it also doesn t affect the ongoing treatment for the underlying condition  which caused the TD disorder Teva is also evaluating Austedo in a phase I study for another involuntary movement disease  Tourette syndrome Per the company s press release  TD affects approximately 500 000 people in the U S  In April 2017  the FDA had approved Neurocrine Biosciences  Ingrezza as a treatment for adults with TD  which is expected to give competition to Austedo in this indication Teva is offering free service to provide support to new patients as well as those already on Austedo therapy Teva Pharmaceutical Industries Limited Price and Consensus
    Zacks Rank   Stocks to ConsiderTeva Pharma has a Zacks Rank  5  Strong Sell  Some better ranked stocks in the health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Aduro BioTech  Inc    NASDAQ ADRO    While Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   Aduro carries a Zacks Rank  2  Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 32 to  5 61 for 2017 and from  6 53 to  6 92 for 2018 over the last 60 days  The company delivered positive earnings surprises in the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 13 1  year to date Regeneron s earnings per share estimates have increased 16  to  14 91 for 2017 and 7 7  to  16 45 for 2018 over the last 30 days  The company pulled off positive earnings surprise in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 32 7  year to date Aduro s loss estimates per share have narrowed 9 6  to  1 32 for 2017 and 12 1  to  1 24 for 2018 over last 30 days  The company came up with positive earnings surprise in two of the trailing four quarters  with an average beat of 2 53  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/teva-austedo-gets-fda-nod-for-label-expansion-in-dyskinesia-200210804,200210804
146975,368491,ALXN,Novo Nordisk s Semaglutide Shows Remarkable Results In Study,opinion,"Novo Nordisk  CO NOVOb    NYSE NVO   announced results from SUSTAIN 7 study  which showed that people with type II diabetes who are treated with once weekly semaglutide experienced superior reduction in HbA1c and body weight compared with treatment with Eli Lilly and Co s   NYSE LLY   Trulicity  dulaglutide    when added to metformin 
In fact  semaglutide is a glucagon like peptide 1  GLP 1  analogue being evaluated for the treatment of adults with type II diabetes  Currently  it is under review by seven regulatory agencies  including the FDA  the European Medicines Agency  and the Japanese Pharmaceuticals and Medical Devices Agency 
Shares of the company have rallied 27 1  compared with the Zacks classified  gain of 11 2  on a year to date basis 

Notably  the 40 week study evaluated the efficacy and safety of two dosages of semaglutide  in addition to initial standard of care therapy metformin against dulaglutide plus metformin  While 0 5 mg semaglutide was compared with 0 75 dulaglutide  1 0 mg semaglutide was compared with 1 5 mg dulaglutide  when added to metformin 
The study presented that both the doses of semaglutide are statistically significant  and results in superior reduction of HbA1c  In addition  it showed people treated with both the doses of semaglutide experienced a statistically significant and superior weight loss at both doses 
Meanwhile  the superior glucose control and weight loss achieved with semaglutide compared to dulaglutide were consistent with the entire SUSTAIN program  In fact  the results revealed the potential of semaglutide to set a new standard for treatment of type II diabetes 
Novo Nordisk has a strong pipeline  primarily focusing on therapeutic proteins within insulin  GLP 1  blood clotting factors and human growth hormone  The company is making efforts to develop new treatments for diabetes  which is its core area of expertise  Key pipeline candidates include semaglutide and nonacog beta pegol  The potential approval of these candidates will boost the company s top line Novo Nordisk A S Price

   Zacks Rank   Stocks to Consider
Novo Nordisk currently holds a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Both Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   You can see  
Alexion Pharmaceuticals  earnings per share estimates have moved up from  4 55 to  4 77 for 2017 and from  5 49 to  6 43 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 12 26   The share price of the company has increased 11 7  year to date 
Regeneron s earnings per share estimates have increased from  10 52 to  13 81 for 2017 and from  12 10 to  14 54 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 6 29   The share price of the company has increased 27 6  year to date 
One Simple Trading Idea
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars  This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-semaglutide-shows-remarkable-results-in-study-200207999,200207999
146976,368492,ALXN,Horizon Pharma  HZNP  Soars  Stock Adds 10 5  In Session,opinion,Horizon Pharma Public Limited Company   NASDAQ HZNP   was a big mover last session  as the company saw its shares rise nearly 11  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  trading within a volatile range of  11 54   13 48 in the past one month time frame  showed a sharp increase yesterday The move came after the company has settled another generic litigation for Pennsaid 2  The company has seen a mixed track record when it comes to estimate revisions of one increase and two decreases over the past one month  while the Zacks Consensus Estimate for the current quarter has moved lower over the same time period  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Horizon Pharma currently has a Zacks Rank  3  Hold   while its  is negative Horizon Pharma PLC Price   A better ranked stock in the Medical   Biomedical and Genetics industry is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which currently sports a Zacks Rank  1  Strong Buy   You can see  Is HZNP going up  Or down  Predict to see what others think   or 4 Surprising Tech Stocks to Keep an Eye onTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-18,Zacks Investment Research,https://www.investing.com/analysis/horizon-pharma-hznp-soars-stock-adds-105-in-session-200208187,200208187
146977,368493,ALXN,Alexion s  ALXN  Soliris  Label Expansion Approved In Europe,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the European Commission  EC  approved a label expansion of lead drug Soliris The European Commission expanded the indication for Soliris to include the treatment of refractory generalized myasthenia gravis  gMG  in adults who are anti acetylcholine receptor  AChR  antibody positive We note that Soliris is approved for two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS  In order to increase the commercial potential of the drug further  Alexion is working on expanding Soliris  label into additional indications  Alexion has aslo filed regulatory application to the FDA for expanding the use of Soliris for the treatment of refractory gMG in patients who are anti acetylcholine receptor antibody positive  The FDA accepted the supplemental Biologics License Application  sBLA  and set a Prescription Drug User Fee Act  PDUFA  date of Oct 23 A potential label expansion in the U S  will boost sales further   Soliris will be launched for this new indication initially in Germany while Alexion is evaluating launches in additional EU countries Alexion s stock price has increased 9 1   outperforming the  gain of 5 3  Additionally  a phase III study  PREVENT  on Soliris in patients with relapsing neuromyelitis optica spectrum disorder is ongoing with enrolment being expected to be completed in 2017 and data expected in 2018  Label expansion into additional indications will give Soliris access to a higher patient population and increase the commercial potential of the drug significantly We note that Soliris has received Orphan Drug Designation  ODD  for the treatment of patients with MG in the U S  and EU  and for the treatment of patients with refractory gMG in Japan We expect growth at Alexion to continue being driven by Soliris  Other new products   Strensiq and Kanuma   are doing well and are expected to boost revenues  However  Soliris quarter to quarter revenue growth   70 million    100 million  will be impacted by the enrolment ramp up of trials The company is expecting Soliris revenues to be lower in the second half of the year due to an accelerating impact from the ALXN1210 trials  In addition  pricing will impact sales by 1  Zacks Rank   Stocks to ConsiderAlexion currently carries a Zacks Rank  1  Strong Buy  
Other top ranked stocks worth considering in the healthcare sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Gilead Sciences  Inc    NASDAQ GILD   and Aduro Biotech  Inc    NASDAQ ADRO    While Regeneron sport a Zacks Rank  1  Gilead Sciences and Aduro carry a Zacks Rank  2  Buy    You can see  Regeneron s earnings per share estimates have increased from  10 52 to  13 81 for 2017 and from  12 10 to  14 54 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 6 29  Gilead s earnings per share estimates increased from  7 98 to  8 53 for 2017  over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-21,Zacks Investment Research,https://www.investing.com/analysis/alexions-alxn-soliris-label-expansion-approved-in-europe-200208791,200208791
146978,368494,ALXN,4 Biotech Stocks To Add To Your Portfolio Post Q2 Earnings,opinion,"The second quarter earnings season is drawing to a close with 94 8  of S P 500 stocks having reported results as of Aug 18  2017  Thirteen of the 16 Zacks sectors recorded earnings growth with total earnings increasing 10 6  from the year ago period on revenue growth of 5 6   While 74 9  beat earnings estimates  68 4  topped revenue expectations   The Medical sector is one of the sectors to consistently record earnings growth over the last few quarters  The sector  which recorded earnings growth of 5 7  on revenue growth of 5 8  in Q1  has recorded earnings growth of 6 7  on the back of revenue growth of 4 3  so far in Q2  A look at the beat ratio shows earnings beat of 82 7  and revenue beat of 67 3  Biotech stocks specifically fared pretty well with most of the key players topping earnings and revenue expectations  Quite a few companies raised their outlook for the year as well  Biotech stocks have had a strong run so far in 2017 with the NASDAQ Biotechnology Index soaring 15  year to date  YTD   This is in sharp contrast to last year s performance when the Index was down 19 1   There were several reasons for the sector s dismal performance last year foremost being the drug pricing controversy  Although drug pricing remains a headline risk this year as well  investors now seem to be more comfortable with the drug pricing scenario and are willing to look at the fundamentals of the sector The FDA has also approved more drugs so far this year than it did in the whole of 2016  Last year  22 drugs were approved while 28 have gained approval so far in 2017  Some of the drugs approved this year represent blockbuster potential The second half of 2017 is expected to be catalyst rich for quite a few companies with data expected across a wide range of therapeutics areas  As far as mergers and acquisitions are concerned  we do not expect much activity in this area given the  wait and watch  stance adopted by most companies regarding the drug pricing situation and tax reforms  Another deterrent could be high valuations with companies remaining wary of bidding wars leading to over priced deals However  licensing deals should continue especially in orphan and rare disease areas as well as highly sought after therapeutic areas like immune oncology Our ChoicesHere is a look at four biotech stocks that delivered positive earnings surprises in the second quarter and are witnessing upward revisions in earnings estimates for 2017  All these companies are either Zacks Rank  1  Strong Buy  or Zacks Rank  2  Buy  stocks   you can see  Alexion Pharmaceuticals  Inc    NASDAQ ALXN    New Haven  CT based Alexion delivered a  beat and raise  quarter with flagship product  Soliris  eculizumab  continuing to perform well  Alexion is working on expanding Soliris  label and has a key catalyst coming up with a decision from the FDA expected by Oct 23  2017  regarding the approvability of Soliris for refractory generalized myasthenia gravis  gMG   Alexion got a boost this week with Soliris gaining EU approval for this indication making it the first and only complement based therapy approved for an ultra rare subset of gMG  The gMG indication represents incremental growth opportunity for Soliris Alexion  which had a rough 2016 with shares falling 35 9   looks set to recover lost ground with shares increasing 9 1  so far in 2017  outperforming the 4 9  rally of the  it belongs to  The efforts of the company s new management team to turn things around are impressive  Alexion is redefining its R D strategy with a focus on its key expertise areas  The company will continue to grow its rare diseases business which includes growing Soliris  Strensiq and Kanuma  To increase productivity  Alexion will focus its internal research efforts on its complement expertise and its development efforts on its core therapeutic areas of hematology  nephrology  neurology and metabolic disorders  The company has also decided to de prioritize certain pipeline candidates and is discontinuing its preclinical programs with mRNA therapies as well as other preclinical programs that do not fall within the complement franchise  Alexion  a Zacks Rank  1 stock  has seen the Zacks Consensus Estimate for current year earnings being revised 5 3  upward over the last 30 days 
Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Tarrytown  NY based Regeneron s key areas of focus include eye diseases  heart disease  allergic and inflammatory diseases  pain  cancer  infectious diseases and rare diseases  While eye drug  Eylea  the company s key growth driver continues to perform well  Regeneron has been working on diversifying its portfolio and gained FDA approval for two drugs this year   Dupixent  moderate to severe atopic dermatitis  and Kevzara  moderately to severely active rheumatoid arthritis   Both drugs have blockbuster potential The company also has a strong pipeline and has an eventful second half of the year coming up with key mid to late stage pipeline catalysts lined up  Top line phase III data on Dupixent for asthma are due later this quarter   positive data would allow the company to go ahead with a U S  filing in the fourth quarter  Dupixent should also gain EU approval for the eczema indication in the third quarter  Regeneron is evaluating Dupixent in the pediatric atopic dermatitis setting  Another important data readout scheduled for the second half of the year is on the company s PD 1 antibody REGN2810  for cutaneous squamous cell carcinoma  CSCC   the second most common skin cancer after basal cell carcinoma and the second deadliest skin cancer after melanoma  Positive data would allow the company to file for FDA approval in the first quarter of 2018 Meanwhile  Eylea is being evaluated in combination with nesvacumab  Top line data from two phase II studies   one in wet age related macular degeneration and another in diabetic macular edema   are expected in the fourth quarter of the year Regeneron has seen the Zacks Consensus Estimate for current year earnings being revised 15 2  upward over the last 30 days  Regeneron  a Zacks Rank  1 stock  has gained 27 9  year to date  substantially outperforming the 4 9  rally of the  it belongs to 
Gilead Sciences  Inc    NASDAQ GILD    Foster City  CA based Gilead is well known for its presence in the hepatitis C virus  HCV  and HIV markets  Gilead topped estimates in the second quarter with its HCV business doing better than expected in the U S  The company said that HCV patient starts in the first six months were better than originally expected  Moreover  the launch of an educational campaign in Oct 2016 to encourage testing of baby boomers has led to an 80  increase in HCV antibody screening by baby boomers  which in turn has led to an increase in diagnosis  The company s HIV franchise also continues to do well and the company is progressing with its pipeline that includes treatments under evaluation for cancer  nonalcoholic steatohepatitis  NASH  and inflammatory diseases  Gilead raised its outlook for the year  Gilead has seen the Zacks Consensus Estimate for current year earnings being revised almost 7  upward over the last 30 days  Gilead is a Zacks Rank  2 stock 
Ligand Pharmaceuticals Incorporated   NASDAQ LGND    San Diego  CA based Ligand s business model is based on developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure  The company is focused on the development and licensing of biopharmaceutical assets  Ligand s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties  The company s partners include big names like Amgen   NASDAQ AMGN   and Novartis   NYSE NVS   among others  Ligand also has licensing deals based on its OmniAb technology Ligand has seen the Zacks Consensus Estimate for current year earnings being revised almost 10 4  upward over the last 30 days  Ligand  a Zacks Rank  1 stock  has gained 24 5  year to date  substantially outperforming the 4 9  rally of the  it belongs to 

Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-21,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-to-add-to-your-portfolio-post-q2-earnings-200208784,200208784
146979,368495,ALXN,Immunomedics  Progress In Phase II Cancer Study Encouraging,opinion,"Immunomedics  Inc     NASDAQ IMMU    announced encouraging interim results from a phase II study on its antibody drug conjugate  ADC   labetuzumab govitecan  IMMU 130   The candidate is being evaluated as a single agent in heavily pretreated patients with metastatic colorectal cancer  mCRC  The company s shares closed 7  higher on Aug 21 after the announcement of the news  In fact  shares of the company have returned 145 5  so far this year  outperforming the   which gained 5 2  in that period Coming back to the news  the study is evaluating once weekly 8mg or 10 mg dose of IMMU 30 in patients who have already received Pfizer Inc s   NYSE PFE   Camptosar therapy  The median progression free survival  PFS  achieved was 4 6 months for 8mg and 3 6 months for 10 mg dosage  Also  median overall survivals  OS  demonstrated by the candidate was 7 5 months  8mg  and 6 4 months  10mg  Moreover  a subset of 23 patients had also received prior treatment with Bayer AG s   OTC BAYRY   Stivarga  In this subset  the median PFS and OS achieved by the candidate was 4 months and 6 7 months  respectively  better than Stivarga s PFS and OS The company is also developing another ADC  sacituzumab govitecan  IMMU 132  in patients with relapsed refractive  metastatic triple negative breast cancer  We remind investors that IMMU 132 enjoys Breakthrough Therapy Designation in the U S  The company is planning to file a Biologics License Application for accelerated approval to the FDA for the same indication IMMU 132 is also being developed for treating other metastatic solid tumors  Another ADC candidate  IMMU 140  is being evaluated in solid and liquid cancers Immunomedics  Inc  Price and Consensus
    Zacks Rank   Stock to ConsiderImmunomedics currently carries a Zacks Rank  3  Hold  A better ranked stock in the pharmaceutical sectors is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    sporting a Zacks Rank  1  Strong Buy   You can see  Alexion s earnings estimates increased from  5 32 to  5 60 for 2017 and from  6 56 to  6 91 for 2018 in the last 30 days  The company delivered a positive earnings surprise in all the four trailing quarters with an average beat of 11 12   Its share price has increased 9 1  year to date Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-21,Zacks Investment Research,https://www.investing.com/analysis/immunomedics-progress-in-phase-ii-cancer-study-encouraging-200208771,200208771
146982,368498,ALXN,Immunomedics  IMMU  Catches Eye  Stock Up 5 1 ,opinion,"Immunomedics  Inc    NASDAQ IMMU   was a big mover last session  as the company saw its shares rise over 5  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  7 74 to  8 91 in the past one month time frame The stock gained after the company reported encouraging interim results from a phase II study on its antibody drug conjugate  ADC   labetuzumab govitecan  IMMU 130  The company has not seen any negative estimate revisions in the past few weeks  but its Zacks Consensus Estimate for the current quarter has moved lower over the past 30 days  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Immunomedics currently has a Zacks Rank  3  Hold  while its is 0 00  A better ranked stock in the Biomedical and Genetics industryis Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which currently carries a Zacks Rank  1  Strong Buy   You can see  
Immunomedics  Inc  Price   Is IMMU going up  Or down  Predict to see what others think   or 4 Surprising Tech Stocks to Keep an Eye onTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ",2017-08-23,Zacks Investment Research,https://www.investing.com/analysis/immunomedics-immu-catches-eye-stock-up-51-200209018,200209018
146984,368500,ALXN,Paratek Pharmaceuticals  Inc   PRTK  Catches Eye  Stock Up 27 3 ,opinion,Paratek Pharmaceuticals  Inc    NASDAQ PRTK   was a big mover last session  as the company saw its shares rise over 27  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  which remained volatile and traded within the range of  18 90   22 90 in the past one month time frame  witnessed a sharp increase yesterday The move came after news leaked that the company is considering a sale The company has seen x negative estimate revisions in the past two months  while its Zacks Consensus Estimate for the current quarter has also moved lower over the same time frame  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Paratek Pharmaceuticals  Inc  Price and Consensus   Paratek Pharmaceuticals currently has a Zacks Rank  3  Hold  while its  is positive A better ranked stock in the Biomedical and Genetics industryis Alexion Pharmaceuticals  Inc   NASDAQ ALXN    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is PRTK going up  Or down  Predict to see what others think  or One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/paratek-pharmaceuticals-inc-prtk-catches-eye-stock-up-273-200209337,200209337
147002,368518,ALXN,Forget Bayer  Buy These 3 Drug Stocks Instead,opinion,"Life science company  Bayer AG  DE BAYGN    OTC BAYRY    reported a mixed second quarter with earnings surpassing expectations but sales falling short  While the Pharmaceuticals  Animal Health and Covestro segments recorded a year over year increase in sales  the Crop Science and Consumer Health divisions recorded a decline The Crop Science business was hit by high channel inventories in Brazil  the world s second largest agriculture market  while a difficult environment in the U S  market weighed on the performance of the Consumer Health segment  Given the performance of these two segments  the company now expects 2017 sales of more than  49 billion instead of sales of about  51 billion Core earnings per share from continuing operations are now expected to grow by a low  to mid single digit percentage  old guidance  mid  to high single digit percentage  The Life Science businesses are expected to generate sales of  35 billion    36 billion  previously  approximately  37 billion   The company lowered its outlook for the Consumer Health and Crop Science segments  The second half of the year is expected to be weak for the Consumer Health business with sales expected in the range of  6 billion  previously  more than  6 billion  The Crop Science business is now expected to generate sales of less than  10 billion  previously  sales of more than  10 billion  Given the lowered outlook  Bayer has been witnessing downward revisions in earnings estimates for both 2017 and 2018 over the last 30 days  While 2017 estimates are down 2 6   2018 estimates have declined 1 6  While Bayer  a Zacks Rank  4  Sell  stock  sorts through the headwinds being faced by the Crop Science and Consumer Health segments  we advise investors to focus on drug stocks with a strong Zacks Rank      1  Strong Buy  or  2  Buy  Our PicksAlexion Pharmaceuticals  Inc    NASDAQ ALXN    New Haven  CT based Alexion reported a strong second quarter with both earnings and revenues topping expectations  The company also raised its revenue and earnings outlook for the year  Flagship product  Soliris  eculizumab  continued to perform well  Alexion is working on expanding Soliris  label and has a key catalyst coming up with a decision from the FDA expected by Oct 23  2017  regarding the approvability of Soliris for refractory generalized myasthenia gravis  gMG   A decision in the EU  where a positive CHMP opinion was received  is also expected in the third quarter Alexion  which had a tough 2016 with shares falling 35 9   looks set to recover lost ground with shares increasing 13 1  so far in 2017  outperforming the 9 7  rally of the  it belongs to  The new management team laid out its strategic roadmap and said that its R D efforts will be focused on its expertise area of complement biology and core therapeutic areas of hematology  nephrology  neurology  and metabolic disorders  Alexion will be working on growing its rare disease business  A Zacks Rank  1 stock  Alexion is witnessing upward revisions in earnings estimates for 2017 and 2018 over the last 30 days  Estimated earnings growth for the current year is 26 1  
Sanofi   NYSE SNY    French pharma giant Sanofi raised its 2017 earnings outlook  at constant exchange rates   CER  following the release of second quarter results  Sanofi has a strong presence in several markets including diabetes  cardiovascular  rare disorders  vaccines and consumer healthcare  The company  which had recorded a decline in share price last year  has gained 18 6  year to date  outperforming the 10 4  rally of the  it belongs to  Earnings estimates for 2017 are up 2 2  over the last 7 days  Although the company s diabetes segment will remain under pressure  Sanofi could well be poised for a turnaround on the back of new product approvals and sales ramp up of recently launched products Sanofi is a Zacks Rank  2 stock  The company also has a  of  B   The VGM style score is a useful tool that allows investors to gain an insight into a stock s strengths and weaknesses While  V  stands for Value   G  stands for Growth and  M  for Momentum    the score is a weighted combination of these three metrics  Our research shows that stocks with a VGM Score of  A  or  B  when combined with a Zacks Rank  1 or  2 offer the best upside potential  You can see  
Gilead Sciences  Inc    NASDAQ GILD    Biotech major Gilead also makes it to our list  Gilead  which has been under pressure mainly due to the performance of its hepatitis C virus  HCV  franchise  reported a strong second quarter with the HCV business doing better than expected in the U S  Gilead s HIV franchise also continues to do well  The company surpassed earnings and revenue estimates and raised its 2017 outlook as well  Earnings estimates for 2017 and 2018 are up over the last 30 days  Gilead is a Zacks Rank  2 stock with a VGM style score of  B  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/forget-bayer-buy-these-3-drug-stocks-instead-200205974,200205974
147003,368519,ALXN,Dynavax Technologies  DVAX  Catches Eye  Stock Adds 11 2  In Session,opinion,Dynavax Technologies Corporation   NASDAQ DVAX    was a big mover last session  as the company saw its shares rise over 11  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company as the stock is now up 104 4  in the past one month time frame The company has seen one positive estimate revision in the past four weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the same time frame  suggesting that more solid trading could be ahead for Dynavax Technologies  So make sure to keep an eye on this stock going forward to see if this recent jump can turn Dynavax Technologiescurrently has a Zacks Rank  3  Hold  while its  is 0 00  Dynavax Technologies Corporation Price and Consensus   A better ranked stock in the  Medical   Biomedical and Geneticsindustry is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is DVAX going up  Or down  Predict to see what others think  or Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/dynavax-technologies-dvax-catches-eye-stock-adds-112-in-session-200206019,200206019
147007,368523,ALXN,Geron  GERN  Q2 Loss Narrows  Sales Miss Estimates  Stock Up,opinion,"Geron Corporation   NASDAQ GERN   reported a loss of 4 cents per share in the second quarter of 2017  which was narrower than the Zacks Consensus Estimate of a loss of 5 cents  In the year ago quarter too  the company had recorded a loss of 5 cents Shares rose 4 7  in after hours trading on Wednesday  However  so far this year  Geron s shares have underperformed the   Shares of Geron rose 3 9  during the period  while the industry witnessed a gain of 8 8  Quarterly revenues came in at  0 17 million compared with  0 21 million in the year ago quarter  Revenues missed the Zacks Consensus Estimate of  0 56 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements Research and development  R D  expenses declined 45 6  to  2 5 million due to lower costs for the proportionate share of clinical development costs for imetelstat  General and administrative expenses declined 2 2  to  4 4 million due to reduced consulting costs The company ended the quarter with  117 2 million in cash and investments compared with  121 7 million at the end of the first quarter Pipeline UpdateGeron is developing anti cancer therapies based on telomerase inhibitors  The company currently has one candidate in its pipeline  imetelstat  It is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis  MF  and myelodysplastic syndromes  MDS   Geron has a collaboration with Johnson   Johnson s   NYSE JNJ   subsidiary Janssen for imetelstat In Sep 2016  Janssen announced unfavorable findings from the planned internal reviews of initial data from the two studies of imetelstat   IMbark  phase II  for the treatment of MF and IMerge  phase II III  for the treatment of MDS However  in Apr 2017  Geron informed that Janssen has completed the second internal data review of the two studies and as a result of the review  both trials are continuing unmodifiedFor IMerge  Janssen said that the benefit risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication  Geron mentioned that if Janssen decides to proceed to Part 2 of IMerge  a larger  170 patient  phase III study   patient enrollment will begin in the fourth quarter of this year  Last month  Geron announced that Part 1 of IMerge will be expanded to enroll additional patients in a refined MDS population to confirm the clinical benefit and safety observed from the current result For IMbark  the results suggested that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications  Janssen is expected to evaluate maturing data from the IMbark study during next year  including an assessment of overall survival Last month  Geron said it expects Janssen  upon examining overall survival  to make a continuation decision in the third quarter of 2018 Geron Corporation Price  Consensus and EPS Surprise
    Stocks to ConsiderGeron currently carries a Zacks Rank  3  Hold   Some better ranked stocksin the pharmaceutical sector are Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    both with a Zacks Rank  1  Strong Buy   You can see  Shares of Regeneron have increased 29 1  this year so far while earnings estimates for 2017 have increased 31 3  in the past seven days Shares of Alexion have risen 11 9  this year so far while earnings estimates for 2017 have increased 4 8  in the past 30 days One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-09,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-q2-loss-narrows-sales-miss-estimates-stock-up-200206583,200206583
147012,368528,ALXN,Puma  PBYI  Q2 Loss Narrower Than Expected  Nerlynx In Focus,opinion,"Puma Biotechnology  Inc    NASDAQ PBYI   reported a loss of  2 10 in the second quarter of 2017  including the impact of stock based compensation expenses   narrower than the Zacks Consensus Estimate of a loss of  2 82  The company had reported a loss of  2 05 Shares of Puma Biotech were down 1 9  on Wednesday  However  so far this year  Puma s shares have outperformed the   Specifically  the company s shares have risen 159  this year while the industry registered an increase of 8 8   Puma Biotechnology s lead pipeline candidate  neratinib received FDA approval in July as an extended adjuvant treatment for patients with early stage HER2 overexpressed amplified breast cancer  who have also been previously treated with Roche Holding  SIX ROG  AG s   OTC RHHBY   Herceptin based adjuvant therapy  The FDA approval was a huge boost for the company  given the immense commercial potential in the target market The drug was launched by the trade name of Nerlynx in early August  However  no sales from the drug will be recorded in the second quarter Neratinib is also under review in the EU for the same indication with an opinion from the Committee for Medicinal Products for Human Use  CHMP  of the EMA expected in the first quarter of 2018 With no other approved products in Puma Biotech s portfolio  the company did not generate any revenues in the second quarter In the second quarter  research and development  R D  expenses were  53 3 million  down 1 7  from the year ago quarter due to lower clinical trial costs  Selling  general and administrative expenses however increased 102  year over year to  24 9 million due to higher professional fees  payroll costs and other corporate expenses Additional Studies on NerlynxSeveral additional studies on Nerlynx targeting different types of breast cancer patient populations and in earlier line settings are currently underway  Puma believes that Nerlynx can also be developed for the treatment of other cancers  including non small cell lung cancer  NSCLC  and other tumor types  which over express or have a mutation in HER2  In June  at the annual meeting of American Society of Clinical Oncology  ASCO   the company announced positive results from a single cohort of a three arm phase II study evaluating neratinib for treating HER2 positive metastatic breast cancer that has metastasized to the brain In addition  several phase II combination studies on neratinib for the treatment of breast cancer are ongoing Zacks Rank   Stocks to ConsiderPuma currently carries a Zacks Rank  3  Hold  Puma Biotechnology Inc Price  Consensus and EPS Surprise
    Some better ranked stocks in the pharmaceutical sector are Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN   both with a Zacks Rank  1  Strong Buy   You can see  Shares of Regeneron have increased 29 1  this year so far while earnings estimates for 2017 have increased 31 3  in the past seven days Shares of Alexion have risen 11 9  this year so far while earnings estimates for 2017 have increased 4 8  in the past 30 days One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-09,Zacks Investment Research,https://www.investing.com/analysis/puma-pbyi-q2-loss-narrower-than-expected-nerlynx-in-focus-200206582,200206582
147016,368532,ALXN,Forget Teva  TEVA   Buy These 4 Drug Stocks Instead,opinion,"It s not been a good quarter for Israel based generic drug maker  Teva Pharmaceutical Industries Limited   NYSE TEVA    Teva missed on both second quarter earnings and revenues and lowered its outlook for 2017  The company s shares are down significantly following the release of disappointing second quarter results  Year to date  YTD   Teva has lost 52 6  of its value versus the 17 4  decline of its  
What Went Wrong A key reason for Teva s dismal performance was generic pricing erosion  The sharp decline in generic drug prices  while a blessing for patients  is proving to be a major challenge for generic drugmakers as well as drug distributors On its second quarter call  Teva said that the ongoing consolidation of customers has led to increasing price erosion and decreasing volume  The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs  Teva said that the finalization of both prices and volumes of its inline products with one of its largest customers  Claris One  and other new contracts had a greater than expected negative impact on second quarter results and the outlook for the rest of the year Moreover  the FDA is speeding up the approval of generic drugs which means more competition  increasing price cuts and decreasing volume  Teva said that price erosion was around 6  in the second quarter and is expected to increase to high single digits over the remainder of the year  All these headwinds will persist for the U S  Generics unit in the near future  resulting in lower revenue and profit in this segment in 2018 and potentially 2019 Meanwhile  the company said that it does not expect any earnings contribution from its businesses in Venezuela given the significant devaluation of the Venezuelan currency Teva also cut its dividend by 75  and could be at risk of breaching its covenants if cash flow is hit by lower than expected proceeds from potential divestments or if there is a delay into early 2018  Also read    Zacks Rank   Estimate RevisionsTeva is a Zacks Rank  5  Strong Sell  stock  With the company reporting disappointing results and lowering its outlook  Teva has seen the Zacks Consensus Estimate for current year earnings being revised 10 3  downward over the last 7 days  The Zacks Consensus Estimate for 2018 earnings was revised 14 9  downward over the last 7 days   
Teva has many challenges ahead   paying down debt  divesting non core businesses to increase focus on core areas and generate cash  hiring a permanent CEO  delivering on the pipeline and getting the U S  generics business back on track While Teva deals with these challenges  here is a look at 4 drug companies that sport a strong Zacks Rank and look well positioned Alexion Pharmaceuticals  Inc    NASDAQ ALXN    New Haven  CT based Alexion reported a  beat and raise  quarter with flagship product  Soliris  eculizumab  continuing to perform well  Alexion is working on expanding Soliris  label and has a key catalyst coming up with a decision from the FDA expected by Oct 23  2017  regarding the approvability of Soliris for refractory generalized myasthenia gravis  gMG   Meanwhile  a decision in the EU  where a positive CHMP opinion was received  is also expected in the third quarter Alexion  which had a rough 2016 with shares falling 35 9   looks set to recover lost ground with shares increasing 8 1  so far in 2017  outperforming the 5 6  rally of the  it belongs to  The company s new management team is focusing on Alexion s expertise area of complement biology and core therapeutic areas of hematology  nephrology  neurology  and metabolic disorders  Alexion will be working on growing its rare disease business  A Zacks Rank  1  Strong Buy  stock  Alexion has seen the Zacks Consensus Estimate for current year earnings being revised 4 8  upward over the last 30 days  Estimated earnings growth for the current year is 26 1  
Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Regeneron s key focus areas include eye diseases  heart disease  allergic and inflammatory diseases  pain  cancer  infectious diseases and rare diseases  While eye drug  Eylea  the company s key growth driver continues to perform well  Regeneron has been working on diversifying its portfolio and gained FDA approval for two drugs this year    Dupixent  moderate to severe atopic dermatitis  and Kevzara  moderately to severely active rheumatoid arthritis   Both drugs have blockbuster potential  The company also has a strong pipeline comprising 17 candidates including for cancer and has key data readouts lined up for the second half of the year  Regeneron has seen the Zacks Consensus Estimate for current year earnings being revised 31 3  upward over the last 7 days Regeneron  a Zacks Rank  1 stock  has gained 25 3  year to date  substantially outperforming the 5 6  rally of the industry it belongs to  Estimated earnings growth for the current year is 67 1  
Sanofi   NYSE SNY    French pharmaceutical giant Sanofi has a strong presence in several markets including diabetes  cardiovascular  rare disorders  vaccines and consumer healthcare  The company raised its 2017 earnings outlook  at constant exchange rates   CER  following the release of second quarter results  Sanofi  which had recorded a decline in share price last year  has gained 17 2  year to date  outperforming the 10 1  rally of the  it belongs to  Sanofi has seen the Zacks Consensus Estimate for current year earnings being revised 3 1  upward over the last 30 days  Although the company s diabetes segment will remain under pressure  new product approvals and sales ramp up of recently launched products should provide some support Sanofi is a Zacks Rank  2  Buy  stock  The company also has a  of B  The VGM style score is a useful tool that allows investors to gain an insight into a stock s strengths and weaknesses Our research shows that stocks with a VGM Style Score of A or B when combined with a Zacks Rank  1 or  2 offer the best upside potential  You can see  
Gilead Sciences  Inc    NASDAQ GILD    Biotech company Gilead also reported better than expected results in the second quarter with its hepatitis C virus  HCV  business doing better than expected in the U S  The company s HIV franchise also continues to do well  Gilead raised its outlook for the year  Gilead has seen the Zacks Consensus Estimate for current year earnings being revised 7 4  upward over the last 30 days  Gilead is a Zacks Rank  2 stock with a VGM style score of B 
Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-08-11,Zacks Investment Research,https://www.investing.com/analysis/forget-teva-teva-buy-these-4-drug-stocks-instead-200206774,200206774
147017,368533,ALXN,Regeneron Vs  Alexion  Which Stock Is A Better Pick Post Q2 Earnings ,opinion,"Second quarter earnings season is almost over for the Medical sector with 94 5  of companies belonging to this segment having reported results  A look at the scorecard for Q2 shows that the Medical sector recorded earnings growth of 6 7  on revenue growth of 4 3   While the earnings beat ratio was 82 7   the revenue beat ratio was 67 3   Biotech stocks  in particular  did pretty well this quarter with quite a few companies raising their guidance for the year  Pharmaceutical companies also fared reasonably well  Generic companies  on the other hand  had a tough quarter  and are facing a bleak outlook for the remainder of the year While several major biotech stocks did well in the second quarter  here is look at how two major names in this sector   Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN     fared in the second quarter and which one looks better positioned for the second half of the year An In Depth Look at 2Q17 Results  Both Regeneron and Alexion surpassed earnings as well as revenue expectations in the second quarter  Regeneron s earnings results were driven by strong Eylea sales as well as a lower tax rate  Flagship drug  Eylea  continued to perform well though PCSK9 inhibitor  Praluent  continues to lag  The company is in discussions with payers with respect to improvement in utilization management criteria  Meanwhile  CVS announced that it would provide co preferred access to Praluent through its CVS Caremark commercial formularies  which cover approximately 25 million lives  Also read     Focus was also on new product launches   Dupixent  eczema  and Kevzara  rheumatoid arthritis    Alexion s results were driven by the performance of flagship drug  Soliris  and continued momentum of Strensiq  The company  however  noted that revenues benefited by  35 million reflecting the favorable timing of orders  Also read    2017 Outlook  Regeneron raised its U S  sales growth outlook for Eylea to approximately 10   old guidance  single digit percentage   The company also lowered its expected tax rate for the year Alexion also raised its outlook for the year  The company expects earnings of  5 40    5 55 per share on revenues of  3 450    3 525 million  old guidance   5 10    5 30 per share on revenues of  3 400    3 500 million  Pipeline Catalysts  For any pharmaceutical or biotech company  the pipeline is of utmost importance and plays an important role in investment decisions  So  it always makes sense to take a look at a company s pipeline and upcoming catalysts Regeneron  which has 17 candidates in its pipeline  has an eventful second half of the year coming up with key mid to late stage pipeline catalysts lined up  Top line phase III data on Dupixent for asthma are due later this quarter   positive data would allow the company to go ahead with a U S  filing in the fourth quarter  Dupixent should also gain EU approval for the eczema indication in the third quarter  Regeneron is evaluating Dupixent in the pediatric atopic dermatitis setting with a phase III study in children 12 to 17 years of age currently enrolling while two additional studies in younger atopic dermatitis patients  the first in children between the ages of 6 and 11  and the second in children between the ages of six months and five years  expected to commence in the second half of the year Another important data readout scheduled for the second half of the year is on the company s PD 1 antibody REGN2810  for cutaneous squamous cell carcinoma  CSCC   the second most common skin cancer after basal cell carcinoma and the second deadliest skin cancer after melanoma  Positive data would allow the company to file for FDA approval in the first quarter of 2018  REGB2810 is being evaluated for additional indications as well Meanwhile  Eylea is being evaluated in combination with nesvacumab  Top line data from two phase II studies   one in wet age related macular degeneration and another in diabetic macular edema   are expected in the fourth quarter of the year Regeneron also expects to report top line data in the second half of the year from a late stage program on REGN2222  which is being evaluated for prophylaxis of respiratory syncytial virus Meanwhile  Alexion is redefining its R D strategy with a focus on its key expertise areas  The company will continue to grow its rare diseases business which includes growing Soliris  Strensiq and Kanuma  To increase productivity  Alexion will focus its internal research efforts on its complement expertise and its development efforts on its core therapeutic areas of hematology  nephrology  neurology and metabolic disorders  The company has also decided to de prioritize certain pipeline candidates and is discontinuing its preclinical programs with mRNA therapies as well as other preclinical programs that do not fall within the complement franchise Alexion has a key regulatory event coming up with the FDA expected to give a decision by Oct 23 regarding the label expansion of Soliris for refractory generalized myasthenia gravis  gMG   A decision in the EU should also come out in the third quarter  Moreover  enrolment for a phase III study on Soliris for relapsing neuromyelitis optica spectrum disorder  NMOSD  is expected to finish this year Estimate Revisions  Both companies have been witnessing upward revisions in earnings estimates for 2017  While Regeneron has seen the Zacks Consensus Estimate for current year earnings being revised 31 3  upward over the last 30 days  Alexion has seen the Zacks Consensus Estimate for current year earnings being revised 4 8  upward during this period Price and Valuation Perspective  A look at Regeneron s year to date  YTD  price performance shows that its shares have gained 27 1  year to date  significantly outperforming the  6 2  rally 

Alexion has also performed better than the industry with shares gaining 8 7   YTD 
Going by the current price to earnings multiple  which is often used to value profitable biotech stocks  Regeneron is trading at a P E multiple of 41 4  well above the S P 500 P E multiple of 17 8  Alexion looks slightly cheaper given its P E multiple of 25 7 Bottom LineAt present  Regeneron looks like the better pick to us  Eylea continues to show strength and we are encouraged by the company s progress with its pipeline  Regeneron has a deep and promising pipeline and has some important pipeline events this year which could act as positive catalysts As far as Alexion is concerned  we are impressed by the new management s efforts to turn things around  Alexion had a rough 2016 with the company facing several challenges including a probe into improper sales practices  the departure of key executives and pipeline setbacks  We are encouraged by the company s decision to re prioritize its efforts toward core areas  However  it could take a while before things fall into place  Soliris sales are expected to be lower in the second half of the year taking into account the favorable order timing in Q2 as well as the accelerating impact of the ALXN1210 studies Regeneron and Alexion are both Zacks Rank  1  Strong Buy  stocks  You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-13,Zacks Investment Research,https://www.investing.com/analysis/regeneron-vs-alexion-which-stock-is-a-better-pick-post-q2-earnings-200207123,200207123
147024,368540,ALXN,Spectrum  SPPI  Initiates Phase II Study For Cancer Drug,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   announced that the company has initiated the registrational phase III study of qapzola  apaziquone  in patients with non muscle invasive bladder cancer  NMIBC  
NMIBC is the fifth most common cancer in the U S  and is an unmet medical need due to high recurrence rates and no FDA approved drugs 
Shares of the company have skyrocketed 111 7  against the Zacks classified  decline of 2 4  on a year to date basis 

In November 2016  Spectrum suffered a regulatory setback when the FDA issued a complete response letter  CRL  for its new drug application  NDA  for Qapzola  In fact  the company was looking to get Qapzola approved for immediate intravesical instillation  post transurethral resection of bladder tumors  post TURBT  in patients with non muscle invasive bladder cancer  NMIBC  
Notably  now the phase III study is being conducted under a special protocol assessment  SPA  from the FDA and includes feedback from the FDA and  key opinion leaders  KOLs  as well as learnings from earlier studies  The study will enroll patients with low and intermediate risk NMIBC as per the American Urology Association  AUA  Guidelines  The study will have lesser patients enrolled  425 patients compared with 1557  and the duration of the study will be reduced 
The protocol includes a single instillation of Qapzola 60   30 minute post TURBT  to avoid inactivation of Qapzola by blood that is present after surgery  Furthermore  the patients will be randomized 2 1 to receive either 8 mg instillation of Qapzola or placebo post TURBT  The primary endpoint for this trial is time to recurrence Spectrum Pharmaceuticals  Inc  Price
 

   Zacks Rank   Key Picks
Spectrum currently holds a Zacks Rank  2  Buy   Some other top ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Sanofi   NYSE SNY    While Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   Sanofi carries the same bullish rank as Spectrum  You can see  
Alexion Pharmaceuticals  earnings per share estimates have moved up from  4 55 to  4 77 for 2017 and from  5 49 to  6 43 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 12 26   The share price of the company has increased 10 6  year to date 
Regeneron s earnings per share estimates have increased from  10 52 to  13 81 for 2017 and from  12 10 to  14 54 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 6 29   The share price of the company has increased 28 7  year to date 
Sanofi s earnings per share estimates have moved up from  3 20 to  3 31 for 2017 and from  3 36 to  3 38 for 2018 over last 30 days  The company came up with positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10   The share price of the company has increased 18 3  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/spectrum-sppi-initiates-phase-ii-study-for-cancer-drug-200207699,200207699
147025,368541,ALXN,MiMedx Group  MDXG  In Focus  Stock Moves 6 1  Higher ,opinion,MiMedx Group  Inc    NASDAQ MDXG   was a big mover last session  as the company saw its shares rise over 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  14 35 to  15 64 in the past one month time frame The company has not seen any estimate revisions over the past one month  while the Zacks Consensus Estimate for the current quarter also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future MiMedx Group currently carries a Zacks Rank  3  Hold  while its  is 0 00   MiMedx Group  Inc Price   A better ranked stock in the Medical   Biomedical and Genetics industry is Alexion Pharmaceuticals  Inc    NASDAQ ALXN    which currently sports a Zacks Rank  1  Strong Buy   You can see  Is MDXG going up  Or down  Predict to see what others think   or The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaries   but that should still leave plenty of money for regular investors who make the right trades early ,2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/mimedx-group-mdxg-in-focus-stock-moves-61-higher-200207571,200207571
147037,368553,ALXN,Is A Beat In Store For Alexion  ALXN  This Earnings Season ,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to report second quarter 2017 results on Jul  27  before the opening bell In the last reported quarter  Alexion s earnings surpassed Zacks Consensus Estimate  Alexion s track record is excellent as the company has consistently beaten expectations in the last four quarters with an average positive earnings surprise of 7 49  over the trailing four quarters Let s see how things are shaping up for this announcement A look at Alexion s share price movement year to date shows that the stock has underperformed the Zacks classified  industry   While the company s shares have gained 4 1   the industry witnessed an addition of 10 6  in the same period Factors Likely to Impact Q2 ResultsAlexion continues to identify and treat a consistently high number of new patients with paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS  with Soliris  across its 50 country operating platform  In order to further increase the commercial potential of the drug  Alexion is working on expanding Soliris  label into additional indications  Label expansion into additional indications would give Soliris access to a higher patient population and increase the commercial potential of the drug significantly  Additionally  the company is working on the launches of both Strensiq and Kanuma Strensiq continues to perform well with revenues benefiting from a growing number of patients  both children as well as adults with pediatric onset disease  owing to HPP disease awareness and diagnostic initiatives  These initiatives are leading to steady identification of new patients with hypophosphatasia  HPP   In fact  the company expects Strensiq to be an additional growth driver in 2017  and beyond Alexion is also looking to achieve annual cost synergies  which are expected to touch at least  150 million in 2017 Meanwhile  Alexion continues to progress with in country funding processes for both the products in additional countries in the EU this year Notably  the company s efforts to develop its pipeline are impressive  particularly in case of ALXN1210  Currently  it is evaluating ALXN1210  a longer acting anti C5 antibody that inhibits terminal complement  in phase III studies for both PNH and aHUS  Additionally  the company is conducting a phase I study on a new formulation of ALXN1210  when administered subcutaneously in healthy volunteers Alexion plans to initiate a phase III PNH switch study of ALXN1210 administered intravenously every eight weeks compared to patients currently treated with Soliris  in 2017  Therefore  we expect investors to focus on updates from ALXN1210 as the successful development and commercialization of the drug will boost growth prospects However  with Soliris accounting for majority of revenues at Alexion  the company relies heavily on the drug for growth  Going forward  Soliris  below par performance might hurt the stock severly as it is considered to be Alexion s key growth driver  It is to be noted that the drug is already witnessing challenges in Latin America  Also  Soliris  quarter to quarter revenue growth will be impacted by the enrollment ramp up of trials on ALXN1210  by  70 million  110 million   particularly in the second half of 2017   Soliris revenues are expected to be down in the second quarter of 2017 What Does the Zacks Model Unveil Our proven model shows that Alexion is likely to beat earnings in the to be reported quarter because it has the right combination of two key ingredients   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    which have a significantly higher chance of beating earnings Zacks ESP  Alexion has an Earnings ESP of  6 48  as the Most Accurate estimate is  1 15 and the Zacks Consensus Estimate is pegged at  1 08  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Alexion carries a Zacks Rank  3  which when combined with a positive ESP of  6 48  makes us reasonably confident of an earnings beat Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Alexion Pharmaceuticals  Inc  Price and Consensus    Stocks That Warrant a LookHere are some pharma stocks that you may want to consider  as our model shows that right combination of elements to post an earnings beat Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  5 56  and a Zacks Rank  1  The company is expected to release results on Jul 27  You can see  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  3 31  and a Zacks Rank  3  The company is scheduled to release results on Jul 26 Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 39  and a Zacks Rank  3   The company is expected to release results on Aug 3 3 Top Picks to Ride the Hottest Tech Trend Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy    Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-alexion-(alxn)-this-earnings-season-200202463,200202463
147038,368554,ALXN,Why Alexion Pharmaceuticals  ALXN  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Alexion Pharmaceuticals  Inc    NASDAQ ALXN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Alexion Pharmaceuticals is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for ALXN in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 15 per share for ALXN  compared to a broader Zacks Consensus Estimate of  1 08 per share  This suggests that analysts have very recently bumped up their estimates for ALXN  giving the stock a Zacks Earnings ESP of  6 48  heading into earnings season Alexion Pharmaceuticals  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ALXN has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Alexion Pharmaceuticals  and that a beat might be in the cards for the upcoming report The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaries   but that should still leave plenty of money for regular investors who make the right trades early ,2017-07-26,Zacks Investment Research,https://www.investing.com/analysis/why-alexion-pharmaceuticals-(alxn)-might-surprise-this-earnings-season-200203597,200203597
147039,368555,ALXN,Alexion  ALXN  Tops Q2 Earnings   Revenues  Ups 2017 View,opinion,Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   posted second quarter 2017 adjusted earnings  including after tax impact of stock based compensation expense  of  1 31 per share higher than the year ago earnings of 93 cents as well as the Zacks Consensus Estimate of  1 08  Strong product revenues drove the bottom line in the quarter Revenues rose 21  year over year to  912 million  also exceeding the Zacks Consensus Estimate of  848 million  Revenues were driven by increased sales of Soliris  Strensiq and Kanuma  Negative impact of currency headwind on the top line was 2    12 million   Revenues in the quarter also benefitted by favorable timing of orders Notably  shares of Alexion were up more than 6  in pre market trading  in response to the better than expected results  However  so far this year  Alexion s share price has increased 14 5   outperforming the Zacks classified  gain of 12  Revenue in DetailSoliris  paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   sales were up 16  to  814 million during the quarter driven by strong volume growth  While Strensiq  hypophosphatasia  HPP   contributed  83 million to revenues  up 84  year over year  Kanuma  lysosomal acid lipase deficiency  LAL D   contributed  15 million  up 114   to quarterly revenues Cost SummaryResearch and Development  R D  expense  excluding stock based compensation  was  179 million  up 8 5  year over year Selling  general and administrative  SG A  expense  excluding stock based compensation  was  227 million   up 13 5  year over year 2017 GuidanceThe company increased its adjusted revenue and earnings guidance for 2017  The company expects adjusted earnings per share to be in the range of  5 40  5 55  excluding stock based compensation expense  up from its previous expectation of  5 40  5 30  It projects revenues to be in the range of  3 45  3 53 billion up from its prior expectation of  3 4  3 5 billion  In fact  revenues for Soliris are expected in the range of  3 07  3 13 billion up from the previous expectation of  3 03  3 1 billion Pipeline UpdateThe company continues to progress with the candidates in its pipeline  Alexion filed regulatory submissions looking for label expansion of Soliris to treat patients with refractory generalized myasthenia in U S   Europe in Jan 2017  The applications have been accepted for review by the FDA with a decision expected on Oct 23  2017  The Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  issued a positive opinion recommending marketing approval to the Soliris label expansion in the reported quarter  Final decision from the European Commission  EC  is expected in the third quarter of 2017 Currently  Alexion is evaluating Soliris in a couple of other phase III studies   PREVENT  for the treatment of relapsing neuromyelitis optica spectrum disorder and expects to complete enrollment in the study in 2017 and report data in 2018 Our TakeAlexion exceeded both earnings and revenue estimates in the second quarter and also raised its earnings and revenue guidance  We expect growth at Alexion to continue being driven by Soliris  Other new products   Strensiq and Kanuma   are doing well and should boost revenues  We are also impressed by Alexion s efforts to develop its pipeline  especially the label expansion efforts for Soliris Alexion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise    Zacks Rank   Stocks to ConsiderAlexion currently carries a Zacks Rank  3  Hold   Better ranked health care stocks in the same space include Enzo Biochem  Inc    NYSE ENZ    Exelixis  Inc    NASDAQ EXEL   and Sanofi   NYSE SNY    While Enzo Biochem and Exelixis sport a Zacks Rank  1  Strong Buy   Sanofi carries the same rank as the former  You can see  Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 55 83   The share price of the company has increased 62 7  year to date Exelixis  pulled off positive earnings surprises in all the trailing four quarters  with an average beat of 512 11   The share price of the company has increased 87 9  year to date Sanofi s earnings per share estimates increased from  3 18 to  3 20 for 2017 and from  3 30 to  3 36 for 2018  over last 30 days  The company came up with positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10   The share price of the company has increased 18 7  year to date More Stock News  Tech Opportunity Worth  386 Billion in 2017 From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ,2017-07-26,Zacks Investment Research,"https://www.investing.com/analysis/alexion-(alxn)-tops-q2-earnings---revenues,-ups-2017-view-200204034",200204034
147068,368584,ALXN,Omeros  OMER  Lead Candidate Gets Breakthrough Designation ,opinion,"Omeros Corporation   NASDAQ OMER   announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721  The candidate will be used to treat Immunoglobulin A  IgA  nephropathy OMS721 is Omeros  lead human monoclonal antibody targeting mannan binding lectin associated serine protease 2  MASP 2  The designation was granted based on data from phase II trial evaluating OMS721 in patients with IgA nephropathy and other kidney diseases  The data revealed unprecedented improvement in proteinuria following only 12 weeks of OMS721 treatment  with a 77  mean reduction in urine albumin to creatinine ratios  p   0 026  and a 73  mean reduction in 24 hour urine protein levels  p   0 013  Following the news  shares of the company went up 2 5   Shares of Omeros has outperformed the Zacks classified industry in the last one year with the stock gaining 73 3  during this period  compared with the industry s gain of 12 4  The breakthrough therapy designation from the FDA enables expedited development and review of a drug candidate for the treatment of a serious or life threatening disease  The designation includes benefits from the eligibility for priority review of the application and rolling submission of portions of the application  The FDA personnel  including senior management  provide guidance to the company to determine the most efficient route to approval Approximately 120 000 to 180 000 patients in the U S  suffer from IgA nephropathy  Since there is no approved treatment for IgA nephropathy  there is a significant unmet need for the same  Approximately 40  of IgA nephropathy patients develop end stage renal disease The successful development and subsequent approval of the candidate will significantly boost the company s growth prospects Meanwhile  OMS721 is also being evaluated in a phase III clinical program for atypical hemolytic uremic syndrome  aHUS  and in a phase II clinical program for hematopoietic stem cell transplant associated thrombotic microangiopathy We note that Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   Soliris is also approved for aHUS The company plans to initiate additional phase III programs on OMS721 in IgA nephropathy and in stem cell transplant associated TMA Omeros currently has one approved drug  Omidria in its portfolio  The drug was launched in the U S  in the second quarter of 2015 for use during cataract surgery or intraocular lens  or IOL  replacement 
Zacks Rank   Key Picks 
Omeros currently has a Zacks Rank  3  Hold  
Some top ranked stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS    and MEI Pharma  Inc    NASDAQ MEIP    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates have narrowed from 50 cents to 39 cents for 2017 over the last 60 days  The company delivered positive earnings surprises in all the four trailing quarters  with an average beat of 233 69  
MEI Pharma s estimates have moved up from loss per share of 1 cent to gain per share of the same for 2017  over the last 60 days  The company delivered positive earnings surprises in three of the four trailing quarters  with average beat of 66 56  
Zacks  2017 IPO Watch List 
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-06-13,Zacks Investment Research,https://www.investing.com/analysis/omeros-(omer)-lead-candidate-gets-breakthrough-designation-200195191,200195191
147069,368585,ALXN,Alexion Reportedly Being Investigated By HHS  Shares Slip,opinion,Shares of Alexion Pharmaceuticals  Inc    NASDAQ ALXN   were down more than 3  on Thursday after a Bloomberg report stated that it is under investigation by the U S  Department of Health and Human Services   HHS  Office of Inspector General  OIG  In fact  so far this year  shares of Alexion have declined 1   against an increase of 8 1  registered by the Zacks classified industry during this period The HHS has reportedly said it is conducting an  open and ongoing investigation  into the biotech  though it did not specify what it was about   The investigation is reportedly related to Alexion s support of charitable organizations that provide financial assistance to Medicare patients who take drugs sold by the company We remind investors that in an SEC filing in January this year  the company disclosed that in Dec 2016  it had received a subpoena from the U S  Attorney s Office for the District of Massachusetts requesting documents related to Alexion s support for the above mentioned charities  At that time  the company said that other companies have also disclosed similar inquiries and it is cooperating with this inquiry The HHS OIG is responsible for investigating abuse  waste and fraud in U S  government health programs like Medicare and Medicaid Investigations into its sales practices are not new for Alexion  Last year in December  Alexion s Chief Executive Officer  CEO   David Hallal  and Chief Financial Officer  CFO   Vikas Sinha resigned unexpectedly during an internal investigation into the sales practices related to its key drug  Soliris  Shares of the company touched a 52 week low in response Alexion carries a Zacks Rank  3  Hold   Better ranked stocks in the sector include Enzo Biochem  Inc    NYSE ENZ    Aduro BioTech  Inc    NASDAQ ADRO   and Agenus Inc    NASDAQ AGEN    While Enzo Biochem has a Zacks  1 Rank  Strong Buy   the other two companies carry a Zacks Rank  2  Buy   You can see  Enzo Biochem s loss per share estimates for 2017 narrowed by almost 42  in the last 60 days  The company delivered a trailing four quarter average positive earnings surprise of 55 83   Shares have risen42 8  in the past three months Aduro BioTech s loss per share estimates for 2017 narrowed by 9 3  in the last 60 days  The company delivered a trailing four quarter average positive earnings surprise of 36 28   Shares have increased 35 9  in the past three months Agenus delivered a trailing four quarter average positive earnings surprise of 8 8   Shares of Agenus have risen21 4  in the past three months Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-06,Zacks Investment Research,"https://www.investing.com/analysis/alexion-reportedly-being-investigated-by-hhs,-shares-slip-200199732",200199732
147087,368603,ALXN,Drug Stocks Q4 Earnings Lineup For Mar 1  MYL  KERX   More,opinion,With the curtains almost down on the Q4 earnings season  we believe this quarter has turned out to be a good one with growth on track to be the highest in the last two years  As of Feb 17  2017  411 S P 500 members  accounting for 88 4  of the index s total market capitalization  have reported results  according to the  report Total earnings for these 411 index members are up 8  from the year ago quarter on a 4 9  improvement in revenues  The beat ratio so far is 68 9  for earnings and 54 7  for revenues  We remind investors that Q3 was the first quarter to see earnings growth  up 3 8   after five consecutive quarters of an earnings decline for the S P 500 index Meanwhile  the positive earnings growth momentum is expected to ramp up in the future quarters  As per our Earnings Preview report  total earnings for the S P 500 companies will grow 7 4  year over year on 3 9  higher revenues  Please note that estimates for the current period  first quarter 2017  are also looking up However  the picture hasn t been as bright for the pharmaceutical companies so far this season  The soft performance of pharma companies seen this earnings season continued with Alexion Pharmaceuticals  Inc    NASDAQ ALXN   delivering in line earnings while missing revenue estimates  Zoetis Inc    NYSE ZTS   surpassed bottom line estimates while revenues came in line with expectations  However  the company narrowed its outlook for 2017 to account for the currency impact Meanwhile  Teva Pharmaceutical Industries Ltd  s   NYSE TEVA   fourth quarter earnings and sales were above expectations  Importantly  the generic drug maker reiterated its 2017 guidance despite the recent Copaxone patent loss Here we have five pharma companies that are set to report fourth quarter results on Mar 1  Let s see how things are shaping up for this quarter Mylan N V    NASDAQ MYL  Mylan is scheduled to release earnings after market close  The company s performance has been mixed so far  having beaten earnings estimates in two of the trailing four quarters and missing in the other two  Overall  it has delivered an average negative surprise of 2 05   Last quarter  the company recorded a negative earnings surprise of 8 0  For this quarter  Mylan has an of  1 42  and a Zacks Rank  3  Hold   You can see  The Zacks Consensus Estimate is pegged at a  1 41 per share It has been a dismal 2016 for Mylan and we do not expect the fourth quarter to be any different from this trend  Mylan has been under immense pressure since Aug 2016 when the company faced criticism for the price increase of EpiPen from lawmakers  consumers and the common people alike  Read More    Keryx Biopharmaceuticals  Inc    NASDAQ KERX  Keryx is scheduled to announce results before the opening bell  Last quarter  the company recorded a negative earnings surprise of 77 27   Keryx s track record has been disappointing so far  Over the four trailing quarters  the company posted an average negative earnings surprise of 43 03   reporting in line earnings only once in the last four quarters  while missing the same on all the other three occasions The Zacks Consensus Estimate for the quarter is pegged at a loss of 27 cents However  the company has an Earnings ESP of  37 04  and a Zacks Rank  3  indicating a likely positive surprise  You can uncover the best stocks to buy or sell before they re reported with our Apart from license fees  Keryx s top line comprises revenues generated by its only marketed product  Auryxia  ferric citrate    Read More    Our previous article said that an earnings beat was not likely  However  estimates changed thereafter and we are more confident of an earnings beat now Juno Therapeutics Inc    NASDAQ JUNO  Juno is expected to report after market close  The company has had a mixed track record  It posted negative surprises in two of the last four quarters  beat expectations in one and met estimates in one  The average negative earnings surprise in the last four quarters was 9   Last quarter  the company delivered a positive earnings surprise of 9 38  The Zacks Consensus Estimate for the quarter is pegged at a loss of 63 cents Our proven model does not conclusively show that Juno is likely to beat earnings estimates this quarter  The company has an Earnings ESP of  20 64  and a Zacks Rank  4 With no approved products in its portfolio  Juno does not generate any product revenues yet  Hence  investor focus will primarily be on the company s cash burn and pipeline updates   Read More   Geron Corporation   NASDAQ GERN  Geron is scheduled to release results after market close  In the last reported quarter  the company recorded a positive earnings surprise of 66 67   Geron s performance over the last four quarters has been mixed  with the company surpassing expectations twice and meeting the same twice  The average positive surprise over the last four quarters is 23 81  For this quarter  Geron has an  of 0 00  and a Zacks Rank  3  The Zacks Consensus Estimate is pegged at a loss of 6 cents With no approved product in its portfolio  Geron s top line solely comprises license fees and royalties  In such a scenario  investor focus will remain on the company s pipeline   Read More    Intrexon Corporation   NYSE XON  Intrexon is scheduled to release results after market close  In the last reported quarter  the company reported in line earnings  Intrexon s performance has been mostly disappointing  with the company missing estimates in two of the four trailing quarters with an average negative earnings surprise of 7 72  For this quarter  Intrexon has an of 0 00  and a Zacks Rank  3  The Zacks Consensus Estimate is pegged at a loss of 23 cents Intrexon s top line comprises mainly of collaboration and license fees  product revenues and service revenues   Read More  Where Do Zacks  Investment Ideas Come From You are welcome to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buy   stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5   Strong Sells   and other private research ,2017-02-28,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-q4-earnings-lineup-for-mar-1:-myl,-kerx---more-200177289",200177289
147088,368604,ALXN,Portage Biotech Stock May Be The Mightiest Micro Cap In The Market,opinion,"Portage Biotech Inc  OTC PTGEF 
When I first introduced Portage Biotech back in September of 2016  PTGEF was trading at just over twelve cents a share  at which time I made clear my feelings that the stock was grossly undervalued using almost any metric of measurement  At the time  management provided a compelling and informative interview and laid the framework for what lay ahead for this emerging company  Despite the under the radar position of the stock  quite a few investors did jump on board the PTGEF train  following the lead of an enormously successful and experienced management team that already owned roughly 50  of the outstanding shares 
It s never a bad idea to follow the insiders  and for those that respected the credibility of the company s leadership team  investors were treated to shares priced at roughly 50  less than where the stock trades today  The good news is that for those that missed the recent increase in PTGEF value  the stock remains mostly misunderstood and still significantly undervalued  Thus  an opportunity still knocks 
What s So Fast Moving 
Let s cut to the chase  For those that missed the buying opportunity at twelve cents a share  an opportunity exists to reconsider that decision and to purchase shares of PTGEF at levels which still don t efficiently price the value inherent to the company  Despite the fact that shares now trade approximately 80  higher from where they were in September  an opportunity is rearing its beautiful head once again  providing a clear basis in value that the market is unwittingly able to ignore  PTGEF has done its part  providing the investment clues and building an asset base that has grown significantly over the past two years  The problem is is that the market still appears to have selective reasoning capability  as well as the capacity to ignore reality  Well  not everyone in the market is ignoring the reality at the company  While it may be the case that retail investors have been slow to buy into the PTGEF story  there has been well over a hundred million dollars raised by the PTGEF management team to advance its company strategy  And  these financing s were on terms as good as or at least equal to some of the most respected biotech companies in the market  which says quite a lot about the credibility of this micro cap company 
Companies at a valuation similar to PTGEF are often plagued by cram down   buy at the market  finance deals  which get funded by a bunch of wolves dressed as virgin sheep  Not the case for PTGEF and from the terms I have read  most investors are giving praise  not pity on the accomplishments at the company  For that reason  PTGEF has attracted investors  those willing to embrace and encourage the vision of the enterprise  leading to substantial investments without the usual perks provided by desperate companies  The PTGEF agreements are mostly free from excessive dilution and warrant overhang  and insiders regularly contribute to the placements  Over time  PTGEF has become a well funded company  flush with an exceptional management team  and a vision that is delivering upon a multifaceted strategy that is on track to deliver meaningful shareholder value in the next 6 24 months 
I ve Liked PTGEF For A Long Time 
Hey  I m long the stock  and I made that known many months ago  In fact  while some questioned my credibility in investing in such a low priced company  I merely pointed to the facts  And while I didn t pound the table and make adamant pleas for investors to take a stake in PTGEF  I did at least lead them to the water  And  as the company has shown  I was not offering the proverbial kool aid  So  am I happy that some missed the first ride  perhaps keeping prices low for now  Nope  In fact  just the opposite  because based on what s to come  I expect that investors may finally get the message that PTGEF is the real deal  even at a share price 80  higher from where the company traded less than six months ago  But  even while accounting for the recent accomplishments at PTGEF  the investment thesis is just now starting to unfold  and I believe that the current momentum will carry forward the deal making prowess of the company 
Portage Biotech Is A Whole Lot Of Good
To keep this article under 10 000 words  only a brief introduction to the entire Portage Biotech can be obliged  However  please refer to my original interview with company management for an in depth presentation 
Portage Biotech is engaged in the discovery and development of pharmaceutical and biotech products through clinical proof of concept with a focus on areas of unmet clinical need  Because of the private nature of its investments  PTGEF has kept many trial details close to the vest  however  it s not hard to comprehend that management has been in full court press in their effort to increase shareholder value  Keep in mind that management owns roughly 130 million shares of the company  so a win for retail is a win for them 
As PTGEF tells it  once they find a proof of concept product  they do their best to get control and then seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization  Taking advantage of opportunities that others may have discarded  PTGEF  with its diversified medical team  can evaluate potential opportunities in a given compound  Then  they weave in and use their expertise to reposition a drug to treat novel targeted therapies  utilizing stem cell therapies  and new indications for older marketed products that have unique and patentable characteristics with the ability to bring therapeutic value to patients 
It s the sum of the parts that make PTGEF valuable  And each of the parts is doing very  very well  It was rumored that President Trump once tweeted   Frankly  PTGEF is doing a magnificently great thing  believe me  they are   I m still searching for the cached tweet  but I do share in the enthusiasm 
OK  Tell Me The PTGEF Story 
I am flat out serious when I say that there is not a weak link at PTGEF  The company has ownership in three companies  all of which are privately held  But  not for long  so don t change the channel just yet   Spoiler Alert  One of them is going public 
PTGEF s three portfolio companies  Biohaven  Sentien  and Portage Pharmaceuticals  Ltd   PPL  are each independent entities with separate management teams that contribute to the overall valuation of PTGEF  The good news for interested newbies is that little value from these assets has trickled down to the share price  which offers a substantial opportunity to investors  Further  each of the three companies is beginning to hit its stride  successfully developing their compounds through both pre clinical and clinical trials  As these trials progress  assuming the data is promising  so should the value in PTGEF  Management has never shied away from the mission to increase shareholder value  and while the share price in PTGEF has grown substantially from 2016 levels  the most recent announcements by the company should continue to generate significant future value once the market begins to understand the real value within its previously guarded  private assets 
The strategy by PTGEF management is straight forward  Their investment in Biohaven  for instance  exemplifies the approach quite well  Approximately two years ago  the company provided critical early funding to Biohaven and helped assemble a highly experienced drug development team that previously worked at Pfizer  NYSE PFE   Bristol Myers Squibb Company  NYSE BMY   and Alexion Pharmaceuticals Inc  NASDAQ ALXN   After assembling the management team  Biohaven then efficiently advanced its lead drug candidate  BHV 0223  its Orphan Drug to treat ALS  acquired additional assets and was granted two other Orphan Drug designations  positioning the company to have multiple drug candidates entering pivotal Phase 3 trials this year 
When PTGEF first invested in Biohaven  the initial valuation of the company was  7M  and Biohaven s last round of funding was at a  133M valuation  With success in its upcoming pivotal clinical trials  the expectation is that Biohaven s value may continue to rise and earn a level of return that investors should find attractive  The strategy used to develop Biohaven remains consistent throughout the PTGEF portfolio  finding and developing an opportunity that can maximize shareholder value 
Not only has the model shown that it can provide opportunity  but management has demonstrated their ability to build a small company into one that can potentially become a prominent story in the public markets  And  therein lay the Biohaven opportunity  whom just announced their IPO plans  and may lead to a financial windfall for PTGEF  who controls a 28 3  interest in the company 
The consummated Biohaven IPO will ultimately place a tangible dollar value on the interest owned  but  that book value is only a starting point  as any investor that discounts the ownership in both Sentien and PPL is likely on hallucinogenics 
Biohaven  BHVN  Is Coming Out
With the asset value at PTGEF being relatively unknown due to the private nature of the company structure  assigning a practical value to each asset has been difficult  Finally  the Biohaven IPO may begin to shred doubt as to how PTGEF should be valued 
Biohaven started to grab footing back in March of 2017 when they raised  80 million in a funding round that featured Osage University Partners and Connecticut Innovations  At that time  total funding into the company reached the  100 million mark  not small time by any means  Part of that  100 million came from insiders at PTGEF  with both John Childs and Dr  Greg Bailey contributing as angel investors  The announced financing followed the November spin out of Biohaven  who had already concluded a previous deal to raise an initial  40 million in funding 
Fast forward  Biohaven  BHVN  the expected trading symbol  has plans to go public with expectations to trade on the NYSE  And what may prove to be a substantial benefit to PTGEF shareholders  is that the company owns 28 3  of that deal  The IPO is expected to generate upwards of  100 million and will occur once the regulatory compliance sessions are over  Factoring in regulatory questions  responses  roadshows  etc   a closing in late 2017 is very likely  and despite shaky market sentiment on a macro basis  the appetite for this deal may remain voracious regardless of market opinion  Included in the table of investors are two undisclosed blue chip pharmaceutical companies that took a stake in Biohaven in 2016 
The IPO is being underwritten by a respectable list of deal makers  led by Morgan Stanley  Piper Jaffrey  Barclays Capital and others  In February 2017  BHVN obtained third party valuations  performed on a retrospective basis  of its common shares as of August 17  2015  the date the company first issued common shares and common share warrants in connection with their license agreement with ALS Biopharma  BHVN received updated valuations as of October 31  2016  the date of the first closing of its Series A preferred share financing  In addition to those two initial assessments  BHVN obtained third party valuations of its common shares as of various dates between December 31  2016  and March 31  2017 
The independent  third party assessments resulted in appreciating valuations of BHVN common shares of  5 23 per share as of August 17  2015   6 73 per share as of October 31  2016   7 45 per share as of December 31  2016   8 68 per share as of January 31  2017   9 85 per share as of February 28  2017 and  10 82 per share as of March 31  2017  These third party valuations were conducted by the guidance outlined in the American Institute of Certified Public Accountants  Accounting and Valuation Guide  Valuation of Privately Held Company Equity Securities Issued as Compensation 
To cipher it down into the potential value reflected back to PTGEF  investors can estimate value based on a fully diluted offering expected to bring the outstanding share count at BHVN to approximately 30 million shares  Assuming that BHVN did not appreciate a single penny since November of 2016  which is ridiculously unlikely  then PTGEF should be recognized at having slightly under  29 cents in share value based on that ownership stake alone  Going further  assuming that the mid range of valuation is given to BHVN once the IPO terms get settled  PTGEF s stake should afford them at least  38 cents in ownership book value  And in a best case  an oversubscribed IPO can bring more than  45 cents in book value to PTGEF  These prognostications are plain vanilla  black and white estimates for BHVN only  by the way  Actual BHVN value may likely include blue sky multiples  Additionally  those estimates include absolutely no value in the Sentien and PPL ownership  which are proving to have significant value and a growing asset base 
To substantiate these opinions  there is some history to the value in BHVN already  In January 2014  the company sold and issued 5 752 000 common shares to PTGEF at a purchase price of  0 61 per share for gross proceeds of  3 5 million  resulting in PTGEF becoming a beneficial owner of more than 5  of BHVN s outstanding shares  In July 2015  BHVN sold and issued 446 500 additional common shares to Portage at a purchase price of  5 60 per share for gross proceeds of  2 5 million  In February 2016  BHVN sold and issued 143 000 common shares to Portage at a purchase price of  7 00 per share for gross proceeds of  1 0 million  It s important to note that Dr  Declan Doogan  the chairman of BHVN s board of directors  is the chief executive officer of PTGEF 
The BHVN Affect
Here s the bottom line on BHVN  There has been an extraordinary amount of interest in the company for quite a while  And  while this article could yield thousands of words to discuss each and every promising asset that BHVN is capable of addressing in the near term  my purpose is to merely point out the value that is going to be directly beneficial to PTGEF from an ownership standpoint  Even with 260 million shares O S  the reflective value to PTGEF after the IPO should generate an additional 40  to its current share price  and if an investor should assume that the value of BHVN will increase over timer  then so shall the value in PTGEF  It s going to be quite a ride to follow  and with the two companies connected at the hip  investors will have quick insight as to when PTGEF shares are not being afforded fair value  offering an additional buying opportunity for potentially mispriced shares 
Sentien And Portage Pharmaceutical Ltd  Are Also Substantial Assets
Investors should be rightly excited about the BHVN deal  but there is substantially more intrinsic asset value that should not be neglected  and PTGEF is again a clear beneficiary 
Sentien Biotechnologies Inc  is an additional asset in the PTGEF portfolio and is generating impressive clinical data  As recent as April 7  2017  Sentien CEO Brian Miller announced that the company s IND application for its lead compound  SBI 101  has received clearance to proceed from the FDA  The combination therapy of SBI 101 combines mesenchymal stromol cells within an approved blood filtration device  which allows for a controlled and sustainable delivery of MSC secreted factors  The IND approval allows Sentien to initiate on its prospective multi center trial to evaluate the safety and therapeutic effect of SBI 101 
The randomized trial will be a controlled  multi dose phase I II study in patients with acute kidney injury  with endpoints measuring safety and efficacy of the treatment  Enrollment is pending and expected to begin in the second quarter of 2017  designed to enroll 24 patients with top line data scheduled for release in 2018  Sentien is well funded  having closed a  12 million Series A investment round announced on April 4th 
The next value magnet is PTGEF s ownership of Portage Pharmaceuticals Ltd   PPL  and EyGen Limited  PPL is currently negotiating a funding arrangement and appears to be in the final processes of bringing  1 million in convertible note financing for PPL  Good news for those that shriek at the term  convertible notes   insiders are participating in the deal  which demonstrates a vested interest in the quality and structure of the deal  PPL is continuing to develop new candidates using its Cellporter technology for cancer and other indications  The company is seeking additional collaborations that can make use of the Cellporter technology  an additional value enhancer for both PPL and PTGEF 
As for EyGen  the same PPL investor group has agreed to fund  1 5 million with a warrant for EyGen shares  Once again  PTGEF insiders will participate in the deal  EyGen is developing a topical ophthalmic formulation of PPL 003 for Dry Eye Disease and other inflammatory eye diseases 
Trial and study results are expected to be released intermittently as determined prudent by management  protecting proprietary data from potential competitors and taking advantages of its current position as a private company  which protects certain disclosure obligations 
PTGEF Still An Undervalued Gem
PTGEF at twelve cents was a gift  And  at twenty two cents  it still is  PTGEF is on the verge of recording a significant milestone from the BHVN IPO  whereby an intrinsic valuation can be appropriately prescribed  But  owning a 28 3  stake in BHVN is only a small part of the story  While the share price may have the ability to trend significantly higher once the deal closes  there is still considerable value to be created through Sentien and EyGen  Following the same methodology  investors may very well be on the right course to expect that additional value creation deals will be made with these two assets as well 
The management team at PTGEF is both strategic and exceptionally smart  As principal financiers in each of the company holdings  betting against these insiders may prove to be a foolish endeavor  PTGEF may very well be one of the best emerging micro cap stocks in the market  While I hold conviction in other small cap investments  few hold the promise that PTGEF does  who holds multiple opportunities for blockbuster treatments 
Undoubtedly  with shares trading at less than a quarter a share  many investors quickly turn a blind eye  believing that the price of a stock is at that level for a reason  But  with only a  55 million valuation  PTGEF may prove to be underpriced by as much as 50   Even if the company elects to sell some of their BHVN holdings to perpetuate additional Sentien and PPL trials  investors should have confidence that the money will be well spent  and if history repeats itself  will most likely lead to even larger gains 
To sum it up  I ve owned PTGEF for well over one year  and while the stock has only recently gained traction to the upside  the stock has all of the elements necessary to continue to build a robust and sustainable brand  They have management  science  cash  and diversity  For investors looking for a true ground floor opportunity  look no further  PTGEF may soon be moving substantially higher  don t miss the ride 
Disclosure  This article was written by Kenny Soulstring  and it reflects my own opinions and unique articulation  This article is not intended to offer investing advice  guarantee 100  accurate predictions or to be interpreted as providing a personal recommendation  What I can guarantee  though  is accurate research  thoughtful analysis and an enthusiasm about any stock that I cover 
While I seek to uncover emerging companies that I feel have true value and potential  it s important that investors assign an appropriate time horizon to each of their investments  understanding that emerging companies need time to mature 
I wrote this article myself and it includes my own research and expresses my own opinions  I am not receiving compensation for it  other than from CNA Finance   I have no business relationship with any company whose stock is mentioned in this article ",2017-04-18,Modest Money,https://www.investing.com/analysis/portage-biotech-(ptgef)-stock-may-be-the-mightiest-micro-cap-in-the-mark-200183266,200183266
147089,368605,ALXN,Alexion  ALXN  Tops Q1 Earnings  Sales  Shares Up,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   focuses on the development and commercialization of life transforming drugs for treating patients suffering from ultra rare disorders  Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven  CT based company  In this scenario  investors focus should remain on Soliris performance 
Under its metabolic franchise  the company markets Strensiq for the treatment of patients with pediatric onset hypophosphatasia  HPP  and Kanuma for the treatment of patients with lysosomal acid lipase deficiency  LAL D  
The company s track record has been mixed  Over the last four quarters  the company has beaten estimates on two occasions  Overall  Alexion has posted an average positive earnings surprise of 2 82  for the four trailing quarters 
Currently  Alexion has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below 
Earnings  Alexion surpassed earnings expectations in the first quarter of 2017  Our consensus called for EPS of  1 05  and the company reported EPS of  1 20  these figures include after tax impact of stock based compensation expense  
Revenue  Revenues also exceeded expectations  Alexion posted revenues of  870 million  compared to our consensus estimate of  821 million Key Stats  Solirus sales increased 17 7  in the quarter to  783 million 
2017 Guidance  The company maintains its revenue guidance and raised its earnings guidance for 2017  The company expects adjusted earnings per share to be in the range of  5 10 to  5 30 up from its previous guidance range of  5 00 to  5 25  It projects revenues to be in the range of  3 4 to  3 5 billion same as the previous expectations  The Zacks Consensus Estimate for earnings was  4 49 per share while for sales it was  3 47 billion 
Share Price Impact  Shares rose 3 5  in pre market trading Alexion Pharmaceuticals  Inc  Price and EPS Surprise   Looking for Ideas with Even Greater Upside  
Most of Zacks  investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/alexion-(alxn)-tops-q1-earnings,-sales;-shares-up-200185762",200185762
147090,368606,ALXN,Alexion  ALXN  Tops Q1 Earnings  Revenues  Ups  17 View,opinion,"Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   first quarter 2017 earnings  including stock based compensation expense  of  1 20 per share compared with the year ago earnings of 76 cents  The reported figure surpassed the Zacks Consensus Estimate of  1 05 
Revenues rose 24 1  year over year to  870 million  exceeding the Zacks Consensus Estimate of  821 million  The impact of currency headwind on the top line was 2    12 million  
Revenues in the quarter benefitted from an accounting change in revenue recognition  However  despite this benefit  total revenues rose 20  
Shares of Alexion were up more than 4  in pre market trading  in response to the better than expected results  Alexion s share price decreased 1 4  year to date  against the Zacks classified  industry s gain of 4 8  
Revenue in Detail
Soliris sales were up 17 7  to  783 million during the quarter  Sales included a benefit of  29 million from the accounting change in revenue recognition 
While Strensiq contributed  74 million  up 124 2  year over year  Kanuma contributed  12 million  up considerably by 500  to quarterly revenues 
2017 Guidance
The company maintained its revenue guidance while raised its earnings guidance for 2017  The company expects adjusted earnings per share to be in the range of  5 10 to  5 30 up from its previously guidance range of  5 00 to  5 25  It projects revenues to be in the band of  3 4 to  3 5 billion same as the previous expectations  In fact  revenues for Soliris are maintained in the range of  3 03 to  3 1 billion 
Pipeline Update
The company continues to progress with the candidates in its pipeline  Alexion filed regulatory submissions for Soliris to treat patients with refractory generalized myasthenia in both the U S  and Europe in Jan 2017  The applications have been accepted for review by the FDA and validated by the European Medicines Agency  EMA  
Alexion is evaluating Soliris in a couple of phase III studies   PREVENT  for the treatment of relapsing neuromyelitis optica spectrum disorder and expects to complete enrollment in this study this year Our Take
Alexion exceeded both earnings and revenue estimates in the first quarter and also raised its earnings guidance  We expect growth at Alexion to continue being driven by Soliris  Other new products   Strensiq and Kanuma   are doing well and should boost revenues  Eventually  reducing the company s dependence on Soliris for growth  We are also impressed by Alexion s efforts to develop its pipeline Alexion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Key Picks
Alexion currently carries a Zacks Rank  3  Hold   Better ranked stocks in the health care sector include Heska Corp    NASDAQ HSKA    Galena Biopharma  Inc    NASDAQ GALE   and Infinity Pharmaceuticals  Inc    NASDAQ INFI   sporting a Zacks Rank  1  Strong Buy   You can see  
Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 80 to  2 01 for 2018  over the last 60 days  The company posted positive surprises in three of the four trailing quarters with an average beat of 291 54   Its share price increased 50 7  year to date 
Galena s loss per share estimates narrowed from  2 03 to 58 cents for 2017 over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 53 83  
Infinity Pharma s loss per share estimates narrowed from  1 10 to  1 03 for 2017 over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters  with an average beat of 36 64  
Just Released   Driverless Cars  Your Roadmap to Mega Profits Today
In this latest Special Report  Zacks  Aggressive Growth Strategist Brian Bolan explores a full blown technological breakthrough in the making   autonomous cars  He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon ",2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/alexion-(alxn)-tops-q1-earnings,-revenues;-ups-'17-view-200185759",200185759
147091,368607,ALXN,What Are We Waiting For ,opinion,"The market continues to run in place just below all time highs despite a number of positive developments  including the solid earnings season and a good jobs report  So what s the hold up  Ultimately of course  stocks want to see tax reform and other pro growth initiatives that were promised during the election  But that will likely take a while 
Fortunately  a few of the editors think we re poised to make a move   I truly believe we will soon break above 2400 touching 2450 or even 2500 before the next consolidation period   said Steve in Reitmeister Trading Alert 
The S P has crossed 2400 intraday  but keeps scurrying to the negative side by the closing bell  The index was down 0 10  today to 2396 9  The Dow also spent a good part of the session in the green  but ended lower by 0 17  to 20 975 8  Only the NASDAQ has been able to reach all time highs and stay there  It was up 0 29  on Tuesday to 6 120 6 
The portfolios found plenty to do even if the market didn t  Zacks Counterstrike banked a double digit profit for the second time on one of its positions  and still has some shares left over for the next leg higher  TAZR added a pharma company  Stocks Under  10 bought a French telecom and Insider Trader picked up a fertilizer company in hopes that the industry is finally bottoming  Finally  Short List swapped out three names this week  Give it all a look below Today s Portfolio Highlights Zacks Counterstrike  The  60 price target for Applied Optoelectronics  AAOI  was hit and surpassed this morning  giving Jeremy a great opportunity to sell half of the remaining position for a return of 34 4  in less than a month  The editor sold part of AAOI last Friday for a more than 36  return  He s holding onto the final third of the original position in anticipation of a move above  70 TAZR Trader  Alexion Pharmaceuticals  NASDAQ ALXN  has been basing between  110 and  120 over the past year  but Kevin feels that this profitable biotech company will be heading back to around  150 moving forward  The company s focus on rare conditions allows it to command premium pricing and a quicker regulatory path to market  EPS and sales are expected to grow 19  and 13   respectively  this year  and then accelerate even further by 23  and nearly 16  next year  The editor added ALXN on Tuesday with a 7  allocation  Make sure to read his complete commentary to learn about the special risks coming out of Brazil and the funds that continue to buy the stock Zacks Short List  There were three swaps this week  and two of the short coverings were positive for the portfolio 
  Incyte Corp   INCY   3 9  
  Halliburton  NYSE HAL   1  
  BIDU was also short covered
The new buys that replaced these names are 
  ConocoPhillips  NYSE COP 
  GoDaddy  GDDY 
  Inphi  IPHI 
Learn more about this emotion free portfolio that takes advantage of falling and volatile markets by reading the Short List Trader Guide Stocks Under  10  Brian Bolan went overseas for his next addition by adding the French telecom Sequans Communications  SQNS   This Zacks Rank  2 is growing revenue on a year over year basis and reported a 25  earnings surprise last time  The editor thinks this company could be profitable by the end of the year and is getting in at a great price as the CAC  the Paris stock exchange index  tumbled yesterday in the aftermath of the election  The full commentary has a lot more on this new buy  While you re there  check out the portfolio s three tech stocks that are each up in the triple digits Insider Trader  Is a bottom forming for the slumping fertilizer industry  A few insiders at Mosaic  MOS  seem to think so  Shares of this phosphate and potash fertilizer company are down nearly 20  year to date  but it mentioned some positive developments in its recent earnings report from earlier this month  Subsequently  the CFO and two directors bought shares in their own company  Do they see a light at the end of the tunnel  Tracey decided to take a chance that they do and bought a 10  position in MOS on Tuesday  The full commentary has more specifics on this new buy 
Until Tomorrow 
Jim GiaquintoOne More Thing   
Remember  the third episode of the Zacks Ultimate Strategy Session will be available for viewing this Wednesday  May 10th  Steve Reitmeister  Sheraz Mian  Dr  John Blank and David Bartosiak will cover the investment landscape from most every angle in this  must see TV  event 
Don t miss your chance to hear 
  Sheraz and John Agree to Disagree on Risk and Earnings Growth
  Steve s answers to your questions in Reity s Mailbag
  Tips for improving your portfolio
  And much more
So be sure to mark your calendar then log on to Zacks com and bookmark this page 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-05-09,Zacks Investment Research,https://www.investing.com/analysis/what-are-we-waiting-for-200188174,200188174
147092,368608,ALXN,Alexion s  ALXN  Strensiq Results Positive In Long Term Study ,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society  ECTS  Congress in Austria 

Alexion s shares declined 4 4  year to date compared with the Zacks classified  industry s gain of 2 1  
The final data from the extension phase of the randomized  open label  dose ranging phase II trial of Strensiq showed the benefits of the drug achieved in adolescents and adults  ages 13 66 years at study entry  suffering from hypophosphatasia  HPP  within the first 6 months were sustained through 5 years of treatment 
The data from the study were in sync with the previously presented interim results 
The results were presented at the ECTS Congress in Austria 
The findings demonstrated a reduction in two key biomarkers of HPP disease activity  as well as improvements in physical function in patients treated with Strensiq  as observed in tests to measure walking distance  running speed and agility  and muscle strength 
We note that Strensiq is approved in the EU and the U S  as a bone targeted enzyme replacement therapy that treats the underlying cause of HPP by replacing the missing TNSALP enzyme 
Strensiq continues to perform well  Revenues continue to benefit from growing number of patients  both children as well as adults with pediatric onset disease  owing to HPP disease awareness and diagnostic initiatives  These initiatives are leading to steady identification of new patients with HPP   Sales of the drug came in at  74 million  up from  33 million in the year ago quarter 
Concurrent with the first quarter results  the company maintained its revenues guidance while raised its earnings guidance for 2017  The company expects adjusted earnings per share in the range of  5 10  5 30 up from its previously guidance range of  5 00  5 25  Revenues are expected around  3 4  3 5 billion 
We expect growth at Alexion to continue being driven by Soliris while new products like Strensiq and Kanuma should boost performance which in turn should reduce the company s dependence on Soliris for growth  We are also impressed by Alexion s efforts to develop its pipeline 
Zacks Rank   Key Picks 
Alexion currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS    MEI Pharma  Inc    NASDAQ MEIP   and Aeglea BioTherapeutics   NASDAQ AGLE     While VIVUS and MEI Pharma sport a Zacks Rank  1  Strong Buy   Aeglea carries a Zacks Rank  2  Buy   You can see  
VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  
MEI Pharma s estimates narrowed from loss per share of 1 cent to gain per share of 1 for 2017 over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters  with an average beat of 66 56  
Aeglea s loss per share estimates narrowed from  3 64 to  2 48 for 2017  over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20 75  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
 It s not the one you think ",2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/alexion's-(alxn)-strensiq-results-positive-in-long-term-study-200189784,200189784
147097,368613,ALXN,Here s Why Alexion Pharma  ALXN  Stock Is Sinking Today,opinion,"On Tuesday  shares of Alexion Pharmaceuticals Inc    NASDAQ ALXN   are sinking  down over about 8 5  in mid morning trading after the company announced a series of changes to its management team 
Alexion s Chief Commercial Officer Carsten Thiel will resign effective June 1  and Brian Goff has been hired to succeed him  Goff has had many years of experience in the biopharmaceutical industry  working at firms like Neurovance  Baxalta  Novartis   NYSE NVS    and Johnson   Johnson   NYSE JNJ    He will lead all global operations  and be responsible for all country operations in each of Alexion s affiliates in North America  Latin America  EMEA  Japan  and Asia Pacific 
Ludwig Hantson  Alexion s Chief Executive Officer  stated   We are delighted to welcome Brian to Alexion as our new Chief Commercial Officer and look forward to his leadership in developing and executing our strategies for long term growth as we focus on creating value for all stakeholders  
Current Chief Financial Officer Dave Anderson will resign from his position at the end of August  Martin Mackay  Executive Vice President  Head of Research   Development  will retire at the end of the year  and Executive Vice President  Chief Human Resources Officer  Clare Carmichael will be exiting Alexion  effective June 1  to pursue new opportunities  Searches and recruiting are currently underway to fill all three of these positions 
Alexion develops pharmaceutical products for the treatment of heart disease  inflammation  diseases of the immune system and cancer in humans  ALXN is a  3  Hold  on the Zacks Rank  with a VGM score of  B  
Zacks  2017 IPO Watch List 
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Could you imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/here's-why-alexion-pharma-(alxn)-stock-is-sinking-today-200190948,200190948
147113,368629,ALXN,Alexion Pharmaceuticals Inc Stock Shares Tumble,opinion,"Alexion Pharmaceuticals Inc  NASDAQ ALXN 
ALXN News And Technicals


Before the market opened today  shares of Alexion Pharmaceuticals slipped in reaction to news that the company will be changing their executive team including CEO David Hallal who resigned for personal reasons and the CFO  ALXN named board member David Brennan as interim CEO and David Anderson has joined the as the CFO 
Shares gapped down big with an opening print of  118 61 after closing Friday at  132 07  marking just over a 10  drop in price  Shares remained heavy for most of the morning  reaching a current low of  109 80  Look for shares to form a base to trade against  as these shares can be volatile so you ll want a clear area of support before taking any longs  Shares are well below their 200 day moving average  currently sitting at  132 48 and with this gap  they are now below their 50 day moving average at  122 94  Expect shares to remain volatile over the coming days 
Chairman Comments
Leonard Bell  M D   Chairman of the Board of Directors  said 

This leadership transition comes during a period of great strength and momentum  The fundamentals of Alexion are very strong  We have three highly effective therapies and a robust rare disease pipeline  We are well positioned for sustainable growth  Moreover  we have a clear strategy to continue our mission to develop and deliver transformative therapies for patients with devastating and rare diseases    

Analyst Notes
We would expect shares to be down at least 10 15  based on what looks like a massive shake up at Alexion after an investigation that commenced on sales in early Nov right before our Credit Suisse healthcare conference  We are very surprised by the Alexion announcement removing CEO and long time CFO  Based on this news  it would lead us to believe that former CEO Hallal  who ran commercial  before was involved  We note that David Hallal had joined Alexion in 2006  We were especially surprised by Vikas leaving as well  
From our conversations  we think many had hoped Lenny Bell might come back as CEO  We don t know if that is out of the question but seems like a no since they have an interim search underway  The company has appointed an interim CEO who was on the board and was previously at AZ as CEO  The company reiterated the need for no restatement historically  We don t know how this impacts revenues going forward  The company expects to file their 10Q in January 2017 or earlier so that may help to answer the question  
With this type of shake up  we would guess a question will be what is the company worth if they were to be acquired  Understanding what a M A valuation for the company here is hard to say  based not fully on knowing impact to revenues going forward  Our back of the envelope M A valuation suggests  167  200 share  If we keep our base case and apply 10  cuts to R D and SG A  our Alexion M A valuation is  200  meaning those cuts add  35 sh in synergies  
 However  we model 1210 separately and assume 75  success on  2 8B in 1210 revenues  We also include some credit for NMO  25  POS on  870M revs   MPSIIIB  25  POS on  370M revs   If we remove these pipeline items  ex 1210 and MG at 50    our Alexion M A valuation is  183  If we remove MG but keep OpEx cuts our DCF is  167    CreditSuisse
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals  Inc  is a biopharmaceutical company  which focuses on serving patients with devastating and ultra rare disorders through the innovation  development and commercialization of life transforming therapeutic products  Its products include soliris  strensiq and kanuma  The company was founded by Joseph A  Madri  David W  Keiser  Stephen P  Squinto and Leonard Bell in January 1992 and is headquartered in New Haven  CT ",2016-12-13,Ticker.tv News,https://www.investing.com/analysis/alexion-pharmaceuticals-inc.-$alxn-stock-shares-tumble-after-news-of-200169520,200169520
147115,368631,ALXN,5 Stocks To Watch That Report Earnings Today,opinion,"Arista Networks  NYSE ANET    roared through 2016 only to hit a massive snag at the start of the new year  In late January  the CBP revoked an earlier court ruling over an ongoing patent infringement case between Arista and Cisco  NASDAQ CSCO   Shares subsequently took a sharp dive but since recovered most of the losses  For the most part  analysts expect the company to continue its trend higher in the fourth quarter  with forecasts for a 30  jump on the top line and 5  on the bottom  A 5  increase in earnings would mark the first quarter since the company went public that earnings failed to reach double digit growth  From a product standpoint Arista continues to find support from cloud networking ports and switches  which topped nearly 10 million cumulative shipments in the third quarter 
MGM Resorts  NYSE MGM   Shares of  soared 61  in 2016 largely on the back of improving travel trends in key markets such as Las Vegas  Improving employment rates and increasing tourism numbers in the region helped MGM record strong occupancy rates and RevPAR  thereby supporting top line growth  That said  ongoing volatility in Macau over the past few quarters wound up offsetting some of the gains at other resorts  Analyst s believe a revival is underway in Macau and will boost performance in the quarter to be reported  But Las Vegas Sands   NYSE LVS  weak fourth quarter results at the end of January suggests otherwise  The success of today s report hinges on whether travel to Macau improved or simply stayed the same during the fourth quarter 
Alexion Pharmaceuticals  NASDAQ ALXN   Biotech companies are some of the biggest crapshoots of earnings season  with  being no different  Top line growth exceeded double digits for 6 consecutive quarters but that couldn t help investors who experienced an 8  decline in share value over the past 12 months  Alexion s two main drugs  Soliris and Strensiq continue to gain traction in core territories including U S   European and Japanese markets on the back of an increasing patient population  Its newest drug  Kanuma  showed progress throughout its early stage launch in U S  and German markets  Investors will be keen on management s comments of the Trump administration s hardened stance on the industry and its potential impact on future performance 
Wendy s  NASDAQ WEN   Analysts are asking  Where s the Growth  after  s posted 3 consecutive quarters of double digit losses and nearly 8 quarters of negative sales growth  And yet the stock soared 50  in the past 12 months due to a string of positive same store sales growth  ongoing efforts to overhaul the menu  and an emphasis on value offerings like the 4 for 4 deal  A large portion of the overall revenue declines come amid a system wide optimization effort intended to reduce the number of company operated restaurants  Furthermore soft consumer spending and a broad shift away from greasy burgers puts greater pressure on financial performance and may hurt traffic trends 
Hyatt Hotels  NYSE H    stands to build on the success of the past 3 quarters owing to increased demand in U S  markets and improving travel trends  Revenue per available room  RevPAR   hotel operators key performance metric  grew 3 8  in domestic markets and 2 5  system wide during the third quarter  The company continues to open new hotels in its broader goal of expanding to global markets like China and India  In Q3  the company opened 11 locations and intends to tack on 20 more in the quarter to be reported  Nonetheless  increasing competition  macroeconomic turmoil and consumer s preference for value channels puts pressure on performance  namely margins ",2017-02-16,Estimize,https://www.investing.com/analysis/5-stocks-to-watch-that-report-earnings-tomorrow-200175859,200175859
147132,368648,ALXN,Biotech Stock Roundup  Gilead In Patent Infringement Lawsuit  Enbrel Biosimilar Approved,opinion,"The overall healthcare sector was under pressure over the last week with focus going back to the pricing policies of pharma and biotech companies  Meanwhile  biosimilars are picking up pace with the FDA approving Sandoz s biosimilar version of Amgen s   NASDAQ AMGN   multi billion dollar drug  Enbrel  Gilead   NASDAQ GILD   is facing a patent infringement lawsuit related to its hepatitis C virus  HCV  drugs that contain sofosbuvir Recap of the Week s Most Important StoriesGilead in HCV Patent Infringement Lawsuit  Gilead is facing a patent infringement lawsuit from the University of Minnesota related to its HCV drugs that contain sofosbuvir  Gilead currently sells three drugs containing sofosbuvir   Sovaldi  Harvoni  and Epclusa According to the lawsuit  patent rights assigned to the University by Dr  Carston R  Wagner  Endowed Chair in Medicinal Chemistry in the University s College of Pharmacy  cover Gilead s drugs  The lawsuit mentions that Gilead has reaped tens of billions of dollars in sales of those drugs  without the University s authorization and also without compensating the University All three drugs brought in total sales of more than  8 billion in the first half of 2016 while combined sales of Harvoni and Sovaldi crossed  19 billion last year  Epclusa is a recent addition to Gilead s HCV portfolio  Although Gilead s HCV product sales have slowed down in recent times  we expect investor focus to remain on such patent infringement lawsuits as an unfavorable outcome could result in the company paying out damages as well as royalties   Biosimilar Version of Amgen s Enbrel Approved  Amgen  which is already facing biosimilar competition for one its drugs  Neupogen   could face biosimilar competition for its top selling drug  Enbrel  as well now that the FDA has approved Sandoz s Erelzi  Erelzi  Sandoz s biosimilar version of Enbrel  has been approved for the treatment of multiple inflammatory diseases  However  Amgen is not giving up without a fight  The company has already filed a patent infringement lawsuit against Sandoz to keep away cheaper versions of Enbrel from the market  Read more    Amgen had some other updates as well   the company reported positive top line results from the primary analysis of a late stage study on Prolia in patients receiving glucocorticoid treatment  Prolia is one of Amgen s six growth products  Amgen also presented data at the European Society of Cardiology  ESC  Congress 2016 on its PCSK9 inhibitor   Repatha  The company said that Repatha consistently reduced low density lipoprotein cholesterol  LDL C  in patients across cardiovascular  CV  risk subgroups or with familial hypercholesterolemia  Read more       Regeneron Also Presents PCSK9 Data  Amgen was not the only company to present data on PCSK9s  Regeneron   NASDAQ REGN   and partner Sanofi  PA SASY  were also at the ESC Congress with detailed positive results from ODYSSEY ESCAPE  a late stage study on their PCSK9 inhibitor  Praluent  Read more    ARIAD Seeks Speedy Review for Lung Cancer Drug  Oncology focused ARIAD   NASDAQ ARIA   has finished submitting its rolling NDA in the U S  for brigatinib  an ALK inhibitor for the potential treatment of patients with metastatic ALK  non small cell lung cancer  NSCLC  who are resistant or intolerant to crizotinib  ARIAD is seeking speedy approval for its drug   if the FDA grants priority review  a response will be out 8 months after the NDA submission instead of 12 months  Approval would make ARIAD a two product commercial company in 2017  Read more    Rigel Could File for Fostamatinib in 1Q17  Clinical stage biotech company Rigel s   NASDAQ RIGL   shares were up on news that fostamatinib met the primary endpoint in the first of two double blind studies in a late stage clinical program for the treatment of adult chronic persistent immune thrombocytopenia  ITP   Results from the second study are expected in October November  Rigel could be in a position to seek FDA approval in the first quarter of 2017 provided the second study is also successful and results from a planned interim analysis of a phase III extension study are favorable  Read more    Performance
The NASDAQ Biotechnology Index declined 1 9  over the last five trading days reflecting the overall weakness in the healthcare sector following the Mylan   NASDAQ MYL   EpiPen pricing controversy  All major biotech stocks declined over the last five trading days with Alexion   NASDAQ ALXN   sliding 4 7   Over the last six months  Amgen was up 14 6  while Alexion lost 16 6   See the last biotech stock roundup here    

What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates from biotech companies Where Do Zacks  Investment Ideas Come From You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research ",2016-08-31,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-gilead-in-patent-infringement-lawsuit,-enbrel-biosimilar-approved-200151414",200151414
147133,368649,ALXN,Alexion  ALXN  Q3 Earnings  Can The Stock Pull A Surprise ,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to report third quarter 2016 results on Oct 27  before the opening bell The company s track record has been mixed  Over the last four quarters  the company has beaten estimates on two occasions  Overall  Alexion has posted an average positive earnings surprise of 3 12  for the four trailing quarters Last quarter  the company recorded a positive earnings surprise of 2 20   Let s see how things are shaping up for this announcement Factors Likely to Impact Q3 ResultsAlexion s key growth driver  Soliris  should continue to perform well in the core territories including the U S   the EU and Japan  driven by a consistently increasing new patient population in the paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome indications  At its last quarterly earnings call  Alexion reiterated its 2016 Soliris guidance of  2 835  2 875 billion  Sales are  however  expected to continue being hurt by macroeconomic weakness in Latin America  Strensiq  a new growth catalyst for Alexion  has seen encouraging uptake in the early stages of its launch  Revenues continue to be boosted by a growing hypophosphatasia  HPP  patient population  including both children and adults with pediatric onset disease  driven by HPP disease awareness and diagnostic initiatives  The strong initial uptake of Strensiq prompted the company to increase its metabolic revenue guidance to  200 million to  220 million from the previous expectations of  180  200 million  Meanwhile  the company is working on the launches of both Strensiq and Kanuma by increasing awareness through diagnostic and disease education programs In the third quarter of 2016  total revenue is expected in the range of  780  790 million  including foreign exchange headwinds of  17  20 million Alexion had guided expenses at the high end of its prior projection mainly due to pipeline investments  expansion of the global commercial launches of Strensiq and Kanuma  and unfavorable currency movement  Consequently  the company lowered its 2016 earnings projection to the range of  4 50 to  4 65  previous guidance   5 00  5 20  per share  For the third quarter  it anticipates earnings in the range of  1 14  1 18 per share On the third quarter call  investor focus will be on the company s performance  and sales ramp up of Strensiq and Kanuma ALEXION PHARMA Price and EPS Surprise
    What Our Model IndicatesOur proven model does not conclusively show that Alexion is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  However  that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   since both the Most Accurate and the Zacks Consensus Estimate are pegged at  1 04 Zacks Rank  Although Alexion s Zacks Rank  3 increases the predictive power of ESP its 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   is expected to report results on Oct 26  The company has an Earnings ESP of  1 79  and a Zacks Rank  3  You can see  The Earnings ESP for ImmunoGen  Inc    NASDAQ IMGN   is  5 41  and it carries a Zacks Rank  3  The company is scheduled to release earnings on Oct 28 Novartis AG   NYSE NVS   has an Earnings ESP of  0 84  and a Zacks Rank  3  The company is slated to report quarterly numbers on Oct 25 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/alexion-(alxn)-q3-earnings:-can-the-stock-pull-a-surprise-200159787,200159787
147146,368662,ALXN,Alexion  ALXN  Tops Q2 Earnings And Revenues  Revised ,opinion,"Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   second quarter 2016 earnings  including stock based compensation expense  of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents  Earnings were  however  lower than the year ago figure of  1 13 Alexion s revenues  on the other hand  soared 18 3  year over year to  753 million  The impact of currency headwinds on the top line was 3    18 million   The majority of the company s revenues were generated by Soliris  The top line also surpassed the Zacks Consensus Estimate of  743 million Soliris Drives GrowthSoliris sales were up 10 2  to  701 million driven by steady growth in patients for both the approved indications   paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome  Sales volumes of Soliris were up 15  year over year Strensiq and Kanuma contributed  45 million and  6 million  respectively  to quarterly revenues Operating expenses  including stock based compensation expense  and upfront and milestone payments related to license and collaboration deals  and other special items  were on the rise  Research and development  R D  expenses were up 36 2   while selling  general and administrative  SG A  expenses rose 4 7  OutlookAlexion has reiterated its guidance for total revenue and Soliris sales for 2016  The company continues to expect revenues in the range of  3 05  3 1 billion  with Soliris contributing in the range of  2 83  2 87 billion The company expects adjusted earnings per share in the range of  4 50  4 65  previous projection  at the low end of the  5 00  5 20 band  Revenues from the metabolic franchise  comprising Kanuma and Strensiq  are now expected in the range  200  220 million   180  200 million expected previously   The company continues to expect R D and SG A expenses to be at the high end of the  650  680 million band and the  760  790 million band  respectively ALEXION PHARMA Price
   Pipeline UpdateThe company continues to progress on the candidates in its pipeline  Currently  the company is evaluating Soliris in three phase III studies   REGAIN  for the treatment of refractory generalized myasthenia gravis  PREVENT  for the treatment of relapsing neuromyelitis optica spectrum disorder  and PROTECT  for the treatment of delayed graft function  Results from the PROTECT study are expected in the second half of 2016 Our TakeAlexion s second quarter results were impressive  with the company beating both top  and bottom line estimates  We expect growth at Alexion to continue being driven by strong sales of Soliris  Launch of new products   Strensiq and Kanuma   should boost revenues and eventually reduce the company s dependence on Soliris for growth  We are also impressed by Alexion s efforts to develop its pipeline Alexion currently carries a Zacks Rank  5  Strong Sell   Some better ranked stocks in the health care sector include Innoviva  Inc    NASDAQ INVA    Nektar Therapeutics   NASDAQ NKTR   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    each sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  We have revised this article to correct a mistake  The previous version  published earlier today  should not be relied upon  ",2016-07-27,Zacks Investment Research,https://www.investing.com/analysis/alexion-(alxn)-tops-q2-earnings-and-revenues-(revised)-200144747,200144747
147147,368663,ALXN,New Strong Sell Stocks For August 22nd,opinion,"Here are 5 stocks added to the Zacks Rank  5  Strong Sell  List today 
     Alexion Pharmaceuticals  Inc    NASDAQ ALXN   develops pharmaceutical products for the treatment of heart disease  and inflammation  diseases of the immune system and cancer in humans  The Zacks Consensus Estimate for its current year earnings has been revised 4 7  downward over the last 30 days 
     Syngenta AG  SIX SYNN    NYSE SYT   offers conventional and biotechnology crop solutions  and also has a broad product line designed to improve crop yields and food quality  The Zacks Consensus Estimate for its current year earnings has declined 8 7  over the last 30 days 
     WageWorks  Inc    NYSE WAGE   is an on demand provider of tax advantaged programs for consumer directed health  commuter and other employee spending account benefits  or CDBs  It has seen the Zacks Consensus Estimate for its current year earnings being revised 12 4  downward over the last 30 days 
     Cabot Corporation   NYSE CBT   is a global specialty chemicals and materials company  The Zacks Consensus Estimate revision for its current year earnings was a negative of 1 5  over the last 30 days 
     HSN  Inc    NASDAQ HSNI   owns and operates a retailer and interactive lifestyle network offering a broad assortment of products  The Zacks Consensus Estimate for its current year earnings has moved 9 1  lower over the last 30 days 
View the entire  ",2016-08-21,Zacks Investment Research,https://www.investing.com/analysis/new-strong-sell-stocks-for-august-22nd-200149299,200149299
147148,368664,ALXN,Countdown To Yellen,opinion,"US Healthcare stocks fear Clinton win

ASX SPI futures are up 5 points
Aussie dollar still very flat  gaining  0 04  to 0 7616
WTI oil gained  1 22  to 47 34 after Iranian oil minister said he would attend OPEC
Economic data  Japanese CPI
Earnings  Coca Cola Amatil  OTC CCLAY    Corporate Travel Mgmt  AX CTD   Mayne Pharma  AX MYX   Saracen Mineral  AX SAR   Select Harvests  AX SHV   Star Entertainment  AX SGR   Super Retail Group  AX SUL 

Well the final countdown to Janet Yellen s speech at midnight AEST has begun  and after a week where most markets have barely moved from where they started  there are likely a number of traders who would relish a bit of volatility this evening  There certainly is a fear evident in markets that Janet Yellen is going to be surprisingly hawkish and talk up a September hike  this may be devoid of any real evidence apart from constant calls from the band of perma hawk US economists  but  nonetheless  market liquidity has dried up in fear  Volumes have been down all week  while the volume on the S P 500 overnight was more than 15  below its 100 day moving average and the Dow Jones had volumes down more than 27  
The gold price has been battered this week as the threat of rising US bond yields has seen it lose 1 5   Gold has been relatively well cushioned above the US 1 312 level since the start of July  but has been pulling back to this support level as hawkish Fed commentary has picked up in the past two weeks  Of course  should Yellen fail to follow through on her  expectedly hawkish  comments about an imminent September rate hike  gold could well be set for a rally 

US durable goods and capital goods orders both performed well overnight  Durable goods ex transport gained 1 5  month on month  MoM  and capital goods nondefense ex aircraft gained 1 6  MoM  If you saw these sorts of figures replicated throughout the third quarter that would be very positive for GDP and could help remove the major drag that we saw from inventories in 2Q  which could provide the basis for a December rate hike  But there are a lot of ifs yet before that happens 

The scandal over Mylan s pricing of its EpiPen has spilled into the broader healthcare sector in the S P 500 overnight with the sector losing 0 8   This is not the first time that Hillary Clinton has emphasised her concerns over seemingly egregious price hikes for healthcare products  and with her dramatically leading in the polls  a number of investors began to pile out of other high pricing biotechs  Alexion Pharmaceuticals  NASDAQ ALXN  has dropped 5 9  in two days as the Mylan  NASDAQ MYL  saga blew up because it mostly relies on the revenue from one of the most expensive drugs in the world   Soliris   a treatment for rare blood disorders that costs US 500 000 a year  These parts of the market may continue to struggle in the lead up to the US election if Clinton s prospects of success continues to firm 

Asian markets are set to open relatively flat  It is likely to be a fairly low volume and unexciting Asian session as many investors sit on the sidelines ahead of Janet Yellen s speech  Oil saw a nice bounce overnight as Iranian oil minister Bijan Zanganeh confirmed he would attend the OPEC meeting in September  which should be a positive for energy stocks  Materials stocks were the best performer in the S P 500 overnight  and BHP s ADR rallied 1 2  boding well for the ASX session today ",2016-08-26,IG,https://www.investing.com/analysis/thoughts-from-collins-place-200150216,200150216
147168,368684,ALXN,Is T  Rowe Price Health Sciences Fund  PRHSX  Worth Another Look ,opinion,"T  Rowe Price Health Sciences     a Zacks Ranked  2  Buy  was incepted in December 1995 and is managed by T Rowe Price Associates  PRHSX s main objective is long term capital appreciation  PRHSX invests at least 80  of its net assets in common stocks of companies engaged in the research  development  production  or distribution of products or services related to health care  medicine  or the life sciences  PRHSX may invest in companies of any size  the majority of fund assets are invested in large and mid capitalization companies 

	This Sector   Health product  as of the last filing  allocates their fund in two major groups  Small Growth and Large Growth  Further  as of the last filing  Allergan  NYSE AGN pa   Alexion Pharmaceuticals  NASDAQ ALXN   Inc  and UnitedHealth Group Incorporated  NYSE UNH  were the top holdings for PRHSX 

	T  Rowe Price Health Sciences  managed by   carries an expense ratio of 0 76   Moreover  PRHSX requires a minimal initial investment of  2 500 

	PRHSX has a history of strong total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 19 26  and 5 year 20 01   To see how this fund performed compared in its category   

	PRHSX s performance  as of the last filing  when compared to funds in its category was in the top 43  in 1 year  top 8  over the past 3 years  and in the 9  over the past 5 years 

Zacks Premium

	To see the Zacks Mutual Fund Rank for the funds you re interested in  plus  gain access to the Zacks Rank for your stocks and ETFs  Premium Screens  Equity Research Reports  Focus List portfolio of 50 longer term stocks and more   ",2016-05-15,Zacks Investment Research,https://www.investing.com/analysis/is-t.-rowe-price-health-sciences-fund-(prhsx)-worth-another-look-200130214,200130214
147169,368685,ALXN,Alexion s  ALXN  Rare Disorder Drug Gets EU Orphan Status ,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the European Commission has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria  PNH  
The European Commission usually grants orphan medicinal product status in order to provide incentives to candidates that are being developed to treat  prevent or diagnose diseases or conditions affecting no more than 5 in 10 000 people in the EU  In addition to providing Alexion with certain benefits and incentives  this status will also allow ALXN1210 to enjoy a period of market exclusivity in the EU  upon approval 
We note that ALXN1210 is a longer acting C5 antibody being developed by Alexion for the treatment of patients with PNH  a life threatening and ultra rare genetic blood disorder 
Currently  Alexion is evaluating ALXN1210 in a dose escalating  phase I II study and an open label  multi dose phase II study in patients with PNH  Preliminary results from ongoing studies on ALXN1210 have shown rapid  complete  and sustained reduction of free C5 activity and a terminal half life of more than 30 days than that of Soliris  which may facilitate a monthly or longer dosing interval 
The company also intends to evaluate ALXN1210 for the treatment of patients with atypical hemolytic uremic syndrome  aHUS  this year 
We note that Soliris is Alexion s key growth driver  which is approved for the treatment of both PNH and aHUS  Alexion is also developing Soliris for several additional indications including generalized myasthenia gravis and delayed kidney transplant graft function among others 
Alexion is a Zacks Rank  4  Sell  stock  Some better ranked stocks in the health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Retrophin  Inc    NASDAQ RTRX   and Bristol Myers Squibb Company   NYSE BMY    All three stocks sport a Zacks Rank  1  Strong Buy  ",2016-06-01,Zacks Investment Research,https://www.investing.com/analysis/alexion's-(alxn)-rare-disorder-drug-gets-eu-orphan-status-200133621,200133621
147170,368686,ALXN,Alexion s Soliris Misses Phase III Primary Efficacy Endpoint,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced disappointing top line data  as per which Soliris failed to meet the primary efficacy endpoint in a phase III study  REGAIN  in patients suffering from refractory generalized myasthenia gravis  gMG   We expect investors to react negatively to the news 
The randomized  double blind  placebo controlled  multi center study was conducted to evaluate the safety and efficacy of Soliris in patients with refractory gMG  The primary efficacy endpoint of change from baseline in a patient reported assessment   Myasthenia Gravis Activities of Daily Living Profile total score at week 26 as measured by a worst rank analysis   failed to achieve statistical significance 
However  the study did meet the first three secondary efficacy endpoints and a series of prospectively defined sensitivity analyses  which showed early and sustained substantial improvements in patients when treated with Soliris compared to placebo over a period of 26 weeks  Moreover  the safety profile of Soliris in this study was found to be consistent with the drug s labels 
Alexion said that it continues to analyze the phase III study results and intends to meet with regulatory authorities to decide on the path forward  The company plans to present detailed results at the International Congress on Neuromuscular Diseases next month 
Per the company s press release  refractory gMG is an ultra rare segment of MG  which is a complement mediated neuromuscular disease  Most gMG patients continue to suffer from this debilitating condition despite treatment with existing MG therapies 
Considering the lack of approved therapies for refractory gMG  there is a significantly unmet need for treatments addressing this disease  We note that Soliris has been granted orphan drug status in the U S   EU  and Japan for the treatment of patients with MG 
Soliris  which is currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome  is a key growth driver at Alexion  In 2015  the drug registered sales of  2 59 billion 
Alexion is also developing Soliris for several additional indications including neuromyelitis optica spectrum disorder and delayed kidney transplant graft function among others 
Alexion is a Zacks Rank  4  Sell  stock  Some better ranked stocks in the health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Retrophin  Inc    NASDAQ RTRX   and Bristol Myers Squibb Company   NYSE BMY    All three stocks sport a Zacks Rank  1  Strong Buy  ",2016-06-06,Zacks Investment Research,https://www.investing.com/analysis/alexion's-soliris-misses-phase-iii-primary-efficacy-endpoint-200134563,200134563
147171,368687,ALXN,Biotech Stock Roundup  Gilead Gets FDA Nod For HCV Drug  Regulus Hit By Clinical Hold,opinion,"Gilead   NASDAQ GILD   once again showed its expertise in the hepatitis C virus  HCV  segment by gaining FDA approval for yet another drug  Epclusa  However  another company  Regulus   NASDAQ RGLS   suffered a setback related to its experimental HCV treatment   Recap of the Week s Most Important Stories1  Gilead got some good news for both its key franchises   HIV and HCV  The company gained European approval for its HIV treatment  Odefsey  the second single tablet regimen containing the Descovy backbone and the third product in the company s new TAF portfolio to gain approval in Europe  Read more       Meanwhile  Gilead continues to expand its blockbuster HCV franchise  The company gained FDA approval for Epclusa  the first all oral  pan genotypic  single tablet regimen for the treatment of adults with genotype 1 6 chronic HCV  Epclusa is also approved for use in certain other patient populations  Read more    2  Regulus suffered a setback with the company receiving a verbal notice from the FDA placing its IND for experimental HCV treatment  RG 101  on clinical hold  The clinical hold was placed after the company reported a second serious adverse event  SAE  of jaundice in an early stage study  The news led to a 49 3  decline in the company s stock price Meanwhile  AbbVie   NYSE ABBV   decided to terminate its collaboration with Infinity Pharma for the development and commercialization of experimental cancer treatment  duvelisib  Efforts to restructure the partnership proved futile and resulted in global rights to the treatment being returned to Infinity  AbbVie s decision was not exactly unexpected considering top line data from the phase II DYNAMO study  while positive  fell short of expectations 
Meanwhile  Infinity said it will be cutting its workforce by 58  and will close certain studies that were being conducted on duvelisib  The company will explore strategic options for the duvelisib program  and will focus on submitting a NDA in the fourth quarter of 2016 3  The Medicines Company   NASDAQ MDCO   got a boost with its experimental antibiotic  Carbavance  meeting FDA as well as EMA pre specified primary endpoints in a late stage study  TANGO I  in patients with complicated urinary tract infections  cUTI   Plans are on to seek FDA approval early next year  Carbavance is one of the four candidates in the company s pipeline that are estimated to have blockbuster potential  Read more    4  GW Pharma s   NASDAQ GWPH   shares are up on positive data from a late stage study on Epidiolex for the treatment of Lennox Gastaut syndrome  LGS   a rare and severe form of childhood onset epilepsy  Earlier this year  Epidiolex had fared well in another late stage study that was conducted for Dravet syndrome  The company expects to file for FDA approval in the first half of 2017  Read more    5  Clinical stage biotech company Xencor   NASDAQ XNCR   has signed up with Novartis for the development and commercialization of a couple of pipeline candidates focused on cancer  The deal will see Xencor getting an upfront payment of  150 million and sharing development costs with Novartis  Importantly  Xencor could earn up to  2 41 billion in the form of milestone payments as well as royalties  The deal is a major positive as it not only provides Xencor with a strong partner  it will also bring in funds   PerformanceThe NASDAQ Biotechnology Index was down 1 63  over the last five trading days  Weakness reflected uncertainty regarding the impact of Brexit on biotech stocks especially companies which generate significant sales in the EU MEDICAL BIOMED GENETICS Industry Price IndexAmong major biotech stocks  Gilead gained 0 6  over the last five trading days while Alexion   NASDAQ ALXN   was impacted by the Brexit sell off with shares declining 7 4   Over the last six months  Alexion lost 39 2  
What s Next in the Biotech World Watch out for the usual pipeline updates and data presentations from biotech companies ",2016-06-29,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-gilead-gets-fda-nod-for-hcv-drug,-regulus-hit-by-clinical-hold-200139054",200139054
147191,368707,ALXN,Why The Bull Market In Biotech Will Continue  Part 2 of 2 ,opinion,"Last week  I discussed how patent expirations are affecting the biotech sector   particularly big names like Astrazeneca Plc  NYSE AZN   I also explained why these larger pharmaceutical firms have been steadily gobbling up small companies left and right   
And  in the process  they ve created sizable paydays for investors who got in at the right time 
Today we re going to look at a few other factors driving biotech higher   
The Silver Tsunami
America s population is getting older  All of those baby boomers are becoming grandparents  retiring and entering their golden years 
Roughly 10 000 boomers turn 65 every day  In 15 years  there will be 75 million Americans over the age of 65  including the youngest of the baby boomers   That s up from 44 7 million in 2013  
And as people get older they tend to get sicker and require more healthcare  According to the Agency for Healthcare Research and Quality  82  of Medicare beneficiaries have at least one chronic condition  The Congressional Budget Office projects that spending on healthcare will go from 4  of America s GDP in 2007 to 7  in 2025  By 2050  that number should rise to 12  
As Americans spend more on healthcare  an increasing percentage of those expenses will be on biotech drugs  Biologics already make up 24  of total drug sales  accounting for  221 billion in annual spending 
Furthermore  biologics are attractive to big pharma companies because they often carry a higher price point  Cancer treating biologics often cost tens of thousands of dollars for a course of treatment  And drugs for rare diseases can cost six figures per year  with many patients dependent on therapy for the rest of their lives 
For example  Soliris  which is made by Alexion Pharmaceuticals  NASDAQ ALXN   is the most expensive drug in the world  It treats a rare and sometimes fatal form of anemia  It costs around  440 000 per year 
These kinds of drugs will have an increasing role over the coming years  Tons of research is being conducted in immunotherapy and other new ways of fighting a wide variety of conditions  such as cancer and diabetes 
And with all of the upcoming patent expirations   which I talked about last week   there will be tremendous interest in the sector from large pharmaceutical companies looking to add to their research capabilities  pipelines and product offerings 

Why the Uptrend Should Continue
To top it all off  the fundamentals for this sector look great  And so do the technicals 
You can see from the chart above that the ARCA Biotechnology has been in a strong uptrend since 2012  It s actually been rising since 2009  but the index has followed this uptrend line perfectly for the past three years 
There s a saying in technical analysis that a trend in motion stays in motion  In other words  these types of trends tend to stay in effect until they break down meaningfully 
As shown above  we could even experience a 10  correction in the index and still be in the long term uptrend 
In fact  if we did see the index pull back 10   I d be buying with both hands 
This is about as strong and perfect of a trend as you ll see on a chart  And it suggests we should see higher prices for the foreseeable future 
The angle of the trend is not too steep  which means it s sustainable  Sometimes when a stock or index rises too fast  even if it tracks along a trend line  it can t maintain that momentum for very long  But this trend line is the kind that you d find in a technical analysis textbook 
It s reassuring when the technicals and fundamentals point in the same direction 
Biotech is a sector you have to be in over the coming decade  It has its risks  And it can be volatile  But over the years  it should generate extraordinary returns as new medicines come on the market and smaller companies get gobbled up by larger ones 
It s my favorite sector in the market and I strongly encourage you to have some portion of your portfolio invested in biotech stocks ",2015-05-28,Investment U,https://www.investing.com/analysis/why-the-bull-market-in-biotech-will-continue-(part-2-of-2)-253142,253142
147192,368708,ALXN,Is There An Acquisition In Gilead Sciences  Future ,opinion," NASDAQ GILD  reports its FQ2  15 results after the closing bell today  Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ  Estimize are forecasting an EPS figure of  2 77 and a revenue target of  7 540B  Wall Street estimates EPS to come in at  2 64 and revenues to be  7 360B 

The success of Gilead over the past 36 months can be attributed to the company s strong revenue growth figures which have blown expectations out of the water consistently over the past 2 years  However  this metric has recently experienced a slowdown and is expected to only further decline  As payers begin to balk at the high price tags of Gilead s Hepatitis C drugs including Sovaldi and Harvoni  sales are expected to be negatively affected 
Despite the potential negatives associated with falling revenue growth  Gilead is in a very strong position in terms of its balance sheet  Gilead has the ability to use its balance sheet to its advantage and potentially acquire desirable businesses in an attempt to bolster growth over the coming years  However  Gilead s management have informed the market that they will not rush into a transaction and pay too much to acquire another company  In February  Gilead announced to the market that they will start paying a  0 43 quarterly dividend and launch a  15B share buyback program  Importantly  the market has previously rewarded drugmakers engaging in M A activity 
Companies such as AbbVie  NYSE ABBV  and Alexion Pharmaceuticals  NASDAQ ALXN  have both benefited from their M A strategies and are both trading at considerable premiums since their acquisition announcements  These success stories place more pressure on Gilead s management to act sooner rather than later with respect to making acquisitions 
Investors will be eager to hear from management with respect to both increasing competition and also their M A strategy moving forward  Investors have become accustomed to Gilead outperforming analyst expectations  therefore if there is a miss today  the stock could potentially experience a significant pull back depending on the severity ",2015-07-28,Estimize,https://www.investing.com/analysis/is-gilead-sciences-about-to-make-an-acquisition-259654,259654
147193,368709,ALXN,What Lies Ahead For Biotech ETFs ,opinion,"The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining 17 5  year to date  Compare this to the spectacular performance over the last few years and one wonders whether the dream run for the sector is over 

Biotech stocks have been under immense pressure since Sep 2015 due to sector specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario as well as other factors like oil prices  global terrorism and China 
Pricing Concerns 

Both pharma and biotech companies are under a lot of pressure regarding the high price tags for new drugs  Democratic presidential frontrunner Hillary Clinton s  price gouging  tweet triggered a slide in healthcare stocks in Sep 2015  Since then  the issue has been gaining focus and is not likely to die down easily    while presidential candidates may have differing opinions about other matters  all are pretty much on the same page where the high prices of drugs are concerned  Proposed health care plans include suggestions on how to rein in the prices of new drugs   Read   
Biosimilar Competition  A New Challenge

Last year  the FDA approved the first biosimilar in the U S    Sandoz s Zarxio   a biosimilar of Amgen s Neupogen  The approval is a landmark decision and follows years of debate regarding the regulatory path for biosimilars  Unlike their pharma counterparts  biotech companies have not been exposed to generic competition in the U S  But with the approval of Zarxio  the floodgates have opened 

Several companies are currently working on bringing in biosimilar versions of multi billion dollar revenue generating products like Enbrel and Humira among others 
Deals to Continue

Licensing agreements and deals including those with opt in arrangements should continue being signed this year with immuno oncology remaining a favorite area  Moreover  with valuations approaching reasonable levels  we could see several merger and acquisition agreements being announced as the year progresses  Quite a few of the major biotech companies are rumored to be on the look out for suitable deals   Read   
New Products Should Gain Traction

Highly awaited new products that gained approval last year should contribute significantly to revenues  Some of the important new product approvals include cystic fibrosis treatment  Orkambi  heart failure treatment  Corlanor  PCSK9 inhibitors  Repatha and Praluent  and Genvoya  HIV  

While 45 new molecular entities  NMEs  and Biologics License Applications  BLAs  were approved by the FDA last year  so far in 2016  the FDA has approved 5 NMEs and BLAs and has expanded the label of cancer drugs like Kyprolis and Imbruvica   Read   


ETFs in Focus

Highlighted below are some biotech ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector 
iShares Nasdaq Biotechnology ETF   

IBB  launched in Feb 2001 by BlackRock Investments LLC  tracks the Nasdaq Biotechnology Index  The fund mainly covers biotech stocks  77 9   with pharma accounting for 14 5   life sciences tools   services for 7 5  and Health care supplies for 0 11   The top 3 holdings include Amgen Inc  NASDAQ AMGN    8 24    Gilead Sciences Inc  NASDAQ GILD    8 20   and Regeneron Pharmaceuticals  Inc   7 71    The total assets of the fund as of Apr 4  2016 were  6 72 billion representing 189 holdings  The fund s expense ratio is 0 48  while dividend yield is 0 09   The trading volume is roughly 2 950 216 shares per day 
SPDR S P Biotech ETF   

XBI  launched in Jan 2006 by State Street Global Advisors   tracks the S P Biotechnology Select Industry Index  The fund primarily covers biotech stocks  99 9    The top 3 holdings include ACADIA Pharmaceuticals Inc   2 67    Medivation  Inc   2 23    and Neurocrine Biosciences Inc   2 20    The total assets of the fund as of Apr 1  2016 were  1 9 billion representing 90 holdings  The fund s expense ratio is 0 35  while dividend yield is 0 76   The trading volume is roughly 9 231 887 shares per day 
First Trust NYSE Arca Biotechnology Index Fund   

FBT  launched in Jun 2006 by First Trust Advisors  tracks the NYSE Arca Biotechnology Index  The top 3 holdings include Medivation  Inc   4 04    Bio Techne Corp   3 97    and Juno Therapeutics Inc   3 95    The fund s expense ratio is 0 58  while dividend yield is 0 09   The trading volume is roughly 159 227 shares per day 
Market Vectors Biotech ETF   

BBH  launched in Dec 2011 by Van Eck  tracks the Market Vectors US Listed Biotech 25 Index  The fund covers health care stocks  The fund s expense ratio is 0 35  while dividend yield is 0 32   The trading volume is roughly 180 238 shares per day 
PowerShares Dynamic Biotechnology   Genome Portfolio   GENOME   

PBE  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Biotech   Genome Intellidex Index  The top 3 holdings include Gilead Sciences Inc   4 97    BioMarin Pharmaceutical Inc   4 90    and Alexion Pharmaceuticals Inc  NASDAQ ALXN    4 88    The total assets of the fund as of Apr 4  2016 were  270 1 million representing 31 holdings  The fund s expense ratio is 0 57  while dividend yield is 1 45   The trading volume is roughly 36 651 shares per day 
Conclusion 

High risk and high returns    this is a term that is often associated with the biotech sector  Biotech drugs  which are developed through a biological process system or by using living organisms  require a lot of investment  The drugs are complex in nature and take several years to develop  Companies which hit the bull s eye become overnight success stories with shares even doubling or tripling on positive news  However  negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies 

Strong pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth in this sector 

On the flip side  the high cost of treatments  pricing controversies and the threat of biosimilars remain dampeners for this high risk high return sector ",2016-05-13,Zacks Investment Research,https://www.investing.com/analysis/what-lies-ahead-for-biotech-etfs-200129894,200129894
147219,368735,ALXN,Top Trade Ideas  The Week Of February 4,opinion,Here are the Rest of the Top 10  Alexion Pharmaceuticals  Ticker  ALXNAlexion Pharmaceuticals has been drifting higher in a broadening wedge  Now at the 200 day Simple Moving Average  SMA  it has support for more upside from the rising Relative Strength Index  RSI  and a Moving Average Convergence Divergence indicator  MACD  that is about to cross to positive  Apache  Ticker  APAApache is consolidating after a continued move higher out of a basing at 76  It has support for more upside from a rising and bullish RSI and a MACD that is positive  The Measured Move higher out of the consolidation takes it to 90  BB T  Ticker  BBTBB T is also consolidating after a series of steps higher from the bottom made at 27 in November  Now moving higher off of the 20 day SMA it has a target on a Measured Move to 33  The rising and bullish RSI supports more upside and the MACD is negative  but barely  Crown Castle  Ticker  CCICrown Castle has had a very long run higher  It made a double top at 75 25 before pulling back to the 50 day SMA as support last week  It printed a Spinning Top  reversal candle  that was confirmed Friday higher  It has support to continue the reversal from a rising RSI that held in bullish territory  Canadian National Rail  Ticker  CNICanadian National Rail has been stair stepping higher off of a pullback that found support at the 200 day SMA in November  The current move higher has a target from a Measured Move to 100  The rising and bullish RSI also supports more upside price movement  with a flat MACD that suggest nothing to prevent that After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which heading into the first full week of February sees that the markets have their bull on  Gold looks to have stayed off a fall and will consolidate while Crude Oil continues higher  The US Dollar Index is moving lower again and US Treasuries are joining it to the downside  The Shanghai Composite is racing higher again after some consolidation and Emerging Markets are biased to the upside but consolidating  Volatility remains near historic lows and showing no signs of rising elevated keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  The weakening US Dollar and Treasuries support higher equity prices as well  And the charts of these ETF s agree  with the QQQ looking to finally join the party higher  Use this information as you prepare for the coming week and trad em well Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-02-04,Gregory W. Harmon,https://www.investing.com/analysis/top-trade-ideas:-the-week-of-february-4-153648,153648
147220,368736,ALXN,Biotechs Still A Trader s Paradise ,opinion,"One of the most speculative parts of the equity market is biotechnology  These stocks come to market generally overpriced  and they usually require a lot more capital to develop anything material 
But while investment risk is super high with these stocks  a drug that s in demand and has high barriers to competitive entry can pay off tremendously 
One company that fits this scenario is Alexion Pharmaceuticals  Inc   NASDAQ ALXN  out of Cheshire  Connecticut  The company s main offering is  Soliris   and it s a huge moneymaker 
Soliris was approved for use in the U S  and European Union markets in 2007  and then in Japan in 2010  It s the only drug that helps in the treatment of patients with a rare blood disease called paroxysmal nocturnal hemoglobinuria  PNH   which is a genetic disorder 
It s a growth story we ve looked at before in these pages  and with consistency  share price retrenchments have been buying opportunities 
According to Alexion  net product sales of Soliris were  567 million in the first quarter of 2014  compared to  339 million for the same quarter in 2013 
The company generated GAAP net earnings of  159 million  or  0 79 per share  in the first quarter of 2014  compared to GAAP net earnings of  82 0 million  or  0 41 per share  the year earlier 
The company finished the first quarter with  1 55 billion in cash and full year 2014 non GAAP earnings per share guidance was raised to  4 75 to  4 85 per share from the previous  4 37 to  4 47 
Alexion s share price definitely got caught up in the recent speculative fervor affecting the biotechnology sector and was a worthy sell for profit taking and risk management purposes 
The position is somewhere around 20 points down from its previous record high  and I wouldn t be surprised if it climbs back up there  even though the company is very expensively priced 
One time wonder drug companies can often keep their stock market price momentum for considerable periods  as Alexion illustrates  This is why  for risk capital speculators  constant perusing of 52 week highs set in this sector is a worthwhile endeavor 
There is still a lot of money swashing around these stocks  and it s a good place to be for the most aggressive traders 
And that s what these stocks are trades  Smaller biotechnology stocks are replete with extreme price volatility  Periods of genuine drug development and stock market success are easily reversed  And it s all beyond your control as an investor  with so many variables that affect the potential outcome 
Therefore  a heavy dose of risk management is appropriate with these positions  and none of them should be considered appropriate for conservative equity portfolios 
Like all capital markets  speculative fervor is perpetually changing and enthusiasm for a particular group of stocks goes in and out of style 
Due to the inherent investment risk with biotechnology stocks  only a small portion of risk capital should be allocated to the sector from a portfolio perspective 
With this in mind  as an industry  the amount of capital that s thrown at it by institutional investors is significant simply because the potential rewards in successful drug development are so great  as Alexion so perfectly illustrates 
Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ",2014-06-08,Mitchell Clark,https://www.investing.com/analysis/biotechs-still-a-traders-paradise-215297,215297
147221,368737,ALXN,Top Trade Ideas For The Week Of December 15  2014,opinion,"Here are the Rest of the Top 10 
Alexion Pharmaceuticals Inc  NASDAQ ALXN 
Alexion Pharmaceuticals  is heading toward support and the rising 50 day SMA  As it gets there this time the RSI has lost the mid line and is falling while the MACD is running down  both supporting more downside price action 
Express Scripts  NASDAQ ESRX 
Express Scripts  broke the rising trend support Friday and is approaching horizontal support with a gap to fill below  The RSI is falling  but has worked off a technically overbought condition while the MACD crossed down and is moving lower supporting more downside price action 
Eaton  NYSE ETN 
Eaton rejected at resistance and Friday broke the consolidation range to a new lower low with a near bearish Marubozu candle  The RSI is into the bearish zone while the MACD is running lower  both supporting more downside price action 
3M Company  NYSE MMM 
3M moved higher out of an expanding wedge in October and stalled at the target higher right around 163  After what could be consolidation it broke support Friday to a lower low  The RSI is cracking below the mid line and the MACD is running lower  These support more downside 
PVH Corp  NYSE PVH 
PVH is approaching a resistance zone from a higher low as it bounced off of the 200 day SMA last week  The RSI held in the bullish zone and is turning back higher while the MACD just crossed up  both supporting more upward price action 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which  heading into the last full week of the year sees the equity markets showing weakness  Elsewhere look for Gold to continue its short term uptrend while Crude Oil continues the trend lower  but with perhaps a short term bounce  The US Dollar Index looks to move sideways in the uptrend while US Treasuries are biased higher  The Shanghai Composite is finally consolidating its strong move in the uptrend while Emerging Markets look to continue their fall lower  Volatility looks to remain slightly elevated in the low zone keeping the short term bias lower for the equity index ETF s SPY  iShares Russell 2000 Index  ARCA IWM  and QQQ  The S P 500 and QQQ  NASDAQ QQQ look weakest and have room to pullback more while the IWM is consolidating but at the bottom of the range  so also vulnerable  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-12-14,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-december-15,-2014-235731",235731
147222,368738,ALXN,Biotech Companies May Produce Blockbusters In 2015  But There Are Risks,opinion,"In the healthcare space  2014 was the year of hepatitis C  April saw the biotechnology industry take heavy losses as investors began to view stocks as overvalued following strong performance throughout 2013  But the launch of hepatitis C cure  Harvoni  by Gilead Sciences Inc  NASDAQ GILD  seemed to force the realization that mega blockbusters addressing big unmet needs could still generate game changing profits  Then came controversy over the cure s pricing  and fear of pushback from regulators  When those fears didn t materialize  the biotech stocks resumed their climb  But later in 2014  the arrival of a competitive hepatitis C product from AbbVie  NYSE ABBV  presented an opening to pharmacy benefit managers  PBMs  such as Express Scripts to negotiate aggressively for lower prices  Biotech stocks reacted with a shudder  
Express Scripts Holding Company  NASDAQ ESRX  also noted that it intends to apply the same aggressive negotiation to other drug categories  including oncology drugs  This is happening just as some promising next generation cancer treatments    so called  immuno oncology  drugs    are nearing the market  with potential blockbuster status and likely blockbuster prices  Wherever there is competition    and GILD has shown us that it is very difficult to build a moat in the biotech industry    there will be scope for PBMs to cut deals  use biotech competition to their advantage  and drive prices down for the consumer  
Profits May Be Under Pressure    But They Could Still Be Very Large
 However  the market may overreact to fears of price wars and competition  We see two spaces within the biotech industry where  for different reasons  profits may still be robust    One is the orphan drug space  Orphan indications are rare diseases  frequently genetic  where the patient population is typically very small  During the initial promulgation and roll out of the Affordable Care Act  ACA   we feared that orphan indications would come under pressure and that budgets for their development would begin to dry up  That prospect made companies that focus on orphan indications seem problematic  However  the ACA has not yet had this effect    and if competition is the key to new price pressures in the biotech industries  orphan drugs may be one place where biotech profits can be preserved  Alexion Pharmaceuticals Inc  NASDAQ ALXN  is one such company  they manufacture a blockbuster drug called Soliris which treats two rare genetic disorders and costs more than  500 000 a year    the world s most expensive pharmaceutical  This year they will likely launch another such drug  asfotase alfa  which could also reach blockbuster status  more than  1 billion in sales per year  in spite of the small patient population 



Another possible haven in biotech where profits may still be robust is in areas of significant unmet need  Hepatitis C itself may fall under this category  The pie of available patients is huge    since until now there has simply been no cure at all  It will take many years to work through the existing population of hep C patients  GILD analysts may have to revise their revenue projections downward    but we think those revenues will still be robust  One area where unmet needs may be big enough to support several entrants is the next generation of anti cholesterol drugs  Amgen Inc  NASDAQ AMGN  and a team of Sanofi  NYSE  SNY  and Regeneron  NASDAQ REGN   NASDAQ  REGN  are nearing commercialization of drugs which inhibit an enzyme called PCSK9 
Data that came from Merck in November bolstered the claim that lower cholesterol actually leads to lowered rates of death from heart disease  The new PCSK9 inhibitors face competition from one another as well as from generics  as current anti cholesterol blockbusters go off patent   There are also unresolved legal issues between the competitors   Should their efficacy prove high enough  though  they could become blockbusters themselves even in the face of all that competition 
Investment implications  Pricing pushback from PBMs may crimp biotechnology companies  profits  and the industry may not fly as high as it did in 2013 and 2014  However  orphan indications and new treatments for widespread chronic conditions could both continue to generate good profits for biotechs  even in the face of pricing pressures and payer pushback  In the first  competition will be muted  and in the second  the pie may be big enough for all competitors to profit  Nonetheless this is a very exciting sector with opportunities for investors ",2015-01-20,Tim Shirata,"https://www.investing.com/analysis/biotech-companies-may-produce-blockbusters-in-2015,-but-there-are-risks-239099",239099
147223,368739,ALXN,Wednesday Pre Market Insights  GEVA  BRDR  MGI  NDLS  ZU,opinion,"Synageva BioPharma Corp  NASDAQ GEVA  increased more than 130  to  221 25 in pre market trading following news that the pharmaceutical company will be acquired by Alexion Pharmaceuticals Inc  NASDAQ ALXN  
Borderfree Inc  NASDAQ BRDR  increased 105  to  13 94 per share after the ecommerce solutions company announced it will be acquired by Pitney Bowes Inc  NYSE PBI  
Moneygram Int  NASDAQ MGI  rose 31  to  10 22 per share in pre market activity following an announcement that The Western Union Company  NYSE WU  is in talk to buy the smaller money transfer company 
Noodles   C  NASDAQ NDLS  decreased 22 74  to  16 per share after the dining establishment missed earnings 
Zulily Inc A  NASDAQ ZU  shares fell nearly 20  in pre market trading to  9 49 after the online retailer cut its revenue forecast for second quarter revenue ",2015-05-06,Sarah Roden,"https://www.investing.com/analysis/wednesday-pre-market-insights:-geva,-brdr,-mgi,-ndls,-zu-250859",250859
147224,368740,ALXN,Why The Bull Market In Biotech Will Continue  Part 1 of 2 ,opinion,"If you ve been paying any attention at all to the stock market  you know that the  has been on fire  The Amex Biotechnology Index is up 19  year to date  versus a 3  gain for the S P 500  

Over the past two years  the index has more than doubled   up 106   At the same time  the S P 500 has climbed 29  

The huge move in biotech has caused many skeptics to declare that the sector is in a bubble  And the recent acquisition of Synageva BioPharma Corp  NASDAQ GEVA  by Alexion Pharmaceuticals  Nasdaq  NASDAQ ALXN  for a 140  premium did little to  that they are wrong 

They are wrong 


Patent Expirations

It s no secret that the giant pharma companies are scrambling to replace drugs that are losing their patents and facing generic competition  Hundreds of billions of dollars in revenue are at stake 

For example  Astrazeneca Plc  NYSE AZN  just reported lower first quarter profits after the patent for its acid reflux medicine Nexium expired  Sales of the drug fell 31   The company s cholesterol fighter Crestor will lose patent protection next year  Combined  these two drugs make up a third of AstraZeneca s revenue 

The story is the same across nearly every large pharmaceuticals company  As a result  big pharma is constantly on the prowl for new drugs to replace lost revenue 

That means smaller companies stand to benefit as the drug giants go shopping  either for individual drugs or for entire companies  Their ultimate goal is to obtain a pipeline of multiple drug prospects   or a certain technology that is used to create drugs 

The way a partnership for an individual drug works is like this 

Biotech Company A has a drug that just finished Phase 1 trials with promising data  Big Pharma Company B pays the biotech company  20 million in cash for the rights to develop and market the drug 

The larger company now takes on the expense  and risk  of clinical trials  Along the way  the biotech company is entitled to  100 million in milestone payments  These might occur after     at the beginning and end of Phase 3 trials    and if when the drug is granted final approval 

Additionally  the smaller company will get a royalty payment on sales of the drug once it s on the market 

Obviously  the numbers vary depending on each company s characteristics 


Insatiable Appetites

As drug companies become more desperate  they are willing to pay higher amounts for drugs 

In January  for example  Amgen  Nasdaq  NASDAQ AMGN  said it would pay Kite Pharma  NASDAQ KITE   60 million for access to its cancer drug that had yet to be tested in humans  Kite is eligible for another  525 million in milestone payments as the drug progresses through development 

Of course  sometimes one drug isn t enough to satisfy the insatiable appetites of large pharmaceutical companies  They want all the drugs  So they buy the entire company and gain access to its pipeline  This often includes  just as importantly  patented technology 

In March  Cellular Dynamics agreed to be acquired by Fujifilm Holdings for  16 50 per share  The stock closed at  7 94 in the trading session prior to the announcement  Cellular Dynamics had  16 7 million in sales in 2014  Its technology will allow Fujifilm to produce fully functioning human cells 

Also in March  Teva Pharmaceutical  Nasdaq  ARCA TEVA  agreed to a  3 5 billion buyout of Auspex  NASDAQ ASPX  Pharmaceuticals to obtain its drug for Huntington s disease  Teva also gained access to its pipeline of drugs for Parkinson s disease and idiopathic pulmonary fibrosis  The  101 per share price represents a 42  premium to where the stock closed just before the announcement 


Everybody s Getting In on the Action

Biotech stocks have always enjoyed much larger acquisition premiums than the rest of the market  With demand so high for new drugs and technology  I expect that to continue for the foreseeable future 

It s never a good idea to buy a stock simply because you think the company will get acquired  But as long as huge premiums are being paid for biotech stocks  big money will likely continue to pour into the sector 

Even some large investors who don t normally invest in biotech are getting in on the action  John Paulson of Paulson   Co   who made billions betting against the U S  subprime mortgage market in 2007  recently bought over 2  of Synergy Pharmaceuticals Inc  NASDAQ SGYP  

Synergy is known to biotech aficionados  but is not front of mind to most big money managers 

Next week  I ll take a look at some other fundamentals that should positively impact biotech  as well as review the sector s technicals ",2015-05-24,Investment U,https://www.investing.com/analysis/why-the-bull-market-in-biotech-will-continue-(part-1-of-2)-252709,252709
